Nothing Special   »   [go: up one dir, main page]

CA2413421A1 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity - Google Patents

N-ureidoalkyl-piperidines as modulators of chemokine receptor activity Download PDF

Info

Publication number
CA2413421A1
CA2413421A1 CA002413421A CA2413421A CA2413421A1 CA 2413421 A1 CA2413421 A1 CA 2413421A1 CA 002413421 A CA002413421 A CA 002413421A CA 2413421 A CA2413421 A CA 2413421A CA 2413421 A1 CA2413421 A1 CA 2413421A1
Authority
CA
Canada
Prior art keywords
alkyl
occurrence
substituted
cycloalkyl
chr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002413421A
Other languages
French (fr)
Inventor
Dean A. Wacker
John V. Duncia
Changsheng Zheng
Ui Tae Kim
Soo S. Ko
George V. Delucca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/597,400 external-priority patent/US6525069B1/en
Application filed by Individual filed Critical Individual
Publication of CA2413421A1 publication Critical patent/CA2413421A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present application describes modulators of CCR3 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Description

TITLE
N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE
RECEPTOR ACTIVITY
FIELD OF THE INVENTION
This invention relates generally to modulators of chemokine receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
BACKGROUND OF THE INVENTION
Chemokines are chemotactic cytokines, of molecular weight 6-15 kDa, that are released by a wide variety of cells to attract and activate, among other cell types, macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils (reviewed in Luster, New Eng. J Med., 338, 436-445 (1998) and Rollins, Blood, 90, 909-928 (1997)). There are two major classes of chemokines, CXC
and CC, depending on whether the first two cysteines in the amino acid sequence are separated by a single amino acid (CXC) or are adjacent (CC). The CXC chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils and T lymphocytes, whereas the CC
chemokines, such as RANTES, MIP-loG, MIP-1(3, the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5) and the eotaxins (-1,-2, and -3) are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, dendritic cells, and basophils. There also exist the chemokines lymphotactin-1, lymphotactin-2 (both C chemokines), and fractalkine (a CXXXC chemokine) that do not fall into either of the major chemokine subfamilies.
The chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, Trends Pharm. Sci., 15, 159-165 (1994)) which are termed "chemokine receptors." On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G proteins, resulting in, among other responses, a rapid increase in intracellular calcium concentration, changes in cell shape, increased expression of cellular adhesion molecules, degranulation, and promotion of cell migration. There are at least ten. human chemokine receptors that bind or respond to CC chemokines with the following characteristic patterns: CCR-1 (or "CKR-1" or "CC-CKR-1") [MIP-loc, MCP-3, MCP-4, RANTES] (Ben-Barruch, et al., Cell, 72, 415-425 (1993), Luster, New Eng. J.
Med., 338, 436-445 (1998)); CCR-2A and CCR-2B (or "CKR-2A"/"CKR-2B" or "CC-CKR-2A"/"CC-CKR-2B") [MCP-1, MCP-2, MCP-3, MCP-4, MCP-5] (Charo et al., Proc. Natl. Acad.
Sci. USA, 91, 2752-2756 (1994), Luster, New Eng. J.
Med., 338, 436-445 (1998)}; CCR-3 (or "CKR-3" or "CC-CKR-3") [eotaxin-1, eotaxin-2, RANTES, MCP-3, MCP-4]
(Combadiere, et al., J. Biol. Chem., 270, 16491-16494 (1995), Luster, New Eng. J. Med., 338, 436-445 (1998));
CCR-4 (or "CKR-4" or "CC-CKR-4") [TARC, MIP-loG, RANTES, MCP-1] (Power et al., J. Biol. Chem., 270, 19495-19500 (1995), Luster, New Eng. J. Med., 338, 436-445 (1998));
CCR-5 (or "CKR-5" OR "CC-CKR-5") [MIP-loG, RANTES, MIP-1(3] (Sanson, et al., Biochemistry, 35, 3362-3367 (1996)); CCR-6 (or "CKR-6" or "CC-CKR-6") [LARC] (Baba et al., J. Biol. Chem., 272, 14893-14898 (1997)); CCR-7 (or "CKR-7" or "CC-CKR-7") [ELC] (Yoshie et al., J.
Leukoc. Biol. 62, 634-644 (1997)); CCR-8 (or "CKR-8" or "CC-CKR-8" ) [I-309, TARC, MIP-1(3] (Napolitano et al. , J.
Immunol., 157, 2759-2763 (1996), Bernardini et al., Eur.
J. Immunol., 28, 582-588 (1998)); and CCR-10 (or "CKR-10" or "CC-CKR-10") [MCP-1, MCP-3] (Bonini et al, DNA
and Cell Biol., 16, 1249-1256 (1997)).
In addition to the mammalian chemokine receptors, mammalian cytomegaloviruses, herpesviruses and poxviruses have been shown to express, in infected cells, proteins with the binding properties of chemokine receptors (reviewed by Wells and Schwartz, Curr. Opin.
Biotech., 8, 741-748 (1997)). Human CC chemokines, such as RANTES and MCP-3, can cause rapid mobilization of calcium via these virally encoded receptors. Receptor expression may be permissive for infection by allowing for the subversion of normal immune system surveillance and response to infection. Additionally, human chemokine receptors, such as CXCR4, CCR2, CCR3, CCR5 and CCR8, can act as co-receptors for the infection of mammalian cells by microbes as with, for example, the human immunodeficiency viruses (HIV).
Chemokine receptors have been implicated as being important mediators of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as~rheumatoid arthritis and atherosclerosis. For example, the chemokine receptor CCR-3 plays a pivotal role in attracting eosinophils to sites of allergic inflammation and in subsequently activating these cells. The chemokine ligands for CCR-3 induce a rapid increase in intracellular calcium concentration, increased expression of cellular adhesion molecules, cellular degranulation, and the promotion of eosinophil migration. Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases. In addition, agents which modulate chemokine receptors would also be useful in infectious diseases such as by blocking infection of CCR3 expressing cells by HTV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses.
A substantial body of art has accumulated over the past several decades with respect to substituted piperidines and pyrrolidines. These compounds have implicated in the treatment of a variety of disorders.
4 describes spiro-substituted azacycles which are useful as modulators of chemokine receptors:
H2~m '(CI
H~~
wherein R1 is C1_6 alkyl, optionally substituted with functional groups such as -NR6CONHR7, wherein R6 and R7 may be phenyl further substituted with hydroxy, alkyl, cyano, halo and haloalkyl. Such spiro compounds are not considered part of the present invention.
WO 95113069 is directed to certain piperidine, pyrrolidine, and hexahydro-1H-azepine compounds of general formula:
H ,R4 Ri-~--NHCO-A-f~
C~=O Rs ~N W
X
(CH2~~

wherein A may be substituted alkyl or Z-substituted alkyl, with Z=NR6a or O. Compounds of this type are claimed to promote the release of growth hormone in humans and animals.

WO 93/06108 discloses pyrrolobenzoxazine derivatives as 5-hydroxytryptamine (5-HT) agonists and antagonists:

N /

Rs CONH-(A)ri R4 wherein A is lower alkylene and R4 may be phenyl optionally substituted with halogen.
U.S. Pat. No. 5,668,151 discloses Neuropeptide Y
(NPY) antagonists comprising 1,4-dihydropyridines with a piperidinyl or tetrahydropyridinyl-containing moiety attached to the 3-position of the 4-phenyl ring:

HN ~ R4 R7 R2 ~ / NHCO-B-(CH2)~ N\
R102C \ I R

wherein B may be NH, NR1, 0, or a bond, and R~ may be substituted phenyl, benzyl, phenethyl and the like.
These reference compounds are readily distinguished structurally by either the nature of the urea functionality, the attachment chain, or the possible substitution of the present invention. The prior art does not disclose nor suggest the unique combination of structural fragments which embody these novel piperidines and pyrrolidines as having activity toward the chemokine receptors.
SUMMARY OF THE INVENTION
Accordingly, one object of the present invention is to provide novel agonists or antagonists of CCR-3, or pharmaceutically acceptable salts or prodrugs thereof.
It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to provide a method for treating inflammatory diseases and allergic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to provide novel N-ureidoalkyl-piperidines for use in therapy.
It is another object of the present invention to provide the use of novel N-ureidoalkyl-piperidines for the manufacture of a medicament for the treatment of " allergic disorders.
In another embodiment, the present invention provides novel N-ureidoalkyl-piperidines for use in therapy.
In another embodiment, the present invention provides the use of novel N-ureidoalkyl-piperidines for the manufacture of a medicament for the treatment of allergic disorders.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula (I):
I~ ~E-N~-R3 L-Q Ri R2 (I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein E, Z, M, J, K, L, Q, R1, R2, R3, and R4 are defined below, are effective modulators of chemokine activity.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[1] In one embodiment, the present invention provides novel compounds of formula (I):
Z

I~ ~ E-N~-R3 ~-Q R1 R2 (I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHRS, CHR13, CR13R13~
and CR5R13~
Q is selected from CH2, CHRS, CHR13, CR13R13, and CR5R13~
J, K and L are independently selected from CH2, CHRS, CHR6, CR6R6 and CR5R6;
with the provisos that:
1) at least one of J, K, or L contains R5;
2) when M is absent, J is selected from CH2, CHRS, CHR13, and CR5R13;
Z is selected from 0, S, NRla, CHCN, CHN02, and C(CN)2;
R1a is selected from H, C1_6 alkyl, C3_6 cycloalkyl, CONRIbRIb~ ORlb~ CN, N02, and (CH2)wphenyl;
R1b is independently selected from H, C1_3 alkyl, C3-6 cycloalkyl, and phenyl;
E is selected from:

R~
A A
~R 14)9 ~R 14)9 R9 'R10 ~R 149 A
R9 R10 ~R14)9 11 12 R9 10 7 Rg 9 10 A W A - R11 R12 A - R~11 R12 ~R 14)g / ~R 14)g ' ~R 14)9 7 8 11 R12 7 8 R R Rs R9 R1o A w A X11 R12 ~ A
R R~RIO '~~
~R 149 R R10 {R 149 ~R 14)9 and R~ R8 9 Rio 11 R12 Rs~R1o A
~R 14).
ring A is a C3-6 carbocyclic residue, provided that the C3-6 carbocyclic residue in Ring A is not phenyl;
R1 and R2 are independently selected from H, C1-6 alkyl, C3-g alkenyl, and C3_g alkynyl;
R3 is selected from a C1-10 alkyl substituted with 0-5 R3g. C3-10 alkenyl substituted with 0-5 R3g, and C3-10 alkynyl substituted with 0-5 R3g;
R3g, at each occurrence, is independently selected from C1, Br, I, F, N02, CN, NR3aR3a', OH, O(CHR')rR3d, SH, C (0) H, S (CHR ~ ) rR3d, C (O) OH, C (O) (CHR' ) rR3b, C (O) NR3aR3a' , OC (O) NR3aR3a' ~ NR3aC (0) oR3d, NR3fC(O)(CHR')rR3b, C(O)O(CHR')rR3d, OC(O)(CHR')rR3b~ C(=NR3f)NR3aR3a'.
2 0 NHC ( =NR3 f ) NR3 f R3 f , S ( 0 ) p ( CHR' ) rR3 b , S ( O ) 2NR3 aR3 a' , NR3fS(0)2(CHR')rR3b, a C3_1o carbocyclic residue substituted with 0-5 R15, and a 5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R15, provided that when R3g is a carbocyclic residue or a heterocyclic system, R3 has at least one other R3g, which is not a carbocyclic residue or a heterocyclic system;

R3a and R3a~, at each occurrence, are selected from H, C1_6 alkyl, C3-g alkenyl, C3_g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R3e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R3e;
R3b, at each occurrence, is selected from C1_6 alkyl, C3-g alkenyl, C3_g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R3e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R3e;
R3d, at each occurrence, is selected from C3-g alkenyl, C3-g alkynyl, methyl, CF3, C~-6 alkyl substituted with 0-3 R3e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R3e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R3e:
R3e, at each occurrence, is selected from C1-6 alkyl, C2_g alkenyl, C2-g alkynyl, (CH2)rC3-6 CYCloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rS(O)pC1-5 alkyl, (CH2)rNR3fR3f~ and (CH2)rphenyl;
R3f, at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and phenyl;

R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)qC(O)R4b, (CH2)qC(O)NR4aR4a'~
(CH2)qC(O)OR4b, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R4c;
R4a and Rya', at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cYcloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, (CH2)rC3-6 cYcloalkyl, C3-g alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, (CH2)rNR4aR4a', and (CH2)rphenyl;
alternatively, R4 joins with R~, R9, R11, or R14 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 Ra;
R5 is selected from a (CR5'R5")t-C3-10 carbocyclic residue substituted with 0-5 R16 and a (CR5'R5")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16;

R5~ and R5~~, at each occurrence, are selected from H, alkyl, (CH2)rC3-6 cYcloalkyl, and phenyl;
R6, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, (CH2)rC3-6 CYCloalkyl, (CF2)rCF3. CN. (CH2)rNR6aR6a'. (CH2)r~H.
(CH2)rOR6b. (CH2)rSH. (CH2)rSR6b. (CH2)rC(O)OH.
(CH2)rC(O)R6b~ (CH2)rC(O)NR6aR6a'.
(CH2)rNR6dC(O)R6a~ (CH2)rC(O)OR6b. (CH2)rOC(0)R6b.
(CH2)rS(O)pR6b. (CH2)rS(O)2NR6aR6a'.
(CH2)rNR6dS(O)2R6b, and (CH2)tphenyl substituted with 0-3 R6C;
R6a and R6a~, at each occurrence, are selected from H, alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-g alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, and (CH2)rNR6dR6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;

with the proviso that when any of J, K or L is CR6R6 and R6 is bonded to the carbon to which it is attached through a heteroatom, the other R6 is not bonded to the carbon to which it is attached through a heteroatom;
R~, is selected from H, C1_6 alkyl, C2-g alkenyl, C2_g alkynyl, (CH2)qOH, (CH2)qSH, (CH2}qOR~d, (CH2)qSR7d, (CH2)qNR~aR7a', (CH2)rC(0)OH, (CH2)rC(O)R~b, (CH2)rC(O)NR~aR~a', (CH2)rOC(O)NR~aR~a', (CH2)qNR~aC(0)OR~b, ( CH2 ) qNR~ aC ( O ) R7 a, ( CH2 ) qNR~ aC ( O ) H. ( CH2 ) rC ( O ) OR~b, (CH2)qOC(O)R~b, (CH2)qS(O)pR7b, (CH2)qS(0)2NR7aR7a', (CH2)qNR~aS(O)2R7b, C1_6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 RFC, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Roc;

Rya and R~a~, at each occurrence, are selected from H, C1-6 alkyl, C3_g alkenyl, C3_g alkynyl, (CH2)rC3-6 cycloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rye, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rye;
alternatively, Rya and R7a~, along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR7g, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
Rib, at each occurrence, is selected from C1-6 alkyl, C3_g alkenyl, C3_g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 Rye, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rye;
RFC, at each occurrence, is selected from C1-6 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR~fR7f~
(CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)R7b, (CH2)rC(O)NR~fR7f, (CH2)rNR~fC(O)R7a~ (CH2)rC(O)OC1-4 alkyl, (CH2)rOC(O)R~b, (CH2)rC(=NR~f)NR~fR7f~
(CH2)rS(O)pR~b, (CH2)rNHC(=NR~f)NR~fR7f~
(CH2)rS(O)2NR~fR7f~ (CH2)rNR~fS(O)2R7b~ and (CH2)rphenyl substituted with 0-3 Rye;
Rid, at each occurrence, is selected from methyl, CF3, C2-6 alkyl substituted with 0-3 Rye, C3-g alkenyl, C3-g alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 Roc;
Rye, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2_g alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR~fR~f, and (CH2)rphenyl;
Ref, at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
Rig is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH~)rphenyl, C(0)R~f, C(O)OR~f, and S02R~f;
R8 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 R8a;
R8a, at each occurrence, is selected from C1_6 alkyl, C~-g alkenyl, C2-g alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH~)rSC1-5 alkyl, (CH2)rNR~fR~f, and (CH2)rphenyl;
Rgb is selected from H, C1-6 alkyl, C3_6 cycloalkyl, ~OH, CN, and (CH2)r-phenyl;
alternatively, R~ and R8 join to form C3-~ cycloalkyl, =O, or =NR8b;
R9, is selected from H, C1-6 alkyl, C~-g alkenyl, C2-g alkynyl, F, Cl, Br, I, N02, CN, (CH~)rOH, (CH2)rSH, (CH2)rOR9d, (CH2)rSR9d, (CH2)rNR9aR9a', (CH2)rC(0)OH, (CH2)rC(O)R9b~ (CH2)rC(O)NR9aR9a', (CH2)rNR9aC(O)R9a, (CH2)rNR9aC(O)H, (CH2)rOC(O)NR9aR9a', (CH2)rNR9aC(O)OR9b, (CH2)rNR9aC(0)NHR9a, (CH2)rC(O)OR9b.
( CH2 ) rOC ( O ) R9b. ( CH2 ) rS ( 0 ) pR9b.
(CH2)rS(O)2NR9aR9a'. (CH2)rNR9aS(O)2R9b~ C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9C, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9C;
R9a and R9a~, at each occurrence, are selected from H, C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
alternatively, R9a and R9a~, along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR9g, 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R9b, at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, C3_g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R9e;
R9c, at each occurrence, is selected from C1-6 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR9fR9f~
(CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-g alkyl, (CH2)rC(0)OH, (CH2)rC(O)R9b~ (CH2)rC(0)NR9fR9f~
(CH2)rNR9fC(O)R9a~ (CH2)rC(0)OC1-4 alkyl, (CH~)rOC(0)R9b, (CH2)rC(=NR9f)NR9fR9f~
(CH2)rS(0)pR9b, (CH2)rNHC(=NR9f)NR9fR9f~
(CH2)rS(0)2NR.9fR9f~ (CH2)rNR9fS(0)2R9b~ and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R9C, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R9C;
R9e, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C~-g alkynyl, (CH~)rC3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH~)rNR9fR9f~
and (CH2)rphenyl;
R9f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R9g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH~)rphenyl, C(O)R9f, C(O)OR9f, and S02R9f;
R10, is selected from H, C1-g alkyl, C~-g alkenyl, C2-g alkynyl, F, C1, Br, I, N02, CN, (CH2)rOH, (CH2)rOR.lOd~ (Cg2)rSRlOd~ (CH2)rNR10aR10a', (CH2)rC(0)OH, (CH2)rC(O)RlOb~ (CH2)rC(O)NR10aR10a'.
(CH2)rNRlOaC(0)RlOa~ (CH2)rNRlOaC(0)H.
(CH2)rC(O)ORlOb~ (CH2)rpC(O)RlOb~
(CH2)rOC(O)NR10aR10a'~ (CH2)rNRlOaC(O)ORlOb~
(CH2)rS(O)pRlOb~ (CH2)rS(0)2NR10aR10a', (CH2)rNRlOaS(O)2R10b~ C1-6 haloalkyl, a (CH2)r-C3-carbocyclic residue substituted with 0-5 RlOc and a (CH2)r-5-10 membered heterocyclic system 10 containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 RlOc RlOa and RlOa', at each occurrence, are selected from H, C1-~ alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 RlOe~ and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 RlOe alternatively, RlOa and RIOa~, along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NRl~g, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
RlOb~ at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 RlOe, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 RlOe;
RlOc~ at each occurrence, is selected from C1_6 alkyl, C2-g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR10fR10f~
(CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-4 alkyl, ( CH2 ) rC ( 0 ) OH , ( CH2 ) rC ( O ) R1 Ob ~ ( CH2 ) rC ( O ) NR10 f R10 f (CH2)rNRlOfC(O)RlOa~ (CH2)rC(0)OC1_4 alkyl, (CH2)rOC(O)RlOb~ (CH2)rC(=NRlOf)NR10fR10f~
(CH2)rS(O)pRlOb, (CH2)rNHC(=NRlOf)NR10fR10f~
(CH2)rs(O)2NR.10fR10f~ (CH2)rNRlOfs(0)2R10b~ and (CH2)rphenyl substituted with 0-3 R.lOe;
RlOd, at each occurrence, is selected from C1_6 alkyl, C3-6 alkenyl, C3_6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 RlOc, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 RlOc;
RlOe~ at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2-g alkynyl, (CH2)rC3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1_5 alkyl, (CH2)rNR10fR10f~
and (CH2)rphenyl;
RlOf, at each occurrence, is selected from H, C1-5 alkyl, and C3_6 cycloalkyl;

RlOg is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)RlOf, C(O)ORlOh, and S02R10h~
RlOh~ at each occurrence, is selected from C1-5 alkyl, and C3-6 cycloalkyl;
alternatively, R9 and R10 join to form =O, a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NRlOg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
with the proviso that when either of R9 or R1~ is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other of R9 or R1~ is not bonded to the carbon to which it is attached through a heteroatom;
R11, is selected from H, C1-6 alkyl, C2-g alkenyl, C2_g alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qORlld, (CH2 ) qSRlld~ (CH2 ) qNR11aR11a' . (CH2 ) rC (O) OH.
(CH2)rC(O)Rllb, (CH2)rC(O)NR11aR11a'~
(CH2)qNRllaC(O)Rlla~ (CH2)qOC(O)NR11aR11a'~
(CH2)qNRllaC(0)ORllb~ (CH2)qNRllaC(O)NHRlla~
(CH2)rC(O)ORllb, (CH2)qOC(O)Rllb, (CH2)qS(O)pRllb~
(CH2)qS(0)2NR11aR11a'. (CH2)qNRllaS(O)2R11b~ C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rllc, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rllc;
Rlla and Rlla', at each occurrence, are selected from H, C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rlle~ and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rlle;
alternatively, Rlla and Rlla', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NRllg, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
Rllb~ at each occurrence, is selected from C1-6 alkyl, C3_g alkenyl, C3_g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 Rlle, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rlle;
Rllc, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR11fR11f~
(CH2)rOH, (CH2)rOC1_4 alkyl, (CH2)rSC1-g alkyl, (CH2)rC(O)OH, (CH2)rC(O)Rllb, (CH2)rC(O)NR11fR11f~
(CH2 ) rNRllfC (O) Rlla~ (CH2 ) rC (O) OC1-4 alkyl, (CH2)rOC(O)Rllb~ (CH2)rC(=NRllf)NR11fR11f~

(CH2)r~C(=NRllf)NR11fR11f~ (CH2)rS(0)pRllb~
(CH2)rS(0)2NR11fR11f~ (CH2)rNRllfS(0)2R11b~ and (CH2)rphenyl substituted with 0-3 Rlle;
Rlld, at each occurrence, is selected from methyl, CF3, C2-6 alkyl substituted with 0-3 Rlle, C3-6 alkenyl, C3-6 alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 Rllc;
Rlle, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR11fR11f~ and (CH2)rphenyl;
Rllf~ at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
Rllg is selected from H, C1_6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)Rllf, C(O)ORllh, and S02R11h;
Rllh~ at each occurrence, is selected from C1-5 alkyl, and C3-( cycloalkyl;
R12 is selected from H, C1-6 alkyl, (CH2)qOH, (CH2)rC3-6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 Rl2a;
Rl2a~ at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3. (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNRgfR9f, and (CH2)rphenyl;
alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NRllg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R13, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, C3-6 cycloalkyl, (CF2)wCF3. (CH2)NR13aR13a'. (CH2)qOH, (CH2)qORl3b~
(CH2)qSH, (CH2)qSRl3b, (CH2)wC(O)OH, (CH2)'"~C(O)Rl3b, (CH2)wC(O)NR13aR13a' (CH2)qNRl3dC(O)Rl3a~ (CH2)wC(O)ORl3b~
(CH2)qOC(O)Rl3b, (CH2)wS(O)pRl3b~
(CH2)wS(O)2NR13aR13a', (CH2)qNRl3ds(O)2R13b~ and (CH2)w-phenyl substituted with 0-3 Rl3c;
Rl3a and Rl3a', at each occurrence, are selected from H, C1_6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3b~ at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 Rl3c;

Rl3c~ at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, and (CH2)rNR13dR13d;
Rl3d~ at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R14, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, N02, CN, (CHR~)rNR14aR14a'~ (CHR~)rOH, (CHR~)r0(CHR~)rRl4d~
(CHR~)rSH, (CHR~)rC(O)H, (CHR~)rS(CHR~)rRl4d~
(CHR~)rC(0)OH, (CHR~)rC(O)(CHR~)rRl4b~
(CHR~)rC(O)NR14aR14a'~ (CHR~)rNRl4fC(O)(CHR~)rRl4b~
(CHR~)rC(O)O(CHR~)rRl4d, (CHR~)rOC(O)(CHR~)rRl4b~
(CHR~)rC(=NRl4f)NR14aR14a'~
(CHR~)rNHC(=NRl4f)NR14fR14f~
(CHR ~ ) rS (O) p (CHR ~ ) ~.Rl4b, (CHR ~ ) rS (0) 2NR14aR14a' (CHR~)rNRl4fS(O)2(CHR~)rRl4b, C1-6 haloalkyl, C2-g alkenyl substituted with 0-3 R~, C2-g alkynyl substituted with 0-3 R~, (CHR~)rphenyl substituted with 0-3 Rl4e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl4e~ or two R14 substituents on adjacent atoms on ring A form to join a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from N, 0, and S substituted with 0-2 Rl4e;

R~, at each occurrence, is selected from H, C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, (CH2)rC3-6 cYcloalkyl, and (CH2)rphenyl substituted with Rl4e;
Rl4a and Rl4a~, at each occurrence, are selected from H, C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rl4e~ and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl4e;
Rl4b~ at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, C3_g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 Rl4e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl4e;
Rl4d~ at each occurrence, is selected from C3-g alkenyl, C3-g alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 Rl4e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 Rl4e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl4e;
Rl4e~ at each occurrence, is selected from C1_6 alkyl, C2-g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, F, Br, T, CN, N02, (CF2)rCF3, (CH2)r0C1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR14fR14f~
and (CH2)rphenyl;

Rl4f~ at each occurrence, is selected from H, C1_6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R14 joins with R4 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle fused to ring A, the spirocycle substituted with 0-3 Ra;
Ra, at each occurrence, is selected from C1_6 alkyl, CZ-g alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNRbRb, ( CH2 ) rOH. ( CH2 ) rORc , ( CH2 ) rSH. ( CH2 ) rSRc , (CH2)rC(O)Rb, (CH2)rC(O)NRbRb, (CH2)rNRbC(0)Rb, (CH2)rC(O)ORb, (CH2)rOC(0)Rc, (CH2)rCH(=NRb)NRbRb, (CH2)rNHC(=NRb)NRbRb, (CH2)rS(O)pRc, (CH2)rS(O)2NRbRb, (CH2)rNRbS(O)2Rc, and (CH2)rphenyl;
Rb, at each occurrence, is selected from H, C1-6 alkyl, C3_6 cycloalkyl, and phenyl;
Rc, at each occurrence, is selected from C1_6 alkyl, C3-cycloalkyl, and phenyl;
R15, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 cYcloalkyl, C1, Br, I, F, N02, CN, (CHR~)rNR15aR15a'~ (CHR~)rOH, (CHR~)r0(CHR~)rRl5d~
(CHR~)rSH, (CHR~)rC(O)H, (CHR~)rS(CHR~)rRlSd~
(CHR~)rC(O)OH, (CHR~)rC(O)(CHR~)rRl5b~

(CHR~)rC(0)NR15aR15a'~ (CHR~)rNRl5fC(O)(CHR~)rRl5b~
(CHR~)rNRl5fC(O)NR15fR15f~ (CHR')rC(O)O(CHR')z.Rl5d~
(CHR')rOC(O)(CHR~)rRl5b, (CH2)rOC(O)NR15aR15a'~
(CH2)rNRl5aC(O)ORl5b~ (CHR~)rC(=NRl5f)NR15aR15a', (CHR~)rNHC(=NRl5f)NR15fR15f~
(CHR~)rS(0)p(CHR~)rRl5b, (CHR~)rS(O)2NR15aR15a'~
(CHR~)rNRlSfS(O)2(CHR~)rRlSb, C1-6 haloalkyl, C2-g alkenyl substituted with 0-3 R~, C2-g alkynyl substituted with 0-3 R~, (CHR~)rphenyl substituted with 0-3 Rl5e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl5e Rl5a and Rl5a', at each occurrence, are selected from H, C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rl5e~ and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 Rl5e;
alternatively, Rl5a and Rl5a'~ along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NRlSg, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
Rl5b~ at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 Rl5e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 RlSe;
RlSd, at each occurrence, is selected from C3-g alkenyl, C3-g alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 RlSe, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 RlSe, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rl5e;
Rl5e~ at each occurrence, is selected from C1_6 alkyl, C2-g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR15fR15f~
and (CH2)rphenyl;
RlSf, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
RlSg is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)RlSf~ C(O)ORl5h, and S02R15h~
Rl5h~ at each occurrence, is selected from C1-5 alkyl, and C3-6 cycloalkyl;
R16, at each occurrence, is selected from C1-g alkyl, C2-g alkenyl, C2-g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, Br, I, F, N02, CN, (CHR~)rNR16aR16a'~

(CHR~)rOH, (CHR~)r0(CHR~)rRl6d, (CHR~)rSH, (CHR~)rC(0)H, (CHR~)rS(CHR~)rRl6d, (CHR~)rC(0)OH, (CHR~)rC(O)(CHR~)rRl6b, (CHR~)rC(O)NR16aR16a'~
(CHR~ ) rNRl6fC (O) (CHR~ ) z.Rl6b~
(CHR~)rC(0)0(CHR~)rRl6d, (CHR~)rOC(0)(CHR~)rRl6b~
(CHR')rC(=NRl6f)NR16aR16a'~
(CHR')rNHC(=NRl6f)NR16fR16f~
(CHR~)rS(O)p(CHR~)rRl6b, (CHR~)rS(O)2NR16aR16a'~
(CHR~)rNRl6fS(0)2(CHR')rRl6b, C1-6 haloalkyl, C2_g alkenyl substituted with 0-3 R~, C2-g alkynyl substituted with 0-3 R~, and (CHR~)rphenyl substituted with 0-3 Rl6e Rl6a and Rl6a', at each occurrence, are selected from H, C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rl6e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R.l6e Rl6b, at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, a (CH2)rC3-6 carbocyclic residue substituted with 0-3 Rl6e~ and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 Rl6e Rl6d~ at each occurrence, is selected from C3-g alkenyl, C3_g alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 Rl6e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 Rl6e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl6e;
Rl6e~ at each occurrence, is selected from C1-~ alkyl, C2-g alkenyl, C2-g alkynyl, (CH2)rC3-6 CYcloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3. (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR16fR16f~
and (CH2)rphenyl;
Rl6f~ at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl, and phenyl;
g is selected from 0, 1, 2, 3, and 4;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5;
p is selected from 0, 1, and 2;
the compounds of Formula (I) do not include the compounds disclosed in U.S. Patent Application No.
09/466,442 filed December 17, 1999.
[2] In another embodiment, the present invention provides novel compounds of formula (I):

Z is selected from 0, S, NCN, NCONH2, CHN02, and C(CN)2;
E is selected from:

A A
(R 14)9 Rg R10 (R 14)9 Rg R10 (R 14)9 11 12 Rg 10 7 R8 9 10 A \ A - R11 R12 A ~ R~11 R12 (R 14)9 ' (R 14)9 ' (R 14)9 ~ and A
(R 14)9 R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-g alkyl, (CH2)rC3-6 cYcloalkyl, and (CH~)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3. (CH2)rOC1_5 alkyl, (CH~)rOH, (CH2)rSC1-5 alkyl, (CH2)rNR4aR4a', and (CH2)rphenyl;
alternatively, R4 joins with R~ or R9 or R14 to form a 5, 6 or 7 membered piperidinium spirocycle substituted with 0-3 Ra;

R1 and R2 are independently selected from H and C1-4 alkyl;
R6, at each occurrence, is selected from C1-g alkyl, C2-g alkenyl, C2-g alkynyl, (CH2)rC3-6 cycloalkyl, (CF2)rCF3, CN, (CH2)rOH, (CH2)rOR6b, (CH2)rC(O)R6b~
(CH2 ) rC (0) NR6aR6a' . (CH2 ) rNR6dC (O) R6a., and (CH2)tphenyl substituted with 0-3 R6C;
R6a and R6a~, at each occurrence, are selected from H, alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 R6C;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF~)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, and (CH2)rNR6dR6d~
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R~, is selected from H, C1-3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qOR~d, (CH2)qNR~aR~a~, (CH2)rC(O)R7b~ (CH2)rC(O)NR~aR7a', (CH2)qNR~aC(O)R~a, (CH2)qOC(O)NR~aR7a', (CH2)qNR~aC(O)OR~b, C1-6 haloalkyl, (CH3)rphenyl with 0-2 Roc;
Rya and R~a~, at each occurrence, are selected from H, C1-6 alkyl, (CH~)rC3-6 cycloalkyl, a (CH2)rphenyl substituted with 0-3 Rye;
Rib, at each occurrence, is selected from C1_6 alkyl, C3-g alkenyl, C3-g alkynyl, (CH2)rC3-6 CYcloalkyl, (CH3)rphenyl substituted with 0-3 Rye;
Roc, at each occurrence, is selected from C1_4 alkyl, C2-g alkenyl, C~-g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, Br, I, F, (CF2)rCF3, N03, CN, (CH2)rNR~fR7f~
(CH2)xOH, (CH2)rOC1-g alkyl, (CH2)rC(O)R7b~
(CH2)rC(0)NR~fR7f~ (CH2)rNR7fC(O)R7a~
(CH2)rs(O)pR~b. (CH2)rS(O)2NR~fR7f~
(CH3)rNR~fS(O)2R~b, and (CH2)rphenyl substituted with 0-2 Rye;
Rid, at each occurrence, is selected from C1-6 alkyl, (CH~)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 Rye;
Rye, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF3)rCF3, (CH3)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR~fR7f~ and (CH2)rphenyl;

Ref, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R8 is H or joins with R~ to form C3_~ cycloalkyl, =O, or =NRgb;
R11, is selected from H, C1_6 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qORlld~
(CH2)qNR11aR11a'~ (CH2)rC(O)Rllb~
(CH2)rC(O)NR11aR11a'~ (CH2)qNRllaC(O)Rlla~
(CH2)qOC(O)NR11aR11a'~ (CH2)qNRllaC(O)ORlla, C1-6 haloalkyl, (CH2)rphenyl with 0-2 R11C, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
Rlla and Rlla', at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cYcloalkyl, a (CH2)rphenyl substituted with 0-3 Rlle;
alternatively, Rlla and Rlla', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NRllg, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
Rllb~ at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, (CH2)rC3-6 CYcloalkyl, (CH2)rphenyl substituted with 0-3 Rlle;

R11C, at each occurrence, is selected from C1-4 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 CYCloalkyl, C1, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR11fR11f~
(CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rC(O)Rllb~
(CH2)rC(O)NR11fR11f~ (CH2)rNRllfC(O)Rlla~
(CH2)rS(O)pRllb~ (CH2)rS(O)2NR11fR11f~
(CH2)rNRllfS(O)2R11b~ and (CH2)rphenyl substituted with 0-2 Rlle;
Rlld, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cYcloalkyl, (CH2)rphenyl substituted with 0-3 Rlle;
Rlle~ at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR11fR11f~ and (CH2)rphenyl;
Rllf, at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;
Rllg is selected from H, C1_6 alkyl, C3_6 cycloalkyl, (CH2)rphenyl, C(O)Rllf, C(O)ORllf, and S02R11f;
R12 is H;
alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NRllg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R13, at each occurrence, is selected from C1-g alkyl, C3-6 cycloalkyl, (CH2)NR13aR13a'~ (CH2)pH, (CH2)ORl3b~ (CH2)wC(O)Rl3b~ (CH2)wC(O)NR13aR13a'~
(CH2)NRl3dC(O)Rl3a~ (CH2)wS(O)2NR13aR13a'~
(CH2)NRl3dS(O)2R13b, and (CH2)w-phenyl substituted with 0-3 Rl3c;
Rl3a and Rl3a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3b~ at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3c, at each occurrence, is selected from C1-6 alkyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3.
(CH2)rOC1-5 alkyl, (CH2)rOH, and (CH2)rNR13dR13d;
Rl3d~ at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
[3] In another embodiment, the present invention provides novel compounds of formula (I):

ring A is selected from:
~''i ~ ~ .~r''J ~i ~R14)9 (R14)9 ~ (R ~9 (R14)9 'R14 \~ ~ R14 and R5 is selected from (CRS~H)t-phenyl substituted with 0-5 R16; and a (CRS~H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
[4] In another embodiment, the present invention provides novel compounds of formula (I-i):
O
I~~ -E-N~-R3 L~ H H
(I-i) R16, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)rNR16aR16a'~ Np2, CN, OH, (CH2)rORl6d~
(CH2)rC(O)Rl6b, (CH2)rC(O)NR16aR16a'~

(CH2 ) rNRl6fC (O) Rl6b, (CH2 ) rS (O) pRl6b~
(CH2)rs(O)2NR16aR16a', (CH2)rNRl6fs(O)2R16b~ and (CH2)rphenyl substituted with 0-3 Rl6e Rl6a and Rl6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;
Rl6b~ at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R.l6e;
Rl6d~ at each occurrence, is selected from C1-6 alkyl and phenyl;
Rl6e~ at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and R.l6f, at each occurrence, is selected from H, and C1-5 alkyl.
[5] In another embodiment, the present invention provides novel compounds of formula (I-ii):
O
-E-N~-R3 H H
(I-ii) R16, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 CYcloalkyl, CF3, Cl, Br, I, F, (CH2)rNR16aR16a', Np2, CN, OH, (CH2)rORl6d, (CH2)rC(O)Rl6b, (CH2)rC(O)NR16aR16a', (CH2)rNRl6fC(0)Rl6b~ (CH2)rS(0)pRl6b, (CH2)rS(O)2NR16aR16a', (CH2)rNRl6fS(O)2R16b, and (CH2)rphenyl substituted with 0-3 Rl6e Rl6a and Rl6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;
Rl6b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;
Rl6d, at each occurrence, is selected from C1-6 alkyl and phenyl;
Rl6e, at each occurrence, is selected from C1-0 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and Rl6f, at each occurrence, is selected from H, and C1-5 alkyl.
[6] In another embodiment, the present invention provides novel compounds of formula (I-i):
R5 is CH2phenyl substituted with 0-3 R16;
Rg, is selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, F, C1, CN, (CH2)rOH, (CH2)rOR9d, (CH2)rNR9aR9a', (CH2)rOC(O)NHR9a, (CH2)rphenyl substituted with 0-5 R9e, and (CH2)r-heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a~, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
R10 is selected from H, C1-5 alkyl, OH, and CH20H;
RlOg is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)RlOf, C(O)ORlOf, and S02R10f;
alternatively, R9 and R10 join to form =O, a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NRlOg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
with the proviso that when either of R9 or R1~ is halogen, cyano, vitro, or bonded to the carbon to which it is attached through a heteroatom, the other of R9 or R1~ is not bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1_g alkyl, (CH2)rphenyl substituted with 0-5 Rlle, and a (CH2)r-heterocyclic system substituted with 0-2 Rlle wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and Rlle~ at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
Rllg is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)Rllf, C(O)ORllf, and S02R11f;
R12 is H;
alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NRllg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R14, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR14aR14a'~ N02, CN, OH, (CH2)rORl4d~
(CH2)rC(O)Rl4b, (CH2)rC(O)NR14aR14a'~
(CH2)rNR.l4fC(p)Rl4b~ (CH2)rS(O)pRl4b~
(CH2)rS(O)2NR14aR14a', (CH2)rNRl4fS(p)2R14b~
(CH2)rphenyl substituted with 0-3 Rl4e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl5e; or two R14 substituents on adjacent atoms on ring A form to join a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from N, 0, and S substituted with 0-2 RlSe;
Rl4a and Rl4a', at each occurrence, are selected from H, C1-~ alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl4e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 Rl5e;
Rl4b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl4e;
Rl4d, at each occurrence, is selected from C1-( alkyl and phenyl;
Rl4e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and Rl4f~ at each occurrence, is selected from H, and C1-5 alkyl;
and r is selected from 0, 1, and 2.
[7] In another embodiment, the present invention provides novel compounds of formula (I-ii):
R5 is CH2phenyl substituted with 0-3 R16;
R9, is selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, F, C1, CN, (CH2)rOH, (CH2)rOR9d, (CH2)rNR9aR9a', (CH2)rOC(0)NHR9a, (CH2)rphenyl substituted with 0-5 R9e, and (CH2)r-heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a~, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
R10 is selected from H, C1-g alkyl, OH, and CH20H;

RlOg is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)RlOf~ C(0)ORlOf~ and S02R10f;
alternatively, R9 and R10 join to form =O, a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from 0, S, and NRlOg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
with the proviso that when either of R9 or R1~ is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other of R9 or R1~ is not bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1-g alkyl, (CH2)rphenyl substituted with 0-5 Rlle, and a (CH2)r heterocyclic system substituted with 0-2 Rlle, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and Rlle~ at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;

Rllg is selected from H, C1-6 alkyl, C3_6 cycloalkyl, (CH2)rphenyl, C(O)Rllf, C(O)ORllf, and S02R11f;
R12 is H;
alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NRllg and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R14, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 CYcloalkyl, CF3, Cl, Br, I, F, (CH2)rNR14aR14a'~ N02, CN, OH, (CH2)rORl4d, (CH2)rC(O)Rl4b~ (CH2)rC(O)NR14aR24a'~
(CH2)rNRl4fC(0)Rl4b~ (CH2)rS(O)pRl4b~
(CH2)rS(O)2NR14aR14a', (CH2)rNRl4fs(0)2R14b~
(CH2)rphenyl substituted with 0-3 Rl4e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl5e; or two R14 substituents on adjacent atoms on ring A form to join a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from N, O, and S substituted with 0-2 Rl5e Rl4a and R1'~a~, at each occurrence, are selected from H, C1_6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl4e;

Rl4b~ at each occurrence, is selected from H, C1-6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl4e;
Rl4d, at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl4e, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02 , (CF2 ) rCF3 , OH, and (CH2)rOCl~5 alkyl;
Rl4f~ at each occurrence, is selected from H, and C1-5 alkyl;
and r is selected from 0, 1, and 2.
[8] In another embodiment, the present invention provides novel compounds of formula (I-i):
J is selected from CH2 and CHRS;
K is selected from CH2 and CHRS;
L is selected from CH2 and CHRS;
R3 is selected from a C1-10 alkyl substituted with 0-3 R3g. C3-10 alkenyl substituted with 0-3 R3g, and C3_10 alkynyl substituted with 0-3 R3g;
R3g, at each occurrence, is selected from Cl, Br, T, F, N02, CN, NR3aR3a', OH, O(CHR')rR3d, SH, C(O)H, S (CHR~ ) rR3d, C (O) OH, C (O) (CHR~ ) rR3b, C (O)NR3aR3a' NR3fC (O) (CHR~ ) rR3b, C (0) O (CHR~ ) rR3d, OC(O)(CHR~)rR3b, (CH2)rOC(O)NR3aR3a'~
(CH2 ) qNR3aC (0) OR3a, S (0) p (CHR~ ) rR3b, S (0) 2NR3aR3a' .
NR3fS(O)2(CHR~)rR3b, phenyl substituted with 0-3 R15, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl, provided that when R3g is a carbocyclic residue or a heterocyclic system, R3 has at least one other R3g, which is not a carbocyclic residue or a heterocyclic system;
R3a and R3a~, at each occurrence, are selected from H, C1-6 alkyl, C3_g alkenyl, C3-g alkynyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3b, at each occurrence, is selected from C1-6 alkyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3d, at each occurrence, is selected from C1-6 alkyl and phenyl substituted with 0-3 R3e;
R3e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH;

R3f, at each occurrence, is selected from H, C1-5 alkyl;
R15, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a'~ N02, CN, OH, (CH2)rORl5d~
(CH2)rC(O)Rl5b, (CH2)rC(O)NR15aR15a'.
(CH2)rNRl5fC(O)Rl5b~ (CH2)rOC(O)NR15aR25a', (CH2)qNRl5aC(O)ORl5a~ (CH2)rS(O)pRl5b~
(CH2)rS(O)2NR15aR15a', (CH2)rNRl5fS(p)2R15b~
(CH2)rphenyl substituted with 0-3 R.l5e, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;
Rl5a and Rl5a', at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl5e;
alternatively, Rl5a and Rl5a', along with the N to which they are attached, are joined to form a morpholine, piperidine, or piperazine ring, and the piperazine optionally substituted with RlSg;

g,l5b~ at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl5e;
RlSd, at each occurrence, is selected from C1-6 alkyl and phenyl;
Rl5e~ at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and Rl5f~ at each occurrence, is selected from H, and C1_5 alkyl.
[9] In another embodiment, the present invention provides novel compounds of formula (I-ii):
K is selected from CH2 and CHRS;
L is selected from CH2 and CHRS;
R3 is selected from a C1-10 alkyl substituted with 0-3 R3g. C3-10 alkenyl substituted with 0-3 R3g, and C3-10 alkynyl substituted with 0-3 R3g;
R3g, at each occurrence, is selected from Cl, Br, I, F, N02, CN, NR3aR3a'~ OH, O(CHR')rR3d, SH, C(0)H, S (CHR ~ ) rR3d, C (O) OH, C (O) (CHR' ) rR3b, C (O) NR3aR3a' NR3fC(O)(CHR')rR3b, C(O)O(CHR')rR3d, OC(O)(CHR')rR3b, (CH2)rOC(0)NR3aR3a'~
(CH2)qNR3aC(O)OR3a, S(O)p(CHR')rR3b, S(0)2NR3aR3a', NR3fS(O)2(CHR~)rR3b, phenyl substituted with 0-3 R15, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl, provided that when R3g is a carbocyclic residue or a heterocyclic system, R3 has at least one other R3g, which is not phenyl or a heterocyclic system;
R3a and R3a~, at each occurrence, are selected from H, C1-6 alkyl, C3-g alkenyl, C3-g alkynyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3b, at each occurrence, is selected from C1-6 alkyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3d, at each occurrence, is selected from C1-6 alkyl and phenyl substituted with 0-3 R3e;
R3e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH;
R3f, at each occurrence, is selected from H, C1-5 alkyl;

R15, at each occurrence, is selected from C1-g alkyl, (CH2)rC3-6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a'~ N02~ CN, OH, (CH2)rORlSd~
(CH2)rC(O)Rl5b, (CH2)rC(O)NR15aR15a'~
(CH2)rNRl5fC(0)Rl5b~ (CH2)rOC(O)NR15aR15a'~
(CH2)qNRl5aC(O)ORl5a~ (CH2)rS(O)pRl5b~
(CH2)rs(O)2NR15aR15a', (CH2)rNRl5fs(O)2R15b~
(CH2)rphenyl substituted with 0-3 Rl5e, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;
Rl5a and Rl5a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl5e;
alternatively, RlSa and Rl5a', along with the N to which they are attached, are joined to form a morpholine, piperidine, or piperazine ring, and the piperazine optionally substituted with R~-5g;
Rl5b~ at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl5e;

R25d~ at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl5e~ at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and Rl5f~ at each occurrence, is selected from H, and C1-5 alkyl.
[10] In another embodiment, the present invention provides novel compounds of formula (I-i):
E is ;
Z is selected from O and N(CN);
R3 is selected from C3_8 alkyl wherein the C3_8 alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, methylpentyl, dimethylpentyl, and trimethylpentyl, and wherein the C3_g alkyl is substituted with 0-2 R3g;
R3g, at each occurrence is selected from C (O) OR3b, OR.3b OH, OC (O) H, NHC (O) R3b, CN, NR3aR3a~ , and phenyl;
R3a and R3a', at each occurrence, are selected from H and methyl;
R3b, at each occurrence, is selected from H, methyl, ethyl, propyl, and phenyl; and R~-6 is selected from F, Cl, Br, and I.
[11] In another embodiment, the present invention provides novel compounds of formula (I-ii):
E is ;
Z is selected from O and N(CN);
R3 is selected from C3_8 alkyl wherein the C3_8 alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, methylpentyl, dimethylpentyl, and trimethylpentyl, and wherein the C3_~ alkyl is substituted with 0-2 R3g;
R3g, at each occurrence is selected from C(O)OR3b, OR3b, OH, OC (O) H, NHC (O) R3b, CN, NR3aR3a~ , and phenyl;
R3a and R3a~, at each occurrence, are selected from H and methyl;
R3b, at each occurrence, is selected from H, methyl, ethyl, propyl, and phenyl; and R16 is selected from F, C1, Br, and I.
[12] Tn another embodiment, the present invention provides novel compounds of formula (I), wherein the compound of formula (I) is selected from:

N-(t-butyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-(i-propyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1 ] -urea, N-(ethoxycarbonylmethyl)-N'-[(2R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[(1R,S)-1-(methoxycarbonyl)-2-methyl-propyl]-N'-[ (~.R, 2S) -2- [ [ (3S) -3- (4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy l ] -urea, N-[(1S)-1-(methoxycarbonyl)-2-phenylethyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[2,4,4-trimethyl-2-pentyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[(1S)-2-hydroxy-1-phenylethyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-urea, 2- ( { [ (1R, 2S) -2-{ [ (3S) -3- (4-fluorobenyl)piperidinyl]methyl}cyclohexyl)amino}car bonyl}amino)acetamide, N-(2-methoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-urea, N-(2-ethoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-urea, N"-cyano-N-(ethoxycarbonylmethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine, 2-{[((1R,2S)-2-{[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl)amino][( 2-methoxyethyl)amino]methylene}malonitrile, N"-cyano-N-(2-phenoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine, N"-cyano-N-(2-methoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine, N-(2-dimethylaminoethyl)-N'-{(1R,2R)-2-[(3S)-3-(4-fluorobenzyl)piperidine-1-carbonyl]cyclohexyl}-urea, and N"-cyano-N-(2-ethoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine.

In another embodiment, the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the present invention.
In another embodiment, the present invention provides a method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of the compounds of the present invention.
In a fifth embodiment, the present invention provides a method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
In a fifth embodiment, the present invention provides a method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
In another embodiment, the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the present invention.
In another embodiment, the present invention provides a method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.

In a preferred embodiment, the present invention provides a method for modulation of chemokine receptor activity comprising contacting a CCR3 receptor with an effective inhibitory amount of a compound of the present invention.
In another embodiment, the present invention provides a method for treating inflammatory disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention In another embodiment, the present invention provides a method for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.
In a preferred embodiment, the present invention provides a method for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, and inflammatory bowel diseases.
In a more preferred embodiment, the present invention provides a method for treating or preventing disorders wherein the disorder is asthma.

In a more preferred embodiment, the present invention provides a method for treating or preventing disorders wherein the disorder is allergic rhinitis.
In a more preferred embodiment, the present invention provides a method for treating or preventing disorders wherein the disorder is atopic dermatitis.
In a more preferred embodiment, the present invention provides a method for treating or preventing disorders wherein the disorder is inflammatory bowel diseases.
In another embodiment, K is selected from CHR5 or CR6R5.
In another embodiment, L is selected from CHRS or DEFINITIONS
The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.
When any variable (e.g., Ra) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 Ra, then said group may optionally be substituted with up to two Ra groups and Ra at each occurrence is selected independently from the definition of Ra. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent.
Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein, "C1_8 alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl. C1_g alkyl, is intended to include C1, C2, C3, Cg, C5, C6, C7, and Cg alkyl groups. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
"Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, and the like. "C3_g cycloalkyl" is intended to include saturated ring groups having the specified number of carbon atoms in the ring, including mono-, bi-, or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl in the case of C7 cycloalkyl. C3-6 cycloalkyl, is intended to include C3, Cg, C5, and C6 cycloalkyl groups "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups, for example CF3, having the specified number of carbon atoms, substituted with 1 or more halogen (for example -CVFW where v = 1 to 3 and w = 1 to (2v+1)).
The compounds of Formula I can also be quaternized by standard techniques such as alkylation of the piperidine or pyrrolidine with an alkyl halide to yield quaternary piperidinium salt products of Formula I.
Such quaternary piperidinium salts would include a counterion. As used herein, "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
As used herein, the term "piperidinium spirocycle or pyrrolidinium spirocycle" is intented to mean a stable spirocycle ring system, in which the two rings form a quarternary nitrogene at the ring junction.
As used herein, the term "5-6-membered cyclic ketal" is intended to mean 2,2-disubstituted 1,3-dioxolane or 2,2-disubstituted 1,3-dioxane and their derivatives.
As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl,;
[3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. As used herein, the term ~~aromatic heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, O and S.
Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ~i-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl., oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolsdinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, and xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiaphenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoidolyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts"
refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines;
alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, malefic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e. g., solubility, bioavailability, manufacturing, etc...) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. "Prodrugs" are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.
Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
SYNTHESIS
The compounds of Formula I can be prepared using the reactions and techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Grou~as In Organic Synthesis, Wiley and Sons, 1991).
Generally, compounds described in the scope of this patent application can be synthesized by the route described in Scheme 1. The appropriately substituted pyrrolidine (n=0) or piperidine (n=1) 1 is alkylated by a N-protected alkylhalide (halide = Cl, Br, I), mesylate, tosylate or triflate, 2, (where E represents a linkage described within the scope of this application in its fully elaborated form with the appropriate protecting groups as understood by one skilled in the art or in a precursor form which can be later elaborated into its final form by methods familiar to one skilled in the art) with or without base or an acid scavenger to yield the piperidinyl- or pyrrolidinylalkyl protected amine 3. If the halide is not I, then KI can also be added to facilitate the displacement, provided the solvent is suitable, such as an alcohol, 2-butanone, DMF
or DMSO, amongst others. The displacement can be performed at room temperature to the reflux temperature of the solvent. The protecting group is subsequently removed to yield amine 4. Protecting groups include phthalimide which can be removed by hydrazine, a reaction familiar to one skilled in the art; bis-BOC
which can be removed by either TFA or HCl dissolved in a suitable solvent, both procedures being familiar to one skilled in the art; a nitro group instead of an amine which can be reduced to yield an amine by conditions familiar to one skilled in the art; 2,4-dimethyl pyrrole (S. P. Breukelman, et al. J. Chem. Soc. Perkin Trans. I, 1984, 2801); N-1,1,4,4-Tetramethyl-disilylazacyclopentane (STABASE) (S. Djuric, J. Venit, and P. Magnus Tet. Lett 1982, 22, 1787) and other protecting groups. Reaction with an isocyanate or isothiocyanate 5 (Z = O,S) yields urea or thiourea _6.
Reaction with a chloroformate or chlorothioformate 7 (Z=O,S) such as o-, p-nitrophenyl-chloroformate or phenylchloroformate (or their thiocarbonyl equivalents), followed by diplacement with an amine 9, also yields the corresponding urea or thiourea 6. Likewise, reaction of carbamate 8 (X = H, or 2- or 4-N02) with disubstituted amine 10 yields trisubstituted urea or thiourea 12.
Reaction of the amine _4 with an N,N-disubstituted carbamoyl chloride 11 (or its thiocarbonyl equivalent) yields the corresponding N,N-disubstituted urea or thiourea 12. Amine 4 can also be reductively aminated to yield 13 by conditions familiar to one skilled in the art and by the following conditions: Abdel-Magid, A. F., et al. Tet. Lett. 1990, 31, (39) 5595-5598. This secondary amine can subsequently be reacted with isocyanates or isothiocyanates to yield trisubstituted ureas 14 or with carbamoyl chlorides to yield tetrasubstituted ureas 15.

NCH E~~- P
/E-N-P

R5 n ) 1 P=protecting group 5 'n X=leaving group: Cl,Br,I, n=0, 1 OTs, OMs, OTf, etc E=linker E---NH
E-NH- ( C=Z ) _NR2R3 2 ~ Cl- (C=Z) -NR~R3 ~ ~n R5 n 12 R5 4 Cl-(C=Z)-OPh R3N=C=Z
R~R3N 7 5 E-NH- (C=Z) -OPh-Y E'~ (C z) NH R3 R3NH2 _ ) n R5 /n 8 9 R5 R~CHO
Y = H, o- or p-N02 Na(Ac0)3BH /
E-NR2-(C=Z)-NHR3 R3N=C=Z
E-NHR~

R5 n 14 / ) R5 'n 13 F~-NR2- (C=Z ) -NR2R3 C1- (C=Z ) -NR2R3 Z=O or S 11 R5 n 15 One can also convert amine 4 into an isocyanate, isothiocyanate, carbamoyl chloride or its thiocarbonyl 5 equivalent (isocyanate: Nowakowski, J. J Prakt.
Chem/Chem-Ztg 1996, 338 (7), 667-671; Knoelker, H.-J. et al., Angew. Chem. 1995, 107 (22), 2746-2749; Nowick, J.
S.et al., J. Org. Chem. 1996, 61 (11), 3929-3934; Staab, H. A.; Benz, W.; Angew Chem 1961, 73; isothiocyanate:
Strekowski L.et al., J. Heterocycl. Chem. 1996, 33 (6), 1685-1688; Kutschy, Pet al., Synlett. 1997, (3), 289-290) carbamoyl chloride: Hintze, F.; Hoppe, D.;
Synthesis (1992) 12, 1216-1218; thiocarbamoyl chloride:
Ried, W.; Hillenbrand, H.; Oertel, G.; Justus Liebigs Ann Chem 1954, 590) (these reactions are not shown in Scheme 1). These isocyanates, isothiocyantes, carbamoyl chlorides or thiocarbamoyl chlorides can then be reacted with R2R3NH to yield di- or trisubstituted ureas or thioureas 12. An additional urea forming reaction involves the reaction of carbonyldiimidazole (CDI) (Romine, J. L.; Martin, S. W.; Meanwell, N. A.;
Epperson, J. R.; Synthesis 1994 (8), 846-850) with 4 followed by reaction of the intermediate imidazolide with 9_ or in the reversed sequence (9 + CDI, followed by 4). Activation of imidazolide intermediates also facilitates urea formation (Bailey, R. A., et al., Tet.
Lett. 1998, 39, 6267-6270). One can also use 13 and 10 with CDI. The urea forming reactions are done in a non-hydroxylic inert solvent such as THF, toluene, DMF, etc., at room temperature to the reflux temperature of the solvent and can employ the use of an acid scavenger or base when necessary such as carbonate and bicarbonate salts, triethylamine, DBU, Hunigs base, DMAP, etc.
Substituted pyrrolidines and piperidines 1 can either be obtained commercially or be prepared as shown in Scheme 2. Commercially available N-benzylpiperid-3-one 16 can be debenzylated and protected with a BOC
group employing reactions familiar to one skilled in the art. Subsequent Wittig reaction followed by reduction and deprotection yields piperidine 20 employing reactions familiar to one skilled in the art.

Substituted pyrrolidines may be made by a similar reaction sequence. Other isomers and analogs around the piperidine ring can also be made by a similar reaction sequence. Chiral pyrrolidines/piperidines can be synthesized via asymmetric hydrogenation of 18 using chiral catalysts (see Parshall, G.W. Homogeneous Catalysis, John Wiley and Sons, New York: 1980, pp. 43-45; Collman, J.P., Hegedus, L.S. Principles and Applications of Organotransition Metal Chemistry, University Science Books, Mill Valley, CA, 1980, pp.
341-348).

H2/Pd Wittig H~/Pd BOC2 O Rxn BOC BOC

H'E' H
The cyanoguanidines (z = N-CN) can be synthesized by the method of K. S. Atwal, et al. and references contained therein (J. Med. Chem. (1998) 41, 217-275).
The nitroethylene analog (Z = C-N02) can be synthesized by the method of F. Moimas, et al. (Synthesis 1985, 509-510) and references contained therein. The malononitrile analog (Z = C(CN)2) may be synthesized by the method of S. Sasho, et al. (J. Med. Chem. 1993, 36, 572-579).

Guanidines (Z=NRla) can be synthesized by the methods outlined in Scheme 3. Compound 21 where Z=S can be methylated to yield the methylisothiourea 22.
Displacement of the SMe group with amines yields substituted guanidines 23 (see H. King and I. M. Tonkin J. Chem. Soc. 1946, 1063 and references therein).
Alternatively, reaction of thiourea 21 with amines in the presence of triethanolamine and "lac sulfur" which facilitates the removal of H2S yields substituted guanidines 23 (K. Ramadas, Tet. Lett. 1996, 37, 5161 and references therein). Finally, the use of carbonimidoyldichloride 24, or 25 followed by sequential displacements by amines yields the corresponding substituted guanidine 23 (S. Nagarajan, et al., Syn.
Comm. 1992, 22, 1191-8 and references therein). In a similar manner, carbonimidoyldichlorides, R2-N=C(C1)2 (not shown in Scheme 3) and R3-N=C(Cl)2 (not shown) can also be reacted sequentially with amines to yield di-and trisubstituted guanidine 23.

Fr-NR1- (C=S ) -NHRla ~Ngl- (C=NHRla) -SMe CH3I a 'n R5 21 R5 n 2 2 n=0,1 HNR~R3 N(CHZOH)3, "lac sulfur" , E-NR1- (C=NHRia) -NR2R3 'n 1. H2NR", Et3N R 23 2 . HNR~R3 or 1 . HNR~R3 , Et3N 1 . HNR2R3 , Et3N
2 . H~NR" 2 . 13 or 1. 13, Et3N
2 . HNR2R3 ~N=C (C1) ~
I~ R1a_N-C (C1)2 R5 n 24 25 A method for introducing substituents in linkage E
is that of A. Chesney et al. (Syn. Comm. 1990, 20 (20), 3167-3180) as shown in Scheme 4. Michael reaction of pyrrolidine or piperidine 1 with Michael acceptor 2&
yields intermediate 27 which can undergo subsequent reactions in the same pot. For example, reduction yields alcohol 28 which can be elaborated to the amine 29 by standard procedures familiar to one skilled in the art. Some of these include mesylation or tosylation followed by displacement with NaN3 followed by reduction to yield amine 29. Another route as depicted in Scheme 4 involves reaction with diphenylphosphoryl azide followed by reduction of the azide to yield amine 29.

~H
+ ~ ~ p Michael R5 n ~ Rx 1 R$ R11 n=0 , 1 Rl2Li or Rl2MgBr NaBH4 OH
R5 n R11 2 8 1~
( Ph0 ) 2 ( P=0 ) N3 3 2 ( Ph0 ) 2 ( P=0 ) N3 H2, Pd/C
H2, Pd/C
a7 ~$ R9 R:J 11 w R5 - wn R11 R12 3 3 29 as described as described ,~ previously previously _ (C=Z ) _NR2R3 _ (C=Z ) _NR2R3 h 1,. ~ 3 4 The mesylate or tosylate can also be displaced by 5 other nucleophiles such as NH3, BOC2N-, potassium phthalimide, etc., with subsequent deprotection where necessary to yield amines 29. Finally, 29 can be converted to urea or thiourea 30 by procedures discussed for Scheme 1 or to the compounds of this invention by procedures previously discussed. Similarly, aldehyde 27 may be reacted with a lithium or a Grignard reagent 31 to yield alcohol adduct 32. This in turn can be converted to urea or thiourea 34 in the same way as discussed for the conversion of 28 to 30.
Scheme 5 shows that intermediate 36 can be extended via a Wittig reaction (A. Chesney, et al. Syn. Comm.
1990, 20 (20), 3167-3180) to yield 37. This adduct can be reduced catalytically to yield 38 or by other procedures familiar to one skilled in the art.
Alkylation yields 39, followed by saponification and Curtius rearrangement (T. L. Capson and C. D. Poulter, Tet. Lett., (1984) 25, 3515-3518) followed by reduction of the benzyl protecting group yields amine 40 which can be elaborated further as was described earlier in Scheme 1 and elsewhere in this application to make the compounds of this invention. Dialkyllithium cuprate, organocopper, or copper-catalyzed Grignard addition (for a review, see G. H. Posner, "An Introduction to Synthesis Using Organocopper Reagents", J. Wiley, New York, 1980; Organic Reactions, 19, 1 (1972)) to alpha,beta-unsaturated ester 37 yields 41 which can undergo subsequent transformations just discussed to yield amine 43 which can be elaborated further to the compounds of this invention as was described earlier.
The intermediate enolate ion obtained upon cuprate addition to 37 can also be trapped by an electrophile to yield 42 (for a review, see R. J. K. Taylor, Synthesis 1985, 364). Likewise, another 2-carbon homologation is reported by A. Chesney et al. (ibid.) on intermediate 36 which involves reacting 36 with an enolate anion to yield aldol condensation product 42 where R1~=OH. The OH
group can undergo synthetic transformations which are familiar to one skilled in the art and which will be discussed in much detail later on in the application.
Chiral auxilliaries can also be used to introduce stereo- and enantioselectivity in these aldol condensations, procedures which are familiar to one skilled in the art.

7 $ R9 ~H
+ R~ O Michael Rxn ~ ~O
"n / ' S n R9 s n=0,1 ~ 35 Wittig ~ PPh3 OMe H2 Pd/C
1.LDA '°

2 . R1~X
R7 $ R9 1 . OH R11 12 2 . ( Ph0 ) 2 ( P=O ) N3 R5 n R9~
I
3.BnOH
39 4.H2 Pd/C 40 to compounds by methods R9 8 9 previously discussed Rll as above 11 R5 'n R9 Rlo NH2 R5 n R9 Rlo OMe 44 41 ~ (Rl°)2CuLi 1.LDA
to compounds by methods 8 R9 ~ ' R12X 8 ~
previously ~ ~ ~ R R9 2 R12X,( discussed ~ 11 12 aS 11 above ~ R12 OMe R5 ri R9 R10 NH2 R5 n R9 R10 Examples of such methods are taught in D. A. Evans, et al., J. Am. Chem. Soc. 1981, 103, 2127; D. A. Evans, J.

Am. Chem.Soc. 1982, 104, 1737; D. A. Evans, J. Am.
Chem. Soc. 1986, 108, 2476; D. A. Evans. et al., J. Am.
Chem. Soc. 1986, 108, 6757; D. A. Evans, J. Am. Chem.
Soc. 1986, 108, 6395; D. A. Evans, J. Am. Chem. Soc.
1985, 107, 4346; A. G. Myers, et al., J. Am. Chem. Soc.
1997, 119, 6496. One can also perform an enantioselective alkylation on esters 38 or 41 with R12X
where X is a leaving group as described in Scheme 1, provided the ester is first attached to a chiral auxiliary (see above references of Evans, Myers and Mauricio de L. Vanderlei, J. et al., Synth. Commum.
1998, 28, 3047).
One can also react alpha,beta-unsaturated ester 37 (Scheme 6) with Corey's dimethyloxosulfonium methylide (E. J. Corey and M. Chaykovsky, J. Am. Chem. Soc. 1965, 87, 1345) to form a cyclopropane which can undergo eventual Curtius rearrangement and subsequent elaboration to the compounds of this invention wherein the carbon containing R9R1~ is tied up in a cyclopropane ring with the carbon containing R11R12. In addition, compound 48 can also undergo the analogous reactions just described to form cyclopropylamine 50 which can be further elaborated into the compounds of this invention as described previously. Compound 48 may be synthesized by an alkylation reaction of pyrrolidine/piperidine 1 with bromide 47 in an inert solvent employing the conditions as described for the alkylation of 2 onto 1 in Scheme 1.
Another way to synthesize the compounds in the scope of this application is shown in Scheme 7. Michael reaction of amine 1 with an acrylonitrile 51 (as described by I. Roufos in J. Med. Chem. 1996, 39, 1514-1520) followed by Raney-Nickel hydrogenation yields amine 53 which can be elaborated to the compounds of this invention as previously described.

_ ~ _ NaH, THF
4~

1. -OH
2 . ( Ph0 ) ~ ( P=O ) N3 3.BnOH
4.H2 Pd/C
g 9 to compounds R11 by methods ~
previously \ /
discussed R5 Jn Rg v ~2 7 8 Rg Me ~ + C02Me NaH, R5 n R11 THF

Rg 1 . -OH
2 . ( Ph0 ) ~ ( P=O ) N3 1 +
Br ~ 3.BnOH
47 CO2Me 4 . H2 Pd/C

7 8 Rg to compounds by methods ~ ~ +
previously ~
discussed 5 " n R11 R
In Schemes 4,5, and 6, we see that there is no gem-s substitution on the alpha-carbon to the electron-withdrawing group of what used to be the Michael acceptor. In other words, in Scheme 4, there is no R10 gem to R9; in Scheme 5, there is no R10 gem to one of the R9s and in Scheme 7 there is no R10 gem to R9.
Gem-substitution can be introduced by reacting pyrrolidine or piperidine 1 with the epoxide of Michael acceptors 26, 35, and 51 to yield the corresponding alcohols (for amines reacting with epoxides of Michael acceptors, see Charvillon, F. B.; Amouroux, R.; Tet.
Lett. 1996, 37, 5103-5106; Chong, J. M.; Sharpless, K.
B.; J Org Chem 1985, 50, 1560). These alcohols eventually can be further elaborated into R10 by one skilled in the art, as, for example, by tosylation of the alcohol and cuprate displacement (Hanessian, S.;
Thavonekham, B.; DeHoff, B.; J Org. Chem. 1989, 54, 5831), etc., and by other displacement reactions which will be discussed in great detail later on in this application.

R
H
' CN Ra-Ni/H~
) R ~ CN --~
5 'n R ) 1 R$ R~ 'n n=0,1 51 CHI -NHS
,~ to compounds by methods previously discussed R5 n R
w Further use of epoxides to synthesize compounds of this invention are shown in Scheme 8. Reaction of pyrrole or piperidine 1 with epoxide 54 yields protected amino-alcohol 55. This reaction works exceptionaly well when R~ and R8 are H but is not limited thereto. The reaction is performed in an inert solvent at room temperature to the reflux temperature of the solvent.
Protecting groups on the nitrogen atom of 54 include BOC
and CBZ but are not limited thereto. The hydroxyl group can be optionally protected by a variety of protecting groups familiar to one skilled in the art.

"/H R~ 9or10 1V + NH- P
R8 _ R5 n R ~12 - P
R

n=0, 1 55 -P

R9or10=H
_P

R9or10 _M 1,.

where M=Li,MgBr, MgCl, ZnCl, etc.
_P
a 7 R9or10 to compounds OH by methods previously discussed _P
R5 v ~ ~n R11 R12 Deprotection of the nitrogen by methods familiar to one skilled in the art yields 56 which can be elaborated to the compounds of this invention by the procedures previously discussed. If R9=H, then oxidation, for example, by using PCC (Corey E.J. and Suggs, J.W., Tet.
Lett. 1975, 31, 2647-2650) or with the Dess-Martin periodinane (Dens, D.B. and Martin, J.C., J. Org. Chem.
1983, 48, 4155-4156) yields ketone 57 which may undergo nucleophilic 1,2-addition with organometallic reagents such as alkyl- or aryllithiums, Grignards, or zinc reagents, with or without CeCl3 (T. Imamoto, et al., Tet. Lett. 1985, 26, 4763-4766; T. Imamoto, et al., Tet. Lett. 1984, 25, 4233-4236) in aprotic solvents such as ether, dioxane, or THF to yield alcohol 58. The hydroxyl group can be optionally protected by a variety of protecting groups familiar to one skilled in the art.
Deprotection of the nitrogen yields 56 which can be finally elaborated to the compounds of this invention as previously discussed. Epoxides disclosed by structure 54 may be synthesized enantio-selectively from amino acid starting materials by the methods of Dellaria, et al. J Med Chem 1987, 30 (11), 2137, and Luly, et al. J
Org Chem 1987, 52 (8), 1487.
The carbonyl group of ketone 57 in Scheme 8 may undergo Wittig reactions followed by reduction of the double bond to yield alkyl, arylalkyl, heterocyclic-alkyl, cycloalkyl, cycloalkylalkyl,, etc. substitution at that position, reactions that are familiar to one skilled in the art. Wittig reagents can also contain functional groups which after reduction of the double bond yield the following functionality: esters (Buddrus, J. Angew Chem., 1968, 80), nitriles (Cativiela, C.et al., Tetrahedron 1996, 52 (16), 5881-5888.), ketone (Stork, G.et al., J Am Chem Soc 1996, 118 (43), 10660-10661), aldehyde and methoxymethyl (Bertram, G.et al., Tetrahedron Lett 1996, 37 (44), 7955-7958.), gamma-butyrolactone Vidari, G.et al.,Tetrahedron: Asymmetry 1996, 7 (10), 3009-3020.), carboxylic acids (Svoboda, J.et al., Collect Czech Chem Commun 1996, 61 (10), 1509-1519), ethers (Hamada, Y.et al., Tetrahedron Lett 1984, 25 (47), 5413), alcohols (after hydrogenation and deprotection--Schonauer, K.; Zbiral, E.; Tetrahedron Lett 1983, 24 (6), 573), amines (Marxer, A.; Leutert, T.
Helv Chim Acta, 1978, 61) etc., all of which may further undergo transformations familiar to one skilled in the art to form a wide variety of functionality at this position.
Scheme 9 summarizes the displacement chemistry and subsequent elaborations that can be used to synthesize the R9 groups. In Scheme 9 we see that alcohol 55 or 58 may be tosylated, mesylated, triflated, or converted to a halogen by methods familiar to one skilled in the art to produce compound 59. (Note that all of the following reactions in this paragraph can be also performed on the compounds, henceforth called carbon homologs of 55 or 58 where OH can be (CH2)rOH and it is also understood that these carbon homologs may have substituents on the methylene groups as well). For example, a hydroxyl group may be converted to a bromide by CBr4 and Ph3P
(Takano, S. Heterocycles 1991, 32, 1587). For other methods of converting an alcohol to a bromide or to a chloride or to an iodide see R.C. Larock, Comprehensive Organic Transformations, VCH Publishers, New York, 1989, pp. 354-360. Compound 59 in turn may be displaced by a wide variety of nucleophiles as shown in Scheme 9 including but not limited to azide, cyano, malonate, cuprates, potassium thioacetate, thiols, amines, etc., all nucleophilic displacement reactions being familiar to one skilled in the art. Displacement by nitrile yields a one-carbon homologation product. Nitrile 60 can be reduced with DIBAL to yield aldehyde 61. This aldehyde can undergo reduction to alcohol 62 with, for example, NaBHg which in turn can undergo all of the SN2 displacement reactions mentioned for alcohol 55 or 58.
Alcohol 62 is a one carbon homolog of alcohol 55 or 58.
Thus'one can envision taking alcohol 62, converting it to a leaving group X as discussed above for compound 55 or 58, and reacting it with NaCN or KCN to form a nitrile, subsequent DIBAL reduction to the aldehyde and subsequent NaBH4 reduction to the alcohol resulting in a two carbon homologation product. This alcohol can undergo activation followed by the same SN2 displacement reactions discussed previously, ad infinitum, to result in 3,4,5...etc. carbon homologation products. Aldehyde 61 can also be reacted with a lithium or Grignard reagent to form an alcohol 61a which can also undergo the above displacement reactions. Oxidation by methods familiar to one skilled in the art yields ketone 61b.
Displacement by malonate yields malonic ester 63 which can be saponified and decarboxylated to yield carboxylic acid 64, a two carbon homologation product. Conversion to ester 65 (A. Hassner and V. Alexanian, Tet. Lett, 1978, 46, 4475-8) and reduction with LAH yields alcohol 68 which can undergo all of the displacement reactions discussed for alcohol 55 or 58. Alcohols may be converted to the corresponding fluoride 70 by DAST
(diethylaminosulfur trifluoride) (Middleton, W. J.;
Bingham, E. M.; Org. Synth. 1988, VI, pg. 835).
Sulfides 71 can be converted to the corresponding sulfoxides 72 (p=1) by sodium metaperiodate oxidation (N. J. Leonard, C. R. Johnson J. Org. Chem. 1962, 27, 282-4) and to sulfones 72 (p=2) by Oxone~ (A. Castro, T.A. Spencer J. Org. Chem. 1992, 57, 3496-9). Sulfones 72 can be converted to the corresponding sulfonamides 73 by the method of H.-C. Huang, E. et al., Tet. Lett.

(1994) 35, 7201-7204 which involves first, treatment with base followed by reaction with a trialkylborane yielding a sulfiniv acid salt which can be reacted with hydroxylamine-O-sulfonic acid to yield a sulfonamide.
Another route to sulfonamides involves reaction of amines with a sulfonyl chloride (G. Hilgetag and A.
Martini, Preparative Organic Chemistry, New York: John Wiley and Sons, 1972, p.679). This sulfonyl chloride (not shown in Scheme 9) can be obtained from the corresponding sulfide (71 where R9d=H in Svheme 9, the hydrolysis product after thioacetate displavement), disulfide, or isothiouronium salt by simply reacting with chlorine in water. The isothiouronium salt may be synthesized from the corresponding halide, mesylate or tosylate 59 via reaction with thiourea (for a discussion on the synthesis of sulfonyl chlorides see G. Hilgetag and A. Martini, ibid., p. 670). Carboxyliv avid 64 can be converted to amides 66 by standard coupling provedures or via an acid chloride by Schotten-Baumann chemistry or to a Weinreb amide (66: R9a=OMe, R9a'= Me in Scheme 9) (S. Nahm and S. M. Weinreb, Tet. Lett., 1981, 22, 3815-3818) which can undergo reduction to an aldehyde 67 (R9b=H in Scheme 9) with LAH (S. Nahm and S.
M. Weinreb, ibid.) or reactions with Grignard reagents to form ketones 67 (S. Nahm and S. M. Weinreb, ibid.).
The aldehyde 67 obtained from the Weinreb amide reduction can be reduced to the alcohol with NaBHg. The aldehyde or ketone 67 (or 61 or 61b for that matter) can undergo Wittig reactions as discussed previously followed by optional catalytic hydrogenation of the olefin. This Wittig sequence is one method for synthesizing the varbocyclic and heterocyclic substituted systems at R9 employing the appropriate carbovyclic or heterocyclic Wittig (or Horner-Emmons) reagents. Of course, the Wittig reavtion may also be used to synthesize alkenes at R9 and other functionality as well. Ester 65 can also form amides 66 by the method of Weinreb (A. Basha, M. Lipton, and S.M. Weinreb, Tet.
Lett. 1977, 48, 4171-74) (J. I. Levin, E. Turos, S. M.
Weinreb, Syn. Comm. 1982, 12, 989-993). Alcohol 68 can be converted to ether 69 by procedures familiar 'to one skilled in the art, for example, NaH, followed by an alkyliodide or by Mitsunobu chemistry (Mitsunobu, O.
Synthesis, 1981, 1-28). Alcohol 55 or 58, 62, or 68, can be acylated by procedures familiar to one skilled in the art, for example, by Schotten-Baumann conditions with an acid chloride or by an anhydride with a base such as pyridine to yield 78. Halide, mesylate, tosylate or triflate 59 can undergo displacement with azide followed by reduction to yield amine 74 a procedure familiar to one skilled in the art. This amine can undergo optional reductive amination and acylation to yield 75 or reaction with ethyl formate (usually refluxing ethyl formate) to yield formamide 75.
Amine 74 can again undergo optional reductive amination followed by reaction with a sulfonyl chloride to yield 76, for example under Schotten-Baumann conditions as discussed previously. This same sequence may be employed for amine 60a, the reduction product of nitrile 60.
Tosylate 59 can undergo displacement with cuprates to yield 77 (Hanessian, S.; Thavonekham, B.; DeHoff, B.; J
Org. Chem. 1989, 54, 5831). Aldehyde 61 or its homologous extensions can be reacted with a carbon anion of an aryl (phenyl, naphthalene, etc.) or heterocyclic group to yield an aryl alcohol. or a heterocyclic alcohol. If necessary, CeCl3 may be added (T. Imamoto, et al., Tet. Lett. 1985, 26, 4763-4766; T. Imamoto, et al., Tet. Lett. 1984, 25, 4233-4236). This alcohol may be reduced with Et3SiH and TFA (J. Org. Chem. 1969, 34, 4; J. Org. Chem. 1987, 52, 2226) (see discussion of aryl and heterocyclic anions for Schemes 20-22). These aryl and heterocyclic anions may also be alkylated by 59 (or its carbon homology to yield compounds where R9 contains an aryl or heterocyclic group. Compound 59 or its carbon homologs may be alkylated by an alkyne anion to produce alkynes at R9 (see R.C. Larock, Comprehensive Organic Transformations, New York, 1989, VCH Publishers, p 297). In addition, carboxaldehyde 61 or its carbon homologs can undergo 1,2-addition by an alkyne anion (Johnson, A.W. The Chemistry of Acetylenic Compounds.
V. 1. "Acetylenic Alcohols," Edward Arnold and Co., London (1946)). Nitro groups can be introduced by displacing bromide 59 (or its carbon homologs) with sodium nitrite in DMF (J.K. Stille and E.D. Vessel J.
Org. Chem. 1960, 25, 478-490) or by the action of silver nitrite on iodide 59 or its carbon homologs (Org.
Syntheses 34, 37-39).

1 ~ 10 9d ' 9d '7 ~ R LOl ~ (O)pR
O(CO)R9b 7 8 ,,,.~~ 7 0 ~ 71 7 2 1.KSAc 2.-OH ~ (O)2N,R9a DAST 3 . R9dX ~R9a or KSR9d ~/~ ~ 73 n7 ,R8 R10 -P
5 9 ~NH- P
1~
5 5 o r 5 8 R5~ ~n R11 R12 If an anion is made of the pyrrolidine/piperidine 1 with LDA or n-BuLi, etc., then that anion in a suitable nonhydroxylic solvent such as THF, ether, dioxane, etc., can react in a Michael-type fashion (1,4-addition) with an alpha, beta-unsaturated ester to yield an intermediate enolate which can be quenched with an electrophile (R9X) (where X is as described in Scheme 1) (Uyehara, T.;
Asao, N.; Yamamoto, Y.; J Chem Soc, Chem Commun 1987, 1410) as shown in Scheme 10.

SCHEME 9 (con't) -P ~ -P
k ;n 55 or 58 , 59 X=OTs; (R9)aCuLi KCN I Et OEt - Na -~ Rlo ~ CN OE
s 1 . N ~ Rio 2. [H 60 ~ O

OEt Rlo ~2 ~ ' CHZ OH 10 CHO
74 ~
62 ~ LAH
l . R9aCH0 Na (Ac0) gBH 1 . R9aCH0, 61 1 . -OH
2 . R9bS0 C1 2 . H+, 2 Na(Ac0)gBH R10 2 . R9aCOC1 or -C02 C_OH to R10 Et0 (c=o) H, D ~~ H R CH2NH2 NRa S02Rb 61a ,~,.~ 76 to ~ 60a ~R9aC ( O) R9a H
(or -NHCHO) ~ $ Rio v 75 R1o 8 b R10 ~-0 reductive OR9d amination +
i R acylation 64 \ 69 ~ if desired 61b OH R9 b R9a R9a ' R9 b R LAH ~ $ Rlo ~ ~ $ Rlo ~ $ R1o 68 ' ~ ~ ~ 66 ~ '~ 65 67 ,- r a /

It is to be understood that R9 is either in its final form or in a suitable protected precursor form. This electrophile can be a carbon-based electrophile, some examples being formaldehyde to introduce a CH20H group, an aldehyde or a ketone which also introduces a one-carbon homologated alcohol, ethylene oxide (or other epoxides) which introduces a -CH2CH20H group (a two-carbon homologated alcohol), an alkyl halide, etc., all of which can be later elaborated into R9. It can also be an oxygen-based electrophile such as MCPBA, Davis' reagent (Davis, F. A.; Haque, M. S.; J Org Chem 1986, 51 (21),4083; Davis, F. A.; Vishwaskarma, L. C.; Billmers, J. M.; Finn, J.; J Org Chem 1984, 49, 3241) or Mo05 (Martin, T. et al., J Org Chem 1996, 61 (18), 6450-6453) which introduces an OH group. These OH groups can undergo the displacement reactions discussed previously in Scheme 9 or protected by suitable protecting groups and deprotected at a later stage when the displacement reactions decribed in Scheme 9 can be performed. In addition, these OH groups can also undergo displacement reactions with heterocycles as described for Schemes 19-22 to introduce N- or C-substituted heterocycles at this position. Ester 80 can be converted into its Weinreb amide 82 (S. Nahm and S. M. Weinreb, Tet. Lett., 1981, 22, 3815-3818) or Weinreb amide 82 can be synthesized via Michael-type addition of 1 to alpha, beta-unsaturated Weinreb amide 83. Subsequent reaction with a Grignard reagent forms ketone 85. This ketone can also be synthesized in one step directly from 1 and alpha,beta-unsaturated ketone 84 using the same procedure. This ketone may be reduced with LAH, NaBH4 or other reducing agents to form alcohol 86. Or else, ketone 85 can be reacted with an organolithium or Grignard reagents to form tertiary alcohol 87 . Or else, ester 80 can be directly reduced with LiBH4 or LAH to yield primary alcohol 88.

R7 Rs H ~ 10 R l.BuLi + 8 _ O ~ 'OMe R ~ ~ Rg R1o R5 n ~ 2 . R X
7 9 OMe R5 n 8 0 n-0,1 1.
R ~ R1o R7 R~ 10 8 4 OH
V
R8 O R11 or12 ) R' 9 'R10 g 5 'n N(CH3)OMe 2.R X R
l.BuLi g1 2.RgX 83 R~
R~ 8 _ ' ' 11or12 ~/~N(CH3)OMe R
g 10 ~
) R R RllMgBr or R' 9 'R10 R5 'n 82 R12M Br 5 n R~ 8 -P
R11or12Mg.Br ' 'R11 or12 Rg 'R10 ~ 8 H
, R
s 'n R~ R8 H

' ~ 'R11 or12 ' ~R11 Rllor l2MgBr ~ Rg R10 g 10 l ~R
R5 n 5 /n R
1 N-P 86 ~ 87 R
' 12 R
Rg R10 ~ OH -~ NH2 R~ 8 9 0 ~ ~ ~ 'OH
to compounds ~ ~ ~ Rg R10 by methods previoiusly R5 n described 88 Alcohols 86, 87 , and 88 can all be tosylated, mesylated, triflated, or converted to a halogen by methods discussed previously and displaced with an amine nucleophile such as azide, diphenylphosphoryl azide (with or without DEAD and Ph3P), phthalimide, etc. as discussed previously (and which are familiar to one skilled in the art) and after reduction (azide) or deprotection with hydrazine (phthalimide), for example, yield the corresponding amines. These can then be elaborated into the compounds of this invention as discussed previously. Ketone 85 can also be converted into imine 89 which can be reacted with a Grignard reagent or lithium reagent, etc., to form a protected amine 90 which can be deprotected and elaborated into the compounds of this invention as discussed previously.
Some protecting groups include benzyl and substituted benzyl which can be removed by hydrogenation, and cyanoethyl, which can be removed with aqueous base, etc.
It is to be understood that R~-12 in Scheme 10 can be in their final form or in precursor form which can be elaborated into final form by procedures familiar to one skilled in the art.
Magnesium amides of amines have been used to add in a Michael-type manner to alpha, beta-unsaturated esters where the substituents at the beta position of the unsaturated ester are tied together to form a cyclopentane ring (for example, compound 79 where R7 and R8 are taken together to be -(CH2)4-) (Kobayashi, K. et al., Bull Chem Soc Jpn, 1997, 70 (7), 1697-1699). Thus reaction of pyrrolidine or piperidine 1 with cycloalkylidine esters 79 as in Scheme 10 yields esters 80 where R7 and R8 are taken together to form a cycloalkyl ring. Subsequent elaboration yields compounds of this invention where R7 and R8 are taken together to form a cycloalkyl ring.

Compounds of structure 95a may also be synthesized from epoxyalcohols which are shown in Scheme 11. Allylic alcohol 91 can be epoxidized either stereoselectively using VO(acac)2 catalyst (for a review, see Evans: Chem.
Rev. 1993, 93, 1307) or enantioselectively (Sharpless:
J. Am. Chem. Soc. 1987, 109, 5765) to epoxyalcohol 92.
SN2 displacement of the alcohol using zinc azide and triphenylphosphine (Yoshida, A. J. Org. Chem. 57, 1992, 1321-1322) or diphenylphosphoryl azide, DEAD, and triphenylphosphine (Saito, A. et al., Tet. Lett. 1997, 38 (22), 3955-3958) yields azidoalcohol 93.
Hydrogenation over a Pd catalyst yields aminoalcohol 94.
This can be protected in situ or in a subsequent step with BOC20 to put on a BOC protecting group, or with CBZ-Cl and base to put on a CBZ-group or other protecting groups. Alternatively, the amino group can be reacted with an isocyanate, an isothiocyanate, a carbamoyl chloride, or any reagent depicted in Scheme 1 to form 95 which can be alkylated with 1 to form the compounds of this invention.

R~ OH Rg OH

R7 9 R'7 9 R$ 2 Rg N3 R

R.~ R
R8 NH_ P R8 NH- ( C=z ) NR2R3 H
as in Scheme 8 R5 /n n=0,1 - ( C=Z ) NR2R3 n_ 95a Sometimes amine 1 might have to be activated with Lewis acids in order to open the epoxide ring (Fujiwara, 5 M.; Imada, M.; Baba, A.; Matsuda, H.;Tetrahedron Lett 1989, 30, 739; Caron, M.; Sharpless, K. B.; J Org Chem 1985, 50, 1557) or 1 has to be deprotonated and used as a metal amide, for example the lithium amide (Gorzynski-Smith, J.; Synthesis 1984 (8), 629) or MgBr amide (Carte, M. C.; Houmounou, J. P.; Caubere, P.;
Tetrahedron Lett 1985, 26, 3107) or aluminum amide (Overman, L. E.; Flippin, L. A.; Tetrahedron Lett 1981., 22, 195) .
The quaternary salts (where R4 is present as a substituent) of pyrrolidines and piperidines can be synthesized by simply reacting the amine with an alkylating agent, such as methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, ethyl or methyl bromoacetate, bromoacetonitrile, allyl iodide, allylbromide, benzyl bromide, etc. in a suitable solvent such as THF, DMF, DMSO, etc. at room temperature to the reflux temperature of the solvent. Spiroquaternary salts can be synthesized in a similar manner, the only difference being that the alkylating agent is located intramolecularly as shown in Scheme 12. It is understood by one skilled in the art that functional groups might not be in their final form to permit cyclization to the quaternary ammonium salt and might have to be in precursor form or in protected form to be elaborated to their final form at a later stage. For example, the NR1(C=Z)NR2R3 group on the rightmost phenyl ring of compound 104 might exist as a nitro group precursor for ease of manipulation during quaternary salt formation. Subsequent reduction and NR1(C=Z)NR2R3 group formation yields product 105. The leaving groups represented by X in Scheme 12 may equal those represented in Scheme 1, but are not limited thereto.
N-oxides of pyrrolidines and piperidines can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514). This simply entails reacting the pyrrolidine or piperidine with MCPBA, for example, in an inert solvent such as methylene chloride.

X4_~ 8 NRl ( C=Z ) NR2R3 x 1 ( C-Z ) NR.2R3 R Rlo X=leaving R5 n group n=0,1 96 97 s R~ 11 R12 X- R~ R8 11 R12 NR.1 ( C=Z ) NR.2R3 NR1 ( C=Z ) NR.2R3 ~R10 ~ ~R10 R5 n R4 _ X R~ Jn R~R9 n=0,1 99 X_ R4/R ~1 ~C=z) ~2R3 1 ~ C=Z ) ~2R3 I + R10 k ~ ~ J R5 n R~ R$ 101 R~ 8 g 10 1 (C=Z) ~2R3 ~1 ~ C-Z ) ~2R3 ~ .0 'a9 a10 =
R5 wn, R4 _ X 7 102 lu.~
~ C=z ) ~2R3 ~1 ~ C=z ) ~2R3 R~~R1 X-' 10 h X04 R~~)n R9 R 105 Multisubstituted pyrrolidines and piperidines may be synthesized by the methods outlined in Scheme 13.
Monoalkylation of 106 via an enolate using LDA or potassium hexamethyldisilazane, or converting 106 first to an enamine, or by using other bases, all of which can be done in THF, ether, dioxane, benzene, or an appropriate non-hydroxylic solvent at -78 oC to room temperature with an alkylating agent such as methyl iodide, benzyl bromide, etc. where X is as defined in Scheme 1, yields product 107. This product can subsequently undergo alkylation again under thermodynamic or kinetic conditions and afterwards, if need be, can undergo two more alkylations to produce tri- and tetrasubstituted analogs of 107. The thermodynamic or kinetic conditions yield regioselectively alkylated products (for a discussion on thermodynamic vs. kinetic alkylations see H. House Modern Synthetic Reactions, W. A. Benjamin, Inc. (Memo Park, CA: 1972) chapter 9).

w ~ R R
Ph 1. Base ph ~Ph n 2. R5-X ~~n n Rsp n=0,1 X = leaving group R5p=precursor to R5 H2 / Pd or Pd(OH)2 R H
to compounds by ~I~
methods previously described R5s n cis and traps CO~Et CO~Et CO~Et BOC20 1 . Base 'R6 2 . R 6X
H BOC BOC
110 111 X=leaving group as 112 defined in 1, [H]
Scheme 1 2.Swern CH~R5* CH ( OH) R5 * R5*MgBr or CHO
'R6 ~ R6 ~ R6 R5*Li Wittig CHI R5* CHI CHAR 5* CH= CHR5 R6 Rg H~ Pd/C R6 H+~ H+
5* 5*
CHI CHAR CH= CHR
R6 'R6 R5*=R5 or a precursor thereof to products by methods previously described Subsequent Wittig olefination yields compound 108.
Hydrogenation (asymmetric hydrogenation is an option here: Parshall, G.W. Homogeneous Catalysis, John Wiley and Sons, New York: 1980, pp. 43-45; Collman, J.P., Hegedus, L.S. Principles and Applications of Organotransition Metal Chemistry, University Science Books, Mill Valley, CA, 1980, pp. 341-348) yields pyrrolidine or piperidine 109 which can be resolved into its relative and/or absolute isomers at this stage or later on in the synthesis either by crystallization, chromatographic techniques, or other methods familiar to one skilled in the art. The amine 109 an then be elaborated into the compounds of this invention by methods discussed previously (Scheme 1). The carbonyl-containing intermediate 107 in Scheme 13 can also be reduced to the methylene analog via a Wolff-Kishner reduction and modifications thereof, or by other methods familiar to one skilled in the art. The carbonyl group can also be reduced to an OH group, which can undergo all of the reactions described in Scheme 9 to synthesize the R6 groups. This piperidine or pyrrolidine can be deprotected and elaborated to the compounds of this invention by methods discussed earlier. Thus, mono-, di-, tri-, or tetraalkylated carbonyl-containing pyrrolidines or piperidines can be synthesized, which in turn can be reduced to the corresponding -CH2- analogs employing the Wolff-Kishner reduction or other methods.
Another method for synthesizing gem-substituted pyrrolidines and piperidines is shown in Scheme 14. It is understood by one skilled in the art that some of the steps in this scheme can be rearranged. It is also understood that gem-disubstitution is only shown at only one position on the piperidine ring and that similar transformations may be performed on other carbon atoms as well, both for piperidine and pyrrolidine. Thus, 3-carboethoxypiperidine 110 may be BOC-protected and alkylated employing a base such as LDA, KHMDS, LHDMS, etc., in THF, ether, dioxane, etc. at -78 °C to room temperature, and an alkylating agent R6X where X is a halide (halide = C1, Br, I), mesylate, tosylate or triflate, to yield 112. Reduction using DIBAL, for example, and if necessary followed by oxidation such as a Swern oxidation (S. L. Huang, K.
Omura, D. Swern J. Org. Chem. 1976, 41, 3329-32) yields aldehyde 113. Wittig olefination (114) followed by deprotection yields 115 which may be elaborated as described previously into the compounds of this invention. Reduction of the Wittig adduct 114 yields 116 which may be deprotected to yield 117 which may be in turn elaborated as described previously into the compounds of this invention. Reaction of aldehyde 113 with an alkyllithium or Grignard reagent yields alcohol 118 which may be reduced catalytically or with Et3SiH/TFA (J. Org. Chem. 1969, 34, 4; J. Org. Chem.
1987, 52, 2226) if R5* (R5* - R5 or a precursor thereof) is aromatic to yield 119. If R5* is not aromatic, then the OH may be reduced by the method of Barton (Barton, D. H. R.; Jaszberenyi, J. C. Tet. Lett. 1989, 30, 2619 and other references therein). Once tosylated, the alcohol can also be displaced with dialkyllithium cuprates (not shown) (Hanessian, S.; Thavonekham, B.;
DeHoff, B.; J Org. Chem. 1989, 54, 5831). Deprotection if necessary yields 120 which may be elaborated as described previously into the compounds of this invention.

R R
n 1. s-BuLi ,n R5orR13 TMEDA
BOC
BOC 2 . R5- or R13 -X 12 2 X=as defined n=0,1 in Scheme 1 1, s-BuLi TMEDA
2. R5- or R13-X
R~ ~ n R
1. s-BuLi R5o rRl3 R5orR13 R5orR13 TMEDA
5~ 5 13 BOC 2 . R - R ~ R o rR
124 or R13-X or R13 BOC

1. s-BuLi TMEDA
2. R5- or R13-X
R
R13r5oR~ R50z'R13 R50rR13/\ ~g,5orR13 BOC

A method for the alkylation of alkyl groups, arylalkyl groups, allylic groups, propargylic groups, 5 etc., and a variety of other electrophiles onto the pyrrolidinyl and/or piperidinyl alpha-carbons (alpha to the ring nitrogen atom) is represented by the work of Peter Beak, et al. as shown in Scheme 15. It is understood by one skilled in the art that the R5 and R13 groups are either in their precursor, protected, or final form. Only one R5 group is shown to be substituted on piperidine/pyrrolidine 121. However it is understood by one skilled in the art that additional functionality may be present on the ring in either precursor, protected, or final form. Thus lithiation with an alkyllithium reagent such as n-BuLi or s-BuLi as shown, followed by quenching with an electrophilic species such as R5X or R13X where X is as defined in Scheme 1 and R5 and R~-3 are in their precursor, protected, or final form, yields monoalkylated piperidine/pyrrolidine 122. This alkylation may occur either stereoselectively (P. Beak and W.K. Lee J. Org.
Chem. 1990, 55, 2578-2580) or enantioselectively if sparteine is included as a source of chirality (P. Beak, et al., J. Am. Chem. Soc. 1994, 116, 3231-3239). The alkylation process may be repeated up to three more times as shown in Scheme 15 to result in di-, tri-, and tetrasubstitution at the alpha-positions.
Compounds where R9 and R1~ form a cyclic 3,4,5,6, or 7-membered ring can be synthesized by the methods disclosed in Scheme 16. These same methods may also be used to synthesize gem-disubstituted compounds in which R9 can be different from R1~ by step-wise alkylation of the malonate derivative. Of course, this scheme may be used to synthesize compounds where R1~=H also. For example, a cyclohexyl-fused malonate may be synthesized by Michael addition and alkylation of I(CH2)4CH=CC02Me with dimethyl malonate employing NaH/DMF (Desmaele, D.;
Louvet, J.-M.; Tet Lett 1994, 35 (16), 2549-2552) or by a double Michael addition (Reddy, D. B., et al., Org.
Prep. Proved. Int. 24 (1992) 1, 21 -26) (Downes, A. M.;
Gill, N. S.; Lions, F.; J Am Chem or by an alkylation followed by a second intromolecular alkylation employing an iodoaldehyde (Suami, T.; Tadano, K.; Kameda, Y.;
Iimura, Y.; Chem Lett 1984, 1919), or by an alkylation followed by a second intramolecular alkylation employing an alkyl dihalide (Kohnz, H.; Dull, B.; Mullen, K.;
Angew Chem 1989, 101 (10), 1375), etc.

diethyl ~ OEt pEt > H OEt malonate H
R5 n n=0,1 t LH~
h h h 1s a h to compounds by methods previously described Subsequent monosaponification (Pallai, P.V., Richman, S., Struthers, R.S., Goodman, M. Int. J.
Peptide Protein Res. 1983, 21, 84-92; M. Goodman Int. J.
Peptide Protein Res. 19831, 17, 72-88), standard coupling with pyrrolidine/ piperidine 1 yields 128.
Reduction with borane yields 129 followed by reduction with LAH yields 130 which can be then converted to amine 131 and then to the compounds of this invention by procedures as discussed previously. Ester 129 can also be converted to a Weinreb amide and elaborated to the compounds of this invention as described in Scheme 10 for ester 80 which would introduce substituents R11 and R12.
Scheme 17 describes another method for the synthesis of compounds where R9 and R1~ are taken together to form cycloalkyl groups. Aminoalcohols 132 are found in the literature (CAS Registry Nos. for n =
0,1,2,3, respectively: 45434-02-4, 2041-56-7, 2239-31-8, 2041-57-8). They can easily be protected, as with a BOC
group (or CBZ, or any other compatible protecting group) by known procedures familiar to one skilled in the art to yield alcohols 133. The alcohols can then be activated either by conversion to a halide or to a mesylate, tosylate or triflate by methods familiar to one skilled in the art and as discussed previously, and then alkylated with pyrrolidine/piperidine _1 by the conditions described in Scheme 1 to yield 135.
Subsequent deprotection yields amine 136 which can be elaborated to the compounds of this invention as described previously. Of course, alcohol 233 can be oxidized to the aldehyde and then reacted with R7°r8MgBr or R7°r8Li with or without CeCl3 to yield the corresponding alcohol 133 where instead of -CH20H, we would have -CHR7°r80H. This oxidation-1,2-addition sequence may be repeated to yield a tertiary alcohol.
The alcohol may then be tosylated, mesylated, triflated, or converted to Cl, Br, or T by procedures familiar to one skilled in the art to yield 134 and then displaced with pyrrolidine/piperidine 1 to yield 135. Subsequent deprotection yields 136 which may undergo elaboration to the compounds of this invention as discussed previously.

(CH2)n (CH2)n (CH2)n H N-C H ~ BOC -NH-C H2 ~ BOC -NH-C H2 BOC~O
OH OH X
n=0,1,2,3 133 H 134 R5 n n=0, 1 ~rr , - BOC
n_ CH+l a to compounds by previously described A method to introduce cycloalkyl groups at R11R12 is shown in Scheme 18. Protection of the nitrogen of compounds 137 which are commercially available yields 138 (the protecting group may be BOC, CBZ, or any other compatible protecting group) by procedures familiar to one skilled in the art. Esterification by any one of a number procedures familiar to one skilled in the art (for example A. Hassner and V. Alexanian, Tet. Lett, 1978, 46, 4475-8) followed by reduction with DIBAL (or alternatively reduction to the alcohol with, for example, LiBH4, followed by Swern oxidation (op. cit.)) yields aldehyde 139. One carbon homologation via the Wittig reaction followed by hydrolysis of the vinyl ether yields aldehyde 141. Reductive amination (Abdel-Magid, A. F., et al. Tet. Lett. 1990, 31, (39) 5595-5598) yields 142 followed by deprotection yields amine 143 which can be elaborated to the compounds of this invention by the methods previously discussed. Of course, aldehyde 139 can be reacted with R9orloMggr or R9or10L1 with or without CeCl3 to yield an alcohol which can be oxidized to a ketone. Wittig one-carbon homologation on this ketone as described above followed by hydrolysis yields 141 where the -CH~CHO is substituted with one R9orlo group (-CHR9orlo CHO) .

(CH~)n BOCZO (CH2)n (CH2)n H2 ~ BOC ~ BOC
2.ROH C02R CHO
COOH DCC
n=0,1,2,3 Dip 138 139 (CH2)n H+ (CH2)n ~-- BOC
B OC CHI CHO CH= CHOMe 1, Na(Ac0)3BH 141 140 Inv_ v -BOC + to compounds ~H ~ -~ by methods described previously R~ R~ 11 Aldehyde 141 (-CH2CH0) or its monosubstituted analog synthesized above (-CHR9°rloCHO) can undergo alkylation with R9or10X where X is as defined in Scheme 1 to yield compound 141 containing one or both of the Rg and RZ~
substituents alpha to the aldehyde group. Alkylation can be performed using LDA or lithium bistrimethylsilyl amide amongst other bases in an inert solvent such as ether, THF, etc., at -78 °C to room temperature.
Aldehyde 141 (-CH~CHO)or its substituted analogs synthesized above (i.e., -CHR9R1~CH0) can undergo reductive amination with 1 and subsequent elaboration to the compounds of this invention. Aldehyde 141 (-CH2CH0)or its substituted analogs synthesized above (i.e., -CHR9R2~CH0) can also undergo 1,2-addition with R7°rgMgBr or R7°r8Li to yield the corresponding alcohol -CH2CHR~°r80H or -CHR9R1~CHR7°r80H. The alcohol may then be tosylated, mesylated, triflated, or converted to Cl, Br, or I by procedures familiar to one skilled in the art and displaced with pyrrolidine/piperidine _1 to yield, after subsequent deprotection and elaboration, the compounds of this invention. Or else alcohol -CH2CHR7°r80H or -CR9R1~CHR7°r80H can be oxidized (i.e., Swern, op. cit.) to the ketone and reductively aminated with 1 and subsequently elaborated to the compounds of this invention. Or else alcohol -CH2CHR~°r80H or -CR9R1~CHR7°r80H can be oxidized (i.e., Swern, op. cit.) to the ketone and reacted once more with R~°r8MgBr or R7°r8Li to yield the corresponding alcohol -CH2CR7R80H or -CR9R1~CR7RgOH. If the ketone enolizes easily, CeCl3 may be used together with the Grignard or lithium reagent.
The alcohol can again be tosylated, mesylated, triflated, or converted to C1, Br, or I by procedures familiar to one skilled in the art and displaced with pyrrolidine/ piperidine 1 to yield, after subsequent deprotection and elaboration, the compounds of this invention. Thus each one of the R7, R8, R9, and R10 groups may be introduced into compounds 141, 142 and 143 and and, of course, in the compounds of this invention, by the methods discussed above.
A method for the synthesis of N-substituted heterocycles at R5 is shown in Scheme 19. The heterocycle can be deprotonated with NaH or by other bases familiar to one skilled in the art, in a solvent such as DMF, THF, or another appropriate non-hydroxylic solvent and reacted with piperidine or pyrrolidine 143 at room temperature to the reflux temperature of the solvent. Deprotection and elaboration as described before yields compounds where R5 contains an N-substituted heterocycle. If the nitrogen atom of the heterocycle is sufficiently nucleophilic, then an acid scavenger, such as K2C03, KHC03, Na2C03, NaHC03, amongst others, can be used in place of NaH, employing THF, DMF, or methyl ethyl ketone as solvents. In this case hydroxylic solvents may be used as well, such as methanol, ethanol, etc. from room temperature to the reflux temperature of the solvent. Compound 143 as well as its other positional isomers are available, for example, from commercially available 4-hydroxymethylpiperidine, 2-, 3-, and 4-carboethoxypiperidine, L- or D-proline ethyl ester, or from methyl 1-benzyl-5-oxo-3-pyrrolidinecarboxylate by methods familiar to one skilled in the art and as discussed previously in this application.

heterocycle het~
~BOC
H
n NaH or KaC03 X

n=0,1 deprotect X = leaving group to compounds by methods described previously A method for the synthesis of C-substituted heterocycles at R5 is shown in Scheme 20. Many heterocycles such as the ones shown in Scheme 20, but not limited thereto, can be metallated with strong bases such as LDA, n-BuLi, sec-BuLi, t-BuLi, etc. to yield the corresponding anionic species. These anions may also be generated via halogen-metal exchange employing n-BuLi, or other alkyllithium reagents. These reactions may be performed in THF, ether, dioxane, DME, benzene, etc. at -78 °C to room temperature.

w (-) / \ (_) i R
(-) (_) ~ (-) heterocycle BOC C
." N N N
> ( _ wn ~ (_) X
143 ~ ~ ( ) ~ / ' (') ~N
n=0,1 X = leaving m=1,2 group ' _ described ~ / ( ) in Scheme 1 C02 Li to compounds by methods described (_) ~ (-) previously N
R=suitable protecting (_) (_) group or functional group 1v N
etc.
For reviews of these metallations and halogen-metal exchange reactions see Organometallics in Organic Synthesis, FMC Corp., Lithium Division, 1993, pp. 17-39;
Lithium Link, FMC Corp., Spring 1993, pp. 2-17; n-Butyllithium in Organic Synthesis, Lithium Corp. of America, 1982, pp. 8-16; G. Heinisch, T. Langer, P.
Lukavsky, J. Het. Chem. 1997, 34, 17-19. The anions can then be quenched with electrophile 143 or its positional isomers to yield the corresponding C-alkylated heterocyclic pyrrolidine or piperidine 145.

(_) i R ~ heterocycle Boc ~ ~(-) ~ (-) ~ (-) C C
N N N
\ () \
H _ 146 ~ ~( ) / ' ( ) NON
n=0 , 1 \ ~ \ \ fH~
(-) ~ / /
CO2Li COZLi ) etc. heterocycle R=suitable protecting group or functional group to compounds by methods described ~ ~.
previously Another method for the synthesis of C-substituted heterocyclic-methylpyrrolidines or piperidines is shown in Scheme 21. The protected aldehyde 146 is reacted with the anion of the heterocycle (its generation as described previously) at -78 °C to room temperature with or without CeCl3 in an inert solvent such as THF, ether, dioxane, DME, benzene, etc. to yield carbinol 147.
Catalytic hydrogenation of the alcohol yields the corresponding methylene compound 145. Other reduction methods include Et3SiHlTFA (J. Org. chem. 1969, 34, 4;
J. Org. Chem. 1987, 52, 2226) amongst others familiar to one skilled in the art. It is understood by one skilled in the art that the aldehyde group can be located in other positions instead of, for example, the 4-position of piperidine in compound 146 as depicted in Scheme 21. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 20 and 21.
The anions of the methyl-substituted heterocycles may also be reacted with a BOC-protected piperidone or pyrrolidone (148) to yield alcohols 149 as shown in Scheme 22 (see above reviews on metallations for references). These alcohols may be reduced using Pt02 and TFA (P. E. Peterson and C. Casey, J. Org. Chem.
1964, 29, 2325-9) to yield piperidines and pyrrolidines 150. These can subsequently be taken on to the compounds of this invention as described previously. It is understood by one skilled in the art that the carbonyl group can be located in other positions instead of, for example, the 4-position of piperidine in compound 148 as depicted in Scheme 22. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 22.

het ~BOC ~ , (-) ~ ~-- (-) C
a N
'n (-) C
148 N (-) n=0 , 1 N
etc. TFA, Et3SiH
R=suitable protecting group or functional heterocycle group ~r to compounds of by methods described previously 150 n One may also react aryl (phenyl, naphthyl, etc.) anions, generated either by halogen-metal exchange or by ortho-directed metallation (Snieckus, V. chem. Rev.
1990, 90, 879-933) using n- or s- or t-BuLi in a non-hydroxylic solvent such as THF, ether, etc., with or without TMEDA and allow them to react with compounds 143, 146, and 148 with subsequent elaboration to yield the compounds of this invention by the methods depicted in Schemes 19-22.
Another method for the preparation of C-substituted heterocycles is shown in Scheme 23. Protected piperidone 148 undergoes a Wittig reaction with heterocyclic phosphorous ylides to yield 151.
Hydrogenation over a noble metal catalyst such as Pd in an alcoholic solvent or with an optically active transition metal catalyst (see asymmetric hydrogenation references of Parshall and Coleman, op. cit.) yields 152 which can be further elaborated into the compounds of this invention by the procedures described previously.
It will be appreciated by one skilled in the art that the carbonyl group can be located in other positions instead of, for example, the 4-position of piperidine in compound 148 as depicted in Scheme 23. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 23.
Scheme 23 Ph3 het ~ocycle C , Ph3C
N
n C
148 N PPh3 ~ ~ 151 n n=0, 1 N PPh3 etc.
R=suitable protecting group or functional group net to compounds by methods described previously Syntheses of amines 9, 10, and the amines which are precursors to isocyanates or isothiocyanates 5 will now be discussed. For example, 3-nitrobenzeneboronic acid (153: Scheme 24) is commerically available and can undergo Suzuki couplings (Suzuki, A. Pure Appl. Chem.
1991, 63, 419) with a wide variety of substituted indo-or bromo aryls (aryls such as phenyl, naphthalene, etc.), heterocycles, alkyls, akenyls (Moreno-manas, M., et al., J. Org. Chem., 1995, 60, 2396), or alkynes. It can also undergo coupling with triflates of aryls, heterocycles, etc. (Fu, J.-m, Snieckus, V. Tet. Lett.
1990, 31, 1665-1668). Both of the above reactions can also undergo carbonyl insertion in the presence of an atmosphere of carbon monoxide (Ishiyama, et al., Tet.
Lett. 1993, 34, 7595). These nitro-containing compounds (155 and 157) can then be reduced to the corresponding amines either via catalytic hydrogenation, or via a number of chemical methods such as Zn/CaCl~ (Sawicki, E.
J Org Chem 1956, 21). The carbonyl insertion compounds (158) can also undergo reduction of the carbonyl group to either the CHOH or CH2 linkages by methods already discussed (NaBH4 or Et3SiH, TFA, etc.). These amines can then be converted to isocyanate _5 via the following methods (Nowakowski, J. J Prakt Chem/Chem-Ztg 2996, 338 (7), 667-671; Knoelker, H.-J. et al., Angew Chem 1995, 107 (22), 2746-2749; Nowick, J. S.et al., J Org Chem 1996, 61 (11), 3929-3934; Staab, H. A.; Benz, W.; Angew Chem 1961, 73); to isothiocyanate 5 via the following methods (Strekowski L.et al., J Heterocycl Chem 1996, 33 (6), 1685-1688; Kutschy, Pet al., Synlett 1997, (3), 289-290); to carbamoyl chloride 11 (after 156 or 158 is reductively aminated with an R2 group) (Hintze, F.;
Hoppe, D.; Synthesis (1992) 12, 1216-1218); to thiocarbamoyl chloride 11 (after 156 or 158 is reductively aminated with an R2 group) (Ried, W.;
Hillenbrand, H.; Oertel, G.; Justus Liebigs Ann Chem 1954, 590); or just used as 9, or 10 (after 156 or 158 is reductively aminated with an R2 group), in synthesizing the compounds of this invention by the methods depicted in Scheme 1.

Suzuki-type X-O coupling B (OH) 2 X=Br, I, OTf /
153 . 154 155 Suzuki-type coupling, CO (g) ~H~
~ h.2 NO~
un2 \ \
/ fHl / ~ \
o ~o /

make isocyanate or isothiocyanate 5, or carbamoyl chlorides 11, or used as _9 or _10 to make the compounds of this invention as described for the compounds of Scheme 1 Likewise, protected aminobromobenzenes or triflates or protected aminobromoheterocycles or triflates 159 (Scheme 25) may undergo Suzuki-type couplings with arylboronic acids or heterocyclic boronic acids (160) These same bromides or triflates 159 may also undergo Stifle-type coupling (Echavarren, A. M., Stifle, J.K. J.
Am. Chem. Soc., 1987, 109, 5478-5486) with aryl, vinyl, or heterocyclic stannanes 163. Bromides or triflates 159 may also undergo Negishi-type coupling with other aryl or heterocyclic bromides 164 (Negishi E. Accts.
Chem. Res. 1982, 15, 340; M. Sletzinger, et al., Tet.

Lett. 1985, 26, 2951). Deprotection of the amino group yields an amine with can be coupled to make a urea and other linkers containing Z as described above and for Scheme 1. Amino protecting groups include phthalimide, 2,4-dimethyl pyrrole (S. P. Breukelman, et al. J. Chem.
Soc. Perkin Trans. I, 1984, 2801); N-1,1,4,4-Tetramethyldisilyl-azacyclopentane (STABASE) (S. Djuric, J. Venit, and P. Magnus Tet. Lett 1981, 22, 1787) and others familiar to one skilled in the art.

-P Suzuki-type -p coupling + (HO) 2H~
Br,I,OTf 160 Stille-type 161 coupliing 9 + Bu3 Srr 163 p Negishi-type coupling 159 + Br or make isocyanate or isothiocyanate 5, or carbamoyl chlorides 11, or used as 9 or 10 to make 162 the compounds of this invention as described for the compounds of Scheme 1 Compounds where R7 and R8 are taken together to form =NRBb can be synthesized by the methods in Scheme 15 25a. Reacting 1 with nitrile a with CuCl catalysis forms amidine b where R8b is H (Rousselet, G.;
Capdevielle, P.; Maumy, M.; Tetrahedron Lett. 1993, 34 (40), 6395-6398). Note that the urea portion may be in final form or in precursor form (for example, a protected nitrogen atom; P = protecting group such as STABASE, bis-BOC, etc., as was discussed previously) which may be subsequently elaborated into the compounds of this invention. Compounds b may be also synthesized by reacting iminoyl chloride c with pyrrolidine/piperidine 1 to yield b where R8b is not H
(Povazanec, F., et al., J. J. Heterocycl. Chem., 1992, 29, 6, 1507-1512). Iminoyl chlorides are readily available from the corresponding amide via PC15 or CC14/PPh3 (Duncia, J.V. et al., J. Org. Chem., 1991, 56, 2395-2400). Again, the urea portion may be in final form or in precursor form.
Scheme 25a H R9 R1o R~ NRl (C=Z) NR2R3 or N-P
R5 Jn ~R12 1 N Rs Rll n=0, 1 a (C=Z) ~2R3 R
H R9 R1o + R~ NR1(C=Z)NR2R3 or N-P
R5 Jn C 8 ~Rs2 ~ b 1 R Rll NR8 b n=0,1 c Many amines are commercially available and can be used as 9, 10, or used as precursors to isocyanates or isothiocyanates 5. There are numerous methods for the synthesis of non-commercially available amines familiar to one skilled in the art. For example, aldehydes and ketones may be converted to their O-benzyl oximes and then reduced with LAH to form an amine (Yamazaki, S.;
Ukaji, Y.; Navasaka, K.; Bull Chem Soc Jpn 1986, 59, 525). Ketones and trifluoromethylketones undergo reductive amination in the presence of TiCl4 followed by NaCNBH4 to yield amines (Barney, C.L., Huber, E.W., McCarthy, J.R. Tet. Lett. 1990, 31, 5547-5550).
Aldehydes and ketones undergo reductive amination with Na(Ac0)3BH as mentioned previously to yield amines (Abdel-Magid, A. F., et al. Tet. Lett. 1990, 31, (39) 5595-5598). Amines may also be synthesized from aromatic and heterocyclic OH groups (for example, phenols) via the Smiles rearrangement (Weidner, J.J., Peet, N.P. J. Het. Chem., 1997, 34, 1857-1860). Azide and nitrile displacements of halides, tosylates, mesylates, triflates, etc. followed by LAH or other types or reduction methods yield amines. Sodium diformyl amide (Yinglin, H., Hongwen, H. Synthesis 1989 122), potassium phthalimide, and bis-BOC-amine anion can all displace halides, tosylates, mesylates, etc., followed by standard deprotection methods to yield amines, procedures which are familiar to one skilled in the art. Other methods to synthesize more elaborate amines involve the Pictet-Spengler reaction, imine/immonium ion Diels-Alder reaction (Larsen, S.D.;
Grieco, P.A. J. Am. Chem. Soc. 1985, 107, 1768-69;
Grieco, P.A., et al., J. Org. Chem. 1988, 53, 3658-3662;
Cabral, J. Laszlo, P. Tet. Lett. 1989, 30, 7237-7238;
amide reduction (with LAH or diborane, for example), organometallic addition to imines (Bocoum, A. et al., J.

Chem. Soc. Chem. Comm. 1993, 1542-4) and others all of which are familiar to one skilled in the art.
Compounds containing an alcohol side-chain alpha to the nitrogen of the piperidine/pyrrolidine ring can be synthesized as shown in Scheme 25b. Only the piperidine case is exemplified, and it is to be understood by one skilled in the art that the alpha-substituted pyrrolidines may be synthesized by a similar route. It is also understood that appropriate substituents may be present on the piperidine/pyrrolidine ring. A 4-benzylpiperidine 196 is protected with a BOC group. The BOC-piperidine 197 is then metallated under conditions similar to those Beak, et al. (P. Beak and W.-K. Lee, J. Org. Chem. 1990, 55, 2578-2580, and references therein) and quenched with an aldehyde to yield alcohol 198. The metallation may also be done enantioselectively using sparteine (P.
Beak, S.T. Kerrick, S. Wu, J. Chu J. Am. Chem. Soc.
1994, 116, 3231-3239). This alcohol can be deprotonated with NaH and cyclized to carbamate 198a which permits structural assignments of the erythro and threo isomers.
Deprotection with base yields aminoalcohol 199.
Subsequent N-alkylation yields phthalimidoalkylpiperidine 201. It is to be understood that the alkyl chain does not necessarily have to be n-propyl, but that n-propyl was chosen for demonstration purposes only. Deprotection of the phthalimido group with hydrazine yields amine 202. Finally, reaction with an isocyanate or via any of the previously described conditions described in Scheme 1 yields urea 203. If an isocyanate is used, the isocyanate can add twice to yield urea-carbamate 204.

Scheme 25b O
N'H N~O
v Di-t-butyl dicarbonate THF, o c to 25 c ~ ~ 197 196 p 1) Et2o, TMEDA, -70 °c 2) sec-BuLi, N O ~ -70 °C to -30 °C &
OH Q again to -70 °C

R ~ 'N 3 ) RCHO, 1 9 8 O -70 °C to -30 °c then v-H R quench with water NaOH, EtOH, reflux,3h \ I 195a '~' threo erythro NH
OH H~C03 , HI, 2-butanone N ~N
_ OH
R 1" o o , R
19 9 Br~N ~ ~ \ ~ 2 01 2 0 0 N2H4, EtOH
O
N ~N~NHR3 R 203 N~NH
THF', 25 °C OH 2 O
N ~N~NHR3 / I R
O H
v R ~ NHR3 2 0 2 Compounds where Z = N-CN, CHN02, and C(CN)2 can be synthesized by the methods shown in Scheme 25c. Thus amine 208 reacts with malononitrile 207 neat or in an inert solvent at room temperature to the reflux temperature of the solvent, or at the melting point of the solid/solid mixture, to yield malononitrile 206.
This in. turn can undergo reaction with amine 205 under similar conditions stated just above to yield molononitrile 209. Likewise, a similar reaction sequence may be used to make 212 and 215 [for Z = C(CN) 2], see for example P. Traxler, et al., J. Med. Chem.
(1997), 40, 3601-3616; for Z = N-CN, see K. S. Atwal, J.
Med. Chem. (1998) 41, 271; for Z = CHN02, see J. M.
Hoffman, et al., J. Med. Chem. (1983) 26, 140-144).

Scheme 25c.
+ R2R3NH

NC CN
\S S/
NC CN
NC CN
s_~N/E\~ ( 2 5_~N/E\N NiR
R ~ Rl + \S N R ~ R ~ R1 R2 N02 ~ 3 ~N E\~ ~N/E\N NiR
R5 ~ Rl + ~s I N/R3 -~ R5 ~ R1 Rz N0~
RzR3NH
S S

~.rCN
N
/~ E CN ~ 3 s I N \~ / N~ /Ew ~ /R
R- I + ( 5 ~N N N
Rl ~ ~ /R3 --~ R ~ Rl R2 O N
205 214 R~ 215 /CN ~, + RZR3NH

Compounds where R11 and R12 join to form a cycloalkyl compounds can be synthesized by the methods shown in Scheme 25d. It is to be understood that the cyclopropyl case shown in Scheme 25d has been chosen only to serve as an example and that other protected aminoacids in place of 216 may also be employed. Thus, BOC-1-aminocyclopropane-1-carboxylic acid 216 is coupled to (S)-3-(4-fluorobenzyl)piperidine using a common amide forming reagent such as BOP, HBTU or HATU to furnish the amide tert-1-{[(3S)-3-(4-fluorobenzyl) piperidinyl]carbonyl}cyclopropylcarbamate (217). Then the amide is reduced to the corresponding amine by a reducing agent such as but not limited to BH3 in THF at room temperature, followed by the removal of BOC
protecting group with TFA and neutralization to afford the free amine 218. The free amine is then condensed with an isocyanate or a carbamate to yield the desired urea 219 .
Scheme 25d.

F F
O
BOP, c NHBoc NH + HO
Huenig's Base DMF
1, BH3-THF
2 , TFA, CH2C12 3, NaOH

R3-NCO or H
R3-NHC00-Ph ~N~R3 Acetonitrile EXAMPLES
The compounds of this invention and their preparation can be understood further by the following working examples. These examples are meant to be illustrative of the present invention, and are not to be taken as limiting thereof.

Part A: Preparation of 4-benzyl-1-(3-N-phthalimido-n-prop-1-yl)piperidine P1~N
4-benzylpiperidine (8.0 g , 45.6 mmol, 1eq), N-(3-bromopropyl)-phthalimide (13.5 g, 50.2 mmol, 1.1 eq), potassium iodide (7.6 g, 45.6 mmol, 1 eq) and potassium carbonate (2.6 g, 91.3 mmol, 2 eq) were refluxed in 125 mL of 2-butanone. The reaction was worked up after 5 hours by filtering off the inorganic solids then adding EtOAc and rinsing the organic layer 2X with water. The organic layer was dried over magnesium sulfate then the solvent removed in vacuo to obtain an amber oil. The oil was purified by flash chromatography in 100% EtOAc to remove impurities then 8:2 chloroform/methanol to isolate 3.67 g of the product as a light amber oil.
NMR(300 MHz, CDC13) S 8.00-7.80 (m, 2H); 7.80-7.60 (m, 2H);7.35-7.10 (m, 3H); 7.08 (d, 2H, J=7 Hz); 3.76 (t, 2H, J = 7 Hz); 2.83 (d, 2H, J=10 Hz); 2.45-2.30 (m, 4H);
1.95-1.30 (m, 7H); 1.20-0.90 (m, 2H).
Part B: Preparaton of 4-benzyl-1-(3-amino-n-prop-1-yl)piperidine I~~NH~
/
4-benzyl-1-(3-N-phthalimido-n-prop-1-yl)piperidine (13.72 g, 37.9 mmol, 1 eq.) was dissoved in 200 mL of EtOH at 25 °C under N2, the anhydrous hydrazine (2.38 mL, 75.7 mmol, 2 eq.) was added. The solution was then refluxed during which time a white precipitate formed.

The reaction was worked up after refluxing 4 hours by filtering off the solids. The solvent was removed in vacuo to obtain an oil which was re-rotovapped from toluene to remove excess hydrazine. Obtained an oil which was stirred in Et20. Insoluble material was filtered then the solvent removed in vacuo to obtain 5.558 of an amber oil as product. NMR (300 MHz, CDC13) S 7.40-7.21 (m, 2H); 7.21-7.05 (m, 3H); 2.92 (d, 2H, J=10 Hz); 2.73 (t, 2H, J=7 Hz); 2.53 (d, 2H, J=7 Hz); 2.40-2.20 (m, 2H); 1.84 (t of t, 2H, J=7,7 Hz);
1.75-1.10 (m, 9H).
Part C: N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]-urea \ n H H ~N
4-benzyl-1-(3-amino-n-prop-1-yl)piperidine (300 mg, 1.29 mmol, 1 eq) was dissoved in THF at 25 °C under N2 then 3-cyanophenyl isocyanate (186 mg, 1.29 mmol, 1 eq) was added. TLC after 30 minutes shows the reaction complete. The solvent was removed in vacuo then the residue was purified over silica gel in 100% EtOAc to 8:2 chloroform/MeOHto yield 437 mg of an amber oil as product.
NMR (300 MHz, DMSO-d6) b 9.90-9.50 (m, 1H); 9.32 (s, 1H); 7.93 (s, 1H); 7.59 (d, 1H, J= 7Hz); 7.43 (t, 1H, J=
7Hz); 7.40-7.24 (m, 3H); 7.24-7.10 (m, 3H); 6.68 (t, 1H, J=7 Hz); 3.50-3.25 (m, 2H); 3.25-3.07 (m, 2H); 3.07-2.90 (m, 2H); 2.90-2.60 (m, 2H); 2.60-2.40 (m, 2H); 2.00-1.60 (m, 5H) ; 1. 60-1.30 (m, 2H) .

Part A: Preparation of 4-benzyl-1-carbomethoxymethyl-1-[3-(3-cyanophenylaminocarbonylamino)prop-1-yl]piperidinium bromide 4-benzyl-1-[3-(3-cyanophenylaminocarbonylamino)prop-1-yl]piperidine (50mg, 0.233 mmol, 1 eq), was dissoved in acetone at 25 °C under N2 then methyl bromoacetate (l3uL, 0.133 mmol, 1 eq),was added. After 16 hours, the solvent was removed in vacuo and the residue was purified over silica gel in 100% EtOAc to 8:2 chloroform/MeOH to yield 50 mg of white solids as product. NMR (300MHz, CD3OD) 8 8.00-7.80 (m, 1H) ; 7.65-7.45 (m, 1H); 7.45-7.33 (m, 1H); 7.33-7.05 (m, 6H); 4.50-4.25 (m, 2H); 4.00-3.60 (m, 5H); 3.50-3.20 (m, 6H); 2.70-2.50 (m, 2H); 2.10-1.60 (m, 7H) .

Part A: Preparation of 1-(t-Butoxycarbonyl)-3-piperidone O i. H2, Pd/C, CH30H, 23 °C
~ ~1-' ~ 1 ii. (Boc)20, NaHC03, H THF, 23 °C O
86%
To a deep yellow solution of 1-benzyl-3-piperidone hydrochloride (3.00 g, 1.33 mmol, 1 equiv) in methanol (100 mL) was added 10 wt. o (dry basis) palladium on activated carbon (600 mg) under a stream of nitrogen.
The resulting black suspension was deoxygenated by alternate evacuation and flushing with nitrogen (3x) followed by alternate evacuation and flushing with hydrogen (3x). The reaction suspension was then shaken vigorously under a hydrogen atmosphere of 55 psi. After 12 hours, gravity filtration of the supsension and concentration of the resulting filtrate in vacuo yielded crude 3-piperidone as a viscous light green oil. The oil was immediately treated with tetrahydrofuran (150 mL) and di-t-butyldicarbonate (4.73 g, 21.7 mmol, 0.98 equiv). Upon addition of saturated aqueous sodium bicarbonate (25 mL), the oil completely dissolved to give a light yellow suspension. After stirring the suspension vigorously for 2 hours, the now white suspension was poured into aqueous hydrogen chloride (1N, 100 mL), and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 70 mL), and the combined organic layers were washed with saturated aqueous sodium chloride (50 mL), dried over sodium sulfate, and filtered. Concentration of the resulting filtrate in vacuo yielded 1-(t-butoxycarbonyl)-3-piperidone (3.79 g, 86%) as a white oily solid. 1H NMR (300 MHz, CDC13), 8:3.94 (s, 2H), 3.53 (t, 2H, J = 6 Hz), 2.41 (t, 2H, J = 7 Hz), 1.92 (m, 2H), 1.41 (s, 9H) Part B: Preparation of 1',3-(2H)-Dehydro-3-benzyl-1-(t- butoxycarbonyl)piperidine NaH, Bn(O)P(OEt)2 DME, 23-80 °C
O
23%
To a flame-dried 100-mL flask charged with sodium hydride (60% wt, dispersion in mineral oil; 601 mg, 15.0 mmol, 2.3 equiv)) and 1,2-dimethoxyethane (20 mL) was added benzyl diethylphosphite (3.42 g, 3.13 mL, 15.0 mmol, 2.3 equiv) dropwise over a period of 5 min. After min, 1-(t-butoxycarbonyl)-3-piperidone was added in one portion to the pale yellow suspension. The flask was fitted with a relfux condensor, and the resulting yellow-gray suspension at heated under reflux conditions for 2 hrs. Upon cooling to 23 °C, the reaction was poured into aqueous hydrogen chloride (0.20 N, 100 mL) and diethyl ether (75 mL). The layers were separated 15 and the aqueous layer was basified with saturated aqueous sodium bicarbonate to pH 9. The aqueous layer was extracted with diethyl ether (4 x 75 mL), and the combined organic layers were dried over sodium sulfate.
Filtration, concentration in vacuo, and purification of 20 the resulting residue by flash column chromatography (5%
ethyl acetate in hexanes) afforded a mixture of the desired olefin (410 mg, 23%) and the corresponding ethoxycarbamate (550 mg, 34%) as a clear oil. The ethoxycarbamate was removed in the subsequent step by flash column chromatography. 1H NMR (300 MHz, CDC13), 8: 7.30 (m, 2H), 7.18 (m, 3H), 6.42 (s, 1H), 4.02 (s, 2H), 3.50 (t, 2H, J = 6 Hz), 2.51 (t, 2H, J = 5 Hz), 1.61 (m, 2H), 1.49 (s, 9H). MS (CI), m+/z: (M+H)+ _ 274, [(M+H)+ - (-C(O)OC(CH3)3)] 174.

Part C: Preparation of 1-(t-Butoxycarbonyl)-3-benzylpiperidine H2, Pd/C
CH30H, 23 °C
99%
To a solution of impure product (410 mg, 1.50 mmol) obtained in the previous step in methanol (100 mL) was added 10 wt. % (dry basis) palladium on activated carbon (200 mg) under a stream of nitrogen. The resulting black suspension was deoxygenated by alternate evacuation and flushing with nitrogen (3x) followed by alternate evacuation and flushing with hydrogen (3x).
The reaction suspension was then shaken vigorously under a hydrogen atmosphere of 55 psi. After 12 hours, gravity filtration of the supsension and concentration of the resulting filtrate in vacuo resulted in a pale yellow residue. Purification of this residue by flash column chromatography afforded 1-(t-butoxycarbonyl)-3-benzyl-piperidine (407 mg, 99%) as a clear oil. 1H NMR
(300 MHz, CDC13), 8: 7.23 (m, 2H), 7.14 (m, 3H), 3.86 (m, 2H), 2.75 (br m, 1H), 2.51 (m, 3H), 1.70 (br. m, 2H), 1.64 (br. m, 1H), 1.41 (s, 9H), 1.34 (br. m, 1H), 1.09 (br. m, 1H). MS (CI), m+/z: (M+ + 1) 276, [(M+H)+
- (-C(O)OC(CH3)3)] - 176.
Part D: 3-Benzylpiperidine hydrochloride /
HCl ~ HCl To a solution of 1-(t-butoxycarbonyl)-3-benzylpiperidine (400 mg, 1.45 mmol) in methanol (5 mL) was added hydrogen chloride in dioxane (4M, 15 mL). The resulting yellow solution was stirred for 1 hr, at which time the reaction was concentrated in vacuo to provide 3-benzylpiperidine hydrochloride (308 mg, 100%) as an amorphous solid. 1H NMR (300 MHz, CD30D), $: 7.27 (m, 2H,), 7.19 (m, 3H), 3.29 (br. d, 1H, J = l2Hz), 3.20 (br. d, 1H, J = 12 Hz), 2.87 (br. t, 1H, J = 12 Hz), 2 . 67 (m, 1H) , 2 . 60 (d, 2H, J = 7Hz) , 2 .08 (m, 1H) 1.70-1.87 (m, 3H), 1.26 (m, 1H). MS (CI), m+/z: (M+H)+ _ 176.
Part E: Preparation of N-(3-methoxyphenyl)-N'-[3-[3-[(phenyl)methyl]-1-piperidinyl]propyl]-urea /) H H
/
I

The above compound was prepared by the methods similar to the ones employed in Example 1, part C.
1H NMR (300 MHz, CD30D), $:7.29-7.13 (m, 4H); 7/07 (d, 1H, J=9 Hz); 7.02 (m, 1H); 6.78 (d, 1H, J = 9 Hz);
6.60 (d, 1H, J = 9 Hz); 3.77 (s, 3H); 3.30 (m, 2H);

2.80 (m, 2H); 2.53-2.32 (m, 4H); 1.85-1.55 (m, 7H);
1.44-0.78 (m, 2H). MS (ESI), m+/z: (M+H)+ = 382.

Part A: Preparation of a,a'-Dibromo-3-nitro-o-xylene B
~+
B iw O
3-Nitro-o-xylene (lO.Og, 66.14 mmol, 1.00 eq), N-bromosuccinimide (24.14 g, 135.6 mmol, 2.05 eq), and benzoyl peroxide (0.8 g, 3.30 mmol, 0.5 eq) were refluxed under N2 in 200 ml of carbon tetrachloride.
The reaction was worked up after two days by washing with 3 x 100 ml of water. The organic phase was dried over sodium sulfate, then the solvent was removed in vacuo to obtain an amber oil. The oil was purified by flash chromatography on a 8 cm x 20 cm quartz column, eluting with 7.5% EtOAc/Hexanes to yield 4.46 g of product as a sticky solid. NMR (300 MHz, CDC13) S 7.88 (d, 1H, J=7 Hz) , 7.64 (d, 1H, J=7 Hz) , 7.48 dd, 1H, J=8 Hz), 4.86 (s, 2H), 4.69(s, 2H).
Part B: Preparation of 1,3-Dihydro-4'-[4-fluorophenylmethyl]-4-nitro-spiro[2H-isoindole-2,1'-piperidinium] bromide ~+ O
~~+
Br 4-Fluorobenzylpiperidine (0.94 g, 4.86 mmol, 1.0 eq), a,a'-dibromo-3-nitro-o-xylene (1.50 g, 4.86 mmol, 1.0 eq), and sodium carbonate (2.57 g, 24.3 mmol, 5.0 eq) were combined in 20 ml THF and stirred at 25~ C
under N2, during which time a white solid precipitated from the reaction mixture. The reaction was worked up after 22 hours by filtering the solids and rinsing with THF. The solids were dissolved in methanol and applied to a 3.5 cm x 5 cm quartz column via silica plug. The product was eluted with 20% MeOH/CHC13 to yield 1.04 g of a white foam. NMR (300 MHz, CD30D) 8 8.27 (d, 1H, J=8 Hz), 7.84 -7.80 (m, 1H), 7.75-7.69 (m, 1H), 7.23 (m, 2H), 7.01 (dd, 2H, J=8 Hz, 8 Hz), 5.38-5.37 (m, 2H), 5.09 (s, 1H), 5.04 (s, 1H), 3.80-3.72 (m, 2H), 3.65-3.54 (m, 2H), 2.71-2.68 (m, 2H), 2.05-1.75 (m, 5H).
Part C: Preparation of 4-Amino-1, 3-dihydro-4'-[4-fluorophenylmethyl]-spiro[2H-isoindole-2,1'-piperidinium] bromide ' 1+
V
1,3-Dihydro-4'-[4-fluorophenylmethyl]-4-nitro-spiro[2H-isoindole-2,1'-piperidinium] bromide (1.03 g, 2.46 mmol, 1.0 eq), zinc (5.32 g, 81.5 mmol, 33.0 eq), and calcium chloride (0.18 g, 1.60 mmol, 0.65 eq) were refluxed under N2 in 25 ml of a 78% ethanol/water solution. The reaction was worked up after 5 hours by filtering through Celite~ and rinsing the cake with methanol. The filtrate was concentrated in vacuo to a mixture of water and an amber oil. The mixture was dissolved in 50 ml of 2-propanol, and concentrated in vacuo to remove excess water. The resulting yellow foam was dissolved in methanol and applied to a 3.5 cm x 5 cm quartz column via silica plug. The product was eluted with 20o MeOH/CHC13 to yield 0.81g of a yellow foam.
NMR (300 MHz, DMSO) 8 7.27-7.05 (m, 5H), 6.61-6.53 (m, 2H), 5.43-5.41 (m, 2H), 4.80 (bs, 1H), 4.74 (bs, 2H), 4.63 (bs, 1H), 3.62-3.43 (m, 4H), 2.60 (bd, 2H, J=7 Hz), 1.98-1.59 (m, 5H).
Part D: Preparation of N-[1,3-Dihydro-4'-[4-fluorophenyl-methyl]spiro[2H-isoindole-2,1'-piperdinium-4-yl]-N'-4-fluorophenylurea bromide 4-Amino-1, 3-dihydro-4'-[4-fluorophenylmethyl]-spiro[2H-isoindole-2, 1'-piperidinium] bromide (0.33 g, 0.84 mmol, 1.0 eq), and 4-fluorophenyl isocyanate (0.23 g, 1.69 mmol, 2.0 eq) were combined in 3 ml DMF and stirred at 25~ C under N2 . The reaction was worked up after 22 hours by removing the solvent in vacuo, dissolving the residue in methanol, and applying the mixture to a 3.5 cm x 15 cm quartz column via silica plug. The product was eluted with 10% MeOH/CHC13 to yield 65 mg of a yellow foam. NMR (300 MHz, DMSO) 8 9.18 (s, 1H), 9.00 (s, 1H), 7.49-7.43 (m, 2H), 7.41-7.34 (m, 2H), 7.26-7.21 (m, 2H), 7.17-7.10 (m, 5H), 4.94 (s, 2H), 4.80 (s, 2H), 3.63-3.45 (m, 4H), 2.61 (bd, j=7 Hz), 1.91-1.62 (m, 5H) Part A. Preparation of 4-benzyl-1-(3-hydroxy-3-phenylprop-1-yl)piperidine To a flame-dried 3-neck flask under a N2 atmosphere with a magnetic stirring bar, 4-benzylpiperidine (5.00 mL, 28 mmol, 1 eq), DBU (42 uL, 0.28 mmol, 0.01 eq), and THF (100 mL) were added, mixed, and cooled to -15 °C
using a CClg/C02(s) bath. Acrolein (1.87 mL, 28 mmol, 1 eq) was then syringed in slowly during 10 minutes maintaining the temp. at -15 °C. After 0.5 hours at -15 °C, phenylmagnesium chloride (2.0 M, 14.0 mL, 28 mmol, 1 eq) was syringed in slowly and the contents allowed to slowly warm to room temperature and then stirred for 48 h. The reaction was worked up by adding 0.1 N NaOH and EtOAc (200 mL each). The viscous magnesium salts were suction filtered through fiberglass filter paper. The layers were separated and the aqueous layer was extracted again with ethyl acetate (2 x 200 mL). The organic layers were combined, washed with brine (1 x 200 mL), dried (MgS04) and the solvent removed in vacuo to yield 7.39 g of an amber oil. Flash chromatography in 1000 ethyl actetate yielded 2.48 g of an orange oil.
NMR (CDC13) 8 7.40-7.10 (m, 10H); 4.93 (d of d, 1H, J=3,7 Hz); 3.12-2.96 (m, 2H); 2.68-2.46 (m, 4H); 2.01 (t of d, 1H, J=2, 10 Hz); 1.86-1.26 (m, 8H). ESI MS
detects (M+H)+ = 310.

Part B: Preparation of 4-benzyl-1-(3-azido-3-phenylprop-1-yl)piperidine The product from part A (209 mg, 0.675 mmol, 1 eq), DBU (123 mg, 0.810 mmol, 1.2 eq), diphenylphosphoryl azide (0.175 mL, 0.810 mmol, 1.2 eq), and toluene (1.0 mL) were mixed and stirred overnight at room temperature under a N2 atmosphere. The reaction was then worked up by adding ethyl acetate (50 mL), washing with water (3 x 25 mL), followed by washing with brine (1 x 25 mL), drying (MgS04) and removing the solvent in vacuo to yield 277 mg of an amber oil. Flash chromatography in 1:1 hexane/ethyl acetate yielded 84 mg of product as an 25 oil. NMR (CDC13) 8 7.41-7.09 (m, 10 H); 4.56 (t, 1H, J=7 Hz); 3.83 (m, 2H); 2.52 (d, 2H, J=7 Hz); 2.32 (t, 2H, J=7 Hz); 2.30-1.77 (m, 5H); 2.59 (m, 2H); 1.98 (m, 1H); 1.39-1.26 (m, 4H). IR (neat) 2095 cmw .
Part C: Preparation of 4-benzyl-1-(3-amino-3-phenylprop-1-yl)piperidine The compound from part B (100 mg), 10% Pd on carbon (120 mg), and methanol (100 mL) were carefully combined in a flask under a N2 atmosphere. The contents were then submitted to 1 atm of H~ being delivered via a sparge tube for 0.5 h at room temperature. Filtration of the contents through Celite~ and removal of the solvent in vacuo yielded 70 mg of product. NMR (CDC13) (key peak only) 83.94 (t, 1, J = 7 Hz). NH4-CI MS detects (M+H)+
- 309.
Part D: N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]-1-phenylpropyl]-urea / /
H H ~N
The compound from Part C (57 mg, 0.185 mmol, 1 eq) was mixed and stirred with 3-cyanophenylisocyanate 26.6 mg, 0.185 mmol, 1 eq) in THF (1 mL) overnight at room temperature under a N2 atmosphere. The solvent was removed in vacuo and the residue flash chromatographed on silica gel in 3:1 to 1:1 hexane/ethyl acetate to 100%
ethyl acetate to yield 44.3 mg of a yellow oil. NMR
(CDC13) 87.58 (s, 1H); 7.52 (d, 1H, J = 9 Hz); 7.42 (s, 1H); 7.30-7.17 9m, 8H); 7.12 (m, 3H); 4.82 (m, 1H); 2.97-2.80 (m, 3H); 2.52 (d, 2H, J=7 Hz); 2.35 (m, 2H); 2.05-1.85 (m, 4H); 1.81-1.60 (m, 2H); 1.54 (m, 1H); 1.25 (m, 1H). ESI MS detects (M+H)+ = 453.

Part A: Preparation of 2-benzyloxycarbonylamino-1-phenyl-3-butene.

/
~H ~ w /
To a stirred suspension of methyltriphenylphosphonium bromide (10.72 g, 0.03 moles) in 100 mL of dry tetrahydofuran at -78°C was added dropwise 1.6M n-butyl lithium (17.5 mL, 0.028 moles), and the mixture was stirred for 0.5 hrs at -78 ~ -20°C.
Then was added a solution of N-Cbz-phenylalaninal (5.67 g, 0.02 moles) in 50 mL of dry tetrahydrofuran, and the mixture was stirred for 16 hrs at room temperature.
After addition of saturated NH4C1 (50 mL) the mixture was extracted with EtOAc, and the extract was washed with water and brine. It was dried over Na2S04 and evaporated to give an oily residue. The crude product was purified by column chromatograpy on silica gel with elution by 5:95 EtOAc-hexane to give pure 2-benzyloxycarbonylamino-1-phenyl-3-butene.
Part B: Preparation of 2-benzyloxycarbonylamino-1-phenyl-3,4-epoxy-butane.
i H
W
To a stirred solution of 2-benzyloxycarbonylamino-1-phenyl-3-butene (1.43 g, 5.08 mmoles) in 20 mL of CH2C12 was added 3-chloroperoxybenzoic acid (2.19 g, 60%, 7.62 mmoles) in several portions, and the mixture was stirred at room temperature for 30 hrs. After addition of EtOAc (60 mL), the mixture was washed with saturated NaHC03 and brine, and the organic layer was dried over Na2S04. Evaporation of the solvent afforded an oily residue. The crude product was purified by column chromatography on silica gel with elution by 2:8 EtOAc-hexane to give pure 2-benzyloxycarbonylamino-1-phenyl-3,4-epoxy-butane.
Part C: Preparation of 2-benzyloxycarbonylamino-4-[4-(4-fluorophenyl)methyl-1-piperidinyl]-1-phenyl-butan-3-ol.
/ O
F
H
/ OH
A solution of 4-(4-fluorophenyl)methyl-piperidine (0.515 g, 2.314 mmoles) and 2-benzyloxycarbonylamino-1-phenyl-3,4-epoxy-butane (0.688 g, 2.314 mmoles) in 5 mL
of DMF was stirred for 4 hours at 100°C and cooled to room temperature. After addition of EtOAc (30 mL), the mixture was washed with water (2x) and brine. The oranic solution was dried over Na2S04, and evaporated to give an oily residue. It was then purified by passing through a plug of silica gel with elution by EtOAc to give pure product.
Part D: Preparation of 2-amino-4-[4-(4-fluorophenyl)methyl-1-piperidinyl]-1-phenyl-butan-3-ol.

~2 The above product was dissolved in 10 mL of ethanol, and was added 0.1 g of 10% Pd on carbon. The mixture was stirred under hydrogen (1 atm) for 8 hours, and filtered through Celite. Evaporation of the solvent gave the titled product as solid (0.662 g).
Part E: Preparation of N-(3-cyanophenyl)-N'-[1-benzyl-2-hydroxy-3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]-urea To a solution of 2-amino-4-[4-(4-fluorophenyl)methyl-1-piperidinyl]-1-phenyl-butan-3-of (50 mg, 0.14 mmoles) in 2.5 mL of dry THF was added 3-cyanophenyl isocyanate (20.2 mg, 0.14 mmoles) and the mixture was stirred for 15 minutes at room temperature. Then the solvent was evaporated off to give an oily residue. It was purified by column chromatography on silica gel with elution by EtOAc to give pure titled compound as an amorphous solid.
MS (ES+) for C3pH33FNg02 . 501.

The following examples were prepared by the procedures previously described in Schemes 1-25 , Examples 1-6 and/or by procedures familiar to one skilled in the art.

TABLE 1*
C~~~N~ N-R3 C~~~H ~ R
O C~,~ H
H H 3 ~~ R3 a b ~, H H G H H H
C~~~ N~ N-R3 /"'~N~ N, N I~
G~ ~ R3 /~ ~ R
H H

d a ~'~~~ H IH~T.

O
g G~~ OH H H C~~ OH H H
~~~R3 ~ .~~~R3 Ph O Ph O
h i G~N H N N.R G~,~N OH N N. G~N N N.
3 ~ R3 ~ ~ R3 p O p 0 Ph O
~ k 1 Ex # Core G R3 M+1 7 a Ph 3-C02Et-Ph 410 8 a Ph 3-I-Ph 464 9 a Ph 1-adamantyl 396 10 a Ph 3-OCH3-Ph 368 11 a Ph Ph 338 12 a Ph 4-F-Ph 356 13 a Ph 4-C02Et-Ph 410 14 a Ph 4-CN-Ph 363 b Ph 1-adamantyl 410 16 b Ph 2-F-5-CF3-Ph 438 17 b Ph 2-naphthyl 402 18 b Ph 2-F-5-N02-Ph 415 19 b Ph 4-N(CH3)2-Ph 395 b Ph 2-N02-Ph 397 21 b Ph 2-C2H5-Ph 380 22 b Ph 4-CF4-Ph 420 23 b Ph 3,5-diCF3-Ph 488 24 b Ph 3-C02Et-Ph 424 25 b Ph 3-CN-Ph 377 26 b Ph 4-OBn-Ph 458 27 b Ph 2-Ph-Ph 428 28 b Ph 2-BrPh 431 29 b Ph 4-I-Ph 478 30 b Ph 3-I-Ph 478 31 b Ph 4-OEt-Ph 396 32 b Ph 4-nBu-Ph 408 33 b Ph 4-nBuO-Ph 424 34 b Ph CH(Bn)C02Et 452 35 b Ph CH(iPr)C02Et 404 36 b Ph nC8H17 388 37 b Ph 3-OCH3-Ph 382 38 b Ph Ph 352 39 b Ph 4-C02Et-Ph 424 40 b Ph 4-F-Ph 370 41 b Ph 2-Phenyl-cyclo 392 ropyl 42 b Ph 2-OCH3-Ph 382 43 b Ph 4-OCH3-Ph 382 44 b 4-F-Ph 3-CN-Ph 395 45 b 4-F-Ph 4-F-Ph 388 46 b 4-F-Ph 4-C02Et-Ph 442 47 b 3,4-OCH20-Ph 3-CN-Ph 421 48 b 4-F-Ph 3-OCH3-Ph 400 49 b 3,4-OCH20-Ph 3-C02Et-Ph 468 50 b 3,4-OCH20-Ph 3-OCH3-Ph 426 51 b 4-OCH3-Ph 3-OCH3-Ph 412 52 b 4-OCH3-Ph 4-F-Ph 400 53 b Ph 4-CN-Ph 377 54 b 3,4-OCH20-Ph 4-F-Ph 414 55 b 4-OCH3-Ph 4-CN-Ph 407 56 b 2,4-diF-Ph 4-F-Ph 406 57 b 2,4-diF-Ph 3-OCH3-Ph 418 58 b 2,4-diF-Ph 3-CN-Ph 413 59 b 3-CF3-Ph 4-F-Ph 438 60 b 3-CF3-Ph 3-OCH3-Ph 450 61 b 4-F-Ph CH2Ph 384 62 b 4-F-Ph CH2CH2Ph 398 63 b 4-F-Ph 2-F-Ph 388 64 b 4-F-Ph 3-F-Ph 388 65 b 4-F-Ph cyclohexyl 376 66 b 4-F-Ph iPr 336 67 b 4-F-Ph 2-phenyl-c clopropyl410 68 b 4-CF3-Ph 3-CN-Ph 445 69 b 3-CF3-Ph 3-CN-Ph 445 70 b 4-CH3-Ph 3-OCH3-Ph 396 71 b 4-CH3-Ph 3-CN-Ph 391 72 b 4-C1-Ph 3-CN-Ph 411 73 b 4-CF3-Ph 4-C02Et-Ph 492 74 b 3-OCH3-Ph 3-OCH3-Ph 412 75 b 3-OCH3-Ph 3-CN-Ph 407 76 b 4-C02CH3-Ph 3-OCH3-Ph 440 77 b 4-C02CH3-Ph 3-CN-Ph 435 78 b 4-C02CH3-Ph 4-F-Ph 428 79 b 4-C02CH3-Ph 4-C02CH3-Ph 482 80 b 4-CF3-Ph 4-F-Ph 438 81 b 4-CF3-Ph 3-OCH3-Ph 450 82 b 3-OCH3-Ph 4-F-Ph 400 83 b 3-OCH3-Ph 4-C02Et-Ph 454 84 b 2-F-Ph 3-CN-Ph 395 85 b 3-OCH3-Ph 3-F-Ph 400 86 b 2-F-Ph 3-OCH3-Ph 400 87 b 3-OCH3-Ph 3-C02Et-Ph 454 88 b 2-F-Ph 3-F-Ph 388 89 b 2-F-Ph 4-F-Ph 388 90 b 2-F-Ph 3-C02Et-Ph 442 91 b 3-F-Ph 3-CN-Ph 395 92 b 3,4-diF-Ph 3-CN-Ph 413 93 b 3,4-diF-Ph 3-OCH3-Ph 418 94 b 4-C1-Ph 4-F-Ph 404 95 b 4-Cl-Ph 3-OCH3-Ph 416 96 b 2-F-Ph 4-C02Et-Ph 442 97 b 3-F-Ph 3-OCH3-Ph 400 98 b 3-F-Ph 4-F-Ph 388 99 b 3-F-Ph 4-C02Et-Ph 442 100 b 3,4-diF-Ph 4-F-Ph 406 101 b 3-Cl-Ph 3-CN-Ph 411 102 b 4-F-Ph 3-COCH3-Ph 412 103 b 3,5-diF-Ph 3-CN-Ph 413 104 b 3,5-diF-Ph 3-OCH3-Ph 418 105 b 4-F-Ph 4-COCH3-Ph 412 106 b 1-naphth 1 3-CN-Ph 427 107 b 1-naphth 1 4-F-Ph 420 108 b 1-naphthyl 3-OCH3-Ph 432 109 b 3-CH3-Ph 3-CN-Ph 391 110 b 3-CH3-Ph 4-F-Ph 384 111 b 3-CH3-Ph 3-OCH3-Ph 396 112 b 4-F-Ph 2-iPr-Ph 412 113 b 4-F-Ph 2-CF3-Ph 438 114 b 4-F-Ph 3-C1-Ph 404 115 b 4-F-Ph 3-CF3-Ph 438 116 b 4-F-Ph 4-Ph-Ph 446 117 b 4-F-Ph 2-C1-Ph 404 118 b 4-F-Ph 2,4-diF-Ph 406 119 c Ph 3-C02Et-Ph 424 120 c Ph 3-CN-Ph 377 121 c Ph 4-F-Ph 370 122 c Ph Ph 352 123 c Ph 1-adamantyl 410 124 c Ph 4-C02Et-Ph 424 125 c 4-F-Ph Ph 370 126 c 4-F-Ph 3-CN-Ph 395 127 c 4-F-Ph 1-adamantyl 428 128 c 4-F-Ph 3-OCH3-Ph 400 129 c 4-F-Ph 3-C02Et-Ph 442 130 c 4-F-Ph 4-F-Ph 388 130a c 4-F-Ph 3-COCH3-Ph 412 131 c 2-F-Ph Ph 370 132 c 2-F-Ph 3-CN-Ph 395 133 c 2-F-Ph 3-OCH3-Ph 400 134 c 2-F-Ph 4-F-Ph 388 135 c 3-F-Ph 3-OCH3-Ph 400 136 c 3-F-Ph 3-CN-Ph 395 137 c 2,4-diF-Ph 3-CN-Ph 413 138 c 2,4-diF-Ph 3-OCH3-Ph 418 139 c 2,4-diF-Ph Ph 388 140 c 2,4-diF-Ph 4-F-Ph 406 141 c ~ 2,4-diF-Ph ~ 3-COCH3-Ph ~ 430 ~

142 d Ph 3-CN-Ph 391 143 d Ph 3-CO2Et-Ph 438 144 d Ph 3-I-Ph 492 145 d Ph 4-OCH2Ph-Ph 472 146 d Ph 1-adamantyl 424 147 d Ph 3-OCH3-Ph 396 148 d Ph Ph 366 149 d Ph 4-F-Ph 384 150 d Ph 4-C02Et-Ph 438 151 d Ph ~-CN-Ph 391 152 a 4-F-Ph Ph 356 153 a 4-F-Ph 3-CN-Ph 381 154 a 4-F-Ph 3-OCH3-Ph 386 155 a 4-F-Ph 4-F-Ph 374 156 a 4-F-Ph 3-C02Et-Ph 428 157 a 4-F-Ph 4-C02Et-Ph 428 158 a 4-F-Ph 1-adamantyl 414 159 f 4-F-Ph 3-CN-Ph 411 160 f 4-F-Ph 3-OCH3-Ph 416 161 j Ph Ph 458 162 j Ph 3-CN-Ph 483 163 j Ph 3-OCH3-Ph 488 164 j 4-F-Ph 3-OCH3-Ph 506 165 j 4-F-Ph 4-F-Ph 494 166 j 4-F-Ph 1-adamantyl 534 167 1 Ph 3-OCH3-Ph 458 168 1 Ph 1-adamantyl 486 169 c imidazol-1-yl 3-OCH3-Ph 372 * All stereocenters are (+/-) unless otherwise indicated EXAMPLE 6a N-(1-{2-(3S)-3-(4-fluorobenzyl)piperidinyl)methyl}-cyclopropyl)-N'-[3-(1-methyl-1H-tetraazole-5 yl)phenyl]urea Part A: Preparation of tert-1-{[(3S)-3-(4-fluorobenzyl)piperidinyl]carbonyl}cyclopropylcarbamate HBoc To a ice-water cooled solution of (S)-3-(4-fluorobenzyl)piperidine (100 mg, 0.517 mmol), Boc-1-aminocyclopropane-1-carboxylic acid (109.3 mg, 0.543 mmol) in DMF (2.2 mL) was added HATU reagent (204 mg, 0.543 mmol), followed by addition of Huenig's base (0.142 mL, 0.815 mmol). The resulting mixture was then warmed to room temperature and stirred for 2h. The reaction mixture was diluted in sat. NaHC03 aq.
solution, and extracted with ethyl acetate (25 mL). The organic layer was washed with sat. NaHC03 aq. Solution, and brine. The organic layer was then dried in MgS04, concentrated and used directly in the next step. Mass:
Spec(ES), 377.2 (M+H); 1H NMR (300 MHz, CDC13): 8 7.15-7.10 (m, 2H), 6.98 (t, 2H, J = 8.8 Hz), 4.42-4.36 (m, 1H), 4.26-4.18 (m, 1H), 2.98-2.84 (m, 1H), 2.82 (s, 2H), 2.61-2.48 (m, 3H), 1.82-1.67 (m, 3H), 1.43 (S, 9H), 1.28-1.13 (m, 3H), 0.97 (bs, 1H).
Part B: Preparation of 1-[j(3S)-3-(4-fluorophenyl)methyl]piperidinylmethyl]cyclopropanamine To a solution of of tert-1-{[(3S)-3-(4-fluorobenzyl)piperidinyl]carbonyl}cyclopropylcarbamate (5.2 g, 13.8 mmol) in THF (40 mL) was dropwise added BH3~THF solution (40 mL, 1.0 M). The resulting solution was stirred at room temperature for additional 4.5 h.
The reaction mixture was then concentrated, and directly treated with a 50% solution of TFA in methylene chloride (52 mL) for 1.0 h at RT. The solvent of the reaction mixture was removed. The resulting residue was suspended in water, extracted with diethyl ether (3 x 25 mL). The aq. solution was then neutralized with 1 N
NaOH solution to pH 9-10, and extracted with ether extensively (6 X 25 mL). The combined organic layer was then dried over NaS04 and concentrated to provide 1-[[(3S)-3-(4-fluorophenyl)methyl]piperidinylmethyl]cyclopropanamine.
Mass: Spec(ES), 263.3 (M+H); 1H NMR (300 MHz, CDC13):
(m, 2H), 6.99-6.93 (m, 2H), 2.91-2.2.80 (m, 2H), 2.52-2.46 (m, 2H), 2.29 (d, 1H, J = 12.5 HZ), 2.13 (d, 1H, J
- 12.5 Hz), 1.89-1.63 (m, 8H), 0.96-0.91 (m, 1H); 0.59-0.54 (m, 2H), 0.32-0Ø30 (m, 2H).
The material was found to have a purity of greater than 95% and was used directly in the next step without further purification.
Part C: Preparation of N-(1-~2-(3S)-3-(4-fluorobenzyl)piperidinyl)methyl}cyclopropyl)-N'-[3-(1-methyl-1H-tetraazole-5-yl)phenyl]urea F
/ N N N NN
N~ O I / \
To a solution of 1-[[(3S)-3-(4-fluorophenyl)methyl]piperidinylmethyl]cyclopropanamine (102 mg, 0.3893 mmol) in acetonitrile (1.55 mL) was phenyl 3-(1-methyl-1H-tetraazole-5-yl)phenylcarbamate (126 mg, 0.4285 mmol). The mixture was stirred RT for 4.0 h and the solevent was evaporated off. The residue was directly purified on silica gel with elution with methylene chloride, and 10% methanol ethylacetate in to give a white solid (162mg, 90% yield); Mass: Spec(ES), 464.2 (M+H); 1H NMR (300MHz, CD30D) . 8.03 (d,2H, J
S

- 1.5 Hz), 7.54-7.53 (m, 2H), 7.46-7.44 (m, 1H), 7.21-7.16 (m, 2H), 6.97-6.94 (m, 2H), 4.20 (s, 3H), 3.90-3.82 (m, 1H), 3.76-3.70 (m, 1H), 3.38-3.3.22 (m, 2H), 2.95-2.80 (m, 1H), 2.78-2.60 (m, 3H), 2.18-2.05 (m, 2H), 1.95-1.78 (m, 2H), 1.30-1.20 (m, 1H), 1.15-0.98 (m, 4H).
The following compounds in Table 1a can be made by the procedures described in Example 6a, and by other procedures described in this application andlor by procedures familiar to one skilled in the art.
TABLE 1a F
H H
N N.R3 NO
Ex. # n R3 Mass spec M+1 169a 1 O 424 / I \
169b 1 N~NN 464 N
Me 169c 1 ~ ~ 495 169d 1 OMe 525 ~N w0 pJ
169e 1 OMe 469 \
HN O
169f 1 OMe 455 1698 1 ~S Me 445.1 N /
O Me 169h 2 N-NN 478.3 , \ N
/ Me EXAMPLE 6b N-f3-f (3S)-3-f (4-Fluorophenyl)methyllpiperidinyllpropyll-N'-f4-(1-methyl 1H-tetrazol-5-yl)phenyll-urea Part A. Preparation of N-Methyl-4-nitro-benzamide O.. N+.O-O NCH
4-Nitrobenzoyl chloride (7.00 g, 38 mmol, 1 eq) was dissolved in 50 ml of THF and added to a 2.0 M solution of methylamine in THF (41.5 ml, 83 mmol, 2.2 eq.) at 0°C. Worked up after 3 hours by adding EtOAc and rinsing 3X with 1N NaOH, 1X with brine. The organic layer was dried over MgS04, then stripped to obtain 2.25 g of off-white solids as product. NMR (300 MHz, DMSO-d6) ~ 8.80 (m, 1H), 8.33 (d, 2H, J = 7 Hz), 8.06 (d, 2H, J = 7 Hz). 2.86 (d, 3H, J = 7 Hz).
Part B. Preparation of 1-Methyl-5-(4-nitro-phenyl)-1H-tetrazole O.. N+,O_ \
N ~ N~
N=N
N-Methyl-4-nitro-benzamide (2.25 g, 12.5 mmol, 1 eq.) and PC15 (2.60 g, 12.5 mmol, 1 eq.) were melted together under house vacuum connected to a NaOH trap behind a safety shield. Melting occurred at 100°C. Heated at 130 °C for 1 hour then purified by kugelrohr distillation at 0.1 mmHg at 130°C. CAUTION: THE
EXPLOSIVE PROPERTIES OF THIS COMPOUND ARE UNKNOWN). The iminoyl chloride (12.5 mmol 1 eq.) in DMF 10 m1 was added to NaN3 in 10 ml of DMF at 25°C and stirred overnight. Worked up by adding EtOAc then rinsing 3X
with H20. The organic layer was dried over MgS04, then stripped to obtain yellow solids which were purified over silica gel in 3:1 hexanesJEtOAc to 100% EtOAc.
Obtained 1.21 g of yellow solids as product. NMR (300 MHz, CDC13) 8 8.46 (d, 2H, J = 7Hz), 8.02 (d, 2H, J =
7Hz),4.27 (S, 3H).
Part C. Preparation of 4-(1-Methyl-1H-tetrazol-5-yl)-phenylamine N ~ N~
\ /
N=N
1-Methyl-5-(4-nitro-phenyl)-1H-tetrazole (470 mg), 20%
Pd(OH)~ (94 mg), and 1:1 MeOH/EtOAc (25 ml), were hydrogenated at 50 PSI for 1 hour. The reaction was filtered through fiberglass filter paper under nitrogen.
The filtrate was stripped to yield 383 mg of yellow solids as product. Mass Spec detects 176 (M+H). NMR
(300 MHz, CDC13) 8 7.57 (d, 2H, J = 7Hz), 6.80 (d, 2H, J
- 7Hz), 4.14 (s, 3H), 4.03 (M, 2H).
Part D. Preparation of [4-(1-Methyl-1H-tetrazol-5-yl)-phenyl]-carbamic acid phenyl ester /
H~N~O \
N ~ N~
\ /
N=N
4-(1-Methyl-1H-tetrazol-5-yl)-phenylamine (190 mg, 1.08 mmol, 1 eq.), triethylamine (0.14 ml, 1.08 mmol, 1 eq.), in 10 ml of THF under nitrogen were cooled to 0°C. A 5 ml solution of phenyl chloroformate (0.14 ml, 1.08 mmol, 1 eq.), was added dropwise via an addition funnel.
Worked up after 16 hours by adding EtOAc then rinsing 3X
with H20. The organic layer was dried over MgSO4, then stripped to obtain yellow solids which were purified over silica gel in 3:1 hexanes/EtOAc to 100% EtOAc.
Obtained 93 mg of white solids as product. Mass Spec, 296 (M+H). NMR (300 MHz, DMSO-dg ) 8 10.65 (s, 2H), 7.86 (d, 2H, J = 7Hz), 7.76 (d, 2H, J = 7Hz), 7.44 (t, 2H, J = 7Hz), 7.28 (t, 2H, J = 7Hz), 4.18 s, 3H).
Part E. Preparation of N-[3-[(3S)-3-[(4-fluorophenyl)methyl]piperidinyl]propyl]-N'-[4-(1-methyl-1H-tetrazol-5-yl)phenyl]-urea N-N
*HC1 O / ANN
N~N~N
H H
F

To a stirring solution of 25 mg 3-[(3S)-3-[(4-fluorophenyl)methyl]piperidinyl]propylamine (0.1 mmol, 1 eq) in 1 ml of dry acetonitrile was added 32.5 mg [4-(1-methyl-1H-tetrazol-5-yl)-phenyl]-carbamic acid phenyl ester (0.1 mmol, 1.1 eq). This mixture was stirred at room temperature for two hours, then concentrated in-vacuo to a pale yellow oil. This oil was purified via radial chromatography, eluting with a 19:1 mixture of methylene chloride and methanol, to yield a white solid.
This solid was dissolved in methylene chloride and treated with 1 M hydrochloric acid in diethyl ether (0.1 ml, 1 eq). This mixture was stirred for 30 minutes, then concentrated in-vacuo to a white solid. This solid was dissolved in a 1:1 mixture of acetonitrile and water, and lyophilized to 26 mg of a white solid as product. NMR (300 MHz, CD30D) 8 7.72 (d, 2H, J = 9 Hz), 7.64 (d, 2H, J = 9Hz), 7.21-7.16 (m, 2H), 7.01 (dd, 2 H, J = 8, 17 Hz), 4.17 (s, 3H), 3.59-3.54 (m, 1H), 3.40-3.11 (m, 4H), 2.89-2.81 (m, 1H), 2.73-2.59 (m, 3H), 2.10-1.70 (m, 7H), 1.43-1.34 (m, 1H). MS (ESI~-) 452 (M
- Cl) .
The following examples were prepared by the procedures previously described in Schemes 1-25, Examples 1-6 and/or by procedures familiar to one skilled in the art.
TABLE 2**
R5 a R5b R5C i1 i2 I ~ N~ I~~~~ Z
R4 !O
X -m Ex Y Z R4 X R5a R5b R5c R1 R2 #

170 H H - - H H H H Ph 172 H 3-OCH3 CH2Ph Br H H H H H

173 H 3-CN - - C02Et H H H H

176 H 3-CN CH2Ph Br H H H H H

177 H 3-CN - - H H H CH2Ph H

178 H 3-CN - - H H H Et H

180 H 4-F CH2Ph Br H H H H H

181 H 4-F CH2C02CH3 Br H H H H H

182 H 3-CN CH2CN Br H H H H H

183 H 3-CN CH2COPh Br H H H H H

189 H 3-OCH3 - - CH2Ph 191 F 3-COCH3 - - H CH2Ph H H H

192 F 4-F-Ph - - H CH2Ph H H H

3 Ph 194 H 3-OCH3 - - H H H CH2Ph H

195 H 3-CN - - H H H CH2Ph H
~ ~

**All compounds are amorphous unless otherwise indicted.
TABLE 3**
X- ~F~ z y + X- ~H~ Z
Y ~ N O 1~~~ N ~ ~ ~l0 n o Ex # Core Y Z X

196 n H 3-CN Br 197 n H 3-CN Br 198 n H 4-F Br 199 n H 4-F Br 200 n F 3-CN Br 201 n F 3-CN Br 202 n F 3-OCH3 Br 203 n F 3-OCH3 Br 204 o F 4-F Br 205 o F 4-F Br 206 o F 3-OCH3 Br 207 o F 3-OCH3 Br 208 0 F 3-CN Br 209 0 ~ F 3-CN Br Call~ compounds are amorphous unless otherwise indicted.

The compounds of the present invention in which E
contains ring A can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
As shown in Scheme 26, 4-benzyl piperidine is N-alkylated with an alkylating agent, such as 165 (2-nitro-benzyl bromide (X = Br, R14 = H), Scheme 26) to give the N-benzyl compound 166. The nitro group of 166 is then reduced using catalytic hydrogenation to give the corresponding aniline 167. The aniline can be converted to the carbamate 168 using chloro-phenyl formate. The carbamate 168 can then be reacted with various amines to give the urea 169. Alternatively, the aniline 167 can be reacted with the appropriate isocyanates to give the urea 169 directly. The saturated ring analogs can also be used. For example, 4-benzyl piperidine can be alkylated with the urea mesylate 185 (Scheme 30) to give corresponding cyclohexyl derivative 186.
As shown in Scheme 27, 4-benzyl piperidine can also be N-alkylated with the phenacyl bromide 170 to give the nitro ketone 171. The nitro group of 171 is then reduced using catalytic hydrogenation to give the corresponding aniline 172. The aniline 172 can be reacted with the appropriate isocyanates to give the ketone urea 173. The ketone of 173 can be reduced with NaBH4 to give the alcohol 174.
Alternatively, the epoxide 175 (R14 = H) can be opened with the 4-benzyl piperidine to give the corresponding nitro benzyl alcohol which is hydrogenated to give the aniline alcohol 176. The aniline 176 may be treated with various isocyanates to give the urea alcohols 174.
The 4-benzyl piperidine can also be N-alkylated with 3-cyanobenzyl bromide (177, Scheme 28) to.give the cyano analog 178. The cyano group is reduced using Raney nickel to give the corresponding benzyl amine 179.
Treatment of 179 with isocyanates gives the urea 180.
As shown in Scheme 29, treatment of 3-cyano aniline with phenylisocyanate gives the urea 182. The cyano group of 182 is converted to the imidate 183 by HCl/ethanol. Reaction with 4-benzyl piperidine in ethanol then gives the amidine 184.
The saturated ring analogs can also be synthesized using analogous procedures as outlined in Schemes 30 and 31. For example, 4-benzyl piperidine can be alkylated with the urea mesylate 185 (Scheme 29) to give corresponding cyclohexyl derivative 186. Alternatively, starting with the enantiomerically pure amino alcohol 187 [J. Am. Chem. Soc. 1996, 128, 5502-5503 and references therein] one can protect the nitrogen to give the N-Cbz alcohol 188. Swern oxidation of the alcohol gives the aldehyde 189. Reductive amination with piperidine analogs gives the cyclohexyl methyl-1-piperidinyl analogue 190. The Cbz group is removed by catalytic hydrogenation to give the free amine 191, which is treated with a phenylisocyanate to give the desired urea analogue 192. Several examples using these synthetic methods are listed in Table 3a and Table 3.1.

o~
X ~~ _ 14 ~ \ ~ N
R \
i / -!- N A 14 _I
N4z ~ R ' /
165 NOz X = Cl, Br, MsO, etc. 166 B

C N
R14 i / H
O ~ N z N

N~ N~ R
O

A: DMF/KzC03/RT or THF/RT. B:lO~Pd/C, Hz 50 psi.
C: THF/Et3N/chlorophenylformate. D:NHR/DMF/50;C.
E: R-N=C=O/THF

O _ p I\
U
R14 ~ \ \ 14 I \ N /
' / + R ' /~
N02 N~ ~ V \N02 171 B
O
N ~ / O \
R14 I \ \ N
/ N N. C R14 ~ v R ~ 1 / NH2 172 D
D
OH I ~ OH
\ N / \ N
R14 ~ R14 ~ _ / N~N.R ~ ~ / NH2 176 p ~ A,B
174 p R14 ~ \ V + N
/

A: DMF/K2C03/RT or DMF/50;C.
B:10%Pd/C, H~ 50 psi. C:
R-N=C=0/THF. D:NaBH4/MeOH/RT

/ \
Br \ / A w N'_ \ / +N

CN CN
177 / ~, B
\
N ~ / \
I ',~c N
i w O ~ I~
N~ 179 A: DMF/IC2C03/RT B:Raney nickel, HZ 50 psi. C: R-N=C=O/THF.

NH NH
~ CN A' ~ ~ CN B' ~ ~ OEt C ~ ~ ~ ~ \
/ / / /
NHS
O / O / O /

A: R-N=C=O/THF. B:EtOH/HCl/RT
C: 4-benzylpiperidine/EtOH/RT

OH OMs A,B
C
' ~~' OMe ~NH2 O /

A: R-N=C=O/DMF. B:Ms-C1/THF
C:4-benzylpiperidine/DMF/RT

OH
OH
_~ b ~'NH2 ~~'NH-CBZ

F F
O
H N
N
d ~~NH-CBZ
~~~~H-CBZ

F
N N
a .~~'NH2 ~ ~''~N~N \ OMe a:Benzyl chloroformate/Na2C03/CH2C1~. b.Swern Oac. c:NaBH(OAc)3 d:H2/10a Pd/C e:R-N=C=O/THF.

SCE 31a OH
OH
b ;~N~ ~
I~~NI~ CBZ

F ,~ ~ ~ F
O
N, ) N
d ,~~NI~CBZ
a ~~~'I~CBZ

19~i ~ F . / ~ F
N~ N
a O
w ~.''~N~ ' .,~~N N

aBenzyl chlomforn~abe/Na2C03/CI~Ch. b.Swern Ox.
c:NaBH(OAc)3 d:HzJlO% Pd/C e:R-N--C=O/THF
The following examples were synthesized using the methods outlined in Schemes 26-31a. These examples are meant to be illustrative of the present invention, and are not to be limiting thereof.

N-[1-(ph~nylmethyl)4-piperidinyl]-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]-methyl]phenyl]-urea.
A solution of 4-benzylpiperidine (1.75 g, 10 mmol) in 25 mL of DMF was treated with 2-nitrobenzyl bromide (2.16 g, 10 mmol) and KZC03 (1.38 g, 10 mmol) and the reaction mixture stirred at room temperature for 2 h.
The mixture was diluted with water and extracted into ethyl acetate. The organic extracts were washed successively with water and brine, and the organic solvent removed under vacuum on a rotary evaporator to give 166 (Scheme 26, R14 = H) as a yellow oil.
The oil was re-dissolved in ethyl acetate (50 ml) and treated with 10% Pd/C and hydrogenated at 50 psi hydrogen at room temperature for 40 min. The solution was then filtered and the solvent removed under vacuum to give the aniline 167 as a white solid. The aniline was purified by chromatography (MPLC, 40% ethyl acetate/
hexane; silica gel) to give 2.0 g of aniline 167 as a white solid.
A solution of aniline 167 (1.2 g, 4.3 mmol) in THF
was treated with Et3N (1.0 g, 10 mmol) and cooled in an ice bath to °0 C. Chlorophenyl formate (0.71 g, 4.5 mmol) was added to the mixture and stirred for 1 h. The mixture was diluted with water and extracted into ethyl acetate. The extracts were washed with water and brine, and the solvent removed under vacuum to give the phenyl carbamate 168 as an off-white solid. The crude product was used without further purification.
A solution of phenylcarbamate 168 (0.2 g, 0.5 mmol) in DMF is treated with 4-amino-1-benzylpiperidine (95 mg, 0.5 mmol) and K2C03 (138 mg, 1 mmol) and the mixture was heated at 50 °C for 2 h. The mixture was diluted with water and extracted into ethyl acetate. The extracts were washed with water and brine, and the solvent removed under vacuum. The residue was purified by chromatography (MPLC, 0-25 % MeOH/ethyl acetate;
silica gel) to give 200 mg of the target compound as a white solid. esi ms: (M+H)+ - 497.

N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]-methyl]phenyl]-urea.
A solution of aniline 167 (Scheme 26; (R14 = H)) (140 mg, 0.5 mmol) in THF is treated with 2,5-difluoro-isocyanate (80 mg, 0.5 mmol) at room temperature for 1 h. The solvent is removed under vacuum and the residue was purified by chromatography (MPLC, 20o EtOAc/Hexane, silica gel) to give the desired urea as a white solid.
esi ms: (M+H)* - 436.

N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]methyl]-urea.
A solution of 4-benzylpiperidine (1.75 g, 10 mmol) in 25 mL of DMF was treated with 3-cyanobenzyl bromide 177 (1.96 g, 10 mmol) and K~C03 (2.76 g, 20 mmol) and the reaction mixture stirred at room temperature for 2 h. The mixture was diluted with water and extracted into ethyl acetate. The organic extracts were washed successively with water and brine, and the organic solvent removed under vacuum on a rotary evaporator to give 178 (Scheme 28) as a yellow oil.
To a suspension of Raney nickel (2.0 g) in EtOH
(saturated with NH3tgas)) was added crude 178 (Scheme 28) (1.45 g, 5 mmol) and hydrogenated at 50 psi for 3 days.
The solution was then filtered and the solvent removed under vacuum to give the amine 179 as a yellow oil. A
solution of amine 179 (200 mg, 0.68 mmol) in THF is treated with 2,5-difluoroisocyanate (115 mg, 0.74 mmol) at room temperature for 1 hour. The solvent is removed under vacuum and the residue is washed with 1 NaOH and water to give the desired urea as a white solid. esi ms:
(M+H)+ - 450.

N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1-piperidinyl]acetyl]phenyl]-urea To an ice cold solution of 2-bromo-2'-nitro-acetophenone 170 (2.4 g, 10 mmol) in DMF is added 4-benzylpiperidine (1.75 g, 10 mmol) and stirred for 30 min. The solution was poured into a mixture of KZC03 (1.38 g, 10 mmol) in water/ice and extracted into ethyl acetate. The ethyl acetate extract was washed several times with water. The resultant ethyl acetate solution of crude nitroketone 171 is treated with 10o Pd/C and hydrogenated at 50 psi hydrogen at room temperature for 40 min. The solution was then filter, the solvent removed under vacuum, and the residue purified by chromatography (MPLC, 30% ethyl acetate/hexane; silica gel) to give 1.8 g of aniline 172 as a tan/brown solid.
A solution of aniline 172 (Scheme 27) (310 mg, 1.0 mmol) in THF is treated with 2,5-difluoroisocyanate (160 mg, 1.0 mmol) at room temperature for 1 h. The solvent is removed under vacuum and the residue is purified by chromatography (MPLC, 20% EtOAc/Hexane, silica gel) to give 420 mg of the desired urea-ketone 173 as a white solid. esi ms: (M+H)+ - 464.

N- (2, 5-difluorophenyl) -N'- [2- [2- [4- (phenylmethyl) -1-piperidinyl]-1-hydroxyethyl]phenyl]-urea A solution of the urea-ketone 173 (260 mg, 0.56 mmol) in MeOH is treated with NaBH4 (400 mg, 11 mmol) at room temp for 1 hour. The solvent is removed under vacuum and the residue is treated with 1 N NaOH and extracted into EtOAc. The extracts are washed with water, brine and the solvent removed under vacuum to give the desired alcohol 174 as a white solid. esi ms:
(M+H)+ - 466.

N-[3-[imino-[4-(phenylmethyl)-1-piperidinyl]methyl]
phenyl]-N'-phenylurea A solution of 3-cyanoaniline (3.54 g, 30 mmol) in THF is treated with phenylisocyanate (3.58 g, 30 mmol) at room temperature for 1 h. The solvent is removed under vacuum and the residue is titurated with hexane to give 7 grams of urea 182 (Scheme 29) as a white solid.
Urea 182 (1.0 g, 4.2 mmol) is dissolved in EtOH, cooled in an ice bath while HC1 is bubbled-in for 20 min. The solution is left standing at room temperature for 24 h.
The solvent is removed under vacuum to give 1.1 g of the imidate 183 as a white solid. The crude imidate (0.5 g, 1.8 mmol) was dissolved in EtOH and treated with 4-benzyl-piperidine (1.8 g, 10 mmol) at room temperature for 2 days. The solvent was removed under vacuum and the residue was purified by chromatography (MPLC, 0 to 300 MeOH/EtOAc, silica gel) to give 200 mg of the desired amidine 184 (Scheme 29) as a white solid. esi ms: (M+H)+
- 413 .

N-(3-methoxyphenyl)-N'-[(1R,2S)-2-[[(4 phenylmethyl) piperidinyl]methyl]cyclohexyl]-urea.
Step a: To a solution of (R, R) amino alcohol 187 [J. .Am.
Chem. Soc. 1996, 118, 5502-5503 and references therein]
(1.9 g, 14.7 mmol) in CH~Cl~ (50 mL) is added 50 ml of an aqueous solution of Na2C03 (2.4 g, 28.9 mmol). While stirring, benzyl chloroformate (2.51 g, 14.7 mmol) is added and the mixture is stirred at room temperature for 1 h. The organic layer is separated and washed with water and brine. The solution is concentrated on a rotary evaporator and the residue is chromatographed on silica gel (30% ethyl acetate/hexane) to give 3.1 g (12 mmol) of 188 as a white solid. 1H NMR (300 MHz, CDC13) S
7.40-7.29 (m, 5 H), 5.11 (s, 2 H), 4.71 (bd, 1 H), 3.76-3.71 (m, 1 H), 3.53-3.28 (m, 3 H), 2.00-1.95 (m, 1 H), 1.90-1.09 (m, 8 H). MS AP+ (M+H)+ - 264.3 (100 %) Step b: A solution of DMSO (2.52 g, 30 mmol) in CH~C1~ (50 mL) is cooled to -78°C. To this solution is added drop-wise oxalyl chloride (1.81 g, 14 mmol) and the resulting solution is stirred for an additional 10 min. Then a solution of alcohol 188 (2.5 g, 9.5 mmol) in CH2C1~ (70 ml) is added via an addition funnel and stirred for 10 min. Then Et3N (5.0 g, 50 mmol) is added and the solution is allowed to warm to room temperature.
The solution is diluted with water and the organic layer washed with water, 1 N HCl, and brine. The organic layer is dried over Na2S04, filtered, and concentrated to give 2.5 g (9.5 mmol) of the aldehyde 189 as a white solid.
1H NMR (300 MHz, CDC13) 8 9.59 (d, 3.6 Hz, 1 H), 7.38-7.28 (m, 5 H), 5.07 (m, 2 H), 4.69 (m, 1 H), 3.84 (m, 21 H), 2.19-2.11 (m,1 H), 2.09-2.01 ( m, 1 H), 1.86-1.75 (m, 3 H), 1.54-1.17 (m, 4 H).
Step c: A solution of aldehyde 189 (2.0 g, 7.7 mmol), 4-(4-fluorophenylmethyl)piperidine hydrochloride (1.8 g, 7.8 mmol) in dichloroethane (80 ml) was treated with Na(OAc)3BH (3.23 g, 15 mmol) and 1 ml AcOH and stirred overnight at room temperature. The resulting solution was diluted with methylene chloride and washed with 1 n NaOH, water, and brine. The organic solvents were removed under vacuum and the residue chromatographed on silica gel (50% EtOAc/hex - 100%
EtOAc) to give 3.0 g (6.8 mmol) of 190 as an oil.
Step d: A solution of 190 (3.0 g, 6.8 mmol) in MeOH
was treated with 1.5 g of 10% Pd/C and hydrogenated at 50 psi overnight in a Parr apparatus. The mixture was filtered and the filtrate concentrated on a rotary evaporator to give 1.8 g (5.9 mmol) of the amine 191 as an oil.
Step e: A solution of amine 191 (200 mg, 0.67 mmol) in THF is treated with 3-methoxyphenyl isocyanate (110 mg, 0.75 mmol) and the mixture is stirred for 30 min.
The solvent is removed on a rotary evaporator and the residue is chromatographed on silica gel (50% EtOAc/hex - 100% EtOAc) to give 250 mg of urea 192 as a solid. MS
esi: (M+H)+ - 454.4 (100%), HRMS (M+H)+- 454.2875.

N-(3-acetylphenyl)-N'-~(1R,2S)-2-ff(3S)-3-(4-fluorophenvl)methyllpiperidin~rllmethyllcyclohexyll-urea.
Step a: To a solution of (R, R) amino alcohol 187 [J.Org.
Chem. 1996, 61, 5557-5563; J. Am. Cheat. Soc. 1996, 118, 5502-5503] (9.5 g, 73.8 mmol) in CH2C1~ (200 mL) is added 200 ml of an aqueous solution of Na~C03 (15 g, 141 mmol). While stirring, benzyl chloroformate (12.6 g, 73.8 mmol) is added slowly and the mixture is stirred at room temperature for 1 h. The organic layer is separated and washed with water and brine. The organic solvent is removed on a rotary evaporator to give a white solid.
The solid is recrystallized from hexane to give 16.3 g (62 mmol) of the alcohol 188 (Scheme 31a)as a white solid. 1H NMR (300 MHz, CDC13) S 7.40-7.29 (m, 5 H), 5.11 (s, 2 H) , 4.71 (bd, 1 H) , 3 .76-3 .71 (m, 1 H) , 3 .53-3.28 (m, 3 H), 2.00-1.95 (m, 1 H), 1.90-1.09 (m, 8 H).
MS AP+ ( M+H ) * - 2 6 4 . 3 ( 10 0 % ) Step b: A solution of DMSO (36 g, 430 mmol) in CH2C12 (200 mL) is cooled to -78°C. To this solution is added drop-wise oxalyl chloride (27.41 g, 216 mmol) and the resulting solution is stirred for an additional 10 min.
A solution of alcohol 188 (38 g, 144 mmol) in CH2C12 (150 ml) is added via an addition funnel and stirred for 10 min. Then, Et3N (58 g, 570 mmol) is added and the solution is stirred for 20 min and the ice bath removed and stirred for an additional 30 min. The solution is diluted with water and the organic layer separated and washed with water, 1 N HCl, and brine. The organic layer is dried over Na2S04, filtered, and concentrated to give 38 g of aldehyde 189 as a white solid. The solid is recrystallized from hexane to give 19.7 grams of a first crop of aldehyde 189 as white needles. A second crop gave an additional 11 grams. 1H NMR (300 MHz, CDC13) 8 9.59 (d, 3.6 Hz, 1 H), 7.38-7.28 (m, 5 H), 5.07 (m, 2 H), 4.69 (m, 1 H), 3.84 (m, 21 H), 2.19-2.11 (m,1 H), 2.09-2.01 ( m, 1 H), 1.86-1.75 (m, 3 H), 1.54-1.17 (m, 4 H) .

Step c: A solution of aldehyde 189 (19.6 g, 75 mmol) and (3S)-3-(4-fluorophenylmethyl)piperidine (14.5 g, 75 mmol) in dichloroethane (400 ml) was treated with Na(OAc)3BH (32 g, 152 mmol) and stirred overnight at room temperature. The resulting solution was poured slowly into a stirred mixture of ice/water/1 N NaOH and stirred for 20 min. The organic layer was separated and washed water, and brine. The solution was dried over MgS04 and the organic solvent was removed under vacuum and the residue chromatographed on basic alumina (50%
EtOAc/hexane) to give 32.1 g (73 mmol) of amine 193 as mixture of (15%)cis and trans isomers. 1H NMR (300 MHz, CDC13) 8 7.79 (bs, 1 H), 7.38-7.29 (m, 5 H), 6.95-6.84 (m, 4 H), 5.08 (m, 2 H), 3.71 (m, 1 H, cis isomer ), 3.06 (m, 1 H, trans isomer), 2.80 (m, 1 H), 2.55-2.36 (m, 2 H) , 2.30 (dd, J = 9 Hz, J = 13 Hz, 1 H, trans isomer), 2.05 (dd, J = 2 Hz, J = 13 Hz , 1 H, trans isomer), 1.81-0.90 (m, 16 H).
Step d: A solution of 193 (32 g, 73 mmol) in MeOH was treated with 8 g of 10% Pd/C and hydrogenated at 50 psi overnight in a Parr apparatus. The mixture was filtered and the filtrate concentrated on a rotary evaporator to give 20 g (65 mmol) of the amine 194, which was used without further purification.
Step e: A solution of amine 194 (10 g, 32.8 mmol) in THF
is treated with 3-acetylyphenyl isocyanate (5.3 g, 32.8 mmol) and the mixture is stirred for 30 min. The solvent is removed on a rotary evaporator and the residue is chromatographed on silica gel (0.5:4.5:95 NH40H/MeOH/CH2C12) to give 11 g of urea 195 (Example 415) as a solid. Also obtained 2 g of cis isomer (Example 416a). The urea Example 415 was further purified by a second chromatography on silica gel (40:60:1 EtAc/Hex/TEA) and final recrystallization from ether to give crystalline solid. mp 115-117 °C, [off]D25 =
+16.8° (CH30H, c = 0.23 g/dL). 1H NMR (300 MHz, CDC13) 87.86 (m, 1 H), 7.78 (bs, 1 H), 7.68-7.64 (m, 1 H), 7.62-7.59(m, 1 H), 7.38 (t, J = 8 Hz, 1 H), 6.95-6.90 (m, 2 H), 6.79-6.72 (m, 2 H), 6.25 (s, 1 H), 3.21 (dt, J
- 3 Hz, 11 Hz, 1 H), 3.00-2.97 (m, 1 H), 2.66-2.56 (m, 1 H), 2.61 (s, 3 H), 2.44-2.32 (m, 4 H), 2.06 (dd, J = 2 Hz, J = 13 Hz, 1 H), 1.80-0.86 (m, 15 H). MS esi: (M+H)+
- 466.3 (100%). Anal. Calcd for C28H36N302F: C, 72.23; H
7.70; N, 9.02. Found: C, 72.33; H, 7.91; N, 9.00.
EXAMPLE 415a N-(3-acetylphenyl)-N'-f(1R,2S)-2-f[(3S)-3-(4-fluorophenyl)methyllpiperidinyllmethyllcyclohexyll-urea Hydrochloride.
A solution of example 415 (15 g, 32 mmol) in 300 ml of THF was cooled in an ice bath and treated drop-wise with 36 ml of a 1 M HC1/ether solution. The resulting solution was stirred for 30 min and concentrated in vacuo. The resulting solid was titurated with ether and the resulting white solid dried under high vacuum overnight to give 16 g of the hydrochloride salt. mp 58-60 °C. [oG]D25 = +20.0 ° (CH30H, c = 0.23 g/dL) . 1H NMR
(400 MHz, DMSO-Dg) ~ 9.61 (s, 1 H), 9.15 (s, 1 H), 8.00 (m, 1 H), 7.63-7.61 (m, 1 H), 7.51-7.49(m, 1 H), 7.39-7.34 (m, 1 H), 7.22-7.17 (m, 2 H), 7.09-7.04 (m, 2 H), 6.86 (d, J = 8 Hz, 1 H), 3.47-3.31 (m, 4 H), 3.11 (m, 1 H), 2.98-2.82 (m, 2 H), 2.67-2.62 (dd, J = 5 Hz, J = 13 Hz, 1 H), 2.58-2.50 (m, 2 H), 2.52 (s, 3 H), 2.39 (dd, J
- 8 Hz, J = 13 Hz, 1 H), 2.16-2.06 (m, 2 H), 1.84-1.556 (m, 7 H), 1.30-1.00 (m, 4 H). Anal. Calcd for C28H37N302FC1~H20~THFp.25: C, 64.73; H 7.68; N, 7.81.
Found: C, 64.89; H, 7.41; N, 7.81.
EXAMPLE 415b N-(3-acetylphenyl)-N'-f(1R,2S)-2-ff(3S)-3-(4-fluorophenyl)methyllpiperidinyllmethyllcyclohexyll-urea Benzenesulfonate.
Bezenesulfonic acid monohydrate (1.06 g, 6 mmol) was dried by azeotroping off the water of a benzene solution (twice) and adding the dried acid solution to a solution of example 415 (2.81 g, 6 mmol) in toluene (40 ml). The solvents were removed in vacuo (twice) and the resulting residue recrystallized twice from toluene and dried under high vacuum overnight give 2.77 g of benzenesulfonic acid salt as a white solid. mp 157-159 °C. [oc]D25 = +16.9 ° (CH30H, c = 0.23 g/dL) . Anal. Calcd for C34H42N3O5FS: C, 65.47; H 6.80; N, 6.75; S, 5.14.
Found: C, 65.48; H, 6.80; N, 6.70; S, 5.35.
The compounds of Table 3a and Table 3.1 were prepared by procedures described in Schemes 26-31A, other examples and methods taught herein, and procedures familiar to one skilled in the art.
TABLE 3a R16 i ~ R16 N.E ~ / N'E
14 ~/ ~Z~O ,R3 14 ~~~Z~O ,R3 R ~~ ~ ~ H R ~~ ~ H
p q R16 ~ ~ R16 ~ ~ + ~CH3 N,E ' / N'E
O ~ ~ O
14 / ~Z~ ,R3 R14 ~~Z~ ~R3 R ~~ ~ ~ H ~~ ~ H
Ex Core R16 E Z R14 R3 MS
#

_ M+H

1-(phenylmethyl)-218 p H CH2 (1) H 4-piperidinyl] 497 NH

2,5-219 p H CH2 (1) H difluorophenyl 436 NH

2,5-220 p H CH2 (2) H difluorophenyl 450 2,5-221 p H , (1) H difluorophenyl 464 ~~~, NH

O

2,5-222 p H ~ (1) H difluorophenyl 466 ~~~ NH

OH

phenyl 223 p H C=NH (2) H 413 NH

1-(phenylmethyl)-224 p H CH2 (2) H 4-piperidinyl] 497 NH

2- ( 4-225 p H CH2 (1) H fluorophenyl)- 446 NH ethyl 3-hydroxypropyl 226 p H CH2 (1) H 382 NH

2- ( 1-227 p H CH2 (1) H piperidinyl)- 435 NH ethyl 228 p H CH2 (1) H (dimethylamino)et395 NH hyl 4-(phenylmethyl) 229 p H CH2 (1) H -1-piperazine 483 NH

4-(phenylmethyl) 230 p H CH2 (1) H -1-piperidine 482 NH

(1,3-benzodioxol-231 p H CH2 (1) H 5-ylmethyl) 458 NH

2,2-232 p H CH2 (1) H (diphenyl)ethyl 504 NH

4- ( 4-233 p H CH2 (1) H Chlorophenyl)-4-518 NH hydroxy-1-piperidine 4-phenyl-4-234 p H CH2 (1) H hydroxy-1- 484 NH piperidine 4-phenyl-1-235 p H CH2 (1) H piperidine 468 NH

(1H)-indazol-5-yl 236 p H CH2 (1) H 440 NH

(1H)-indazol-6-yl 237 p H CH2 (1) H 440 NH

phenylmethyl 238 p H CH2 (1) H 414 NH

1,3-benzodioxol-239 p H CH2 (1) H 5-yl 444 NH

(3-4) 1-(phenylmethyl)-240 p H CH2 (1) 4-piperidinyl] 541 NH

(3-4) 2-(4-241 p H CH2 (1) fluorophenyl)- 490 NH ~ ethyl (3-4) 4-((2-242 p H CH2 (1) phenyl)ethyl) 541 NH ~ piperazine (3-4) (1H)-indazol-5-yl 243 p H CH2 (1) 484 NH O

(3-4) (1H)-indazol-6-yl 244 p H CH2 (1) 484 NH O

(3-4) benzothiazol-6-yl 245 p H CH2 (1) 501 NH

f2_ (4_ 246 p H CH2 (1) (4) fluorophenyl)- 462 NH OH ethyl 1-(phenylmethyl)-247 p H CH2 (1) (4) 4-piperidinyl] 513 NH OH

(3-4) 3-phenylpropyl 248 p H CH2 (1) 486 NH O

(1H)-indazol-5-yl 249 p H CH2 (2) H 440 NH

f2_(4_ 250 p H CH2 (2) H fluorophenyl)- 446 NH ethyl 2,5-251 p H bond (1) H difluorophenyl 422 NH

Phenyl 252 p H CH2 (1) H 400 NH

4-methoxyphenyl 253 p H CH2 (1) H 430 NH

3-methoxyphenyl 254 p H CH2 (1) H 430 NH

3-methoxyphenyl 255 q 4-F CH2 (2) H 454 NH

3-acetylphenyl 256 q 4-F CH2 (2) H 466 NH

3-methoxyphenyl 257 r H CH2 (1) H 430 NH

3-cyanophenyl 258 p H CH2 (2) H 425 NH

3-cyanophenyl 259 p H CH2 (3) H 425 NH

4-methoxyphenyl 260 p H CH2 (3) H 430 NH

2-phenylethyl 261 p H CH2 (3) H 428 NH

3-carboethoxy-262 p H CH2 (1) H phenyl 472 NH

3-cyanophenyl 263 p H CH2 (1) H 425 NH

phenyl 264 p 4-F CH2 (1) H 418 NH

phenyl 265 p H CH2 (1) H 490 N-Benzyl 3-cyanophenyl 266 p H CH2 (1) H 515 N-Benzyl 2-phenylethyl 267 p H CH2 (1) H 428 NH

(3-4) 3-cyanophenyl 268 p H CH2 (1) 469 NH

(3-4) 3-carboethoxy-269 p H CH2 (1) phenyl 516 NH O

(3-4) 4-carboethoxy-270 p H CH2 (1) phenyl 516 NH

phenyl 271 p H CH2 (1) (4) 416 NH OH

3-cyanophenyl 272 p H CH2 (1) (4) 441 NH OH

(4) 3-methoxyphenyl 273 p H CH2 (1) 524 NH O~~
~O

S

-O~ CHs (4) Trans-2-phenyl-274 p H CH2 (1) cyclopropyl 534 NH O~~ e0 S

-O~ CHs (3) 3-cyanophenyl 275 p H CH2 (1) 483 NH C02Me (3) 3-methoxyphenyl 276 p H CH2 (1) 488 NH C02Me (4) 3-cyanophenyl 277 p H CH2 (1) 519 NH O~~ ~O

S

-O~ CHs (3) 3-methoxyphenyl 278 p H CH2 (1) 460 NH ~OH

(3) 3-cyanophenyl 279 p H CH2 (1) 455 NH ~OH

(4) 3-cyanophenyl 280 p 4-F CH2 (1) 501 NH C02Me (5) 3-cyanophenyl 280a p 4-F CH2 (1) 501 NH C02Me (5) 3-cyanophenyl 280b p 4-F CH2 (1) 500 NH CONMe (5) 3-cyanophenyl 280c p 4-F CH2 (1) 486 (5) 3-(1-280d P 4-F CH2 (1) hydroxyethyl)- 520 NH C02Me phenyl (5) phenyl 280e r H CH2 (1) 458 NH C02Me (5) phenyl 280f P 4-F CH2 (1) 462 (5) 3-cyanophenyl 2808 r H CH2 (1) 483 NH C02Me (5) 3-methoxyphenyl 280h r H CH2 (1) 488 NH C02Me (5) 3-acetylphenyl 2801 r H CH2 (1) 500 NH C02Me (5) 3-acetylphenyl 280j p 4-F CH2 (1) 518 HCl(sal ~ C02Me t) (5) 3-cyanophenyl 280k p 4-F CH2 (1) 501 HCl(salNH C02Me t) (4) phenyl 281 p 4-F CH2 (1) 476 NH C02Me (5) phenyl 281a p 4-F CH2 (1) 476 NH C02Me (5) phenyl 281b p 4-F CH2 (1) 475 NH CONMe (5) phenyl 281c p 4-F CH2 (1) 461 3-methoxyphenyl 282 p 4-F CH2 (1) (4) 506 NH

C02Me 3-methoxyphenyl 282a p 4-F CH2 (1) (5) 506 NH

C02Me (5) 3-methoxyphenyl 282b p 4-F CH2 (1) 505 NH CONMe (5) 3-acetylphenyl 282c p 4-F CH2 (1) 518 NH C02Me (5) 3-acetylphenyl 282d p 4-F CH2 (1) 517 NH CONMe (5) 3-acetylphenyl 282e p 4-F CH2 (1) 503 (4) 3-cyanophenyl 283 p 4-F CH2 (1) 473 NH ~.OH

3-cyanophenyl 284 p 4-F CH2 (1) (3-4) 493 NH fused Phenyl 3-methoxyphenyl 285 p 4-F CH2 (1) (3-4) 498 NH fused Phenyl 3-cyanophenyl 286 p 4-F CH2 (1) (4) 562 NH

-CONPh 3-cyanophenyl 286a p 4-F CH2 (1) (5) 562 NH

-CONPh 3-acetylphenyl 286b p 4-F CH2 (1) (5) 579 NH

-CONPh (4) 3-methoxyphenyl 287 p 4-F CH2 (1) 478 NH OOH

(4) 3-cyanophenyl 288 p 4-F CH2 (1) 500 NH CONMe (4) 3-cyanophenyl 288a p 4-F CH2 (1) 500 HCl(salNH CONMe t) (5) 3-acetylphenyl 288b p 4-F CH2 (1) 517 HC1(sal~ CONMe t) (5) 3-acetylphenyl 288c p 4-F CH2 (1) 574 NH CON

(CH2)2 NMe2 (5) 3-acetylphenyl 288d p 4-F CH2 (1) 557 NH CON

(CH2)2 NMe2 (5) 3-acetylphenyl 288e p 4-F CH2 (1) 453 NH CON

(5) 3-acetylphenyl 288f p 4-F CH2 (1) 531 NH CON

(5) 3-methoxyphenyl 2888 p 4-F CH2 (1) 519 NH CONMe2 (5) 3-acetylphenyl 288h p 4-F CH2 (1) 531 NH CONMe2 (5) 3-acetylphenyl 2881 p 4-F CH2 (1) 580 NH CON(2-pyridin y1) (5) 3-methoxyphenyl 288j p 4-F CH2 (1) 568 NH CONMe2 2,5-289 p H CH2 (1) H difluorophenyl 450 3-cyanophenyl 290 p H CH2 (1) H 439 3-carboethoxy-291 p H CH2 (1) H phenyl 486 3-methoxyphenyl 292 p H CH2 (1) H 444 4-methoxyphenyl 293 p H CH2 (1) H 444 3-methoxyphenyl 294 p H ~ (1) H 460 ~~~ NH

OH

3-methoxyphenyl 295 r H (1) H 460 ~~~~ NH

OH

3-cyanophenyl 296 p H ~ (1) H 455 ~~~ NH

OH

3-carboethoxy-297 p H ~ (1) H phenyl 502 ~~~ NH

OH

phenyl 298 p H ~ (1) H 430 ~~~ NH

OH

(5) phenyl 299 p 4-F CH2 (1) 448 NH ~OH

phenyl 300 p H ~~~~ (1) H 443 NH

NOH

phenyl 301 p H ~ (2) H 428 ~~, NH

O

phenyl 302 p H ~ (2) H 430 ~~~ NH

OH

phenyl 303 p 4-F ~ (1) H 448 ~~~ NH

OH

3-methoxyphenyl 304 p 4-F ~ (1) H 478 ~~~ NH

OH

3-cyanophenyl 305 p 4-F ~ (1) H 473 ~~~ NH

OH

(3-4) 3-cyanophenyl 306 p H ~ (1) 499 ~~~ NH

OH
O

3-cyanophenyl 307 p H CH2-CH2 (1) H 439 NH

3-cyanophenyl 308 p 4-F CH2-CH2 (1) H 457 NH

3-methoxyphenyl 309 p H CH2-CH2(1) H 444 NH

3-methoxyphenyl 310 p 4-F CH2CH2 (1) H 462 NH

3-methoxyphenyl 311 r H CH2-CH2(1) H 444 NH

3-acetylphenyl 312 p 4-F CH2-CH2(1) H 474 NH

4-fluorophenyl 313 p 4-F CH2-CH2(1) H 450 NH

1-adamantyl 314 p 4-F CH2-CH2(1) H 490 NH

(3-4) 3-cyanophenyl 315 s H CH2 (1) 483 NH O~ (M+) 3-cyanophenyl 316 s H CH2 (1) (4) 455 NH OH (M+) 3-cyanophenyl 317 s H CH2 (1) (4) 539 (M+) (2-THP) TABLE 3.1 Ris N Ris HN~NHR3 U
O ~ N
HN~NHR3 Ris O
b N-HN~NHR3 O
MS
Ex Core R16 Stereo- Salt # 3 +

M+H

chemistry Form 400 a H 1,2 trans - 3-methoxylphenyl 436 racemic 401 a 4-F 1,2 trans - 3-methoxylphenyl 454 racemic 402 a H 1,2 cis - 3-methoxylphenyl 436 racemic 403 a 4-F 1,2 trans - 3-cyanophenyl 449 racemic 403a a 4-F 1,2 trans - 3-acetylphenyl 466 racemic 403b a 4-F 1,2 trans - 3-nitrophenyl 469 racemic 403c a 4-F 1,2 trans - 4-nitrophenyl 469 racemic 403d a 4-F 1,2 trans - 4-pyridinyl 425 racemic 403e a 4-F 1,2 trans HC1 3-acetylphenyl 466 racemic 403f a 4-F 1,2 trans - (1H)-indazol-5-yl 464 racemic 404 a 4-F 1S,2R - 3-acetylphenyl 466 405 a 4-F 1S,2R - 3-cyanophenyl 449 406 a 4-F 1S,2R - 3-methoxylphenyl 454 407 a 4-F 1S,2R - phenyl 424 408 a 4-F 1R,2S - 3-acetylphenyl 466 409 a 4-F 1R,2S - 3-cyanophenyl 449 410 a 4-F 1R,2S - 3-methoa~yphenyl 454 411 a 4-F 1R,2S - phenyl 424 412 a 4-F 1R,2S - phenylmethyl 438 413 a 4-F 1R,2S - (1H)-indazol-5-yl 464 414 a 4-F 1R,2S - (1H)-indol-5-yl 463 414a b H 1,2 traps - 3-methoxyphenyl 464 (3RS) racemic 414b b H 1,2 traps - 3-cyanophenyl 431 (3RS) racemic 414c b H 1,2 traps - 3-acetylphenyl 448 (3RS) racemic 414d b 4-F 1,2 traps - 3-acetylphenyl 466 (3RS) racemic 414e b 4-F 1,2 traps - 3-cyanophenyl 449 (3RS) racemic 414f b 4-F 1,2 traps - 3-methoxyphenyl 454 (3RS) racemic 4148 b 4-F 1,2 traps - 3-nitrophenyl 469 (3RS) racemic 415 b 4-F 1R,2S,3S - 3-acetylphenyl 466 415a b 4-F 1R,2S,3S HC1 3-acetylphenyl 466 415b b 4-F 1R,2S,3S Besyl 3-acetylphenyl 466 416 b 4-F 1R,2S,3R - 3-acetylphenyl 466 416a b 4-F 1R,2R,3S - 3-acetylphenyl 466 416b b 4-F 1R,2S,3R HC1 3-acetylphenyl 466 417 b 4-F 1R,2S,3S - 3-cyanophenyl 449 418 b 4-F 1R,2S,3R - 3-cyanophenyl 449 419 b 4-F 1R,2S,3S - 3-methoxylphenyl 454 420 b 4-F 1R,2S,3R - 3-methoxylphenyl 454 421 b 4-F 1R,2S,3S - 4-fluorohenyl 442 422 b 4-F 1R,2S,3R - 4-fluorohenyl 442 423 b 4-F 1R,2S,3S - phenyl 424 424 b 4-F 1R,2S,3S - (1H)-indazol-5-yl 464 425 b 4-F 1R,2S,3S - (1H)-indazol-6-yl 464 426 b 4-F 1R,2S,3S - benzthiazol-6-yl 481 427 b 4-F 1R,2S,3S - (1H)-indol-5-yl 463 428 b 4-F 1R,2S,3S - (1H)-indol-6-yl 463 429 b 4-F 1R,2S,3S - (1H)-2,3- 491 dimethylindol-5-yl 430 b 4-F 1R,2S,3S - benzimidazol-5-yl 464 431 b 4-F 1R,2S,3S - indolin-5-yl 465 432 b 4-F 1R,2S,3S - 3-cyano-4-fluorophenyl467 433 b 4-F 1R,2S,3S - 3-acetyl-4- 484 fluorophenyl 434 b 4-F 1R,2S,3S - 3,5-diacetylphenyl 508 435 b 4-F 1R,2S,3S - 3-(1-hydroxyethyl)- 468 phenyl 436 b 4-F 1R,2S,3S - 4-methyl-thiazol-2-yl445 437 b 4-F 1R,2S,3S - 4-methyl-5-acetyl- 487 thiazol-2-yl 438 b 4-F 1R,2S,3S - 1,3,4-thiadiazol-2-yl432 439 b 4-F 1R,2S,3S - 4-chlorol-benzthiazol-515 2-yl 440 b 4-F 1R,2S,3S - thiazol-2-yl 431 441 b 4-F 1R,2S,3S - 5-methyl-isoxazol-3-yl429 442 b 4-F 1R,2S,3S - 1-methyl-pyrazol-3-yl428 443 b 4-F 1R,2S,3S - 4-(1,2,4-triazol-1- 491 yl)phenyl 443a b 4-F 1R,2R,3S - 4-(1,2,4-triazol-1- 491 yl)phenyl 444 b 4-F 1R,2S,3S - (1H)-3-chloro-indazol-499 5-yl 445 b 4-F'1R,2S,3S - 4-fluorophenyl 492 446 b 4-F 1R,2S,3S - 4-chlorophenyl 458 447 b 4-F 1R,2S,3S - 4-bromophenyl 502 448 b 4-F 1R,2S,3S - 3-bromophenyl 502 449 b 4-F 1R,2S,3S - 3-fluorophenyl 442 450 b 4-F 1R,2S,3S - 3,4-difluorophenyl 460 451 b 4-F 1R,2S,3S - 3-chloro-4- 476 fluorophenyl 452 b 4-F 1R,2S,3S - 3,5-dichlorophenyl 492 453 c 4-F 1R,2S,3S - 3-acetylphenyl 452 454 c 4-F 1R,2S,3R - 3-acetylphenyl 452 455 c 4-F 1R,2R,3S - 3-acetylphenyl 452 456 c 4-F 1R,2S,3S - 3-cyanophenyl 435 457 c 4-F 1R,2S,3R - 3-cyanophenyl 435 458 c 4-F 1R,2R,3S - 3-cyanophenyl 435 458a c 4-F 1R,2R,3R - 3-cyanophenyl 435 459 c 4-F 1R,2S,3S - phenyl 410 460 c 4-F 1R,2S,3R - phenyl 410 461 c 4-F 1R,2R,3S - phenyl 410 462 b 4-F 1R,2S,3S - (1H)-5-amino-indazol-464 1-yl 463 b 4-F 1R,2S,3S - 3-chlorophenyl 458 464 b 4-F 1R,2S,3S - 3-fluoro-4- 456 methylphenyl 465 b 4-F 1R,2S,3S - 3-cyano-4-(1- 515 pyrazolyl)phenyl 466 b 4-F 1R,2S,3S - 2-methylphenyl ' 454 467 b 4-F 1R,2S,3S - 2-methylphenyl 438 468 b 4-F 1R,2S,3S - 2,4-dimethylphenyl 452 469 b 4-F 1R,2S,3S - 2,4-dimetho~cyphenyl484 470 b 4-F 1R,2S,3S - 2,5-dimethoxyphenyl 484 471 b 4-F 1R,2S,3S - 2-methoxy-5- 468 methylphenyl 472 b 4-F 1R,2S,3S - 2-methyl-5- 456 fluorophenyl 473 b 4-F 1R,2S,3S - 3,5-bis((1H)-1- 588 methyltetrazol-5-yl)phenyl 474 b 4-F 1R,2S,3S - (3-((1H)-1- 506 methyltetrazol-5-1)phenyl 475 b 4-F 1R,2S,3S - (4- 517 (carboethoxymethyl)thi azol-2-yl 476 b 4-F 1R,2S,3S - 5-bromothiazol-2-yl 509 477 b 4-F 1R,2S,3S - 4,5-di(4- 619 fluorophenyl)thiazol-2-yl 478 b 4-F 1R,2S,3S - 2-fluorophenyl 442 479 b 4-F 1R,2S,3S - 2-chlorophenyl 458 480 b 4-F 1R,2S,3S CF3C02H indanon-6-yl 478 481 b 4-F 1R,2S,3S CF3CO2H indanon-4-yl 478 482 b 4-F 1R,2S,3S CF3C02H 4-(isopropyl)phenyl 466 483 b 4-F 1R,2S,3S CF3C02H 3-nitro-4-methylphenyl483 484 b 4-F 1R,2S,3S CF3C02H trans-2- 464 phenylcycloprop-1-yl 485 b 4-F 1R,2S,3S CF3C02H 2,4-difluorophenyl 460 486 b 4-F 1R,2S,3S CF3C02H 2,5-difluorophenyl 460 487 b 4-F 1R,2S,3S CF3C02H 2,4-dichlorophenyl 492 488 b 4-F 1R,2S,3S CF3C02H 2,5-dichlorophenyl 492 489 b 4-F 1R,2S,3S CF3C02H 2-methoxyphenyl 454 490 b 4-F 1R,2S,3S CF3C02H 2,4-dimethoxy-phenyl484 491 b 4-F 1R,2S,3S CF3C02H 2,5-dimethoxyphenyl 484 492 b 4-F 1R,2S,3S CF3C02H 2- 492 trifluoromethylyphenyl 493 b 4-F 1R,2S,3S CF3C02H 2-methylphenyl 438 494 b 4-F 1R,2S,3S CF3C02H 3-trifluoromethyly- 492 phenyl 495 b 4-F 1R,2S,3S CF3C02H 3-methylphenyl 438 496 b 4-F 1R,2S,3S CF3C02H 4-methoxyphenyl 454 497 b 4-F 1R,2S,3S CF3C02H 4-carboethoxy-phenyl496 498 b 4-F 1R,2S,3S CF3C02H 4-trifluoromethyly- 492 phenyl 499 b 4-F 1R,2S,3S CF3C02H 4-methylphenyl 438 500 b 4-F 1R,2S,3S CF3C02H 2-fluorophenyl 442 501 b 4-F 1R,2S,3S CF3C02H 2-chloropheny 458 502 b 4-F 1R,2S,3S CF3C02H 2-nitrophenyl 469 503 b 4-F 1R,2S,3S CF3C02H 2,4-dichlorophenyl 563 504 b 4-F 1R,2S,3S CF3C02H 3-nitrophenyl 469 505 b 4-F 1R,2S,3S CF3C02H 3,5-di 560 (trifluoromethyly)-phenyl 506 b 4-F 1R,2S,3S CF3C02H 2,4-dimethylyphenyl 452 507 b 4-F 1R,2S,3S CF3C02H 2,4-dimethoxy-5- 518 chlorophenyl 508 b 4-F 1R,2S,3S CF3C02H 3,4,5-trimethoxyphenyl514 509 b 4-F 1R,2S,3S CF3C02H 3,5-dimethylphenyl 452 510 b 4-F 1R,2S,3S CF3C02H 3-trifluoromethyl-4-526 chlorophenyl 511 b 4-F 1R,2S,3S CF3C02H 4-phenoxyphenyl 516 512 b 4-F 1R,2S,3S CF3C02H 4-ethoxyphenyl 468 513 b 4-F 1R,2S,3S CF3C02H 4-thiomethylphenyl 470 514 b 4-F 1R,2S,3S CF3C02H 2-naphthyl 474 515 b 4-F 1R,2S,3S CF3C02H 4-acetylphenyl 466 516 b 4-F 1R,2S,3S CF3C02H 2,6-dichloro-pyridin-493 4-yl 517 b 4-F 1R,2S,3S CF3C02H 5-indan-4-yl 464 518 b 4-F 1R,2S,3S CF3C02H 4-chloronaphth-1-yl 508 519 b 4-F 1R,2S,3S CF3C02H 3-fluoro-4- 472 methoxyphenyl 520 b 4-F 1R,2S,3S CF3C02H 4-(methylsulfonyl)- 502 phenyl) 521 b 4-F 1R,2S,3S CF3C02H 3-(methylsulfonyl)- 502 phenyl 522 b 4-F 1R,2S,3S CF3C02H 2-((1H)-pyrrol-1- 489 yl)phenyl 523 b 4-F 1R,2S,3S CF3C02H 1,3-benzodioxol-5-yl468 524 b 4-F 1R,2S,3S CF3C02H 1-acetylindolin-6-yl507 525 b 4-F 1R,2S,3S CF3C02H 4-(6- 571 methylbenzothiazol-2-1)phenyl 526 b 4-F 1R,2S,3S CF3C02H 4-((2,2- 523 - dimethylpropanoyl)amin o)phen 1 527 b 4-F 1R,2S,3S CF3C02H 4-(1-methyltetrazol-5-506 yl)phenyl 528 b 4-F 1R,2S,3S CF3C02H 4-(1-morpholino)phenyl509 529 b 4-F 1R,2S,3S CF3C02H quinolin-8-yl 475 530 b 4-F 1R,2S,3S CF3C02H 3-hydroxyphenyl 440 531 b 4-F 1R,2S,3S CF3C02H 4-(acetylamino)-phenyl481 532 b 4-F 1R,2S,3S CF3C02H 4-hydroxyphenyl 440 533 b 4-F 1R,2S,3S CF3C02H 3-hydro~cy-4- 470 methoxyphenyl 534 b 4-F 1R,2S,3S CF3C02H 3-(acetylamino)-phenyl481 535 b 4-F 18,25,35 CF3C02H 4-fluoro-3- 456 methylphenyl 536 b 4-F 18,2S,35 CF3C02H 3-methoxy-4- 468 methylphenyl 537 b 4-F 1R,2S,3S CF3C02H 4-chloro-3- 472 methylphenyl 538 b 4-F 1R,2S,3S CF3C02H 4-(N- 481 methylcarboacamide)phen y1 539 b 4-F 1R,2S,3S CF3C02H 1-adamantyl 482 540 b 4-F 1R,2S,3S CF3C02H quinolin-5-yl 475 541 b 4-F 1R,2S,3S CF3C02H quinolin-6-yl 475 542 b 4-F 1R,2S,3S CF3C02H 1,4-benzodioxan-6-yl482 543 b 4-F 1R,2S,3S CF3C02H isoquinolin-5-yl 475 544 b 4-F 1R,2S,3S CF3C02H 4-(sulfonamide)-phenyl503 545 b 4-F 1R,2S,3S CF3C02H benzotriazol-5-yl 465 546 b 4-F 1R,2S,3S CF3C02H 2-hydroxy-4- 454 methylphenyl 547 b 4-F 1R,2S,3S CF3C02H 3-hydroxy-4- 454 methylphenyl 548 b 4-F 1R,2S,3S CF3C02H 2-methyl-benzothiazol-495 5-yl 549 b 4-F 1R,2S,3S CF3C02H (4-methoxylphenyl)- 468 methyl 550 b 4-F 1R,2S,3S CF3C02H (4-fluorophenyl)- 456 methyl 551 b 4-F 1R,2S,3S CF3C02H (4-methylphenyl)- 452 methyl 552 b 4-F 1R,2S,3S CF3C02H (1R)-1-(phenyl)ethyl452 553 b 4-F 1R,2S,3S CF3C02H 1-acetylindolin-5-yl507 554 b 4-F 1R,2S,3S CF3C02H 5,6,7,8- 478 tetrahydronaphth-1-yl 555 b 4-F 1R,2S,3S CF3C02H 3-acetyl-4- 482 hydroxyphenyl 556 b 4-F 1R,2S,3S CF3C02H 4-(piperidin-1- 507 yl)phenyl 557 b 4-F 1R,2S,35 CF3C02H cyclohexyl 430 558 b 4-F 1R,2S,3S CF3C02H 2-methoxyphenyl 468 559 b 4-F 1R,2S,3S CF3C02H 2,6-dimethylphenyl 452 560 b 4-F 1R,2S,3S CF3C02H 2-ethylphenyl 452 561 b 4-F 1R,2S,3S CF3C02H 2,4,6-trimethylphenyl466 562 b 4-F 1R,2S,3S CF3C02H 2,5-dimethoxyphenyl 484 563 b 4-F 1R,2S,3S CF3C02H t-butyl 404 564 b 4-F 1R,2S,3S CF3C02H i-propyl 390 565 b 4-F 1R,2S,3S CF3C02H Ethoxycarbonyl-methyl)434 566 b 4-F 1R,2S,3S CF3C02H 2-trifluoromethoxy- 508 phenyl 567 b 4-F 1R,2S,3S CF3C02H (1R,S)-1-- 462 (methoxycarbonyl)-2-methyl-prop 1 568 b 4-F 1R,2S,3S CF3C02H [(1S)-1- 510 (methoxycarbonyl)-2-henylethyl 569 b 4-F 1R,2S,3S CF3C02H 2,4,4-trimethyl-2- 460 pentyl 570 b 4-F 1R,2S,3S CF3C02H 2-phenylethyl 452 571 b 4-F 1R,2S,3S CF3C02H 3-acetylphenyl 466 572 b 4-F 1R,2S,3S CF3C02H 2-carbomethoa~y-phenyl482 573 b 4-F 1R,2S,3S CF3C02H (1S)-1-(phenyl)ethyl452 574 b 4-F 1R,2S,3S CF3C02H 4-(phenyl)phenyl 500 575 b 4-F 1R,2S,3S CF3C02H 1-naphthyl 474 576 b 4-F 1R,2S,3S CF3C02H 2-(phenyl)phenyl 500 577 b 4-F 1R,2S,3S CF3C02H Phenylmethoxy 454 578 b 4-F 1R,2S,3S CF3C02H 3,4-dimethoxyphenyl 484 579 b 4-F 1R,2S,3S CF3C02H (3H)-2- 520 ethylquinazolin-4-on-3-yl 580 b 4-F 1R,2S,3S CF3C02H 3-pyridinyl 425 581 b 4-F 1R,2S,3S CF3C02H 6-methoxy-3-pyridinyl455 582 b 4-F 1R,2S,3S CF3C02H 2-methylquinolin-8-yl489 583 b 4-F 1R,2S,3S CF3C02H 2-methylnaphth-1-yl 488 584 b 4-F 1R,2S,3S CF3C02H 4-((1H)-1-propyl- 534 tetrazol-5-yl)phenyl 585 b 4-F 1R,2S,3S CF3C02H 3-aminophenyl 439 586 b 4-F 1R,2S,3S - 3-(acetylamino)-phenyl481 587 b 4-F 1R,2S,3S CF3C02H 3-(N-methylcarbamoyl)-481 phenyl 588 b 4-F 1R,2S,3S CF3C02H 2-nitro-4- 499 methoxyphenyl 589 b 4-F 1R,2S,3S CF3C02H 8-hydroxyquinolin-5-yl491 590 b 4-F 1R,2S,3S CF3C02H 3-methylpyridin-2-yl439 591 b 4-F 1R,2S,3S CF3C02H isoquinolin-1-yl 475 Example 318 N ~0 Part A: Preparation of 1-t-butyloxycarbonyl-4-benzylpiperidine 4-benzylpiperidine (10.0 g, 57.1 mmol, 1.0 eq.) was dissolved in 100 mL of THF under N2 and subsequently cooled to 0 °C. Di-tert-butyl Bicarbonate (11.21 g, 51.3 mmol, 0.9 eq.) dissolved in 50 mL of THF, was added dropwise. Gas evolution was observed. Once gas evolution ceased, the ice bath was removed. After 20 hours, the THF was removed in vacuo then the residue was dissolved in EtOAc and rinsed 3X with 1N citric acid, 1X
with brine. The organic was dried over magnesium sulfate and stripped to yield 15.4 g of colorless oil as product. Yield = 97.9%. NMR (300 MHz, CDC13)8 7.35-7.17 (m,3H); 7.14 (d, 2H, J = 7 Hz); 4.20-3.90 (m, 2H);
2.75-2.55 (m, 2H); 2.54 (d, 2H, J = 7 Hz); 1.70-1.50 (m, 3H); 1.46 (s, 9H); 1.20-1.00 (m, 2H).

O O
O
)H + OH
erythro threo Part B: Preparation of erythro-and threo-cis-4-benzyl-1-t-butoxycarbonyl-oc-ethylpiperidinemethanol 1-t-butyloxycarbonyl-4-benzylpiperidine (5.0 g, 18.2 mmol, 1.0 eq.) was dissolved in Et20 at 25 °C under NZ and cooled to -78 °C. N,N,N',N'-Tetramethylethylenediamine (TMEDA) (3.29 mL, 21.8 mmol, 1.2 eq.) was added followed by the dropwise addition of sec-butyllithium (16.76 mL, 21.8 mmol, 1.2 eq.). The reaction was allowed to warm and stir at -30 °C for 30 minutes then again cooled to -78 °C. Once cool, propionaldehyde (1.31 mL, 20.0 mmol, 1.1 eq.) was added neat. The reaction was allowed warmed to warm to -30 °C
then immediately quenched with 10 mL of water and the organic layer was separated. The aqueous layer was extracted 2X more with Et20. The organic layers were combined, dried over magnesium sulfate and the solvent removed in vacuo to yield a colorless oil which was purified by flash chromatography in 4 . 1 to 1 . 1 hexane/ EtOAc. Obtained 0.68 g of a colorless oil as isomer A, yield = 11.20 and 0.91 g of a colorless oil as isomer B, yield = 15.0%.
Isomer A NMR (300 MHz, CDC13)87.40-7.25 (m, 2H); 7.21 (d, 1H, J = 7 Hz); 7.16 (d, 2H, J = 7 Hz); 3.60-3.30 (m, 2H); 2.56 (d, 2H J = 7 Hz); 1.90-1.00 (m, 7H); 1.46 (s, 9H); 1.00-0.70 (m, 5H).

Isomer B NMR (300 MHz, CDC13)$ 7.30-7.23 (m, 2H); 7.20 (d, 1H, J = 7 Hz); 7.14 (d, 2H, J = 7 Hz.); 3.60-3.20 (m, 2H); 2.60-2.40 (m, 2H); 1.90-1.00 (m, 9H); 1.44 (s, 9H); 0.96 (t, 3H, J = 7 Hz).
O
' N- \
O
H
erythro Part C: Structure determination of Isomer B via cyclization to 40G, 60~, 7oG-4-benzyl-7-ethyl-8-oxa-1-azabicyclo[4.3.0]nonane-9-one Isomer B (60 mg, 0.18 mmol, 2 eq.) was dissolved in DMF
at 25 °C under N2 then NaH (7.9 mg, 0.198 mmol, 1 eq.) was added. After 20 hours, 2 mL of water was added followed by EtOAc. The layers were separated. The aqueous layer was extracted 2X more with EtOAc. The organic layers were combined, dried over magnesium sulfate, and the solvent removed in vacuo to yield an oil which was purified over silica gel in 9:1 to 1:1 hexane/EtOAc. Obtained 30 mg. Yield = 640. Product structure confirmed by N.O.E. NMR (300 MHz, CDC13) 8 7.40-7.20 (m, 3H); 7.16 (d, 2H, J = 7 Hz); 4.45-4.25 (m, 1H); 4.00-3.80 (m, 1H); 3.65-3.45 (m, 1H); 2.95-2.70 (m, 1H); 2.65-2.45 (m, 2H); 1.85-1.40 (m, 4H); 1.40-1.00 (m, 6H) .

)H
Part D: Preparation of erythro-cis-4-benzyl-OC-ethylpiperidinemethanol Erythro-cis-4-benzyl-1-t-butoxycarbonyl-oc-ethylpiperidinemethanol(isomer B from part B)(815 mg, 2.44 mmol, 1 eq.) was dissolved in 8 mL of ethanol at 25 °C under N2. NaOH (391 mg, 9.78 mmol, 4 eq.) was added and the mixture refluxed for 4 hours. The solvent was removed in vacuo to yield an oil. Water was added followed by EtOAc. The layers were separated. The aqueous layer was extracted 2X more with EtOAc. The organic layers were combined dried over magnesium sulfate, and the solvent removed in vacuo to yield 390 mg of an oil. Yield = 68%. NMR (300 MHz, CDC13) 8 7.35-7.20 (m, 2H); 7.23-7.00 (m, 3H); 3.75-3.65 (m, 1H);
3.20-3.00 (m, 1H); 2.90-2.40 (m, 4H); 1.70-1.50 (m, 2H);
1.50-1.30 (m, 1H); 1.20-0.80 (m, 5H).
O
-- ~N
>H o v Part E: Preparation of erythro-cis-4-benzyl-oc-ethyl-1-(3-N-phthalimido-n-prop-1-yl)piperidinemethanol Erythro-cis-4-benzyl-oc-ethylpiperidinemethanol (195 mg, 0.84 mmol, 1 eq.), N-(3-bromopropyl)phthalimide (224 mg, 0.84 mmol, 1 eq.), potassium iodide (139 mg, 0.84 mmol, 1 eq.), and potassium carbonate (231 mg, 0.84 mmol, 1 eq.) were refluxed in 10 mL of 2-butanone for 3 hours. The reaction was worked up by filtering off the inorganic solids. The filtrate solvent was removed in vacuo to yield an oil. Purified by flash chromatography in 200% EtOAc then 4:1 chloroform/MeOH. Obtained 200 mg. Yield = 57%.
NMR (300 MHz, CDC13) S 7.95-7.80 (m, 2H); 7.80-7.65 (m, 2H); 7.35-7.00 (m, 5H); 3.90-3.60 (m, 3H); 3.20-2.90 (m, 2H); 2.65-2.30 (m, 3H); 2.20-2.00 (m, 2H); 2.00-1.75 (m, 2H); 1.70-1.40 (m, 4H); 1.35-0.90 (m, 3H); 0.96 (t, 3H, J = 7 Hz) .
~NH~
)H
Part F: Preparation of erythro-cis-1-(3-amino-n-prop-1-yl)-4-benzyl-oc-ethylpiperidinemethanol Erythro-cis-4-benzyl-a-ethyl-1-(3-N-phthalimido-n-prop-1-yl)piperidinemethanol(200 mg, 0.48 mmol, 1 eq.) was dissolved in 5 mL of ethanol at 25 °C under N2.
Anhydrous hydrazine (0.03mL, 0.95 mmol, 2 eq.) was added and the reaction refluxed for 3 hours during which time a white precipitate (phthalhydrazide) formed. Once cool, The solids were filtered. The filtrate solvent was removed in vacuo to yield an oil which was stirred in Et20. The triturated solids were filtered and the filtrate solvent was removed in vacuo to yield 120 mg of an oil. Yield = 870. NMR (300 MHz, CDC13) 8 7.27 (t, 2H, J = 7 Hz); 7.17 (d, 1H, J = 7 Hz); 7.13 (d, 2H, J =
7 Hz); 3.70-3.30 (m, 2H); 3.20-3.00 (m, 2H); 3.00-2.70 (m, 2H); 2.70-2.40 (m, 2H); 2.30-2.10 (m, 1H); 2.10-1.90 (m, 2H); 1.90-1.40 (m, 5H); 1.40-1.00 (m, 3H); 0.96 (t, 3H, J = 7 Hz ) .

H H H
.~ ~N~N O + ~ ~N~ H O
H
)H )~N
O /
O
Part G: preparation of erythro-cis-1-[3-(3-acetylphenylaminocarbonylamino)-n-prop-1-yl]-4-benzyl-oG-ethylpiperidinemethanol and erythro-cis-1-[3-(3-acetylphenylaminocarbonylamino)-n-prop-1-yl]-2-[1-(3-acetylphenylaminocarbonyloxy)-n-prop-1-yl)-4-benzylpiperidine Erythro-cis-1-(3-amino-n-prop-1-yl)-4-benzyl-OG-ethylpiperidinemethanol (120 mg, 0.41 mmol, 1 eq.) was dissolved in 5 mL of THF at 25 °C under N~ then 3-acetylphenyl isocyanate added neat. After 1 hour the solvent was removed in vacuo to yield an oil. Purified by flash chromatography in 100% EtOAc to 4:1 chloroform/MeOH. Isolated mono-addition product (product A) along with an additional bis-addition product (product B). Proud A yielded 81 mg of an oil.
Yield = 43%. Product B yielded 43 mg of an oil.
Product A NMR (300 MHz, CDC13) 8 7.86 (bs, 1H); 7.73 (d, 1H, J = 7 Hz);7.60 (s, 1H); 7.56 (d, 1H, J = 7 Hz);

7.40 -7.15 (m, 4H); 7.12(d, 2H, = Hz); 6.30-6.05 (m, 1H); 4.00-3.80 (m, 1H);3.50-3.30 (m, 1H); 3.30-2.90 (m, 5H); 2.60-2.40 (m, 2H);2.57 (s, 3H);2.30 -2.10 (m, 1H);

2.10 -1.90 (m, 2H); 1.80-1.40 (m, 5H);1.30 -1.05 (m, 2H);

0.94 (t, 3H, = Hz).

Product B NMR (300 MHz, CDC13) 8 10.80-10.60 (m, 1H);
8.20-8.00 (m, 1H); 7.91 (bs, 1H); 7.80-7.18 (m, 9H);
7.11 (d, 2H, J = 7 Hz); 6.20-6.00 (m, 1H); 5.20-5.00 (m, 1H); 3.50-3.00 (m, 4H); 2.57 (s, 3H); 2.56 (s, 3H);
2.55-2.00 (m, 5H); 2.00-1.00 (m, 10H); 1.00-0.80 (m, 3H) Product A was separated into its enantiomers employing a Daicel Chiral Pack AD column, eluting with 0.10 diethylamine in methanol. (-)-isomer [oG]D25 (c = 0.300 g/dL, MeOH) - -14.9°. (+) -isomer [oc]D~5 (c = 0.290 g/dL, MeOH) - +20.2°.
The following compounds can be synthesized by the methods discussed previously:
TABLE 3b.

O 61 / ~3R3 6 / ~ R3 O 1 ' 3 ~N~N 2 N~N 2 N H H N' ' H H
OH OH

R1 ~ R1 a 3 O 61 \ , 3R
R ~3 O 1 \ 3 \' ~N 2 ~N~N 2 N H N H H
H O
NH

R2 O ~ R3 R1 ~ /

O 1 ' ~ 3 ~N~N 2 N H H
_ O~NH

/ R2 O ~ / R3 Cores R1 R2 R2a, R2b R3 M+1 319 a,b H CH3 --- 3-COCH3 438 320 a,b H CH3 --- 4-N02 441 321 a,b H CH3CH2 --- 3-COCH3 452 322 c H --- CH3, CH3 3-COCH3 452 323 a,b H CH3CH2CH2 --- 3-COCH3 466 324 a,b H (CH3)2CH --- 3-COCH3 466 325 a,b H CH3CH2CH2CH2 --- 3-COCH3 480 326 a,b H (CH3)2CHCH2 --- 3-COCH3 480 327 d,e H CH3CH2 --- 3-COCH3 613 328 d,e H CH3CH2CH2 --- 3-COCH3 627 329 d,e H (CH3)2CH --- 3-COCH3 627 330 d,e H CH3CH2CH2CH2 --- 3-COCH3 641 331 d,e H (CH3)2CHCH2 --- 3-COCH3 641 Part A Preparation of N-cyano-N'-3-methoxyphenylcarbamimidic acid, phenyl ester ,N
i N~ ~
w ~ o~N w ~ o m-Anisidine (4.56 mL, 4.06 mmol, 1 eq.), and diphenylcyanocarbonimidate (967 mg, 4.06 mmol, 1 eq.) were mixed and refluxed in acetonitrile under N2 for 1 hour. Solids precipitated. The reaction was worked up by filtering off the solids. Obtained 580 mg as product. M.P. - 170.0 - 171.0 °C. NMR (300 MHz, DMSO-d6) 8 8.70 - 8.50 (m, 1H) ; 7.43 (t, 2H, J = 7 Hz) ; 7.40 - 7.20 (m, 2H); 7.14 (d, 2H, J = 7 Hz); 7.00 - 6.80 (m, 2H); 6.80 - 6.70 (m, 1H); 3.80 (s, 3H).
Part B Preparation of N " -cyano-N'-(3-f4-(4-fluorobenzyl)piperidinelpropyl-N-(3-methoxyphenyl)auanidine ~N
~I I
N~N~N ~
~I

3-(4-(4-fluorophenylmethyl)piperidin-1-yl)propylamine, (synthesized in a similar fashion to the previously described des-fluoro compound) (53 mg, 0.20 mmol, 1 eq.) and the product from Part A (50 mg, 0.20 mmol, 1 eq.) were mixed and refluxed in 2-propanol under N2 for 1 hour. The reaction was stripped and the residue then purified over silica gel in 100 % ethyl acetate followed by 8:2 chloroform/methanol. Obtained 55 mg of off-white solids as product. NMR (300 MHz, CDC13) 8 7.33 (t, 1H, J = 7 Hz); 7.10 - 6.90 (m, 4H); 6.90 - 6.80 (m, 3H); 3.83 (s, 3H); 3.50 - 3.35 (m, 2H); 2.90 - 2.70 (m, 2H); 1.50 - 1.20 (m, 3H). Mass Spec detects 424 (M+H) .

Part A: Preparation of f(Methylthio)(3-acetylphenyl amino)lmethylenepropanedinitrile N' ,~N
~S N
O
[Bis(methylthio)methylene]propanedinitrile 3.00 g, 17.6 mmol, 1 eq.), and 3'amino-acetophenone (2.38 g, 17.6 mmol, 1 eq.), were mixed and refluxed under N~ in ethanol for 16 hours. Solids precipitated while cooling to 25 °C.
The solids were filtered. Obtained 1.86 g of tan solids.
M.P. - 165.0 - 166.5 °C. NMR (300 MHz, DMSO-d6) 8 10.66 (m, 1H); 7.90 - 7.80 (m, 2H); 7.60 - 7.50 (m, 2H); 2.60 (s, 3H); 2.54 (s, 3H).
Part B: Preparation of 2-[(3-acetylanilino)({3-[4-(4-fluorobenzyl)-1-piperidinyl]propyl}
amino)methylene]malononitrile N'~ , N
/ NON N ~
O
3-(4-(4-fluorophenylmethyl)piperidin-1-yl)propylamine, 49 mg, 0.194 mmol, 1 eq.) and the product from Part A
(50 mg, 0.194 mmol, 1 eq.) were mixed then stirred under N2 overnight. The reaction was stripped and the residue purified over Chloroform/methanol. Obtained 17 mg of a white amphorphous solid. NMR (300 MHz, CDC13) S 7.82 (d, 1H, J = 7 Hz) ; 3 1H) ; 7.51 (t, 1H, J= 7 Hz) ;
7.7 (s, 7.34 (d, 1H, J = 7Hz); 7.10-6.80 (m, 4H); 3.28 (m, 2H); 2.62 (s, 3H); 2.64-2.40 (m, 2H); 2.40-2.25 (m, 2H); 2.05-1.70 (m, 2H); 1.70-1.35 (m, 3H); 1.20-0.80 (m, 2H).

Mass Spec detects 460 (M+H).

Part A: Preparation of N-[1-(methylthio)-2-nitroethenyl]-3-acetylbenzenamine O
H
/S N

A neat mixture of 1,1-bismethylthio-2-nitroethylene (6.5 g, 38.5 mmol, 10 eq) and 3-aminoacetophenone (0.5 g, 3.85 mmol, 1eq) was melted together and heated at 140° C for four hours. The mixture was cooled to room temperature, then subjected to flash chromatography, eluting with 50% ethyl acetatelhexanes, to yield 0.63 g of a yellow powder as product. Yield = 65%. NMR (300 MHz, CDC13) S 11.82 (bs, 1H), 7.95-7.91 (m, 2H), 7.59-7.48 (m, 2H) , 6.73 (s, 1H) , 2.65 (s, 3H) , 2 .41 (s, 3H} .
Part B: Preparation of 1-(3-{[(E)-1-({-[4-(4-fluorobenzyl)-1-piperidinyl]propyl}amino)-2-nitroethylenyl]amino}phenyl)ethanone H H
N N N
F
O~N
To a suspension of N-[1-(methylthio)-2-nitroethenyl]-3-acetylbenzenamine (0.30 g, 1.19 mmol, 2.00 eq) in 20 ml of methanol was added 3-(4-fluorobenzyl)piperidin-1-yl)propylamine (0.31 g, 1.25 mmol, 1.05 eq), and the mixture was stirred at room temperature. After three days, a colorless solution was observed. The solvent was removed in-vacuo, and the residue was subjected to flash chromatography, eluting with 10% methanol/chloroform, to yield 0.38 g of an orange glass as product. Yield = 70%. NMR (300 MHz, CDC13) $ 10.51 (bs, 1H), 7.92 (d, 1H, j - 8 Hz), 7.72 (bs, 1H), 7.54 (dd, 1H, j - 8 Hz, 8 Hz), 7.35 (bd, 1H), 6.90-6.88 (m, 5H), 6.17 (s, 1H), 3.54 (bs, 2H), 2.92-2.84 (m, 2H), 2.63 (s, 3H), 2.51 (m, 2H), 1.99-1.91 (m, 4H), 1.55-1.50 (m, 3H), 0.88-0.85 (m, 2H). MS (ESI) detects (M+H)+ - 455.
The following compounds can be prepared by procedures described previously:

Table 3c H H F ~ \ ~ H H
F / N~/\~N~N.R3 / ~,~..r N~N~N'.R3 Z Z
b F \ F \
/ a"~~N H H I / d..vN \ Z 'R3 .,,~N~N.R H H

c Z d F
/ ~~~~N H H
/ N II N.R

z Core Z R3 Mass Spec M+1 332 a N-CN 3-methoxyphenyl 424 333 a N-CN 3-acetylphenyl 460 334 a C(CN)2 3-acetylphenyl 460 335 a CHN02 3-acetylphenyl 455 336 b N-CN 3-acetylphenyl 436 337 b C(CN)2 3-acetylphenyl 460 338 b NCONH2 3-acetylphenyl 454 339 b CHN02 3-acetylphenyl 455 340 b N-CN 3,5-diacetylphenyl 478 341 b NCONH2 3,5-diacetylphenyl 496 342 b NC02CH3 3,5-diacetylphenyl 511 343 b C(CN)2 3,5-diacetylphenyl 344 b N-CN 3-(1-methyl-1H-tetrazol-476 5-yl)phenyl 345 b C(CN)2 3-(1-methyl-1H-tetrazol-500 5-yl)phenyl 346 b NCONH2 3-(1-methyl-1H-tetrazol-494 5-yl)phenyl 347 b N-CN 2,4-dimethoxy-phenyl 454 348 b N-CN 5-acetyl-2-methoxy- 466 phenyl 349 d N-CN 3-(1-methyl-1H-tetrazol-488 5-yl)phenyl 350 c N-CN phenyl 448 351 c N-CN 3-acetylphenyl 490 352 c N-CN 3-cyanopneyl 473 353 c N-CN 2,4-dimethoxyphenyl 508 354 c N-CN 2,5-dimethoxyphenyl 508 355 c N-CN 5-acetyl-2-methoxy- 520 phenyl 356 c N-CN 2,4-dimethylphenyl 476 357 c N-CN 4-(1-methyl-1H-tetrazol-530 5-yl)phenyl 358 c N-CN 4-(1-propyl-1H-tetrazol-558 5-yl)phenyl 359 c N-CN 5,6,7,8-tetrahydro- 502 naphthy-2-yl-phenyl 360 c N-CN 4-(4-morpholinyl)-phenyl533 361 C N-CN 2,5-dimethylphenyl 362 c N-CN 4-hydroxy-2-methylphenyl 363 c N-CN 2-methylphenyl 364 c N-CN 2-phenylethyl 365 c N-CN 1-adamantyl 366 c N-CN 2-adamantyl 367 c C(CN)2 3-acetylphenyl 514 368 c C(CN)2 5-acetyl-2-metho~cy- 544 phenyl 369 c CHN02 3-acetylphenyl 509 370 a CHN02 3-acetylphenyl 560 371 a N-CN 3,5-diacetylphenyl 583 372 a N-CN 3-acetylphenyl 541 373 a N-CN 4-(1-propyl-1H-tetrazol-581 5-yl)phenyl The following examples were synthesized using the methods outlined in Schemes 31a and 25c.

N-f2,4,4-Trimethyl-2-pentyll-N'-f(1R,2S)-2-ff(3S) 3-(4-fluorophenyl)methyl)pi~eridinyllmethyllcyclohexyl urea ,, / \ F
A solution of amine 194 (Scheme 31a, see also Example 415, step d) (6 mg, 0.02 mmol) in 1 mL of THF is treated with 2,4,4-trimethyl-2-pentyl isocyanate (3 ~.,I,L, 0.03 mmol) at room temperature for 1 h. PS-trisamine (33 mg, 0.15 mmol, Argonaut Technologies Inc.) was added and stirred for 1 h. The reaction mixture was filtered and the polymer was washed with CH2C12, and the combined filtrate was concentrated under vacuum. The residue is further purified by HPLC, using a VYDAC C18 prepacked column (10 mm, 22 x 250 mm) and UV detection at 214 nm, elution with MeCN-H20-TFA (90:10:0.1-10:90:0.1), flow rate 15 mL/min, to afford 5.6 mg of the urea product as a solid. 1H NMR (300 MHz, DMDO-D6) 8.33 (bs, 1 H), 7.23-7.10 (m, 5 H), 6.75-6.72 (d, 1H, J = 7 Hz, 1 H), 5.75 5.70 (d, J = 8 Hz, 1H), 3.40 (m, 1 H), 3.18 (m, 1 H), 3.05 (m, 1 H), 2.95 (m, 1 H), 2.75 (m, 1 H), 2.60 (m, 1 H), 2.45 (m, 1 H), 2.00 (bs, 1 H), 1.90-1.55 (m, 10 H), 1.22 (s, 6 H) , 1.20-1.05 (m, 6 H) , 0.92 (s, 9 H) . MS
esi: (M+H)+ - 460 N-f(1S)-2-HVdroxy-1-phenylethyll-N'-f(1R,2S)-2-1 f (3S) -3- (4 fluorophenyl)methyl)pi~eridinyllmethyllcyclohexyll-urea F
N, ) '/H~N ''°'~OH
O
Part A. Preparation of phenyl (1R)-2-hydroxy-1-phenylethyl carbamate H
\ O~N ''°'~OH
O
To a mixture of 137.2 mg of R-(-)-2-phenylglycinol (1.0 mmol) and 250 mg polyvinyl-pyridine (Aldrich, 25%
crosslinked) in 3 mL THF were added 188 ~,L (1.5 mmol) phenyl chloroformate. The reaction mixture was mixed at room temperature for overnight. To this mixture were then added 500 mg (2 mmols) PS-trisamine and the reaction mixed for additional 3 h. The reaction mixture was then filtered and the volatiles evaporated to give the title compound. MS esi: (M+H)+ - 258. This compound is used for next step without purification.
Part B. preparation of N-f(1R) -2-hydroxy-1-phenylethyll-N'-(1R,2S)-2-ff(3S)-3-(4-fluorophenyl)methyl)piperidinyllmethyllcyclohexyll-urea F
N' ./
,, °' OOH
O
Amine 194 (Scheme 31a, see also Example 415, step d) (6 mg, 0.02 mmol) and the product from Part A (25.8 mg, 0.1 mmol, ca 5 eq.) were mixed and then stirred overnight. PS-trisamine (44 mg, 0.2 mmol, Argonaut Technologies Inc.) was added and stirred for 8 h. The reaction mixture was filtered and the polymer was washed with CH2C12, and the combined filtrate was concentrated under vacuum. The residue is further purified by HPLC, using a VYDAC C18 prepacked column (10 mm, 22 x 250 mm) and W detection at 214 nm, elution with MeCN-H20-TFA
(90:10:0.1-10:90:0.1), flow rate 15 mL/min, to afford 2.6 mg of urea 607 as a solid. MS esi: (M+H)+ - 468.

N"-Cyano-N-(2-ethoxyethyl)-N'-llR,2S)-2-ff(3S)-3-(4-fluorophenyl)methyl)piperidinyllmethyllcyclohexyll-auanidine \ l F
N
~~NH
N/'H-~O~
CN
Part A. Preparation of N-cyano-N'-3-ethoxyeth~rlcarbamimidic acid, phenyl ester NC, n ~O N O
H

2-Ethoxyethylamine (0.315 mL, 3 mmol, 1 eq.), and diphenylcyanocarbonimidate (715 mg, 3 mmol, 1 eq.) were mixed and refluxed in acetonitrile for overnight. The solvent was removed in vacuo, and the residue was subjected to flash chromatography, eluting with 50%
Ethyl acetate/hexane, to yield 467 mg product as a white solid. MS esi: (M+H)+ - 234.
Part B. Preparation of N"-cyano-N-(2-ethox~rethyl)-N'-(1R,2S)-2-ff(3S)-3-(4-fluorophenyl)methyl)piperidinyllmethyllcyclohexyll-ctuanidine Amine 194 (Scheme 31a) (15 mg, 0.05 mmol) and the product from Part A (117 mg, 0.5 mmol, 10 eq.) were mixed then stirred overnight. The reaction was stripped and the residue then purified in silica gel in 100%
ethyl acetate followed by 9:1 ethyl acetate/methanol.
The product was further purified by HPLC, using a VYDAC
C18 prepacked column (10 mm, 22 x 250 mm) and W
detection at 214 nm, elution with MeCN-H20-TFA
(90:10:0.1-10:90:0.1), flow rate 15 mLlmin, to afford 13.6 mg of pure product as a white solid. 1H NMR (300 MHz, CD30D) 7.20 (m, 2 H), 7.05 (m, 2 Hj, 3.62-3.35 (m, 11 H), 3.15 (m, 1 H), 3.10-2.8 (m, 2 H), 2.70-2.50 (m, 3 H), 2.10-2.65 (m, 8 H), 1.45-1.10 (m, 5 H), 1.10 (t, J =
8 Hz, 3 H). MS esi: (M+H)+ - 444.
The following compounds can be prepared by procedures described previously.
Table 3d F I i ,,,..~N
H H
..~N Z N~R3 Ex. 2 R3 Mass Spec # M+1 601 O t-butyl 404 602 O i-proryl 390 CH3' 605 O Ph~~ 510 3 ~I L
H3C~~3 607 O Ph~~ 468 HO' 608 O NH2COCH~ 405 6 0 0 CH3 OCH~ CH2 4 0 6 612 N(CN)2 CH30CH2CH2 454 613 NCN PhOCH2CH2 492 614 NCN CHgOCH2CH~ 430 The following tables contain representative examples of the present invention, and may be prepared by procedures described above, or methods familiar to one skilled in the art. Each entry in each table is intended to be paired with each formulae at the start of the table. For example, Entry 1 in Table 4 is intended to be paired with each of formulae 1a-44.
TABLE 4*
G/~N~ ~ R3 G/~N~N N_R G/~N~N~N'R.3 H H p 3 H H
1a 2a 3a C~.,~N~ ~~ R~ C'~Nw/~,.N N_R C~~N~N~N,R3 H H p 3 H H
1b 2b 3b ~N~N~I~T'R3 G~N~N~N R3 G~N~N~N'R3 G H H ~ H H

G/~N~ G/~N ~N~
G ~ H
i H
N'R3 ~'~R3 ~~R3 8a ~ 9a ~ 10 C~,~N~ C~,~N G~N
i H - I 1 H H
~N.R3 ~N.R3 ~N.R3 8b ~ 9b ~ 11 J H ~ H
HNY~R3 HNY~R3 12a ~ 13a H ~ H
HN~N_R3 HN~~'R3 12b ~ 13b G~ ~ H G
N N _ H
I~R3 HN~'I~R3 G/~ G/

~ ~ H
H HN~~ R3 ~~~ R3 16a 0 17a 0 HN ~
R3 ~ R3 16b O 17b 0 G~ ~ H R
N N _ 1 ~N. 1 HNYN.

G~~ G~~N~' ~ ~ R
~

R3 IvI-H H N
20a H H
21a C~~~t~ N~ N-R3 C~~~~ ~ R3 H H H H
20b 21b ~~I~ ~~~/Q"' ~ ~
R2 .R2 N R N N
N_ 1 H H
Rl H H

G/~N~ N N. R ~;~~N~ N N_ /~N~ N N.
3 ~ R3 G Y R3 G/~N H N N. R C~,~N H N N. R G~N OH N N_R3 3 ~ 3 Me O Me 0 Me O

G H H H C~y~ H H H ~ H H H
'~N N N. N~N N.R3 G N~N~N.R3 iPrO iPrO iPrO

G/~N H N N. R C~~N H N N. R ~N OH N N.
3 ~ ~ 3 G R
'~ Y
iBuO iBuO iBuO

G/~N H N N. R C~~N H N N. R ~N H N N.
3 ~ ~ 3 R
G ~ Y 3 Ph O Ph O Ph 0 36 37 3g OH H ~ ~~ OH H ~ ~N H H
R3 ~ R3 G~, ~ R3 Ph O Ph O Ph O

H I~ ~~,~ H H g~ R l-~N OH H IH'I.
R3 ~ 3 G ~ R3 Ph O Ph 0 Ph O

Entry G R3 1 4-F-Ph Ph 2 4-F-Ph 3-CN-Ph 3 4-F-Ph 3-COCH3-Ph 4 4-F-Ph 3-C02Me-Ph 4-F-Ph 3-C02Et-Ph 6 4-F-Ph 3-C02H-Ph 7 4-F-Ph 3-CONH2-Ph 8 4-F-Ph 3-CONHMe-Ph 9 4-F-Ph 3-F-Ph 4-F-Ph 3-C1-Ph 11 4-F-Ph 3-Br-Ph 12 4-F-Ph 3-N02-Ph 13 4-F-Ph 3-NH2-Ph 14 4-F-Ph 3-NHMe-Ph 4-F-Ph 3-NMe2-Ph 16 4-F-Ph 3-NHCOCH3-Ph 17 4-F-Ph 3-S02NH2-Ph 18 4-F-Ph 3-S02NHMe-Ph 19 4-F-Ph 3-CF3-Ph 4-F-Ph 3-OCH3-Ph 21 4-F-Ph 3-OPh-Ph 22 4-F-Ph 3-OCF3-Ph 23 4-F-Ph 3-SCH3-Ph 24 4-F-Ph 3-SOCH3-Ph 25 4-F-Ph 3-S02CH3-Ph 26 4-F-Ph 3-OH-Ph 27 4-F-Ph 3-CH20H-Ph 28 4-F-Ph 3-CHOHCH3-Ph 29 4-F-Ph 3-COH(CH3)2-Ph 30 4-F-Ph 3-CHOHPh-Ph 31 4-F-Ph 3-CH3-Ph 32 4-F-Ph 3-C2H5-Ph 33 4-F-Ph 3-iPr-Ph 34 4-F-Ph 3-tBu-Ph 35 4-F-Ph 3-Ph-Ph 36 4-F-Ph 3-CH2Ph-Ph 37 4-F-Ph 3-CH2C02Me-Ph 38 4-F-Ph 3-(1- i eridinyl)-Ph 39 4-F-Ph 3-(1-pyrrolidinyl)-Ph 40 4-F-Ph 3-(2-imidazolyl)-Ph 41 4-F-Ph 3-(1-imidazolyl)-Ph 42 4-F-Ph 3-(2-thiazolyl)-Ph 43 4-F-Ph 3-(3- razolyl)-Ph 44 4-F-Ph 3-(1-pyrazol 1)-Ph 45 4-F-Ph 3-(1-tetrazol 1)-Ph 46 4-F-Ph 3-(5-tetrazolyl)-Ph 47 4-F-Ph 3-(2-pyridyl)-Ph 48 4-F-Ph 3-(2-thienyl)-Ph 49 4-F-Ph 3-(2-furanyl)-Ph 50 4-F-Ph 4-CN-Ph 51 4-F-Ph 4-COCH3-Ph 52 4-F-Ph 4-C02Me-Ph 53 4-F-Ph 4-C02Et-Ph 54 4-F-Ph 4-C02H-Ph 55 4-F-Ph 4-CONH2-Ph 56 4-F-Ph 4-CONHMe-Ph 57 4-F-Ph 4-CONHPh-Ph 58 4-F-Ph 4-NHCONH2-Ph 59 4-F-Ph 4-F-Ph 60 4-F-Ph 4-C1-Ph 61 4-F-Ph 4-Br-Ph 62 4-F-Ph 4-N02-Ph 63 4-F-Ph 4-NH2-Ph 64 4-F-Ph 4-NHMe-Ph 65 4-F-Ph 4-NMe2-Ph 66 4-F-Ph 4-NHCOCH3-Ph 67 4-F-Ph 4-S02NH2-Ph 68 4-F-Ph 4-S02NHMe-Ph 69 4-F-Ph 4-CF3-Ph 70 4-F-Ph 4-OCH3-Ph 71 4-F-Ph 4-OPla.-Ph 72 4-F-Ph 4-OCF3-Ph 73 4-F-Ph 4-SCH3-Ph 74 4-F-Ph 4-SOCH3-Ph 75 4-F-Ph 4-S02CH3-Ph 76 4-F-Ph 4-OH-Ph 77 4-F-Ph 4-CH20H-Ph 78 4-F-Ph 4-CHOHCH3-Ph 79 4-F-Ph 4-COH(CH3)2-Ph 80 4-F-Ph 4-CH3-Ph 81 4-F-Ph 4-C2H5-Ph 82 4-F-Ph 4-iPr-Ph 83 4-F-Ph 4-tBu-Ph 84 4-F-Ph 4-Ph-Ph 85 4-F-Ph 4-CH2Ph-Ph 86 4-F-Ph 4-CH2C02Me-Ph 87 4-F-Ph 4-(1- iperidinyl)-Ph 88 4-F-Ph 4-(1-pyrrolidinyl)-Ph 89 4-F-Ph 4-(2-imidazolyl)-Ph 90 4-F-Ph 4-(1-imidazolyl)-Ph 91 4-F-Ph 4-(2-thiazolyl)-Ph 92 4-F-Ph 4-(3- razolyl)-Ph 93 4-F-Ph 4-(1-pyrazolyl)-Ph 94 4-F-Ph 4-(1-tetrazolyl)-Ph 95 4-F-Ph 4-(5-tetrazolyl)-Ph 96 4-F-Ph 4-(2-pyrid 1)-Ph 97 4-F-Ph 4-(2-thien 1)-Ph 98 4-F-Ph 4-(2-furanyl)-Ph 99 4-F-Ph 2-CN-Ph 100 4-F-Ph 2-COCH3-Ph 101 4-F-Ph 2-C02Me-Ph 102 4-F-Ph 2-C02Et-Ph 103 4-F-Ph 2-C02H-Ph 104 4-F-Ph 2-CONH2-Ph 105 4-F-Ph 2-CONHMe-Ph 206 4-F-Ph 2-F-Ph 107 4-F-Ph 2-C1-Ph 108 4-F-Ph 2-Br-Ph 109 4-F-Ph 2-N02-Ph 110 4-F-Ph 2-NH2-Ph 111 4-F-Ph 2-NHMe-Ph 112 4-F-Ph 2-NMe2-Ph 113 4-F-Ph 2-NHCOCH3-Ph 114 4-F-Ph 2-S02NH2-Ph 115 4-F-Ph 2-S02NHMe-Ph 116 4-F-Ph 2-CF3-Ph 117 4-F-Ph 2-OCH3-Ph 118 4-F-Ph 2-OPh-Ph 119 4-F-Ph 2-OCF3-Ph 120 4-F-Ph 2-SCH3-Ph 121 4-F-Ph 2-SOCH3-Ph 122 4-F-Ph 2-S02CH3-Ph 123 4-F-Ph 2-OH-Ph 124 4-F-Ph 2-CH20H-Ph 125 4-F-Ph 2-CHOHCH3-Ph 126 4-F-Ph 2-COH(CH3)2-Ph 127 4-F-Ph 2-CHOHPh-Ph 128 4-F-Ph 2-CH3-Ph 129 4-F-Ph 2-C2H5-Ph 130 4-F-Ph 2-iPr-Ph 131 4-F-Ph 2-tBu-Ph 132 4-F-Ph 2-Ph-Ph 133 4-F-Ph 2-CH2Ph-Ph 134 4-F-Ph 2-CH2C02Me-Ph 135 4-F-Ph 2-(1-piperidinyl)-Ph 136 4-F-Ph 2-(1-pyrrolidinyl)-Ph 137 4-F-Ph 2-(2-imidazolyl)-Ph 138 4-F-Ph 2-(1-imidazolyl)-Ph 139 ~ 4-F-Ph 2-(2-thiazolyl)-Ph 140 4-F-Ph 2-(3-pyrazolyl)-Ph 141 4-F-Ph 2-(1- razol 1)-Ph 142 4-F-Ph 2-(1-tetrazolyl)-Ph 143 4-F-Ph 2-(5-tetrazolyl)-Ph 144 4-F-Ph 2-(2-pyridyl)-Ph 145 4-F-Ph 2-(2-thienyl)-Ph 146 4-F-Ph 2-(2-furan 1)-Ph 147 4-F-Ph 2,4-diF-Ph 148 4-F-Ph 2,5-diF-Ph 149 4-F-Ph 2,6-diF-Ph 150 4-F-Ph 3,4-diF-Ph 151 4-F-Ph 3,5-diF-Ph 152 4-F-Ph 2,4-diCl-Ph 153 4-F-Ph 2,5-diCl-Ph 154 4-F-Ph 2,6-diCl-Ph 155 4-F-Ph 3,4-diCl-Ph 156 4-F-Ph 3,5-diCl-Ph 157 4-F-Ph 3,4-diCF3-Ph 158 4-F-Ph 3,5-diCF3-Ph 159 4-F-Ph 5-Cl-2-Me0-Ph 160 4-F-Ph 5-Cl-2-Me-Ph 161 4-F-Ph 2-F-5-Me-Ph 162 4-F-Ph 2-F-5-N02-Ph 163 4-F-Ph 3,4-OCH20-Ph 164 4-F-Ph 3,4-OCH2CH20-Ph 165 4-F-Ph 2-Me0-4-Me-Ph 166 4-F-Ph 2-Me0-5-Me-Ph 167 4-F-Ph 1-naphthyl 168 4-F-Ph 2-naphthyl 169 4-F-Ph 2-thienyl 170 4-F-Ph 3-thienyl 171 4-F-Ph 2-furanyl 172 4-F-Ph 3-furanyl 173 4-F-Ph 2-pyridyl 174 4-F-Ph 3- yridyl 175 4-F-Ph 4- yridyl 176 4-F-Ph 2-indolyl 177 4-F-Ph 3-indolyl 178 4-F-Ph 5-indolyl 179 4-F-Ph 6-indolyl 180 4-F-Ph 3-indazolyl 181 4-F-Ph 5-indazolyl 182 4-F-Ph 6-indazolyl 183 4-F-Ph 2-imidazolyl 184 4-F-Ph 3-pyrazolyl 185 4-F-Ph 2-thiazolyl 186 4-F-Ph 5-tetrazolyl 187 4-F-Ph 2-benzimidazol 1 188 4-F-Ph 5-benzimidazolyl 189 4-F-Ph 2-benzothiazolyl 190 4-F-Ph 5-benzothiazolyl 191 4-F-Ph 2-benzoxazolyl 192 4-F-Ph 5-benzoxazolyl 193 4-F-Ph 1-adamantyl 194 4-F-Ph 2-adamantyl 195 4-F-Ph t-Bu 196 2-F-Ph 3-CN-Ph 197 2-F-Ph 3-COCH3-Ph 198 2-F-Ph 3-C02Me-Ph 199 2-F-Ph 3-C02Et-Ph ~

200 2-F-Ph 3-C02H-Ph 201 2-F-Ph 3-CONH2-Ph 202 2-F-Ph 3-F-Ph 203 2-F-Ph 3-Cl-Ph 204 2-F-Ph 3-NH2-Ph 205 2-F-Ph 3-S02NH2-Ph 206 2-F-Ph 3-CF3-Ph 207 2-F-Ph 3-OCH3-Ph 208 2-F-Ph 3-OEt-Ph 209 2-F-Ph 3-OCF3-Ph 210 2-F-Ph 3-S02CH3-Ph 211 2-F-Ph 3-OH-Ph 212 2-F-Ph 3-CH3-Ph 213 2-F-Ph 3-C2H5-Ph 214 2-F-Ph 4-CN-Ph 215 2-F-Ph 4-COCH3-Ph 216 2-F-Ph 4-C02Me-Ph 217 2-F-Ph 4-C02Et-Ph 218 2-F-Ph 4-C02H-Ph 219 2-F-Ph 4-CONH2-Ph 220 2-F-Ph 4-F-Ph 221 2-F-Ph 4-Cl-Ph 222 2-F-Ph 4-NH2-Ph 223 2-F-Ph 4-S02NH2-Ph 224 2-F-Ph 4-CF3-Ph 225 2-F-Ph 4-OCH3-Ph 226 2-F-Ph 4-OEt-Ph 227 2-F-Ph 4-OCF3-Ph 228 2-F-Ph 4-S02CH3-Ph 229 2-F-Ph 4-OH-Ph 230 2-F-Ph 4-CH3-Ph 231 2-F-Ph 4-C2H5-Ph 232 2-F-Ph 2,4-diF-Ph 233 2-F-Ph 2,5-diF-Ph 234 2-F-Ph 3,4-diF-Ph 235 2-F-Ph 3,5-diF-Ph 236 2-F-Ph 2,4-diCl-Ph 237 2-F-Ph 2,5-diCl-Ph 238 2-F-Ph 3,4-diCl-Ph 239 2-F-Ph 3,5-diCl-Ph 240 2-F-Ph 3,4-OCH20-Ph 241 2-F-Ph 3,4-OCH2CH20-Ph 242 2-F-Ph 2-thienyl 243 2-F-Ph 2-furanyl 244 2-F-Ph 2-pyridyl 245 2-F-Ph 4-pyridyl 246 2-F-Ph 2-imidazolyl 247 2-F-Ph 3-pyrazolyl 248 2-F-Ph 2-thiazol 1 249 2-F-Ph 5-tetrazolyl 250 2-F-Ph 1-adamant 1 251 2,4-diF-Ph 3-CN-Ph 252 2,4-diF-Ph 3-COCH3-Ph 253 2,4-diF-Ph 3-C02Me-Ph 254 2,4-diF-Ph 3-C02Et-Ph 255 2,4-diF-Ph 3-C02H-Ph 256 2,4-diF-Ph 3-CONH2-Ph 257 2,4-diF-Ph 3-F-Ph 258 2,4-diF-Ph 3-C1-Ph 259 2,4-diF-Ph 3-NH2-Ph 260 2,4-diF-Ph 3-S02NH2-Ph 261 2,4-diF-Ph 3-CF3-Ph 262 2,4-diF-Ph 3-OCH3-Ph 263 2,4-diF-Ph 3-OEt-Ph 264 2,4-diF-Ph 3-OCF3-Ph 265 2,4-diF-Ph 3-S02CH3-Ph 266 2,4-diF-Ph 3-OH-Ph 267 2,4-diF-Ph 3-CH3-Ph 268 2,4-diF-Ph 3-C2H5-Ph 269 2,4-diF-Ph 4-CN-Ph 270 2,4-diF-Ph 4-COCH3-Ph 271 2,4-diF-Ph 4-C02Me-Ph 272 2,4-diF-Ph 4-C02Et-Ph 273 2,4-diF-Ph 4-C02H-Ph 274 2,4-diF-Ph 4-CONH2-Ph 275 2,4-diF-Ph 4-F-Ph 276 2,4-diF-Ph 4-C1-Ph 277 2,4-diF-Ph 4-NH2-Ph 278 2,4-diF-Ph 4-S02NH2-Ph 279 2,4-diF-Ph 4-CF3-Ph 280 2,4-diF-Ph 4-OCH3-Ph 281 2,4-diF-Ph 4-OEt-Ph 282 2,4-diF-Ph 4-OCF3-Ph 283 2,4-diF-Ph 4-S02CH3-Ph 284 2,4-diF-Ph 4-OH-Ph 285 2,4-diF-Ph 4-CH3-Ph 286 2,4-diF-Ph 4-C2H5-Ph 287 2,4-diF-Ph 2,4-diF-Ph 288 2,4-diF-Ph 2,5-diF-Ph 289 2,4-diF-Ph 3,4-diF-Ph 290 2,4-diF-Ph 3,5-diF-Ph 291 2,4-diF-Ph 2,4-diCl-Ph 292 2,4-diF-Ph 2,5-diCl-Ph 293 2,4-diF-Ph 3,4-diCl-Ph 294 2,4-diF-Ph 3,5-diCl-Ph 295 2,4-diF-Ph 3,4-OCH20-Ph 296 2,4-diF-Ph 3,4-OCH2CH20-Ph 297 2,4-diF-Ph 2-thienyl 298 2,4-diF-Ph 2-furanyl 299 2,4-diF-Ph 2-pyridyl 300 2,4-diF-Ph 4-pyridyl 301 2,4-diF-Ph 2-imidazolyl 302 2,4-diF-Ph 3-pyrazolyl 303 2,4-diF-Ph 2-thiazolyl 304 2,4-diF-Ph 5-tetrazolyl 305 2,4-diF-Ph 1-adamantyl 306 4-Cl-Ph ph 307 4-Cl-Ph 3-CN-Ph 308 4-C1-Ph 3-COCH3-Ph 309 4-C1-Ph 3-C02Me-Ph 310 4-C1-Ph 3-C02Et-Ph 311 4-C1-Ph 3-C02H-Ph 312 4-C1-Ph 3-CONH2-Ph 313 4-C1-Ph 3-CONHMe-Ph 314 4-C1-Ph 3-F-Ph 315 4-C1-Ph 3-C1-Ph 316 ~ 4-C1-Ph 3-Br-Ph 317 4-C1-Ph 3-N02-Ph 318 4-C1-Ph 3-NH2-Ph 319 4-C1-Ph 3-NHMe-Ph 320 4-C1-Ph 3-NMe2-Ph 321 4-C1-Ph 3-NHCOCH3-Ph 322 4-C1-Ph 3-S02NH2-Ph 323 4-Cl-Ph 3-S02NHMe-Ph 324 4-Cl-Ph 3-CF3-Ph 325 4-Cl-Ph 3-OCH3-Ph 326 4-Cl-Ph 3-OPh-Ph 327 4-C1-Ph 3-OCF3-Ph 328 4-C1-Ph 3-SCH3-Ph 329 4-Cl-Ph 3-SOCH3-Ph 330 4-C1-Ph 3-S02CH3-Ph 331 4-C1-Ph 3-OH-Ph 332 4-C1-Ph 3-CH20H-Ph 333 4-C1-Ph 3-CHOHCH3-Ph 334 4-C1-Ph 3-COH(CH3)2-Ph 335 4-C1-Ph 3-CHOHPh-Ph 336 4-C1-Ph 3-CH3-Ph 337 4-C1-Ph 3-C2H5-Ph 338 4-Cl-Ph 3-iPr-Ph 339 4-Cl-Ph 3-tBu-Ph 340 4-C1-Ph 3-Ph-Ph 341 4-C1-Ph 3-CH2Ph-Ph 342 4-Cl-Ph 3-CH2C02Me-Ph 343 4-C1-Ph 3-(1-piperidinyl)-Ph 344 4-C1-Ph 3-(1-pyrrolidinyl)-Ph 345 4-C1-Ph 3-(2-imidazolyl)-Ph 346 4-C1-Ph 3-(1-imidazolyl)-Ph 347 4-C1-Ph 3-(2-thiazolyl)-Ph 348 4-C1-Ph 3-(3-pyrazolyl)-Ph 349 4-C1-Ph 3-(1-pyrazolyl)-Ph 350 4-C1-Ph 3-(1-tetrazolyl)-Ph 351 4-C1-Ph 3-(5-tetrazolyl)-Ph 352 4-C1-Ph 3-(2-p ridyl)-Ph 353 4-C1-Ph 3-(2-thienyl)-Ph 354 4-C1-Ph 3-(2-furanyl)-Ph 355 4-C1-Ph 4-CN-Ph 356 4-C1-Ph 4-COCH3-Ph 357 4-Cl-Ph 4-C02Me-Ph 358 4-C1-Ph 4-C02Et-Ph 359 4-Cl-Ph 4-C02H-Ph 360 4-C1-Ph 4-CONH2-Ph 361 4-Cl-Ph 4-CONHMe-Ph 362 4-C1-Ph 4-CONHPh-Ph 363 4-Cl-Ph 4-NHCONH2-Ph 364 4-Cl-Ph 4-F-Ph 365 4-C1-Ph 4-CI-Ph 366 4-Cl-Ph 4-Br-Ph 367 4-Cl-Ph 4-N02-Ph 368 4-C1-Ph 4-NH2-Ph 369 4-Cl-Ph 4-NHMe-Ph 370 4-C1-Ph 4-NMe2-Ph 371 4-C1-Ph 4-NHCOCH3-Ph 372 4-Cl-Ph 4-S02NH2-Ph 373 4-C1-Ph 4-S02NHMe-Ph 374 4-C1-Ph 4-CF3-Ph 375 ~ 4-C1-Ph 4-OCH3-Ph 376 4-Cl-Ph 4-OPh-Ph 377 4-Cl-Ph 4-OCF3-Ph 378 4-C1-Ph 4-SCH3-Ph 379 4-C1-Ph 4-SOCH3-Ph 380 4-C1-Ph 4-S02CH3-Ph 381 4-C1-Ph 4-OH-Ph 382 4-C1-Ph 4-CH20H-Ph 383 4-Cl-Ph 4-CHOHCH3-Ph 384 4-Cl-Ph 4-COH(CH3)2-Ph 385 4-C1-Ph 4-CH3-Ph 386 4-C1-Ph 4-C2H5-Ph 387 4-C1-Ph 4-iPr-Ph 388 4-Cl-Ph 4-tBu-Ph 389 4-C1-Ph 4-Ph-Ph 390 4-C1-Ph 4-CH2Ph-Ph 391 4-Cl-Ph 4-CH2C02Me-Ph 392 4-C1-Ph 4-(1-piperidin 1)-Ph 393 4-C1-Ph 4-(1- rrolidinyl)-Ph 394 4-C1-Ph 4-(2-imidazolyl)-Ph 395 4-Cl-Ph 4-(1-imidazolyl)-Ph 396 4-C1-Ph 4-(2-thiazol 1)-Ph 397 4-C1-Ph 4-(3-pyrazolyl)-Ph 398 4-C1-Ph 4-(1-pyrazolyl)-Ph 399 4-Cl-Ph 4-(1-tetrazolyl)-Ph 400 4-Cl-Ph 4-(5-tetrazolyl)-Ph 401 4-Cl-Ph 4-(2-pyridyl)-Ph 402 4-Cl-Ph 4-(2-thienyl)-Ph 403 4-C1-Ph 4-(2-furanyl)-Ph 404 4-Cl-Ph 2-CN-Ph 405 4-Cl-Ph 2-COCH3-Ph 406 4-C1-Ph 2-C02Me-Ph 407 4-C1-Ph 2-C02Et-Ph 408 4-C1-Ph 2-C02H-Ph 409 4-Cl-Ph 2-CONH2-Ph 410 4-Cl-Ph 2-CONHMe-Ph 411 4-CI-Ph 2-F-Ph 412 4-Cl-Ph 2-Cl-Ph 413 4-Cl-Ph 2-Br-Ph 414 4-CI-Ph 2-N02-Ph 415 4-C1-Ph 2-NH2-Ph 416 4-C1-Ph 2-NHMe-Ph 417 4-C1-Ph 2-NMe2-Ph 418 4-C1-Ph 2-NHCOCH3-Ph 419 4-C1-Ph 2-S02NH2-Ph 420 4-C1-Ph 2-S02NHMe-Ph 421 4-C1-Ph 2-CF3-Ph 422 4-Cl-Ph 2-OCH3-Ph 423 4-C1-Ph 2-OPh-Ph 424 4-C1-Ph 2-OCF3-Ph 425 4-C1-Ph 2-SCH3-Ph 426 4-C1-Ph 2-SOCH3-Ph 427 4-C1-Ph 2-S02CH3-Ph 428 4-C1-Ph 2-OH-Ph 429 4-C1-Ph 2-CH20H-Ph 430 4-C1-Ph 2-CHOHCH3-Ph 431 4-C1-Ph 2-COH(CH3)2-Ph 432 4-C1-Ph 2-CHOHPh-Ph 4_3_3 4-C1-Ph 2-CH3-Ph 434 ~ 4-C1-Ph 2-C2H5-Ph 435 4-Cl-Ph 2-iPr-Ph 436 4-C1-Ph 2-tBu-Ph 437 4-C1-Ph 2-Ph-Ph 438 4-C1-Ph 2-CH2Ph-Ph 439 4-C1-Ph 2-CH2C02Me-Ph 440 4-C1-Ph 2-(1-piperidinyl)-Ph 441 4-C1-Ph 2-(1-pyrrolidinyl)-Ph 442 4-Cl-Ph 2-(2-imidazolyl)-Ph 443 4-Cl-Ph 2-(1-imidazolyl)-Ph 444 4-Cl-Ph 2-(2-thiazolyl)-Ph 445 4-Cl-Ph 2-(3-pyrazolyl)-Ph 446 4-C1-Ph 2-(1-pyrazolyl)-Ph 447 4-Cl-Ph 2-(1-tetrazolyl)-Ph 448 4-C1-Ph 2-(5-tetrazolyl)-Ph 449 4-Cl-Ph 2-(2-pyridyl)-Ph 450 4-C1-Ph 2-(2-thienyl)-Ph 451 4-C1-Ph 2-(2-furanyl)-Ph 452 4-Cl-Ph 2,4-diF-Ph 453 4-Cl-Ph 2,5-diF-Ph 454 4-C1-Ph 2,6-diF-Ph 455 4-C1-Ph 3,4-diF-Ph 456 4-C1-Ph 3,5-diF-Ph 457 4-C1-Ph 2,4-diCl-Ph 458 4-C1-Ph 2,5-diCl-Ph 459 4-C1-Ph 2,6-diCl-Ph 460 4-Cl-Ph 3,4-diCl-Ph 461 4-C1-Ph 3,5-diCl-Ph 462 4-C1-Ph 3,4-diCF3-Ph 463 4-C1-Ph 3,5-diCF3-Ph 464 4-Cl-Ph 5-C1-2-Me0-Ph 465 4-Cl-Ph 5-Cl-2-Me-Ph 466 4-Cl-Ph 2-F-5-Me-Ph 467 4-C1-Ph 2-F-5-N02-Ph 468 4-Cl-Ph 3,4-OCH20-Ph 469 4-C1-Ph 3,4-OCH2CH20-Ph 470 4-Cl-Ph 2-Me0-4-Me-Ph 471 4-C1-Ph 2-Me0-5-Me-Ph 472 4-C1-Ph 1-naphthyl 473 4-C1-Ph 2-naphthyl 474 4-C1-Ph 2-thienyl 475 4-Cl-Ph 3-thienyl 476 4-C1-Ph 2-furanyl 477 4-C1-Ph 3-furanyl 478 4-C1-Ph 2-pyridyl 479 4-Cl-Ph 3-pyridyl 480 4-Cl-Ph 4-pyridyl 481 4-C1-Ph 2-indolyl 482 4-C1-Ph 3-indolyl 483 4-C1-Ph 5-indolyl 484 4-C1-Ph 6-indolyl 485 4-C1-Ph 3-indazolyl 486 4-C1-Ph 5-indazol 1 487 4-C1-Ph 6-indazolyl 488 4-C1-Ph 2-imidazol 1 489 4-C1-Ph 3-pyrazolyl 490 4-Cl-Ph 2-thiazolyl 491 4-Cl-Ph 5-tetrazolyl 492 4-Cl-Ph 2-benzimidazolyl 493 ~ 4-C1-Ph 5-benzimidazolyl 494 4-Cl-Ph 2-benzothiazolyl 495 4-Cl-Ph 5-benzothiazol 1 496 4-C1-Ph 2-benzoxazolyl 497 4-C1-Ph 5-benzoxazolyl 498 4-Cl-Ph 1-adamantyl 499 4-C1-Ph 2-adamantyl 500 4-C1-Ph t-Bu 501 2-C1-Ph 3-CN-Ph 502 2:-C1-Ph 3-COCH3-Ph 503 2-Cl-Ph 3-C02Me-Ph 504 2-Cl-Ph 3-C02Et-Ph 505 2-Cl-Ph 3-C02H-Ph 506 2-Cl-Ph 3-CONH2-Ph 507 2-Cl-Ph 3-F-Ph 508 2-Cl-Ph 3-Cl-Ph 509 2-C1-Ph 3-NH2-Ph 510 2-Cl-Ph 3-S02NH2-Ph 511 2-Cl-Ph 3-CF3-Ph 512 2-Cl-Ph 3-OCH3-Ph 513 2-Cl-Ph 3-OEt-Ph 514 2-Cl-Ph 3-OCF3-Ph 515 2-C1-Ph 3-S02CH3-Ph 516 2-C1-Ph 3-OH-Ph 517 2-Cl-Ph 3-CH3-Ph 518 2-C1-Ph 3-C2H5-Ph 519 2-Cl-Ph 4-CN-Ph 520 2-C1-Ph 4-COCH3-Ph 521 2-C1-Ph 4-C02Me-Ph 522 2-C1-Ph 4-C02Et-Ph 523 2-C1-Ph 4-C02H-Ph 524 2-Cl-Ph 4-CONH2-Ph 525 2-Cl-Ph 4-F-Ph 526 2-Cl-Ph 4-C1-Ph 527 2-Cl-Ph 4-NH2-Ph 528 2-C1-Ph 4-S02NH2-Ph 529 2-C1-Ph 4-CF3-Ph 530 2-Cl-Ph 4-OCH3-Ph 531 2-C1-Ph 4-OEt-Ph 532 2-C1-Ph 4-OCF3-Ph 533 2-C1-Ph 4-S02CH3-Ph 534 2-C1-Ph 4-OH-Ph 535 2-C1-Ph 4-CH3-Ph 536 2-C1-Ph 4-C2H5-Ph 537 2-C1-Ph 2,4-diF-Ph 538 2-C1-Ph 2,5-diF-Ph 539 2-C1-Ph 3,4-diF-Ph 540 2-C1-Ph 3,5-diF-Ph 541 2-Cl-Ph 2,4-diCl-Ph 542 2-Cl-Ph 2,5-diCl-Ph 543 2-Cl-Ph 3,4-diCl-Ph 544 2-Cl-Ph 3,5-diCl-Ph 545 2-C1-Ph 3,4-OCH20-Ph 546 2-Cl-Ph 3,4-OCH2CH20-Ph 547 2-C1-Ph 2-thienyl 548 2-Cl-Ph 2-furanyl 549 2-Cl-Ph 2-pyridyl 550 2-C1-Ph 4-p ridyl 551 2-C1-Ph 2-imidazol 1 ~52 2-Cl-Ph 3-pyrazolyl 553 2-C1-Ph 2-thiazolyl 554 2-Cl-Ph 5-tetrazolyl 555 2-C1-Ph 1-adamantyl 556 2,4-diCl-Ph 3-CN-Ph 557 2,4-diCl-Ph 3-COCH3-Ph 558 2,4-diCl-Ph 3-C02Me-Ph 559 2,4-diCl-Ph 3-C02Et-Ph 560 2,4-diCl-Ph 3-C02H-Ph 561 2,4-diCl-Ph 3-CONH2-Ph 562 2,4-diCl-Ph 3-F-Ph 563 2,4-diCl-Ph 3-C1-Ph 564 2,4-diCl-Ph 3-NH2-Ph 565 2,4-diCl-Ph 3-S02NH2-Ph 566 2,4-diCl-Ph 3-CF3-Ph 567 2,4-diCl-Ph 3-OCH3-Ph 568 2,4-diCl-Ph 3-OEt-Ph 569 2,4-diCl-Ph 3-OCF3-Ph 570 2,4-diCl-Ph 3-S02CH3-Ph 571 2,4-diCl-Ph 3-OH-Ph 572 2,4-diCl-Ph 3-CH3-Ph 573 2,4-diCl-Ph 3-C2H5-Ph 574 2,4-diCl-Ph 4-CN-Ph 575 2,4-diCl-Ph 4-COCH3-Ph 576 2,4-diCl-Ph 4-C02Me-Ph 577 2,4-diCl-Ph 4-C02Et-Ph 578 2,4-diCl-Ph 4-C02H-Ph 579 2,4-diCl-Ph 4-CONH2-Ph 580 2,4-diCl-Ph 4-F-Ph 581 2,4-diCl-Ph 4-C1-Ph 582 2,4-diCl-Ph 4-NH2-Ph 583 2,4-diCl-Ph 4-S02NH2-Ph 584_ 2,4-diCl-Ph 4-CF3-Ph 585 2,4-diCl-Ph 4-OCH3-Ph 586 2,4-diCl-Ph 4-0Et-Ph 587 2,4-diCl-Ph 4-OCF3-Ph 588 2,4-diCl-Ph 4-S02CH3-Ph 589 2,4-diCl-Ph ' 4-0H-Ph 590 2,4-diCl-Ph 4-CH3-Ph 591 2,4-diCl-Ph 4-C2H5-Ph 592 2,4-diCl-Ph 2,4-diF-Ph 593 2,4-diCl-Ph 2,5-diF-Ph 594 2,4-diCl-Ph 3,4-diF-Ph 595 2,4-diCl-Ph 3,5-diF-Ph 596 2,4-diCl-Ph 2,4-diCl-Ph 597 2,4-diCl-Ph 2,5-diCl-Ph 598 2,4-diCl-Ph 3,4-diCl-Ph 599 2,4-diCl-Ph 3,5-diCl-Ph 600 2,4-diCl-Ph 3,4-OCH20-Ph 601 2,4-diCl-Ph 3,4-OCH2CH20-Ph 602 2,4-diCl-Ph 2-thienyl 603 2,4-diCl-Ph 2-furanyl 604 2,4-diCl-Ph 2-p ridyl 605 2,4-diCl-Ph 4- ridyl 606 2,4-diCl-Ph 2-imidazolyl 607 2,4-diCl-Ph 3-pyrazolyl 608 2,4-diCl-Ph 2-thiazolyl 609 2,4-diCl-Ph 5-tetrazolyl 610 2,4-diCl-Ph 1-adamantyl 611 3-OCH3-Ph 3-CN-Ph 612 3-OCH3-Ph 3-COCH3-Ph 613 3-OCH3-Ph 3-C02Me-Ph 614 3-OCH3-Ph 3-C02Et-Ph 615 3-OCH3-Ph 3-C02H-Ph 616 3-OCH3-Ph 3-CONH2-Ph 617 3-OCH3-Ph 3-F-Ph 618 3-OCH3-Ph 3-C1-Ph 619 3-OCH3-Ph 3-NH2-Ph 620 3-OCH3-Ph 3-S02NH2-Ph 621 3-OCH3-Ph 3-CF3-Ph 622 3-OCH3-Ph 3-OCH3-Ph 623 3-OCH3-Ph 3-OEt-Ph 624 3-OCH3-Ph 3-OCF3-Ph 625 3-OCH3-Ph 3-S02CH3-Ph 626 3-OCH3-Ph 3-OH-Ph 627 3-OCH3-Ph 3-CH3-Ph 628 3-OCH3-Ph 3-C2H5-Ph 629 3-OCH3-Ph 4-CN-Ph 630 3-OCH3-Ph 4-COCH3-Ph 631 3-OCH3-Ph 4-C02Me-Ph 632 3-OCH3-Ph 4-C02Et-Ph 633 3-OCH3-Ph 4-C02H-Ph 634 3-OCH3-Ph 4-CONH2-Ph 635 3-OCH3-Ph 4-F-Ph 636 3-OCH3-Ph 4-C1-Ph 637 3-OCH3-Ph 4-NH2-Ph 638 3-OCH3-Ph 4-S02NH2-Ph 639 3-OCH3-Ph 4-CF3-Ph 640 3-OCH3-Ph 4-OCH3-Ph 641 3-OCH3-Ph 4-OEt-Ph 642 3-OCH3-Ph 4-OCF3-Ph 643 3-OCH3-Ph 4-S02CH3-Ph 644 3-OCH3-Ph 4-OH-Ph 645 3-OCH3-Ph 4-CH3-Ph 646 3-OCH3-Ph 4-C2H5-Ph 647 3-OCH3-Ph 2,4-diF-Ph 648 3-OCH3-Ph 2,5-diF-Ph 649 3-OCH3-Ph 3,4-diF-Ph 650 3-OCH3-Ph 3,5-diF-Ph 651 3-OCH3-Ph 2,4-diCl-Ph 652 3-OCH3-Ph 2,5-diCl-Ph 653 3-OCH3-Ph 3,4-diCl-Ph 654 3-OCH3-Ph 3,5-diCl-Ph 655 3-OCH3-Ph 3,4-OCH20-Ph 656 3-OCH3-Ph 3,4-OCH2CH20-Ph 657 3-OCH3-Ph 2-thienyl 658 3-OCH3-Ph 2-furanyl 659 3-OCH3-Ph 2-pyridyl 660 3-OCH3-Ph 4-pyridyl 661 3-OCH3-Ph 2-imidazolyl 662 3-OCH3-Ph 3-pyrazolyl 663 3-OCH3-Ph 2-thiazolyl 664 3-OCH3-Ph 5-tetrazol 1 665 3-OCH3-Ph 1-adamantyl 666 2-thienyl 3-CN-Ph 667 2-thienyl 3-COCH3-Ph 668 2-thienyl 3-F-Ph 669 2-thien 1 3-Cl-Ph I 670 ~ 2-thienyl ( 3-NH2-Ph 671 2-thienyl 3-OCH3-Ph 672 2-thienyl _ 3-OH-Ph 673 2-thienyl 4-CN-Ph 674 2-thienyl 4-COCH3-Ph 675 2-thienyl 4-F-Ph 676 2-thienyl 4-C1-Ph 677 2-thienyl 4-NH2-Ph 678 2-thienyl 4-OCH3-Ph 679 2-thienyl 4-OH-Ph 680 2-thienyl 3,4-diF-Ph 681 2-thienyl 3,5-diF-Ph 682 2-thienyl 3,4-diCl-Ph 683 2-thienyl 3,5-diCl-Ph 684 2-thienyl 3,4-OCH20-Ph 685 2-thienyl 3,4-OCH2CH20-Ph 686 3-thienyl 3-CN-Ph 687 3-thienyl 3-COCH3-Ph 688 3-thienyl 3-F-Ph 689 3-thienyl 3-Cl-Ph 690 3-thienyl 3-NH2-Ph 691 3-thienyl 3-OCH3-Ph 692 3-thienyl 3-OH-Ph 693 3-thien 1 4-CN-Ph 694 3-thien 1 4-COCH3-Ph 695 3-thienyl 4-F-Ph 696 3-thienyl 4-C1-Ph 697 3-thienyl 4-NH2-Ph 698 3-thienyl 4-OCH3-Ph 699 3-thienyl 4-OH-Ph 700 3-thienyl 3,4-diF-Ph 701 3-thienyl 3,5-diF-Ph 702 3-thienyl 3,4-diCl-Ph 703 3-thienyl 3,5-diCl-Ph 704 3-thienyl 3,4-OCH20-Ph 705 3-thienyl 3,4-OCH2CH20-Ph 706 2-furanyl 3-CN-Ph 707 2-furanyl 3-COCH3-Ph 708 2-furanyl 3-F-Ph 709 2-furanyl 3-C1-Ph 710 2-furanyl 3-NH2-Ph 711 2-furanyl 3-OCH3-Ph 712 2-furanyl 3-OH-Ph 713 2-furanyl 4-CN-Ph 714 2-furanyl 4-COCH3-Ph 715 2-furanyl 4-F-Ph 716 2-furanyl 4-C1-Ph 717 2-furan 1 4-NH2-Ph 718 2-furan 1 4-OCH3-Ph 719 2-furanyl 4-OH-Ph 720 2-furan 1 3,4-diF-Ph 721 2-furanyl 3,5-diF-Ph 722 2-furanyl 3,4-diCl-Ph 723 2-furanyl 3,5-diCl-Ph 724 2-furanyl 3,4-OCH20-Ph 725 2-furanyl 3,4-OCH2CH20-Ph 726 3-furanyl 3-CN-Ph 727 3-furanyl 3-COCH3-Ph 728 3-furanyl 3-F-Ph 729 3-furanyl 3-Cl-Ph 730 3-furanyl 3-NH2-Ph 73l 3-furanyl 3-OCH3-Ph 732 3-furanyl 3-OH-Ph 733 3-furanyl 4-CN-Ph 734 3-furanyl 4-COCH3-Ph 735 3-furanyl 4-F-Ph 736 3-furanyl 4-Cl-Ph 737 3-furanyl 4-NH2-Ph 738 3-furanyl 4-OCH3-Ph 739 3-furan 1 4-OH-Ph 740 3-furanyl 3,4-diF-Ph 741 3-furanyl 3,5-diF-Ph 742 3-furanyl 3,4-diCl-Ph 743 3-furanyl 3,5-diCl-Ph 744 3-furanyl 3,4-OCH20-Ph 745 3-furanyl 3,4-OCH2CH20-Ph 746 2- yridyl 3-CN-Ph 747 2-pyridyl 3-COCH3-Ph 748 2-pyrid 1 3-F-Ph 749 2-pyridyl 3-Cl-Ph 750 2- ridyl 3-NH2-Ph 751 2- yridyl 3-OCH3-Ph 752 2-pyridyl 3-OH-Ph 753 2-pyridyl 4-CN-Ph 754 2-pyridyl 4-COCH3-Ph 755 2-pyrid 1 4-F-Ph 756 2-pyridyl 4-C1-Ph 757 2-pyridyl 4-NH2-Ph 758 2-pyrid 1 4-OCH3-Ph 759 2- yridyl 4-OH-Ph 760 2-pyrid 1 3,4-diF-Ph 761 2-pyridyl 3,5-diF-Ph 762 2-pyridyl 3,4-diCl-Ph 763 2-pyrid 1 3,5-diCl-Ph 764 2-pyridyl 3,4-OCH20-Ph 765 2-p ridyl 3,4-OCH2CH20-Ph 766 3-pyridyl 3-CN-Ph 767 3-pyridyl 3-COCH3-Ph 768 3-pyridyl 3-F-Ph 769 3- yrid 1 3-C1-Ph 770 3- yrid 1 3-NH2-Ph 771 3-pyridyl 3-OCH3-Ph 772 3-pyridyl 3-OH-Ph 773 3-pyridyl 4-CN-Ph 774 3-pyrid 1 4-COCH3-Ph 775 3-pyridyl 4-F-Ph 776 3-p ridyl 4-C1-Ph 777 3- ridyl 4-NH2-Ph 778 3-pyridyl 4-OCH3-Ph 779 3-p ridyl 4-OH-Ph 780 3-pyridyl 3,4-diF-Ph 781 3-pyridyl 3,5-diF-Ph 782 3-pyridyl 3,4-diCl-Ph 783 3-pyridyl 3,5-diCl-Ph 784 3-pyridyl 3,4-OCH20-Ph 785 3-pyridyl 3,4-OCH2CH20-Ph 786 4-pyridyl 3-CN-Ph 787 4-pyridyl 3-COCH3-Ph 788 4-pyridyl 3-F-Ph 789 4-pyridyl 3-Cl-Ph 790 4-pyridyl 3-NH2-Ph 791 4-pyridyl 3-OCH3-Ph 792 4-pyridyl 3-OH-Ph 793 4-pyridyl 4-CN-Ph 794 4-pyridyl 4-COCH3-Ph 795 4-pyridyl 4-F-Ph 796 4-pyridyl 4-C1-Ph 797 4-p ridyl 4-NH2-Ph.

798 4-pyridyl 4-OCH3-Ph 799 4-pyridyl 4-OH-Ph 800 4-pyridyl 3,4-diF-Ph 801 4-pyridyl 3,5-diF-Ph 802 4-p ridyl 3,4-diCl-Ph 803 4-pyridyl 3,5-diCl-Ph 804 4-pyrid 1 3,4-OCH20-Ph 805 4-pyrid 1 3,4-OCH2CH20-Ph 806 3-indolyl 3-CN-Ph 807 3-indolyl 3-COCH3-Ph 808 3-indolyl 3-F-Ph 809 3-indol 1 3-C1-Ph 810 3-indol 1 3-NH2-Ph 811 3-indolyl 3-OCH3-Ph 812 3-indolyl 3-OH-Ph 813 3-indolyl 4-CN-Ph 814 3-indolyl 4-COCH3-Ph 815 3-indolyl 4-F-Ph 816 3-indolyl 4-Cl-Ph 817 3-indolyl 4-NH2-Ph 818 3-indol 1 4-OCH3-Ph 819 3-indolyl 4-OH-Ph 820 3-indolyl 3,4-diF-Ph 821 3-indolyl 3,5-diF-Ph 822 3-indolyl 3,4-diCl-Ph 823 3-indolyl 3,5-diCl-Ph 824 3-indolyl 3,4-OCH20-Ph 825 3-indolyl 3,4-OCH2CH20-Ph 826 5-indolyl 3-CN-Ph 827 5-indolyl 3-COCH3-Ph 828 5-indolyl 3-F-Ph 829 5-indolyl 3-Cl-Ph 830 5-indolyl 3-NH2-Ph 831 5-indolyl 3-OCH3-Ph 832 5-indolyl 3-OH-Ph 833 5-indolyl 4-CN-Ph 834 5-indolyl 4-COCH3-Ph 835 5-indolyl 4-F-Ph 836 5-indolyl 4-C1-Ph 837 5-indolyl 4-NH2-Ph 838 5-indolyl 4-OCH3-Ph 839 5-indolyl 4-OH-Ph 840 5-indolyl 3,4-diF-Ph 841 5-indolyl 3,5-diF-Ph 842 5-indol 1 3,4-diCl-Ph 843 5-indolyl 3,5-diCl-Ph 844 5-indolyl 3,4-OCH20-Ph 845 5-indolyl 3,4-OCH2CH20-Ph 846 5-indazolyl 3-CN-Ph 847 5-indazolyl 3-COCH3-Ph 848 5-indazolyl 3-F-Ph 849 5-indazolyl 3-C1-Ph 850 5-indazolyl 3-NH2-Ph 851 5-indazolyl 3-OCH3-Ph 852 5-indazolyl 3-OH-Ph 853 5-indazol 1 4-CN-Ph 854 5-indazol 1 4-COCH3-Ph 855 5-indazolyl 4-F-Ph 856 5-indazol 1 4-C1-Ph 857 5-indazolyl 4-NH2-Ph 858 5-indazolyl 4-OCH3-Ph 859 5-indazol 1 4-OH-Ph 860 5-indazolyl 3,4-diF-Ph 861 5-indazolyl 3,5-diF-Ph 862 5-indazolyl 3,4-diCl-Ph 863 5-indazolyl 3,5-diCl-Ph 864 5-indazol 1 3,4-OCH20-Ph 865 5-indazol 1 3,4-OCH2CH20-Ph 866 5-benzimidazolyl 3-CN-Ph 867 5-benzimidazolyl 3-COCH3-Ph 868 5-benzimidazolyl 3-F-Ph 869 5-benzimidazol 1 3-C1-Ph 870 5-benzimidazolyl 3-NH2-Ph 871 5-benzimidazolyl 3-OCH3-Ph 872 5-benzimidazolyl 3-OH-Ph 873 5-benzimidazolyl 4-CN-Ph 874 5-benzimidazolyl 4-COCH3-Ph 875 5-benzimidazol 1 4-F-Ph 876 5-benzimidazolyl 4-C1-Ph 877 5-benzimidazolyl 4-NH2-Ph 878 5-benzimidazolyl 4-OCH3-Ph 879 5-benzimidazolyl 4-OH-Ph 880 5-benzimidazol 1 3,4-diF-Ph 881 5-benzimidazolyl 3,5-diF-Ph 882 5-benzimidazolyl 3,4-diCl-Ph 883 5-benzimidazolyl 3,5-diCl-Ph 884 5-benzimidazolyl 3,4-OCH20-Ph 885 5-benzimidazolyl 3,4-OCH2CH20-Ph 886 5-benzothiazolyl 3-CN-Ph 887 5-benzothiazolyl 3-COCH3-Ph 888 5-benzothiazolyl 3-F-Ph 889 5-benzothiazolyl 3-Cl-Ph 890 5-benzothiazolyl 3-NH2-Ph 891 5-benzothiazolyl 3-OCH3-Ph 892 5-benzothiazolyl 3-OH-Ph 893 5-benzothiazolyl 4-CN-Ph 894 5-benzothiazolyl 4-COCH3-Ph 895 5-benzothiazolyl 4-F-Ph 896 5-benzothiazolyl 4-C1-Ph 897 5-benzothiazolyl 4-NH2-Ph 898 5-benzothiazolyl 4-OCH3-Ph 899 5-benzothiazolyl 4-OH-Ph 900 5-benzothiazolyl 3,4-diF-Ph 901 5-benzothiazolyl 3,5-diF-Ph 902 5-benzothiazolyl 3,4-diCl-Ph 903 5-benzothiazolyl 3,5-diCl-Ph 904 5-benzothiazolyl 3,4-OCH20-Ph 905 5-benzothiazolyl 3,4-OCH2CH20-Ph 906 5-benzoxazolyl 3-CN-Ph 23l 907 5-benzoxazolyl 3-COCH3-Ph 908 5-benzoxazolyl 3-F-Ph 909 5-benzoxazolyl 3-Cl-Ph 910 5-benzoxazolyl 3-NH2-Ph 911 5-benzoxazolyl 3-OCH3-Ph 912 5-benzoxazol 1 3-OH-Ph 913 5-benzoxazolyl 4-CN-Ph 914 5-benzoxazolyl 4-COCH3-Ph :915 5-benzoxazol 1 4-F-Ph 916 5-benzoxazolyl 4-Cl-Ph 917 5-benzoxazol 1 4-NH2-Ph 918 5-benzoxazolyl 4-OCH3-Ph 919 5-benzoxazolyl 4-OH-Ph 920 5-benzoxazol 1 3,4-diF-Ph 921 5-benzoxazolyl 3,5-diF-Ph 922 5-benzoxazolyl 3,4-diCl-Ph 923 5-benzoxazolyl 3,5-diCl-Ph 924 5-benzoxazolyl 3,4-OCH20-Ph 925 5-benzoxazolyl 3,4-OCH2CH20-Ph TABLE 6*

HN~ N-R HN~ N R HN~ N-R
_ H F H ~.. H

HN~ H R ~~ N R3 HN~ N R3 C ~ ~ H ~ H
Cl R R

C1 ~ HN~N~R3 v H

HN~H R3 ~ HNnH Rs i /~ I' 3 7 ~'V/~~ HN ~H R g HN~H R3 HN~H R3 1 HN~N'R3 / " H
F F
~~ ~R ~ R3 i~~~~N

F F
R~ Q R14 C1 ~~N.R3 15 ~ 3 17 ~ R3 N HN- 'H R R14 , HN H
Cl~~~~~ C

R~ R14 ~ HNJ~N.R3 H

O
N HN N'R3 R14 ~ _Rs H 2 0 F\~~~~ ~ H
F
F

~ 3 HN" H R
F
~~N.R13 R14 ~~N.R3 H 23 C1 ~ H

H HN- 'N-R3 H ~ .R3 H i~',,~~~ HIV H

H HN~IV-R3 F

~\ J~~N HN~H-R'3 2 6 Cl HN H R
R14 F HN_ _N'R3 3 0 14 H R

~14 H HN_ _N'R3 29 C1 H HN~~R3 H H

F H ~ Rs HN~I~ 3 3 R

HN H.R 32 C1 HN,~H R3 H ~ _R3 C1 H ~ Rs ~.~N.R3 HN- _IdR3 C1 ~NR3 H _ H '~~~~~~ _HN ~H

0 3 O ~ O 3 N HN,~N.R 1 ~ N ~~N.R3 F 1 ~ N ~~H.R
~ H ~~~~ ~ H 14 R14~ F R14~ R \ /

_ ~ O O
N HN N~R'3 Cl ' ~ N ~ HN~N~R.3 F 1 ~ N HN~N~R3 Cl 14 H 14 H F ~ 14 H
R \ / R \ / R
\ /

F ~ ~N HN~H~F' C1 I ~ N ~ J~N.R3 C1 1 \ N ~~N'R3 F R \ / C1 R14 \ / C1 R14 H
\ /

F O 3 Cl O
O
F ~ N HN~N~R C1~~\~~N HN~N'R.3 C1'~~,.~~~N HN~N'R3 14 H ' ~ H
R \ / R14 F 14 H
\ / R
\ /

O O
N HN~N~R3 F t ~ N HN~N~R3 \ N HN~N~R3 14 H \~~~ H
R \ / R14 F R14 H
\ / \ /

O
F I ~ HN~N~R3 F ~ ~ N HN~H~I'3 \ ~ 3 i N HN N~R' H F 14 ~ /
Cl R14 R \ / F i4 H
\ / R
F \ /

0 ~ 0 s C1 1 ~ N HN~N~R3 1 ~ N HN~H~R CZ ~ N ~~N,R3 14 H C 1 R14 ~ s' H
R \ / C1 i4 \ / R
\ /

Entry R3 R14 1 Ph CN

2 Ph F

3 Ph C1 4 Ph CH20H

Ph OH

6 Ph NH2 7 Ph C02Me 8 Ph C02Et 9 Ph CONH2 Ph NHPh 11 Ph NHMe 12 Ph OMe 13 Ph C(O)(2-imidazolyl) 14 Ph C(0)(4-imidazolyl) Ph C(O)(2-thiazolyl) 16 Ph C(0)(4-thiazolyl) 17 Ph C(O)(2-oxazolyl) 18 Ph C(O)(4-oxazolyl) 19 Ph C{O){3-pyrazolyl) Ph C(0)(4-pyrazolyl) 21 Ph C(O)(5-tetrazolyl) 22 Ph C(0)(2-pyridyl) 23 Ph C(0)(3-pyridyl) 24 Ph C(O)(4-pyridyl) Ph C(0)(2-thienyl) 26 Ph C(O){3-thienyl) 27 Ph C(0)(2-furanyl) 28 Ph C(O)(3-furanyl) 29 Ph 2-thienyl Ph 3-thienyl 31 Ph 2-furanyl 32 Ph 3-furanyl 33 Ph 2-pyridyl 34 Ph 3-pyridyl Ph 4-pyridyl 36 Ph 1-imidazolyl 37 Ph 2-imidazolyl 38 Ph 4-imidazolyl 39 Ph 1-pyrazolyl Ph 3-pyrazolyl 41 Ph 4-pyrazolyl 42 Ph 2-thiazolyl 43 Ph 4-thiazolyl 44 Ph 5-tetrazolyl Ph 2-oxazolyl 46 Ph 4-oxazolyl 47 Ph C(0)N(2-imidazolyl) 48 Ph C(0)N(4-imidazolyl) 49 Ph C(O)N(2-thiazolyl) Ph C(0)N(4-thiazolyl) 51 Ph C(0)N(2-oxazolyl) 52 Ph C(O)N{4-oxazolyl) 53 Ph C(O)N(3-pyrazolyl) 54 Ph C(OjN(4-pyrazolyl) 55 Ph C(0)N(2-pyridyl) 56 Ph C(0)N(3-pyridyl) 57 Ph C{0)N(4-pyridyl) .

58 Ph C(O)N(2-thienyl) 59 Ph C(0)N(3-thienyl) 60 Ph C(O)N(2-furanyl) 61 Ph C(0)N(3-furanyl) 62 Ph C(0)N(2-pyrrolyl) 63 Ph C(O)N(3-pyrrolyl) 64 Ph CH2(1-imidazolyl) 65 Ph CH2(1-(1,2,3-triazolyl)) 66 Ph CH2{2-(1,2,3-triazolyl)) 67 Ph CH2(1-(1,2,4-triazolyl)) 68 Ph CH2 (1-pyrazolyl) 69 3-CN-Ph CN

70 3-CN-Ph F

71 3-CN-Ph C1 72 3-CN-Ph CH20H

73 3-CN-Ph OH

74 3-CN-Ph NH2 75 3-CN-Ph C02Me 76 3-CN-Ph C02Et 77 3-CN-Ph C0NH2 78 3-CN-Ph NHPh 79 3-CN-Ph NHMe 80 3-CN-Ph OMe 81 3-CN-Ph C(0)(2-imidazolyl) 82 3-CN-Ph C(0)(4-imidazolylj 83 3-CN-Ph C(0)(2-thiazolyl) 84 3-CN-Ph C(O)(4-thiazolyl) 85 3-CN-Ph C(0)(2-oxazolyl) 86 3-CN-Ph C(O){4-oxazolyl) 87 3-CN-Ph C(0)(3-pyrazolylj 88 3-CN-Ph C(O)(4-pyrazolyl) 89 3-CN-Ph C(0)(5-tetrazolyl) 90 3-CN-Ph C(O)(2-pyridyl) 91 3-CN-Ph C(O)(3-pyridyl) 92 3-CN-Ph C(O)(4-pyridyl) 93 3-CN-Ph C(0)(2-thienyl) 94 3-CN-Ph C{O)(3-thienyl) 95 3-CN-Ph C(0)(2-furanyl) 96 3-CN-Ph C(0)(3-furanylj 97 3-CN-Ph 2-thienyl 98 3-CN-Ph 3-thienyl 99 3-CN-Ph 2-furanyl 100 3-CN-Ph 3-furanyl 101 3-CN-Ph 2-pyridyl 102 3-CN-Ph 3-pyridyl 103 3-CN-Ph 4-pyridyl 104 3-CN-Ph 1-imidazolyl 105 3-CN-Ph 2-imidazolyl 106 3-CN-Ph 4-imidazolyl 107 3-CN-Ph 1-pyrazolyl 108 3-CN-Ph 3-pyrazolyl 109 3-CN-Ph 4-pyrazolyl 110 3-CN-Ph 2-thiazolyl 111 3-CN-Ph 4-thiazolyl 112 3-CN-Ph 5-tetrazolyl 113 3-CN-Ph 2-oxazolyl 114 3-CN-Ph 4-oxazolyl 115 3-CN-Ph C(O)N(2-imidazolyl) 116 3-CN-Ph C(O)N(4-imidazolyl) 117 3-CN-Ph C(0)N(2-thiazolyl) 118 3-CN-Ph C(0)N(4-thiazolyl) 119 3-CN-Ph C(O)N(2-oxazolyl) 120 3-CN-Ph C(0)N(4-oacazolyl) 121 3-CN-Ph C(0)N(3-pyrazolyl) 122 3-CN-Ph C(0)N(4-pyrazolyl) 123 3-CN-Ph C(0)N(2-pyridyl) 124 3-CN-Ph C(O)N(3-pyridyl) 125 3-CN-Ph C(O)N(4-pyridyl) 126 3-CN-Ph C(0)N(2-thienyl) 127 3-CN-Ph C(0)N(3-thienyl) 128 3-CN-Ph C(O)N(2-furanyl) 129 3-CN-Ph C(O)N(3-furanyl) 130 3-CN-Ph C(0)N(2-pyrrolyl) 131 3-CN-Ph C(O)N(3-pyrrolyl) 132 3-CN-Ph CH2(1-imidazolyl) 133 3-CN-Ph CH2(1-(1,2,3-triazolyl)) 134 3-CN-Ph CH2(2-(1,2,3-triazolyl)) 135 3-CN-Ph CH2(1-(1,2,4-triazolyl)) 136 3-CN-Ph CH2(1-pyrazolyl) 137 3-OMe-Ph CN

138 3-OMe-Ph F

139 3-OMe-Ph C1 140 3-OMe-Ph CH20H

141 3-OMe-Ph OH

142 3-OMe-Ph NH2 143 3-OMe-Ph C02Me 144 3-OMe-Ph C02Et 145 3-OMe-Ph CONA2 146 3-OMe-Ph NHPh 147 3-OMe-Ph NHMe 148 3-OMe-Ph OMe 149 3-OMe-Ph C(O)(2-imidazolyl) 150 3-OMe-Ph C(O)(4-imidazolyl) 151 3-OMe-Ph C(O)(2-thiazolyl) 152 3-OMe-Ph C(O)(4-thiazolyl) 153 3-OMe-Ph C(O)(2-oxazolyl) 154 3-OMe-Ph C(O)(4-oxazolyl) 155 3-OMe-Ph C(O)(3-pyrazolyl) 156 3-OMe-Ph C(O)(4-pyrazolyl) 157 3-OMe-Ph C(0)(5-tetrazolyl) 158 3-OMe-Ph C(O)(2-pyridyl) 159 3-OMe-Ph C(O)(3-pyridyl) 160 3-OMe-Ph C(O)(4-pyridyl) 161 3-OMe-Ph C(O)(2-thienyl) 162 3-OMe-Ph C(O)(3-thienyl) 263 3-OMe-Ph C(O)(2-furanyl) 164 3-OMe-Ph C(0)(3-furanyl) 165 3-OMe-Ph 2-thienyl 166 3-OMe-Ph 3-thienyl 167 3-OMe-Ph 2-furanyl 168 3-OMe-Ph 3-furanyl 169 3-OMe-Ph 2-pyridyl 170 3-OMe-Ph 3-pyridyl 171 3-OMe-Ph 4-pyridyl 172 3-OMe-Ph 1-imidazolyl 173 3-OMe-Ph 2-imidazolyl 174 3-OMe-Ph 4-imidazolyl 175 3-OMe-Ph 1-pyrazolyl 176 3-OMe-Ph 3-pyrazolyl 177 3-OMe-Ph 4-pyrazolyl 178 3-OMe-Ph 2-thiazolyl 179 3-OMe-Ph 4-thiazolyl 180 3-OMe-Ph 5-tetrazolyl 281 3-OMe-Ph 2-oxazolyl 182 3-OMe-Ph 4-oxazolyl 183 3-OMe-Ph C(0)N(2-imidazolyl) 184 3-OMe-Ph C(O)N(4-imidazolyl) 185 3-OMe-Ph C(O)N(2-thiazolyl) 186 3-OMe-Ph C(O)N(4-thiazolyl) 187 3-OMe-Ph C(O)N(2-oxazolyl) 188 3-OMe-Ph C(O)N(4-oxazolyl) 189 3-OMe-Ph C(O)N(3-pyrazolyl) 190 3-OMe-Ph C(O)N(4-pyrazolyl) 191 3-OMe-Ph C(O)N(2-pyridyl) 192 3-OMe-Ph C(O)N(3-pyridyl) 193 3-OMe-Ph C(O)N(4-pyridyl) 194 3-OMe-Ph C(0)N(2-thienyl) 195 3-OMe-Ph C(O)N(3-thienyl) 196 3-OMe-Ph C(O)N(2-furanyl) 197 3-OMe-Ph C(O)N(3-furanyl) 198 3-OMe-Ph C(O)N(2-pyrrolyl) 199 3-OMe-Ph C{O)N(3-pyrrolyl) 200 3-OMe-Ph CH2{1-imidazolyl) 201 3-OMe-Ph CH2{1-(1,2,3-triazolyl)j 202 3-OMe-Ph CH2(2-(1,2,3-triazolyl)) 203 3-OMe-Ph CH2(1-(1,2,4-triazolyl)) 204 3-OMe-Ph CH2(1-pyrazolyl) 205 3-C(O)Me-Ph CN

206 3-C(O)Me-Ph F

207 3-C(OjMe-Ph Cl 208 3-C(O)Me-Ph CH20H

209 3-C(O)Me-Ph OH

210 3-C (0j Me-Ph NH2 211 3-C{O)Me-Ph C02Me 212 3-C(O)Me-Ph C02Et 213 3-C(O)Me-Ph CONH2 214 3-C(O)Me-Ph NHPh 215 3-C(O)Me-Ph NHMe 216 3-C(O)Me-Ph OMe 217 3-C(0)Me-Ph C(0)(2-imidazolyl) 218 3-C(0)Me-Ph C(O)(4-imidazolyl) 219 3-C(O)Me-Ph C(O)(2-thiazolyl) 220 3-C(0)Me-Ph C(0)(4-thiazolyl) 221 3-C(0)Me-Ph C(O)(2-oxazolyl) 222 3-C(0)Me-Ph C(O)(4-oxazolyl) 223 3-C(0)Me-Ph C(O)(3-pyrazolyl) 224 3-C(0)Me-Ph C(O)(4-pyrazolyl) 225 3-C(O)Me-Ph C(O)(5-tetrazolyl) 226 3-C{0)Me-Ph C{O)(2-pyridyl) 227 3-C(0)Me-Ph C(O)(3-pyridyl) 228 3-C(0)Me-Ph C(O)(4-pyridyl) 229 3-C(0)Me-Ph C(O)(2-thienyl) 230 3-C(0)Me-Ph C{Oj(3-thienyl) 231 3-C(O)Me-Ph C(0)(2-furanyl) 232 3-C(O)Me-Ph C(O){3-furanyl) 233 3-C{O)Me-Ph 2-thienyl 234 3-C(0)Me-Ph 3-thienyl 235 3-C(O)Me-Ph 2-furanyl 236 3-C(O)Me-Ph 3-furanyl 237 3-C{O)Me-Ph 2-pyridyl 238 3-C(O)Me-Ph 3-pyridyl 239 3-C(O)Me-Ph 4-pyridyl 240 3-C(O)Me-Ph 1-imidazolyl 241 3-C(O)Me-Ph 2-imidazolyl 242 3-C(O)Me-Ph 4-imidazolyl 243 3-C(O)Me-Ph 1-pyrazolyl 244 3-C{O)Me-Ph 3-pyrazolyl 245 3-C(O)Me-Ph 4-pyrazolyl 246 3-C(O)Me-Ph 2-thiazolyl 247 3-C(O)Me-Ph 4-thiazolyl 248 3-C(O)Me-Ph 5-tetrazolyl 249 3-C(O)Me-Ph 2-oxazolyl 250 3-C(O)Me-Ph 4-oxazolyl 251 3-C(O)Me-Ph C(O)N(2-imidazolyl) 252 3-C(O)Me-Ph C(O)N(4-imidazolyl) 253 3-C(O)Me-Ph C(O)N(2-thiazolyl) 254 3-C(O)Me-Ph C(O)N(4-thiazolyl) 255 3-C{O)Me-Ph C(O)N(2-oxazolyl) 256 3-C(O)Me-Ph C(O)N(4-oxazolyl) 257 3-C(O)Me-Ph C(O)N(3-pyrazolyl) 258 3-C(O)Me-Ph C(O)N(4-pyrazolyl) 259 3-C(O)Me-Ph C(O)N(2-pyridyl) 260 3-C(O)Me-Ph C(O)N(3-pyridyl) 261 3-C(O)Me-Ph C(O)N{4-pyridyl) 262 3-C(O)Me-Ph C(O)N(2-thienyl) 263 3-C(O)Me-Ph C(O)N(3-thienyl) 264 3-C(O)Me-Ph C(O)N(2-furanyl) 265 3-C(O)Me-Ph C(O)N(3-furanyl) 266 3-C(O)Me-Ph C(O)N(2-pyrrolyl) 267 3-C(O)Me-Ph C(O)N(3-pyrrolyl) 268 3-C(O)Me-Ph CH2(1-imidazolyl) 269 3-C(O)Me-Ph CH2(1-(1,2,3-triazolyl)) 270 3-C(O)Me-Ph CH2(2-(1,2,3-triazolyl)) 271 3-C(O)Me-Ph CH2(1-(1,2,4-triazolyl)) 272 3-C(O)Me-Ph CH2(1-pyrazolyl) 273 4-F-Ph CN

274 4-F-Ph F

275 4-F-Ph C1 276 4-F-Ph CH20H

277 4-F-Ph OH

278 4-F-Ph NH2 279 4-F-Ph C02Me 280 4-F-Ph C02Et 281 4-F-Ph CONH2 282 4-F-Ph NHPh 283 4-F-Ph NHMe 284 4-F-Ph OMe 285 4-F-Ph C(O)(2-imidazolyl) 286 4-F-Ph C(O)(4-imidazolyl) 287 4-F-Ph C(O)(2-thiazolyl) 288 4-F-Ph C(O)(4-thiazolyl) 289 4-F-Ph C(O)(2-oxazolyl) 290 4-F-Ph C(O)(4-oxazolyl) 291 4-F-Ph C(O)(3-pyrazolyl) 292 4-F-Ph C (O) (4-pyrazolyl) 293 4-F-Ph C(O)(5-tetrazolyl) 294 4-F-Ph C(O)(2-pyridyl) 295 4-F-Ph C(O)(3-pyridyl) 296 4-F-Ph C (O) (4-pyridyl) 297 4-F-Ph C(O)(2-thienyl) 298 4-F-Ph C(O)(3-thienyl) 299 4-F-Ph C(O)(2-furanyl) 300 4-F-Ph C(O)(3-furanyl) 301 4-F-Ph 2-thienyl 302 4-F-Ph 3-thienyl 303 4-F-Ph 2-furanyl 304 4-F-Ph 3-furanyl 305 4-F-Ph 2-pyridyl 306 4-F-Ph 3-pyridyl 307 4-F-Ph 4-pyridyl 308 4-F-Ph 1-imidazolyl 309 4-F-Ph 2-imidazolyl 310 4-F-Ph 4-imidazolyl 311 4-F-Ph 1-pyrazolyl 312 4-F-Ph 3-pyrazolyl 313 4-F-Ph 4-pyrazolyl 314 4-F-Ph 2-thiazolyl 315 4-F-Ph 4-thiazolyl 316 4-F-Ph 5-tetrazolyl 317 4-F-Ph 2-oxazolyl 328 4-F-Ph 4-oxazolyl 319 4-F-Ph C(O)N(2-imidazolyl) 320 4-F-Ph C(O)N(4-imidazolyl) 321 4-F-Ph C(O)N(2-thiazolyl) 322 4-F-Ph C(O)N(4-thiazolyl) 323 4-F-Ph C(O)N(2-oxazolyl) 324 4-F-Ph C(O)N(4-oxazolyl) 325 4-F-Ph C(O)N(3-pyrazolyl) 326 4-F-Ph C(O)N(4-pyrazolyl) 327 4-F-Ph C(0)N(2-pyridyl) 328 4-F-Ph C(O)N(3-pyridyl) 329 4-F-Ph C(O)N(4-pyridyl) 330 4-F-Ph C(O)N(2-thienyl) 331 4-F-Ph C(0)N(3-thienyl) 332 4-F-Ph C(O)N(2-furanyl) 333 4-F-Ph C(O)N(3-furanyl) 334 4-F-Ph C(O)N(2-pyrrolyl) 335 4-F-Ph C(O)N(3-pyrrolyl) 336 4-F-Ph CH2(1-imidazolyl) 337 4-F-Ph CH2(1-(1,2,3-triazolyl)) 338 4-F-Ph CH2(2-(1,2,3-triazolyl)) 339 4-F-Ph CH2(1-(1,2,4-triazolyl)) 340 I 4-F-Ph CH2(1-pyrazolyl) Table 7.

N ~N ~LN.R3 N ~ N ~ N. R3 N.~'~/~N ~LN. R3 R ~OH H H R1 OH O Rl OH H H
2a 3a 1a G N~N~N.R2 G N~N~N.R3 G N~N~N-R3 Rl OH H H Rl OH O R1 OH H H
1b 2b 3b O H H O
.R NON N. N~ ~ ~R3 G N'/~N N 3 G~~ ~ R3 G~~ N N
R R
Rl OH H H 1 OH O 1 OH H H

G ~ G
N N H G N" H
H
R1 OH HN~N.R3 R OOH HN~N.R3 Rl OH ~T~N'R3 O 9a O 10 O
8a G N~ G N H G N~ H
,H
R1 OH ~~N~R3 Rl OH ~~N R3 Rl OH ~~N R3 8b O 9b O 11 O
G ~ ~ G
N H ~N~ H G N
~ H
R1 OH ~~N~R3 Rl OH HN~.N.R3 Ri 'OH HN N'R
p ~ 3 12a 13a O 12b O
G N~ H
R1 OH_ ~' ~N R

13b O

G N~ H G N~ H
Rl OH HN~N R3 Rl OH HN~N~R3 G ~ G
N~ H N~ H
R1 OH ~~N'g,3 R1 OH HN~N R3 16a O 17a 0 G N~ H G N~ H
Rl OH ~~N R. R1 OH ~~N R3 16b 0 17b 0 G N~ H G N~ H
Rl OH ~~N R3 Rl OH ~~N~R3 G ~ O G ~, O
N N~LN.R3 N .nN~N.R3 R ~ H H
1 OH 20a H H R1 OH 21a O O
G N~N~N.Rg G N.,~r~" ~L -R3 N N
R ~OH 2 Ob H H R ~OH 21b H H

N~ J~ .R2 N~'~~,~.~N.R~
Rl N N G
H H R H H

N~N~N.R3 G N~N~N R3 G N~N~N'R.3 R1 OH 0 Rl OH 2 5 O Rl OH 2 6 O

G , OH H H ~ OH H H OH H H
N~N~N.R3 G N~N~N.Rg G N'~N~N-R3 R OH Me O R OH Me O R OH Me O
1 2~ 1 28 1 29 OH H H OH H H
G N OH N N G N~N N.R N'~N~N~R3 G
r0 R3 Rl OH ipr0 3 R ~OH lPrO

N~N~N.R3 G N~N~N R3 G N~N~N'R.3 R1 OH iBuO Rl OH iBuO Rl OH iBuO

G 1 OH H H ~ OH H H OH H H
N~N~N.R3 G N~N~N.R3 G N~N~N R3 Rl OH Ph O Rl OH Ph 0 R1 OH Ph O
36 3~ 38 N~N~N.R3 G N~N~N R3 G N~N~Ny,3 Rl OH ph O R1 OH ph O Rl OHphJ O

N N N. G N~N O N R3 G N~N~N R3 R1 OH Ph O R1 OH Ph R1 OH Ph G N ~ ~ G N ~ I H N
H G ~ H
R ~OH ~ ~ N R3 Rl OH HN ~ N ~ R3 Rl OH ~ N R

R1 = a) H, b) methyl, c) ethyl, d) n-propyl, e) allyl, f) n-butyl, g) n-pentyl, and h) n-hexyl.
Entry G R3 1 4-F-Ph Ph 2 4-F-Ph 3-CN-Ph 3 4-F-Ph 3-COCH3-Ph 4 4-F-Ph 3-C02Me-Ph 5 4-F-Ph 3-C02Et-Ph 6 4-F-Ph 3-C02H-Ph 7 4-F-Ph 3-CONH2-Ph 8 4-F-Ph 3-CONHMe-Ph 9 4-F-Ph 3-F-Ph 20 4-F-Ph 3-Cl-Ph 11 4-F-Ph 3-Br-Ph 12 4-F-Ph 3-N02-Ph 13 4-F-Ph 3-NH2-Ph 14 4-F-Ph 3-NHMe-Ph 4-F-Ph 3-NMe2-Ph 16 4-F-Ph 3-NHCOCH3-Ph 17 4-F-Ph 3-S02NH2-Ph 18 4-F-Ph 3-S02NHMe-Ph 19 4-F-Ph 3-CF3-Ph 4-F-Ph 3-OCH3-Ph 21 4-F-Ph 3-OPh-Ph 22 4-F-Ph 3-OCF3-Ph 23 4-F-Ph 3-SCH3-Ph 24 4-F-Ph 3-SOCH3-Ph 4-F-Ph 3-S02CH3-Ph 26 4-F-Ph 3-OH-Ph 27 4-F-Ph 3-CH20H-Ph 28 4-F-Ph 3-CHOHCH3-Ph 29 4-F-Ph 3-COH(CH3)2-Ph 4-F-Ph 3-CHOHPh-Ph 31 4-F-Ph 3-CH3-Ph 32 4-F-Ph 3-C2H5-Ph 33 4-F-Ph 3-iPr-Ph 34 4-F-Ph 3-tBu-Ph 4-F-Ph 3-Ph-Ph 36 4-F-Ph 3-CH2Ph-Ph 37 4-F-Ph 3-CH2C02Me-Ph 38 4-F-Ph 3-(1-pi eridinyl)-Ph 39 4-F-Ph 3-(1-pyrrolidinyl)-Ph 4-F-Ph 3-(2-imidazolyl)-Ph 41 4-F-Ph 3-(1-imidazolyl)-Ph 42 4-F-Ph 3-(2-thiazolyl)-Ph 43 4-F-Ph 3-(3-pyrazolyl)-Ph 44 4-F-Ph 3-(1-pyrazolyl)-Ph 45 4-F-Ph 3-(1-tetrazolyl)-Ph 46 4-F-Ph 3-(5-tetrazolyl)-Ph 47 4-F-Ph 3-(2-pyridyl)-Ph 48 4-F-Ph 3-(2-thienyl)-Ph 49 4-F-Ph 3-(2-furanyl)-Ph 50 4-F-Ph 4-CN-Ph 51 4-F-Ph 4-COCH3-Ph 52 4-F-Ph 4-C02Me-Ph 53 4-F-Ph 4-C02Et-Ph 54 4-F-Ph 4-C02H-Ph 55 4-F-Ph 4-CONH2-Ph 56 4-F-Ph 4-CONHMe-Ph 57 4-F-Ph 4-CONHPh-Ph 58 4-F-Ph 4-NHCONH2-Ph 59 4-F-Ph 4-F-Ph 60 4-F-Ph 4-C1-Ph 61 4-F-Ph 4-Br-Ph 62 4-F-Ph 4-N02-Ph 63 4-F-Ph 4-NH2-Ph 64 4-F-Ph 4-NHMe-Ph 65 4-F-Ph 4-NMe2-Ph 66 4-F-Ph 4-NHCOCH3-Ph 67 4-F-Ph 4-S02NH2-Ph 68 4-F-Ph 4-S02NHMe-Ph 69 4-F-Ph 4-CF3-Ph 70 4-F-Ph 4-OCH3-Ph 71 4-F-Ph 4-OPh-Ph 72 4-F-Ph 4-OCF3-Ph 73 4-F-Ph 4-SCH3-Ph 74 4-F-Ph 4-SOCH3-Ph 75 4-F-Ph 4-S02CH3-Ph 76 4-F-Ph 4-OH-Ph 77 4-F-Ph 4-CH20H-Ph 78 4-F-Ph 4-CHOHCH3-Ph 79 4-F-Ph 4-COH(CH3)2-Ph 80 4-F-Ph 4-CH3-Ph 81 4-F-Ph 4-C2H5-Ph 82 4-F-Ph 4-iPr-Ph 83 4-F-Ph 4-tBu-Ph 84 4-F-Ph 4-Ph-Ph 85 4-F-Ph 4-CH2Ph-Ph 86 4-F-Ph 4-CH2C02Me-Ph 87 4-F-Ph 4-(1-piperidinyl)-Ph 88 4-F-Ph 4-(1-pyrrolidinyl)-Ph 89 4-F-Ph 4-(2-imidazolyl)-Ph 90 4-F-Ph 4-(1-imidazolyl)-Ph 91 4-F-Ph 4-(2-thiazolyl)-Ph 92 4-F-Ph 4-(3-pyrazolyl)-Ph 93 4-F-Ph 4-(1-pyrazolyl)-Ph 94 4-F-Ph 4-(1-tetrazolyl)-Ph 95 4-F-Ph 4-(5-tetrazolyl)-Ph 96 4-F-Ph 4-(2-pyridyl)-Ph 97 4-F-Ph 4-(2-thienyl)-Ph 98 4-F-Ph 4-(2-furanyl)-Ph 9 9 4-F-Ph 2 -CN-Ph 100 4-F-Ph 2-COCH3-Ph 101 4-F-Ph 2-C02Me-Ph 102 4-F-Ph 2-C02Et-Ph 103 4-F-Ph 2-C02H-Ph 104 4-F-Ph 2-CONH2-Ph 105 4-F-Ph 2-CONHMe-Ph 106 4-F-Ph 2-F-Ph 107 4-F-Ph 2-C1-Ph 108 4-F-Ph 2-Br-Ph 109 4-F-Ph 2-N02-Ph 110 4-F-Ph 2-NH2-Ph 111 4-F-Ph 2-NHMe-Ph 112 4-F-Ph 2-NMe2-Ph 123 4-F-Ph 2-NHCOCH3-Ph 114 4-F-Ph 2-S02NH2-Ph 115 4-F-Ph 2-S02NHMe-Ph 116 4-F-Ph 2-CF3-Ph 117 4-F-Ph 2-OCH3-Ph 118 4-F-Ph 2-OPh-Ph 119 4-F-Ph 2-OCF3-Ph 120 4-F-Ph 2-SCH3-Ph 121 4-F-Ph 2-SOCH3-Ph 122 4-F-Ph 2-S02CH3-Ph 123 4-F-Ph 2-OH-Ph 124 4-F-Ph 2-CH20H-Ph 125 4-F-Ph 2-CHOHCH3-Ph 126 4-F-Ph 2-COH(CH3)2-Ph 127 4-F-Ph 2-CHOHPh-Ph 128 4-F-Ph 2-CH3-Ph 129 4-F-Ph 2-C2H5-Ph 130 4-F-Ph 2-iPr-Ph 131 4-F-Ph 2-tBu-Ph 132 4-F-Ph 2-Ph-Ph 133 4-F-Ph 2-CH2Ph-Ph 134 4-F-Ph 2-CH2C02Me-Ph 135 4-F-Ph 2-(1-piperidinyl)-Ph 136 4-F-Ph 2-(1-pyrrolidinyl)-Ph 137 4-F-Ph 2-(2-imidazolyl)-Ph 138 4-F-Ph 2-(1-imidazolyl)-Ph 139 4-F-Ph 2-(2-thiazolyl)-Ph 140 4-F-Ph 2-(3-pyrazolyl)-Ph 141 4-F-Ph 2-(1-pyrazolyl)-Ph 142 4-F-Ph 2-(1-tetrazolyl)-Ph 143 4-F-Ph 2-(5-tetrazolyl)-Ph 144 4-F-Ph 2-(2-p ridyl)-Ph 145 4-F-Ph 2-(2-thienyl)-Ph 146 4-F-Ph 2-(2-furanyl)-Ph 147 4-F-Ph 2,4-diF-Ph 148 4-F-Ph 2,5-diF-Ph 149 4-F-Ph 2,6-diF-Ph 150 4-F-Ph 3,4-diF-Ph 151 4-F-Ph 3,5-diF-Ph 152 4-F-Ph 2,4-diCl-Ph 153 4-F-Ph 2,5-diCl-Ph 154 4-F-Ph 2,6-diCl-Ph 155 4-F-Ph 3,4-diCl-Ph 156 4-F-Ph 3,5-diCl-Ph 157 4-F-Ph 3,4-diCF3-Ph 158 4-F-Ph 3,5-diCF3-Ph 159 4-F-Ph 5-Cl-2-Me0-Ph 160 4-F-Ph 5-Cl-2-Me-Ph 161 4-F-Ph 2-F-5-Me-Ph 162 ~ 4-F-Ph 2-F-5-N02-Ph 163 4-F-Ph 3,4-OCH20-Ph 164 4-F-Ph 3,4-OCH2CH20-Ph 165 4-F-Ph 2-Me0-4-Me-Ph 166 4-F-Ph 2-Me0-5-Me-Ph 167 4-F-Ph 1-naphth 1 168 4-F-Ph 2-naphthyl 169 4-F-Ph 2-thien 1 170 4-F-Ph 3-thienyl 171 4-F-Ph 2-furanyl 172 4-F-Ph 3-furanyl 173 4-F-Ph 2-pyridyl 174 4-F-Ph 3-pyrid 1 175 4-F-Ph 4-pyridyl 176 4-F-Ph 2-indolyl 177 4-F-Ph 3-indolyl 178 4-F-Ph 5-indolyl 179 4-F-Ph 6-indolyl 180 4-F-Ph 3-indazolyl 181 4-F-Ph 5-indazolyl 182 4-F-Ph 6-indazolyl 183 4-F-Ph 2-imidazol 1 184 4-F-Ph 3-pyrazol 1 185 4-F-Ph 2-thiazolyl 186 4-F-Ph 5-tetrazolyl 187 4-F-Ph 2-benzimidazolyl 188 4-F-Ph 5-benzimidazolyl 189 4-F-Ph 2-benzothiazolyl 190 4-F-Ph 5-benzothiazolyl 191 4-F-Ph 2-benzoxazolyl 192 4-F-Ph 5-benzoxazolyl 193 4-F-Ph 1-adamantyl 194 4-F-Ph 2-adamantyl 195 4-F-Ph t-Bu 196 2-F-Ph 3-CN-Ph 197 2-F-Ph 3-COCH3-Ph 198 2-F-Ph 3-C02Me-Ph 199 2-F-Ph 3-C02Et-Ph 200 2-F-Ph 3-C02H-Ph 201 2-F-Ph 3-CONH2-Ph 202 2-F-Ph 3-F-Ph 203 2-F-Ph 3-C1-Ph 2 04 2-F-Ph 3 -NH2-Ph 205 2-F-Ph 3-S02NH2-Ph 206 2-F-Ph 3-CF3-Ph 207 2-F-Ph 3-OCH3-Ph 208 2-F-Ph 3-OEt-Ph 209 2-F-Ph 3-OCF3-Ph 210 2-F-Ph 3-S02CH3-Ph 211 2-F-Ph 3-OH-Ph 212 2-F-Ph 3-CH3-Ph 213 2-F-Ph 3-C2H5-Ph 214 2-F-Ph 4-CN-Ph 215 2-F-Ph 4-COCH3-Ph 216 2-F-Ph 4-C02Me-Ph 217 2-F-Ph 4-C02Et-Ph 218 2-F-Ph 4-C02H-Ph 219 2-F-Ph 4-CONH2-Ph 220 2-F-Ph 4-F-Ph 221 2-F-Ph 4-C1-Ph 222 2-F-Ph 4-NH2-Ph 223 2-F-Ph 4-S02NH2-Ph 224 2-F-Ph 4-CF3-Ph 22S 2-F-Ph 4-OCH3-Ph 226 2-F-Ph 4-OEt-Ph 227 2-F-Ph 4-OCF3-Ph 228 2-F-Ph 4-S02CH3-Ph 229 2-F-Ph 4-OH-Ph 230 2-F-Ph 4-CH3-Ph 231 2-F-Ph 4-C2H5-Ph 232 2-F-Ph 2,4-diF-Ph 233 2-F-Ph 2,5-diF-Ph 234 2-F-Ph 3,4-diF-Ph 235 2-F-Ph 3,5-diF-Ph 236 2-F-Ph 2,4-diCl-Ph 237 2-F-Ph 2,5-diCl-Ph 238 2-F-Ph 3,4-diCl-Ph 239 2-F-Ph 3,5-diCl-Ph 240 2-F-Ph 3,4-OCH20-Ph 241 2-F-Ph 3,4-OCH2CH20-Ph 242 2-F-Ph 2-thien 1 243 2-F-Ph 2-furan 1 244 2-F-Ph 2- ridyl 245 2-F-Ph 4- yridyl 246 2-F-Ph 2-imidazolyl 247 2-F-Ph 3-pyrazolyl 248 2-F-Ph 2-thiazolyl 249 2-F-Ph 5-tetrazolyl 250 2-F-Ph 1-adamantyl 251 2,4-diF-Ph 3-CN-Ph 252 2,4-diF-Ph 3-COCH3-Ph 253 2,4-diF-Ph 3-C02Me-Ph 254 2,4-diF-Ph 3-C02Et-Ph 255 2,4-diF-Ph 3-C02H-Ph 256 2,4-diF-Ph 3-CONH2-Ph 257 2,4-diF-Ph 3-F-Ph 258 2,4-diF-Ph 3-C1-Ph 259 2,4-diF-Ph 3-NH2-Ph 260 2,4-diF-Ph 3-S02NH2-Ph 261 2,4-diF-Ph 3-CF3-Ph 262 2,4-diF-Ph 3-OCH3-Ph 263 2,4-diF-Ph 3-OEt-Ph 264 2,4-diF-Ph 3-OCF3-Ph 265 2,4-diF-Ph 3-S02CH3-Ph 266 2,4-diF-Ph 3-OH-Ph 267 2,4-diF-Ph 3-CH3-Ph 268 2,4-diF-Ph 3-C2H5-Ph 269 2,4-diF-Ph 4-CN-Ph 270 2,4-diF-Ph 4-COCH3-Ph 271 2,4-diF-Ph 4-C02Me-Ph 272 2,4-diF-Ph 4-C02Et-Ph 273 2,4-diF-Ph 4-C02H-Ph 274 2,4-diF-Ph 4-CONH2-Ph 275 2,4-diF-Ph 4-F-Ph 276 2,4-diF-Ph 4-C1-Ph 277 2,4-diF-Ph 4-NH2-Ph 278 2,4-diF-Ph 4-S02NH2-Ph 279 2,4-diF-Ph 4-CF3-Ph 280 2,4-diF-Ph 4-OCH3-Ph 281 2,4-diF-Ph 4-OEt-Ph 282 2,4-diF-Ph 4-OCF3-Ph 283 2,4-diF-Ph 4-S02CH3-Ph 284 2,4-diF-Ph 4-OH-Ph 285 2,4-diF-Ph 4-CH3-Ph 286 2,4-diF-Ph 4-C2H5-Ph 287 2,4-diF-Ph 2,4-diF-Ph 288 2,4-diF-Ph 2,5-diF-Ph 289 2,4-diF-Ph 3,4-diF-Ph 290 2,4-diF-Ph 3,5-diF-Ph 291 2,4-diF-Ph 2,4-diCl-Ph 292 2,4-diF-Ph 2,5-diCl-Ph 293 2,4-diF-Ph 3,4-diCl-Ph 294 2,4-diF-Ph 3,5-diCl-Ph 295 2,4-diF-Ph 3,4-OCH20-Ph 296 2,4-diF-Ph 3,4-OCH2CH20-Ph 297 2,4-diF-Ph 2-thienyl 298 2,4-diF-Ph 2-furanyl 299 2,4-diF-Ph 2-pyridyl 300 2,4-diF-Ph 4-pyridyl 301 2,4-diF-Ph 2-imidazol 1 302 2,4-diF-Ph 3- yrazolyl 303 2,4-diF-Ph 2-thiazolyl 304 2,4-diF-Ph 5-tetrazolyl 305 2,4-diF-Ph 1-adamantyl 306 4-Cl-Ph Ph 307 4-C1-Ph 3-CN-Ph 308 4-Cl-Ph 3-COCH3-Ph 309 4-Cl-Ph 3-C02Me-Ph 310 4-Cl-Ph 3-C02Et-Ph 311 4-C1-Ph 3-C02H-Ph 312 4-C1-Ph 3-CONH2-Ph 313 4-C1-Ph 3-CONHMe-Ph 314 4-Cl-Ph 3-F-Ph 315 4-Cl-Ph 3-C1-Ph 316 4-Cl-Ph 3-Br-Ph 317 4-C1-Ph 3-N02-Ph 318 4-C1-Ph 3-NH2-Ph 319 4-Cl-Ph 3-NHMe-Ph 320 4-C1-Ph 3-NMe2-Ph 321 4-C1-Ph 3-NHCOCH3-Ph 322 4-C1-Ph 3-S02NH2-Ph 323 4-C1-Ph 3-S02NHMe-Ph 324 4-C1-Ph 3-CF3-Ph 325 4-C1-Ph 3-OCH3-Ph 326 4-C1-Ph 3-OPh-Ph 327 4-C1-Ph 3-OCF3-Ph 328 4-C1-Ph 3-SCH3-Ph 329 4-Cl-Ph 3-SOCH3-Ph 330 4-C1-Ph 3-S02CH3-Ph 331 4-C1-Ph 3-OH-Ph 332 4-C1-Ph 3-CH20H-Ph 333 4-Cl-Ph 3-CHOHCH3-Ph 334 4-Cl-Ph 3-COH(CH3)2-Ph 335 4-Cl-Ph 3-CHOHPh-Ph 336 4-C1-Ph 3-CH3-Ph 337 4-C1-Ph 3-C2H5-Ph 338 4-C1-Ph 3-iPr-Ph 339 ~ 4-Cl-Ph 3-tBu-Ph 340 4-C1-Ph 3-Ph-Ph 341 4-C1-Ph 3-CH2Ph-Ph 342 4-Cl-Ph 3-CH2C02Me-Ph 343 4-C1-Ph 3-(1-piperidinyl)-Ph 344 4-C1-Ph 3-(1-pyrrolidinyl)-Ph 345 4-Cl-Ph 3-(2-imidazol 1)-Ph 346 4-C1-Ph 3-(1-imidazolyl)-Ph 347 4-C1-Ph 3-(2-thiazolyl)-Ph 348 4-C1-Ph 3-(3- razolyl)-Ph 349 4-CI-Ph 3-(1-pyrazolyl)-Ph 350. 4-C1-Ph 3-(1-tetrazol 1)-Ph 351 4-C1-Ph 3-(5-tetrazol 1)-Ph 352 4-C1-Ph 3-(2-pyridyl)-Ph.

353 4-C1-Ph 3-(2-thien 1)-Ph 354 4-C1-Ph 3-(2-furanyl)-Ph 355 4-Cl-Ph 4-CN-Ph 356 4-C1-Ph 4-COCH3-Ph 357 4-C1-Ph 4-C02Me-Ph 358 4-C1-Ph 4-C02Et-Ph 359 4-C1-Ph 4-C02H-Ph 360 4-C1-Ph 4-CONH2-Ph 361 4-C1-Ph 4-CONHMe-Ph 362 4-Cl-Ph 4-CONHPh-Ph 3&3 4-C1-Ph 4-NHCONH2-Ph 364 4-C1-Ph 4-F-Ph 365 4-C1-Ph 4-C1-Ph 366 4-Cl-Ph 4-Br-Ph 367 4-C1-Ph 4-N02-Ph 368 4-C1-Ph 4-NH2-Ph 369 4-Cl-Ph 4-NHMe-Ph 370 4-C1-Ph 4-NMe2-Ph 371 4-Cl-Ph 4-NHCOCH3-Ph 372 4-C1-Ph 4-S02NH2-Ph 373 4-C1-Ph 4-S02NHMe-Ph 374 4-C1-Ph 4-CF3-Ph 375 4-C1-Ph 4-OCH3-Ph 376 4-C1-Ph 4-OPh-Ph 377 4-C1-Ph 4-OCF3-Ph 378 4-C1-Ph 4-SCH3-Ph 379 4-C1-Ph 4-SOCH3-Ph 380 4-Cl-Ph 4-S02CH3-Ph 381 4-Cl-Ph 4-OH-Ph 382 4-Cl-Ph 4-CH20H-Ph 383 4-Cl-Ph 4-CHOHCH3-Ph 384 4-C1-Ph 4-COH(CH3)2-Ph 385 4-Cl-Ph 4-CH3-Ph 386 4-C1-Ph 4-C2H5-Ph 387 4-C1-Ph 4-iPr-Ph 388 4-C1-Ph 4-tBu-Ph 389 4-C1-Ph 4-Ph-Ph 390 4-C1-Ph 4-CH2Ph-Ph 391 4-C1-Ph 4-CH2C02Me-Ph 392 4-C1-Ph 4-(1-piperidin 1)-Ph 393 4-C1-Ph 4-(1-pyrrolidin 1)-Ph 394 4-Cl-Ph 4-(2-imidazolyl)-Ph 395 4-C1-Ph 4-(1-imidazolyl)-Ph 396 4-C1-Ph 4-(2-thiazolyl)-Ph 397 4-Cl-Ph 4-(3-pyrazolyl)-Ph 398 ~ 4-C1-Ph 4-(1-pyrazolyl)-Ph 399 4-C1-Ph 4-(1-tetrazolyl)-Ph 400 4-C1-Ph 4-(5-tetrazol 1)-Ph 401 4-C1-Ph 4-(2-pyridyl)-Ph 402 4-C1-Ph 4-(2-thienyl)-Ph 403 4-C1-Ph 4-(2-furanyl)-Ph 404 4-C1-Ph 2-CN-Ph 405 4-C1-Ph 2-COCH3-Ph 406 4-Cl-Ph 2-C02Me-Ph 407 4-C1-Ph 2-C02Et-Ph 408 4-C1-Ph 2-C02H-Ph 409 4-C1-Ph 2-CONH2-Ph 410 4-Cl-Ph 2-CONHMe-Ph 411 4-C1-Ph 2-F-Ph 412 4-Cl-Ph 2-C1-Ph 413 4-C1-Ph 2-Br-Ph 414 4-C1-Ph 2-N02-Ph 415 4-C1-Ph 2-NH2-Ph 416 4-Cl-Ph 2-NHMe-Ph 417 4-Cl-Ph 2-NMe2-Ph 418 4-C1-Ph 2-NHCOCH3-Ph 419 4-C1-Ph 2-S02NH2-Ph 420 4-C1-Ph 2-S02NHMe-Ph 421 4-Cl-Ph 2-CF3-Ph 422 4-Cl-Ph 2-OCH3-Ph 423 4-C1-Ph 2-OPh-Ph 424 4-C1-Ph 2-OCF3-Ph 425 4-C1-Ph 2-SCH3-Ph 426 4-C1-Ph 2-SOCH3-Ph 427 4-C1-Ph 2-S02CH3-Ph 428 4-C1-Ph 2-0H-Ph 429 4-C1-Ph 2-CH20H-Ph 430 4-C1-Ph 2-CHOHCH3-Ph 431 4-C1-Ph 2-COH(CH3)2-Ph 432 4-Cl-Ph 2-CHOHPh-Ph 433 4-Cl-Ph 2-CH3-Ph 434 4-Cl-Ph 2-C2H5-Ph 435 4-Cl-Ph 2-iPr-Ph 436 4-C1-Ph 2-tBu-Ph 437 4-C1-Ph 2-Ph-Ph 438 4-C1-Ph 2-CH2Ph-Ph 439 4-Cl-Ph 2-CH2C02Me-Ph 440 4-Cl-Ph 2-(1-piperidinyl)-Ph 441 4-C1-Ph 2-(1-pyrrolidinyl)-Ph 442 4-C1-Ph 2-(2-imidazolyl)-Ph 443 4-C1-Ph 2-(1-imidazolyl)-Ph 444 4-C1-Ph 2-(2-thiazolyl)-Ph 445 4-C1-Ph 2-(3-pyrazolyl)-Ph 446 4-C1-Ph 2-(1-pyrazolyl)-Ph 447 4-C1-Ph 2-(1-tetrazolyl)-Ph 448 4-Cl-Ph 2-(5-tetrazolyl)-Ph 449 4-C1-Ph 2-(2-pyridyl)-Ph 450 4-C1-Ph 2-(2-thienyl)-Ph 451 4-C1-Ph 2-(2-furanyl)-Ph 452 4-C1-Ph 2,4-diF-Ph 453 4-C1-Ph 2,5-diF-Ph 454 4-C1-Ph 2,6-diF-Ph 455 4-C1-Ph 3,4-diF-Ph 456 4-Cl-Ph 3,5-diF-Ph 457 4-C1-Ph 2,4-diCl-Ph 458 4-Cl-Ph 2,5-diCl-Ph 459 4-C1-Ph 2,6-diCl-Ph 460 4-Cl-Ph 3,4-diCl-Ph 461 4-Cl-Ph 3,5-diCl-Ph 462 4-Cl-Ph 3,4-diCF3-Ph 463 4-Cl-Ph 3,5-diCF3-Ph 464 4-C1-Ph 5-Cl-2-Me0-Ph 465 4-C1-Ph 5-C1-2-Me-Ph 466 4-C1-Ph 2-F-5-Me-Ph 467 4-C1-Ph 2-F-5-N02-Ph 468 4-Cl-Ph 3,4-OCH20-Ph 469 4-Cl-Ph 3,4-OCH2CH20-Ph 470 4-Cl-Ph 2-Me0-4-Me-Ph 471 4-Cl-Ph 2-Me0-5-Me-Ph 472 4-C1-Ph 1-naphthyl 473 4-Cl-Ph 2-na hthyl 474 4-Cl-Ph 2-thienyl 475 4-C1-Ph 3-thien 1 476 4-C1-Ph 2-furanyl 477 4-Cl-Ph 3-furanyl 478 4-C1-Ph 2-p ridyl 479 4-C1-Ph 3- ridyl 480 4-C1-Ph 4-pyridyl 481 4-Cl-Ph 2-indolyl 482 4-C1-Ph 3-indolyl 483 4-C1-Ph 5-indol 1 484 4-Cl-Ph 6-indolyl 485 4-C1-Ph 3-indazol 1 486 4-C1-Ph 5-indazolyl 487 4-C1-Ph 6-indazol 1 488 4-C1-Ph 2-imidazolyl 489 4-Cl-Ph 3-pyrazolyl 490 4-C1-Ph 2-thiazol 1 491 4-C1-Ph 5-tetrazolyl 492 4-Cl-Ph 2-benzimidazolyl 493 4-C1-Ph 5-benzimidazolyl 494 4-C1-Ph 2-benzothiazolyl 495 4-Cl-Ph 5-benzothiazolyl 496 4-Cl-Ph 2-benzoxazolyl 497 4-C1-Ph 5-benzoxazolyl 498 4-C1-Ph 1-adamantyl 499 4-C1-Ph 2-adamantyl 500 4-C1-Ph t-Bu 501 2-C1-Ph 3-CN-Ph 502 2-C1-Ph 3-COCH3-Ph 503 2-C1-Ph 3-C02Me-Ph 504 2-C1-Ph 3-C02Et-Ph 505 2-C1-Ph 3-C02H-Ph 506 2-C1-Ph 3-CONH2-Ph 507 2-C1-Ph 3-F-Ph 508 2-C1-Ph 3-C1-Ph 509 2-C1-Ph 3-NH2-Ph 510 2-C1-Ph 3-S02NH2-Ph 511 2-C1-Ph 3-CF3-Ph 512 2-C1-Ph 3-OCH3-Ph 513 2-C1-Ph 3-OEt-Ph 514 2-Cl-Ph 3-OCF3-Ph 515 2-C1-Ph 3-S02CH3-Ph 516 2-C1-Ph 3-OH-Ph 517 2-Cl-Ph 3-CH3-Ph 518 2-C1-Ph 3-C2H5-Ph 519 2-Cl-Ph 4-CN-Ph 520 2-Cl-Ph 4-COCH3-Ph 521 2-C1-Ph 4-C02Me-Ph 522 2-C1-Ph 4-C02Et-Ph 523 2-C1-Ph 4-C02H-Ph 524 2-Cl-Ph 4-CONH2-Ph 525 2-C1-Ph 4-F-Ph 526 2-C1-Ph 4-C1-Ph 527 2-Cl-Ph 4-NH2-Ph 528 2-C1-Ph 4-S02NH2-Ph 529 2-C1-Ph 4-CF3-Ph 530 2-C1-Ph 4-OCH3-Ph 531 2-Cl-Ph 4-OEt-Ph 532 2-C1-Ph 4-OCF3-Ph 533 2-Cl-Ph 4-S02CH3-Ph 534 2-C1-Ph 4-OH-Ph 535 2-C1-Ph 4-CH3-Ph 536 2-C1-Ph 4-C2H5-Ph 537 2-Cl-Ph 2,4-diF-Ph 538 2-C1-Ph 2,5-diF-Ph 539 2-C1-Ph 3,4-diF-Ph 540 2-C1-Ph 3,5-diF-Ph 541 2-C1-Ph 2,4-diCl-Ph 542 2-Cl-Ph 2,5-diCl-Ph 543 2-Cl-Ph 3,4-diCl-Ph 544 2-Cl-Ph 3,5-diCl-Ph 545 2-C1-Ph 3,4-OCH20-Ph 546 2-C1-Ph 3,4-OCH2CH20-Ph 547 2-C1-Ph 2-thien 1 548 2-C1-Ph 2-furanyl 549 2-C1-Ph 2-pyridyl 550 2-C1-Ph 4-pyridyl 551 2-Cl-Ph 2-imidazolyl 552 2-Cl-Ph 3-pyrazolyl 553 2-C1-Ph 2-thiazolyl 554 2-C1-Ph 5-tetrazolyl 555 2-C1-Ph 1-adamantyl 556 2,4-diCl-Ph 3-CN-Ph 557 2,4-diCl-Ph 3-COCH3-Ph 558 2,4-diCl-Ph 3-C02Me-Ph 559 2,4-diCl-Ph 3-C02Et-Ph 560 2,4-diCl-Ph 3-C02H-Ph 561 2,4-diCl-Ph 3-CONH2-Ph 562 2,4-diCl-Ph 3-F-Ph 563 2,4-diCl-Ph 3-C1-Ph 564 2,4-diCl-Ph 3-NH2-Ph 565 2,4-diCl-Ph 3-S02NH2-Ph 566 2,4-diCl-Ph 3-CF3-Ph 567 2,4-diCl-Ph 3-OCH3-Ph 568 2,4-diCl-Ph 3-OEt-Ph 569 2,4-diCl-Ph 3-OCF3-Ph 570 2,4-diCl-Ph 3-S02CH3-Ph 571 2,4-diCl-Ph 3-OH-Ph 572 2,4-diCl-Ph 3-CH3-Ph 573 2,4-diCl-Ph 3-C2H5-Ph 574 2,4-diCl-Ph 4-CN-Ph 575 2,4-diCl-Ph 4-COCH3-Ph 576 2,4-diCl-Ph 4-C02Me-Ph 577 2,4-diCl-Ph 4-C02Et-Ph 578 2,4-diCl-Ph 4-C02H-Ph 579 2,4-diCl-Ph 4-CONH2-Ph 580 2,4-diCl-Ph 4-F-Ph 581 2,4-diCl-Ph 4-Cl-Ph 582 2,4-diCl-Ph 4-NH2-Ph 583 2,4-diCl-Ph 4-S02NH2-Ph 584 2,4-diCl-Ph 4-CF3-Ph 585 2,4-diCl-Ph 4-OCH3-Ph 586 2,4-diCl-Ph 4-OEt-Ph 587 2,4-diCl-Ph 4-OCF3-Ph 588 2,4-diCl-Ph 4-S02CH3-Ph 589 2,4-diCl-Ph 4-OH-Ph 590 2,4-diCl-Ph 4-CH3-Ph 591 2,4-diCl-Ph 4-C2H5-Ph 592 2,4-diCl-Ph 2,4-diF-Ph 593 2,4-diCl-Ph 2,5-diF-Ph 594 2,4-diCl-Ph 3,4-diF-Ph 595 2,4-diCl-Ph 3,5-diF-Ph 596 2,4-diCl-Ph 2,4-diCl-Ph 597 2,4-diCl-Ph 2,5-diCl-Ph 598 2,4-diCl-Ph 3,4-diCl-Ph 599 2,4-diCl-Ph 3,5-diCl-Ph 600 2,4-diCl-Ph 3,4-OCH20-Ph 601 2,4-diCl-Ph 3,4-OCH2CH20-Ph 602 2,4-diCl-Ph 2-thienyl 603 2,4-diCl-Ph 2-furanyl 604 2,4-diCl-Ph 2-pyridyl 605 2,4-diCl-Ph 4-pyridyl 606 2,4-diCl-Ph 2-imidazolyl 607 2,4-diCl-Ph 3-pyrazolyl 608 2,4-diCl-Ph 2-thiazolyl 609 2,4-diCl-Ph 5-tetrazolyl 610 2,4-diCl-Ph 1-adamantyl 611 3-OCH3-Ph 3-CN-Ph 612 3-OCH3-Ph 3-COCH3-Ph 613 3-OCH3-Ph 3-C02Me-Ph 614 3-OCH3-Ph 3-C02Et-Ph 615 3-OCH3-Ph 3-C02H-Ph 616 3-OCH3-Ph 3-CONH2-Ph 617 3-OCH3-Ph 3-F-Ph 618 3-OCH3-Ph 3-Cl-Ph 619 3-OCH3-Ph 3-NH2-Ph 620 3-OCH3-Ph 3-S02NH2-Ph 621 3-OCH3-Ph 3-CF3-Ph 622 3-OCH3-Ph 3-OCH3-Ph 623 3-OCH3-Ph 3-OEt-Ph 624 3-OCH3-Ph 3-OCF3-Ph 625 3-OCH3-Ph 3-S02CH3-Ph 626 3-OCH3-Ph 3-OH-Ph 627 3-OCH3-Ph 3-CH3-Ph 628 3-OCH3-Ph 3-C2H5-Ph 629 3-OCH3-Ph 4-CN-Ph 630 3-OCH3-Ph 4-COCH3-Ph 631 3-OCH3-Ph 4-C02Me-Ph 632 3-OCH3-Ph 4-C02Et-Ph 633 3-OCH3-Ph 4-C02H-Ph 634 3-OCH3-Ph 4-CONH2-Ph 635 3-OCH3-Ph 4-F-Ph 636 3-OCH3-Ph 4-Cl-Ph 637 3-OCH3-Ph 4-NH2-Ph 638 3-OCH3-Ph 4-S02NH2-Ph 639 3-OCH3-Ph 4-CF3-Ph 640 3-OCH3-Ph 4-OCH3-Ph 641 3-OCH3-Ph 4-OEt-Ph 642 3-OCH3-Ph 4-OCF3-Ph 643 3-OCH3-Ph 4-S02CH3-Ph 644 3-OCH3-Ph 4-OH-Ph 645 3-OCH3-Ph 4-CH3-Ph 646 3-OCH3-Ph 4-C2H5-Ph 647 3-OCH3-Ph 2,4-diF-Ph 648 3-OCH3-Ph 2,5-diF-Ph 649 3-OCH3-Ph 3,4-diF-Ph 650 3-OCH3-Ph 3,5-diF-Ph 651 3-OCH3-Ph 2,4-diCl-Ph 652 3-OCH3-Ph 2,5-diCl-Ph 653 3-OCH3-Ph 3,4-diCl-Ph 654 3-OCH3-Ph 3,5-diCl-Ph 655 3-OCH3-Ph 3,4-OCH20-Ph 656 3-OCH3-Ph 3,4-0CH2CH20-Ph 657 3-OCH3-Ph 2-thienyl 658 3-OCH3-Ph 2-turan 1 659 3-OCH3-Ph 2-pyridyl 660 3-OCH3-Ph 4- yridyl 661 3-OCH3-Ph 2-imidazolyl 662 3-OCH3-Ph 3-pyrazolyl 663 3-OCH3-Ph 2-thiazolyl 664 3-OCH3-Ph 5-tetrazolyl 665 3-OCH3-Ph 1-adamantyl 666 2-thienyl 3-CN-Ph 667 2-thienyl 3-COCH3-Ph 668 2-thienyl 3-F-Ph 669 2-thienyl 3-Cl-Ph 670 2-thienyl 3-NH2-Ph 671 2-thienyl 3-OCH3-Ph 672 2-thienyl 3-OH-Ph 673 2-thienyl 4-CN-Ph 674 2-thienyl 4-COCH3-Ph 675 2-thienyl 4-F-Ph 676 2-thienyl 4-C1-Ph 677 2-thienyl 4-NH2-Ph 678 2-thienyl 4-OCH3-Ph 679 2-thienyl 4-OH-Ph 680 2-thienyl 3,4-diF-Ph 681 2-thienyl 3,5-diF-Ph 682 2-thienyl 3,4-diCl-Ph 683 2-thienyl 3,5-diCl-Ph 684 2-thienyl 3,4-OCH20-Ph 685 2-thienyl 3,4-OCH2CH20-Ph 686 3-thienyl 3-CN-Ph 687 3-thienyl 3-COCH3-Ph 688 3-thienyl 3-F-Ph 689 3-thienyl 3-Cl-Ph 690 3-thienyl 3-NH2-Ph 691 3-thienyl 3-OCH3-Ph 692 3-thienyl 3-OH-Ph 693 3-thienyl 4-CN-Ph 694 3-thienyl 4-COCH3-Ph 695 3-thienyl 4-F-Ph 696 3-thienyl 4-Cl-Ph 697 3-thienyl 4-NH2-Ph 698 3-thienyl 4-OCH3-Ph 699 3-thienyl 4-OH-Ph 700 3-thien 1 3,4-diF-Ph 701 3-thienyl 3,5-diF-Ph 702 3-thienyl 3,4-diCl-Ph 703 3-thien 1 3,5-diCl-Ph 704 3-thienyl 3,4-OCH20-Ph 705 3-thienyl 3,4-OCH2CH20-Ph 706 2-furanyl 3-CN-Ph 707 2-furanyl 3-COCH3-Ph 708 2-furanyl 3-F-Ph 709 2-furanyl 3-C1-Ph 710 2-furanyl 3-NH2-Ph 711 2-furanyl 3-OCH3-Ph 712 2-furanyl 3-OH-Ph 713 2-furanyl 4-CN-Ph 714 2-furan 1 4-COCH3-Ph 715 2-furan 1 4-F-Ph 716 2-furanyl 4-Cl-Ph 717 2-furanyl 4-NH2-Ph 718 2-furanyl 4-OCH3-Ph 719 2-furanyl 4-OH-Ph 720 2-furanyl 3,4-diF-Ph 721 2-furanyl 3,5-diF-Ph 722 2-furanyl 3,4-diCl-Ph 723 2-furan 1 3,5-diCl-Ph 724 2-furanyl 3,4-OCH20-Ph 725 2-furanyl 3,4-OCH2CH20-Ph 726 3-furanyl 3-CN-Ph 727 3-furanyl 3-COCH3-Ph 728 3-furanyl 3-F-Ph 729 3-furan 1 3-Cl-Ph 730 3-furanyl 3-NH2-Ph 731 3-furanyl 3-OCH3-Ph 732 3-furanyl 3-OH-Ph 733 3-furanyl 4-CN-Ph 734 3-furanyl 4-COCH3-Ph 735 3-furanyl 4-F-Ph 736 3-furanyl 4-C1-Ph 737 3-furanyl 4-NH2-Ph 738 3-furanyl 4-OCH3-Ph 739 3-furanyl 4-OH-Ph 740 3-furanyl 3,4-diF-Ph 741 3-furanyl 3,5-diF-Ph 742 3-furanyl 3,4-diCl-Ph 743 3-furanyl 3,5-diCl-Ph 744 3-furanyl 3,4-OCH20-Ph 745 3-furanyl 3,4-OCH2CH20-Ph 746 2-pyridyl 3-CN-Ph 747 2-pyridyl 3-COCH3-Ph 748 2-pyridyl 3-F-Ph 749 2-pyridyl 3-C1-Ph 750 2- ridyl 3-NH2-Ph 751 2- ridyl 3-OCH3-Ph 752 2-pyridyl 3-OH-Ph 753 2-pyridyl 4-CN-Ph 754 2-pyridyl 4-COCH3-Ph 755 2-pyridyl 4-F-Ph 756 2-p ridyl 4-Cl-Ph 757 2-p ridyl 4-NH2-Ph 758 2- yrid 1 4-OCH3-Ph 759 2-p ridyl 4-OH-Ph 760 2-pyridyl 3,4-diF-Ph 761 2- yrid 1 3,5-diF-Ph 762 2-p rid 1 3,4-diCl-Ph 763 2- yridyl 3,5-diCl-Ph 764 2- yrid 1 3,4-OCH20-Ph 765 2-pyridyl 3,4-OCH2CH20-Ph 766 3-pyridyl 3-CN-Ph 767 3-pyridyl 3-COCH3-Ph 768 3-p ridyl 3-F-Ph 769 3-pyridyl 3-C1-Ph 770 3-pyridyl 3-NH2-Ph 771 3-pyridyl 3-OCH3-Ph 772 3-pyridyl 3-OH-Ph 773 3-p ridyl 4-CN-Ph 774 3-p rid 1 4-COCH3-Ph 775 3-pyridyl 4-F-Ph 776 3-pyridyl 4-C1-Ph 777 3-pyridyl 4-NH2-Ph 778 3-pyridyl 4-OCH3-Ph 779 3-pyridyl 4-OH-Ph 780 3- yridyl 3,4-diF-Ph 781 3-pyridyl 3,5-diF-Ph 782 3- yridyl 3,4-diCl-Ph 783 3-pyridyl 3,5-diCl-Ph 784 3-pyridyl 3,4-OCH20-Ph 785 3-pyridyl 3,4-OCH2CH20-Ph 786 4-pyridyl 3-CN-Ph 787 4-pyrid 1 3-COCH3-Ph 788 4-pyridyl 3-F-Ph 789 4-pyridyl 3-C1-Ph 790 4-pyridyl 3-NH2-Ph 791 4-pyridyl 3-OCH3-Ph 792 4-pyridyl 3-OH-Ph 793 4-pyridyl 4-CN-Ph 794 4-pyridyl 4-COCH3-Ph 795 4-pyridyl 4-F-Ph 796 4-pyridyl 4-Cl-Ph 797 4-pyridyl 4-NH2-Ph 798 4-pyridyl 4-OCH3-Ph 799 4-pyridyl 4-OH-Ph 800 4-pyridyl 3,4-diF-Ph 801 4-pyridyl 3,5-diF-Ph 802 4-pyridyl 3,4-diCl-Ph 803 4-pyridyl 3,5-diCl-Ph 804 4- yridyl 3,4-OCH20-Ph 805 4-pyridyl 3,4-OCH2CH20-Ph 806 3-indolyl 3-CN-Ph 807 3-indolyl 3-COCH3-Ph 808 3-indolyl 3-F-Ph 809 3-indolyl 3-C1-Ph 810 3-indolyl 3-NH2-Ph 811 3-indolyl 3-OCH3-Ph 812 3-indolyl 3-OH-Ph 813 3-indolyl 4-CN-Ph 814 3-indolyl 4-COCH3-Ph 815 3-indolyl 4-F-Ph 816 3-indolyl 4-C1-Ph 817 3-indolyl 4-NH2-Ph 818 3-indolyl 4-OCH3-Ph 819 3-indolyl 4-OH-Ph 820 3-indolyl 3,4-diF-Ph 821 3-indolyl 3,5-diF-Ph 822 3-indolyl 3,4-diCl-Ph 823 3-indolyl 3,5-diCl-Ph 824 3-indolyl 3,4-OCH20-Ph 825 3-indolyl 3,4-OCH2CH20-Ph 826 5-indolyl 3-CN-Ph 827 5-indolyl 3-COCH3-Ph 828 5-indolyl 3-F-Ph 829 5-indolyl 3-Cl-Ph 830 5-indolyl 3-NH2-Ph 831 5-indolyl 3-OCH3-Ph 832 5-indolyl 3-OH-Ph 833 5-indolyl 4-CN-Ph 834 5-indol 1 4-COCH3-Ph 835 5-indolyl 4-F-Ph 836 5-indolyl 4-C1-Ph 837 5-indolyl 4-NH2-Ph 838 5-indolyl 4-OCH3-Ph 839 5-indolyl 4-OH-Ph 840 5-indolyl 3,4-diF-Ph 841 5-indolyl 3,5-diF-Ph 842 5-indolyl 3,4-diCl-Ph 843 5-indolyl 3,5-diCl-Ph 844 5-indolyl 3,4-OCH20-Ph 845 5-indolyl 3,4-OCH2CH20-Ph 846 5-indazolyl 3-CN-Ph 847 5-indazolyl 3-COCH3-Ph 848 5-indazolyl 3-F-Ph 849 5-indazolyl 3-C1-Ph 850 5-indazolyl 3-NH2-Ph 851 5-indazolyl 3-OCH3-Ph 852 5-indazolyl 3-OH-Ph 853 5-indazol 1 4-CN-Ph 854 5-indazolyl 4-COCH3-Ph 855 5-indazolyl 4-F-Ph 856 5-indazolyl 4-C1-Ph 857 5-indazolyl 4-NH2-Ph 858 5-indazolyl 4-OCH3-Ph 859 5-indazolyl 4-OH-Ph 860 5-indazolyl 3,4-diF-Ph 861 5-indazolyl 3,5-diF-Ph 862 5-indazolyl 3,4-diCl-Ph 863 5-indazolyl 3,5-diCl-Ph 864 5-indazolyl 3,4-OCH20-Ph 865 5-indazolyl 3,4-OCH2CH20-Ph 866 5-benzimidazolyl3-CN-Ph 867 5-benzimidazolyl3-COCH3-Ph 868 5-benzimidazolyl3-F-Ph _869 5-benzimidazol 3-C1-Ph 870 5-benzimidazolyl3-NH2-Ph 871 5-benzimidazolyl3-OCH3-Ph 872 5-benzimidazol 3-OH-Ph 873 5-benzimidazolyl4-CN-Ph 874 5-benzimidazolyl4-COCH3-Ph 875 5-benzimidazolyl4-F-Ph 876 5-benzimidazol 4-C1-Ph 877 5-benzimidazolyl4-NH2-Ph 878 5-benzimidazolyl4-OCH3-Ph 879 5-benzimidazol 4-OH-Ph 880 5-benzimidazolyl3,4-diF-Ph 881 5-benzimidazol 3,5-diF-Ph 882 5-benzimidazolyl3,4-diCl-Ph 883 5-benzimidazolyl3,5-diCl-Ph 884 5-benzimidazol 3,4-OCH20-Ph 885 5-benzimidazolyl3,4-OCH2CH20-Ph 886 5-benzothiazolyl3-CN-Ph 887 5-benzothiazolyl3-COCH3-Ph 888 5-benzothiazolyl3-F-Ph 889 5-benzothiazolyl3-C1-Ph 890 5-benzothiazolyl3-NH2-Ph 891 5-benzothiazolyl3-OCH3-Ph 892 5-benzothiazolyl3-OH-Ph 893 5-benzothiazol 4-CN-Ph 894 5-benzothiazolyl4-COCH3-Ph 895 5-benzothiazolyl4-F-Ph 896 5-benzothiazol 4-C1-Ph 897 5-benzothiazolyl4-NH2-Ph 898 5-benzothiazolyl4-OCH3-Ph 899 5-benzothiazol 4-OH-Ph 900 5-benzothiazolyl3,4-diF-Ph 901 5-benzothiazol 3,5-diF-Ph 902 5-benzothiazolyl3,4-diCl-Ph 903 5-benzothiazolyl3,5-diCl-Ph 904 5-benzothiazolyl3,4-OCH20-Ph 905 5-benzothiazolyl3,4-OCH2CH20-Ph 906 5-benzoxazolyl 3-CN-Ph 907 5-benzoxazolyl 3-COCH3-Ph 908 5-benzoxazolyl 3-F-Ph 909 5-benzoxazolyl 3-C1-Ph 910 5-benzoxazolyl 3-NH2-Ph 911 5-benzoxazolyl 3-OCH3-Ph 912 5-benzoxazolyl 3-OH-Ph 913 5-benzoxazolyl 4-CN-Ph 914 5-benzoxazolyl 4-COCH3-Ph 915 5-benzoxazolyl 4-F-Ph 916 5-benzoxazolyl 4-C1-Ph 917 5-benzoxazolyl 4-NH2-Ph 918 5-benzoxazolyl 4-OCH3-Ph 919 5-benzoxazolyl 4-OH-Ph 920 5-benzoxazolyl 3,4-diF-Ph 921 5-benzoxazolyl 3,5-diF-Ph 922 5-benzoxazolyl 3,4-diCl-Ph 923 5-benzoxazolyl 3,5-diCl-Ph 924 5-benzoxazolyl 3,4-OCH20-Ph 925 ~ 5-benzoxazolyl 3,4-OCH2CH20-Ph Utility The utility of the compounds in accordance with the present invention as modulators of chemokine receptor activity may be demonstrated by methodology known in the art, such as the assays for CCR-2 and CCR-3 ligand binding, as disclosed by Ponath et al., J. Exp. Med., 183, 2437-2448 (1996) and Uguccioni et al., J. Clin.
Invest., 100, 1137-1143 (1997). Cell lines for expressing the receptor of interest include those naturally expressing the chemokine receptor, such as EOL-3 or THP-1, those induced to express the chemokine receptor by the addition of chemical or protein agents, such as HL-60 or AML14.3D10 cells treated with, for example, butyric acid with interleukin-5 present, or a cell engineered to express a recombinant chemokine receptor, such as CHO or HEK-293. Finally, blood or tissue cells, for example human peripheral blood eosinophils, isolated using methods as described by Hansel et al., J. Immunol. Methods, 145, 105- 110 (1991), can be utilized in such assays. In particular, the compound of the present invention have activity in binding to the CCR-3 receptor in the aforementioned assays. As used herein, "activity" is intended to mean a compound demonstrating an IC50 of 10 ~.tM or lower in concentration when measured in the aforementioned assays. Such a result is indicative of the intrinsic activity of the compounds as modulators of chemokine receptor activity. A general binding protocol is described below.
CCR3-Receptor Binding Protocol Millipore filter plates (#MABVN1250) are treated with 5 [ug/ml protamine in phosphate buffered saline, pH
7.2, fox ten minutes at room temperature. Plates are washed three times with phosphate buffered saline anal incubated with phosphate buffered saline for thirty minutes at room temperature. For binding, 50 [..l.l of binding buffer (0.5o bovine serum albumen, 20 mM HEPES
buffer and 5 mM magnesium chloride in RPMI 1640 media) with or without a test concentration of a compound present at a known concentration is combined with 50 ~.l of 125-I labeled human eotaxin (to give a final concentration of 150 pM radioligand) and 50 ~,l of cell suspension in binding buffer containing 5x105 total cells. Cells used for such binding assays can include cell lines transfected with a gene expressing CCR3 such as that described by Daugherty et al. (2996), isolated human eosinophils such as described by Hansel et al.
(2991) or the AML14.3D10 cell line after differentiation with butyric acid as described by Tiffany et al. (1998).
The mixture of compound, cells and radioligand are incubated at room temperature for thirty minutes.
Plates are placed onto a vacuum manifold, vacuum applied, and plates washed three times with binding buffer with 0.5M NaCl added. The plastic skirt is removed from the plate, the plate allowed to air dry, the wells punch out and CPM counted. The percent inhibition of binding is calculated using the total count obtained in the absence of any competing compound or chemokine ligand and the background binding determined by addition of 100 nM eotaxin in place of the test compound.
The utility of the compounds in accordance with the present invention as inhibitors of the migration of eosinophils or cell lines expressing the chemokine receptors may be demonstrated by methodology known in the art, such as the chemotaxis assay disclosed by Bacon et al., Brit. J. Pharmacol., 95, 966-974 (1988). In particular, the compound of the present invention have activity in inhibition of the migration of eosinophils in the aforementioned assays. As used herein, "activity" is intended to mean a compound demonstrating an IC50 of 10 [~.M or lower in concentration when measured in the aforementioned assays. Such a result is indicative of the intrinsic activity of the compounds as modulators of chemokine receptor activity. A human eosinophil chemotaxis assay protocol is described below.
Human Eosinophil Chemotaxis Assay Neuroprobe MBA96 96-well chemotaxis chambers with Neuroprobe polyvinylpyrrolidone-free polycarbonate PFD5 5-micron filters in place are warmed in a 37°C incubator prior to assay. Freshly isolated human eosinophils, isolated according to a method such as that described by Hansel et al. (1991), are suspended in RPMI 1640 with 0.1% bovine serum albumin at 1 x 106 cells/ml and warmed in a 37°C incubator prior to assay. A 20 nM solution of human eotaxin in RPMI 1640 with 0.1o bovine serum albumin is warmed in a 37°C incubator prior to assay.
The eosinophil suspension and the 20 nM eotaxin solution are each mixed 1:1 with prewarmed RPMI 1640 with 0.1%
bovine serum albumin with or without a dilution of a ~, test compound that is at two fold the desired final concentration. These mixtures are warmed in a 37°C
incubator prior to assay. The filter is separated from the prewarmed Neuroprobe chemotaxis chamber and the eotaxin/compound mixture is placed into a Polyfiltronics MPC 96 well plate that has been placed in the bottom part of the Neuro Probe chemotaxis chamber. The approximate volume is 370 microliters and there should be a positive meniscus after dispensing. The filter is replaced above the 96 well plate, the rubber gasket is attached to the bottom of the upper chamber, and the chamber assembled. A 200 ~,1 volume of the cell suspension/compound mixture is added to the appropriate wells of the upper chamber. The upper chamber is covered with a plate sealer, and the assembled unit placed in a 37°C incubator for 45 minutes. After incubation, the plate sealer is removed and all remaining cell suspension is aspirated off. The chamber is disassembled and, while holding the filter by the sides at a 90-degree angle, unmigrated cells are washed away using a gentle stream of phosphate buffered saline dispensed from a squirt bottle and then the filter wiped with a rubber tipped squeegee. The filter is allowed to completely dry and immersed completely in Wright Giemsa stain for 30-45 seconds. The filter is rinsed with distilled water fox 7 minutes, rinsed once with water briefly, and allowed to dry. Migrated cells are enumerated by microscopy.
Mammalian chemokine receptors provide a target for interfering with or promoting immune cell function in a mammal, such as a human. Compounds that inhibit or promote chemokine receptor function are particularly useful for modulating immune cell function for therapeutic purposes. Accordingly, the present invention is directed to compounds which are useful in the prevention and/or treatment of a wide variety of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, infection by pathogenic microbes (which, by definition, includes viruses), as well as autoimmune pathologies such as the rheumatoid arthritis and atherosclerosis.
For example, an instant compound which inhibits one or more functions of a mammalian chemokine receptor (e. g., a human chemokine receptor) may be administered to inhibit (i.e., reduce or prevent) inflammation or infectious disease. As a result, one or more inflammatory process, such as leukocyte emigration, adhesion, chemotaxis, exocytosis (e. g., of enzymes, histamine) or inflammatory mediator release, is inhibited. For example, eosinophilic infiltration to inflammatory sites (e. g., in asthma or allergic rhinitis) can be inhibited according to the present method. In particular, the compound of the following examples has activity in blocking the migration of cells expressing the CCR-3 receptor using the appropriate chemokines in the aforementioned assays. As used herein, "activity" is intended to mean a compound demonstrating an IC50 of 10 E1M or lower in concentration when measured in the aforementioned assays. Such a result is also indicative of the intrinsic activity of the compounds as modulators of chemokine receptor activity.
Similarly, an instant compound which promotes one or more functions of the mammalian chemokine receptor (e. g., a human chemokine) as administered to stimulate (induce or enhance) an immune or inflammatory response, such as leukocyte emigration, adhesion, chemotaxis, exocytosis (e. g., of enzymes, histamine) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes. For example, eosinophils can be recruited to combat parasitic infections. In addition, treatment of the aforementioned inflammatory, allergic and autoimmune diseases can also be contemplated for an instant compound which promotes one or more functions of the mammalian chemokine receptor if one contemplates the delivery of sufficient compound to cause the loss of receptor expression on cells through the induction of chemokine receptor internalization or the delivery of compound in a manner that results in the misdirection of the migration of cells.
In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals, including but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. However, the method can also be practiced in other species, such as avian species. The subject treated in the methods above is a mammal, male or female, in whom modulation of chemokine receptor activity is desired. "Modulation" as used herein is intended to encompass antagonism, agonism, partial 25 antagonism andlor partial agonism.
Diseases or conditions of human or other species which can be treated with inhibitors of chemokine receptor function, include, but are not limited to:
inflammatory or allergic diseases and conditions, including respiratory allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic cellulitis (e. g., Well's syndrome), eosinophilic pneumonias (e. g., Loeffler's syndrome, chronic eosinophilic pneumonia), eosinophilic fasciitis (e. g., Shulman's syndrome), delayed-type hypersensitivity, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), eosinophilia-myalgia syndrome due to the ingestion of contaminated tryptophan, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes;
glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e. g., in transplantation), including allograft rejection or graft-versus-host disease; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies;
scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as an dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e. g., necrotizing, cutaneous, and hypersensitivity vasculitis);
eosinophilic myositis, eosinophilic fasciitis; cancers with leukocyte infiltration of the skin or organs.
Other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, atherosclerosis, certain hematologic malignancies, cytokine-induced toxicity (e. g., septic shock, endotoxic shock), polymyositis, dermatomyositis.
Infectious diseases or conditions of human or other species which can be treated with inhibitors of chemokine receptor function, include, but are not limited to, HIV.
Diseases or conditions of humans or other species which can be treated with promoters of chemokine receptor function, include, but are not limited to:
immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS or other viral infections, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or drug therapy (e. g., corticosteroid therapy), which causes immunosuppression; immunosuppression due to congenital deficiency in receptor function or other causes; and infections diseases, such as parasitic diseases, including, but not limited to helminth infections, such as nematodes (round worms); (Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, filariasis); trematodes (flukes) (Schistosomiasis, Clonorchiasis), cestodes (tape worms) (Echinococcosis, Taeniasis saginata, Cysticercosis); visceral worms, visceral larva migraines (e. g., Toxocara), eosinophilic gastroenteritis (e. g., Anisaki sp., Phocanema sp.), cutaneous larva migraines (Ancylostona braziliense, Ancylostoma caninum). The compounds of the present invention are accordingly useful in the prevention and treatment of a wide variety of inflammatory, infectious and immunoregulatory disorders and diseases. In addition, treatment of the aforementioned inflammatory, allergic and autoimmune diseases can also be contemplated for promoters of chemokine receptor function if one contemplates the delivery of sufficient compound to cause the loss of receptor expression on cells through the induction of chemokine receptor internalization or delivery of compound in a manner that results in the misdirection of the migration of cells.
In another aspect, the instant invention may be used to evaluate the putative specific agonists or antagonists of a G protein coupled receptor. The present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds that modulate the activity of chemokine receptors. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other compounds to chemokine receptors, e.g., by competitive inhibition or as a reference in an assay to compare its known activity to a compound with an unknown activity. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness.
Specifically, such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving the aforementioned diseases. The compounds of the instant invention are also useful for the evaluation of putative specific modulators of the chemokine receptors. In addition, one could utilize compounds of this invention to examine the specificity of G protein coupled receptors that are not thought to be chemokine receptors, either by serving as examples of compounds which do not bind or as structural variants of compounds active on these receptors which may help define specific sites of interaction.
Combined therapy to prevent and treat inflammatory, infectious and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and those pathologies noted above is illustrated by the combination of the compounds of this invention and other compounds which are known for such utilities. For example, in the treatment or prevention of inflammation, the present compounds may be used in conjunction with an anti-inflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin-1 inhibitor, a tumor necrosis factor inhibitor, an NMDA antagonist, an inhibitor or nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal anti-inflammatory agent, a phosphodiesterase inhibitor, or a cytokine-suppressing anti-inflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, fentaynl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, interferon alpha and the like.

Similarly, the instant compounds may be administered with a pain reliever; a potentiator such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levodesoxy-ephedrine; and antitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; and a sedating or non-sedating antihistamine. Likewise, compounds of the present invention may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compound of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention. Examples of other active ingredients that may be combined with a compound of the present invention, either administered separately or in the same pharmaceutical compositions, include, but are not limited to: (a) integrin antagonists such as those for selectins, ICAMs and VLA-4; (b) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; (c) immunosuppressants such as cyclosporin, tacrolimus, rapamycin and other FK-506 type immunosuppressants; (d) antihistamines (H1-histamine antagonists) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like;
(e) non-steroidal anti-asthmatics such as b2-agonists (terbutaline, metaproterenol, fenoterol, isoetharine, albuteral, bitolterol, and pirbuterol), theophylline, cromolyn sodium, atropine, ipratropium bromide, leukotriene antagonists (zafirlukast, montelukast, pranlukast, iralukast, pobilukast, SKB-102,203), leukotriene biosynthesis inhibitors (zileuton, BAY-1005); (f) non-steroidal antiinflammatory agents (NSATDs) such as propionic acid derivatives (alminoprofen, benxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxican), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone); (g) cyclooxygenase-2 (COX-2) inhibitors; (h) inhibitors of phosphodiesterase type IV

(PDE-IV); (I) other antagonists of the chemokine receptors; (j) cholesterol lowering agents such as HMG-COA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvsatatin, and other statins), sequestrants (cholestyramine and colestipol), nicotonic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzafibrate), and probucol; (k) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), a-glucosidase inhibitors (acarbose) and glitazones (troglitazone ad pioglitazone); (1) preparations of interferons (interferon alpha-2a, interferon-2B, interferon alpha-N3, interferon beta-1a, interferon beta-1b, interferon gamma-1b); (m) antiviral compounds such as efavirenz, nevirapine, indinavir, ganciclovir, lamivudine, famciclovir, and zalcitabine; (o) other compound such as 5-aminosalicylic acid an prodrugs thereof, antimetabolites such as azathioprine and 6-mercaptopurine, and cytotoxic cancer chemotherapeutic agents. The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective doses of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200.
Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.
Dosage and Formulation The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts.
They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient,and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.
By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. when administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfate, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
Also used are citric acid and its salts and sodium EDTA.
In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers. are described in Reminaton's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:
Capsules A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Capsules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried.
Tablets Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
Ink ectable A parenteral composition suitable for administration by injection may be prepared by stirring 1.5o by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized.

Suspension .An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.
Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 2 to 5 milligrams per dosage unit.
V~here two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.
Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between .the active ingredients is minimized (that is, reduced).
For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.
These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.
As will be appreciated by one of skill in the art, numerous modifications and variations of the present invention are possible in light of the above teachings.
It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

Claims (19)

What is Claimed is:
1. A compound of formula (I):
or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
Q is selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
J, K and L are independently selected from CH2, CHR5, CHR6, CR6R6 and CR5R6;
with the provisos that:
1) at least one of J, K, or L contains R5;
2) when M is absent, J is selected from CH2, CHR5, CHR13, and CR5R13;
Z is selected from O, S, NR1a, CHCN, CHNO2, and C(CN)2;
R1a is selected from H, C1-6 alkyl, C3-6 cycloalkyl, CONR1b R1b, OR1b, CN, NO2, and (CH2)w phenyl;

R1b is independently selected from H, C1-3 alkyl, C3-6 cycloalkyl, and phenyl;
E is selected from:
ring A is a C3-6 carbocyclic residue, provided that the C3-6 carbocyclic residue in Ring A is not phenyl;

R1 and R2 are independently selected from H, C1-6 alkyl, C3-8 alkenyl, and C3-8 alkynyl;
R3 is selected from a C1-10 alkyl substituted with 0-5 R3g, C3-10 alkenyl substituted with 0-5 R3g, and C3-10 alkynyl substituted with 0-5 R3g;
R3g, at each occurrence, is independently selected from Cl, Br, I, F, NO2, CN, NR3a R3a', OH, O(CHR')r R3d, SH, C(O)H, S(CHR')r R3d, C(O)OH, C(O)(CHR')r R3b, C(O)NR3a R3a', OC(O)NR3a R3a', NR3a C(O)OR3d, NR3f C(O)(CHR')r R3b, C(O)O(CHR')r R3d, OC(O)(CHR')r R3b, C(-NR3f)NR3a R3a', NHC(=NR3f)NR3f R3f, S(O)p(CHR')r R3b, S(O)2NR3a R3a', NR3f S(O)2(CHR')r R3b, a C3-10 carbocyclic residue substituted with 0-5 R15, and a 5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15, provided that when R3g is a carbocyclic residue or a heterocyclic system, R3 has at least one other R3g, which is not a carbocyclic residue or a heterocyclic system;
R3a and R3a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R3e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R3e;

R3b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R3e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, anal S, substituted with 0-2 R3e;
R3d, at each occurrence, is selected from C3-8 alkenyl, C3-8 alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 R3e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R3e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R3e;
R3e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r S(O)p C1-5 alkyl, (CH2)r NR3f R3f, and (CH2)r phenyl;
R3f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)q C(O)R4b, (CH2)q C(O)NR4a R4a', (CH2)q C(O)OR4b, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R4c;

R4a and R4a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, (CH2)r C3-6 cycloalkyl, C3-8 alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4a R4a', and (CH2)r phenyl;
alternatively, R4 joins with R7, R9, R11, or R14 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a;
R5 is selected from a (CR5'R5")t-C3-10 carbocyclic residue substituted with 0-5 R16 and a (CR5'R5")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16;
R5' and R5", at each occurrence, are selected from H, alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R6, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CF2)r CF3, CN, (CH2)r NR6a R6a', (CH2)r OH.
(CH2)r OR6b, (CH2)r SH, (CH2)r SR6b, (CH2)r C(O)OH, (CH2)r C(O)R6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)R6a, (CH2)r C(O)OR6b, (CH2)r OC(O)R6b, (CH2)r S(O)p R6b, (CH2)r S(O)2NR6a R6a', (CH2)r NR6d S(O)2R6b, and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6C;
R6b, at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
with the proviso that when any of J, K or L is CR6R6 and R6 is bonded to the carbon to which it is attached through a heteroatom, the other R6 is not bonded to the carbon to which it is attached through a heteroatom;
R7, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)q OH, (CH2)q SH, (CH2)q OR7d, (CH2)q SR7d, (CH2)q NR7a R7a', (CH2)r C(O)OH, (CH2)r C(O)R7b, (CH2)r C(O)NR7a R7a', (CH2)r OC(O)NR7a R7a', (CH2)q NR7a C(O)OR7b, (CH2)q NR7a C(O)R7a, (CH2)q NR7a C(O)H, (CH2)r C(O)OR7b, (CH2)q OC(O)R7b, (CH2)q S(O)p R7b, (CH2)q S(O)2NR7a R7a', (CH2)q NR7a S(O)2R7b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R7c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R7c;
R7a and R7a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, (CH2)r C3-6 cycloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R7e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
alternatively, R7a and R7a', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR7g, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R7b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R7e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
R7c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR7f R7f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R7b, (CH2)r C(O)NR7f R7f, (CH2)r NR7f C(O)R7a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R7b, (CH2)r C(=NR7f)NR7f R7f, (CH2)r S(O)pR7b, (CH2)r NHC(=NR7f)NR7f R7f, (CH2)r S(O)2NR7f R7f, (CH2)r NR7f S(O)2R7b, and (CH2)r phenyl substituted with 0-3 R7e;
R7d, at each occurrence, is selected from methyl, CF3, C2-6 alkyl substituted with 0-3 R7e, C3-8 alkenyl, C3-8 alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 R7C;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R7f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R7f, C(O)OR7f, and SO2R7f;

R8 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)t phenyl substituted with 0-3 R8a;
R8a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R8b is selected from H, C1-6 alkyl, C3-6 cycloalkyl, OH, CN, and (CH2)r-phenyl;
alternatively, R7 and R8 join to form C3-7 cycloalkyl, =O, or =NR8b;
R9, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)r OH, (CH2)r SH, (CH2)r OR9d, (CH2)r SR9d, (CH2)r NR9a R9a', (CH2)r C(O)OH, (CH2)r C(O)R9b, (CH2)r C(O)NR9a R9a', (CH2)r NR9a C(O)R9a, (CH2)r NR9a C(O)H, (CH2)r OC(O)NR9a R9a', (CH2)r NR9a C(O)OR9b, (CH2)r NR9a C(O)NHR9a, (CH2)r C(O)OR9b, (CH2)r OC(O)R9b, (CH2)r S(O)p R9b, (CH2)r S(O)2NR9a R9a', (CH2)r NR9a S(O)2R9b, haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9c;

R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
alternatively, R9a and R9a', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR9g, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R9b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR9f R9f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R9b, (CH2)r C(O)NR9f R9f, (CH2)r NR9f C(O)R9a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R9b, (CH2)r C(=NR9f)NR9f R9f, (CH2)r S(O)p R9b. (CH2)r NHC(=NR9f)NR9f R9f, (CH2)r S(O)2NR9f R9f, (CH2)r NR9f S(O)2R9b, and (CH2)r phenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R9C, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R9C;
R9e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR9f R9f, and (CH2)r phenyl;
R9f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R9g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R9f, C(O)OR9f, and SO2R9f;
R10, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)r OH, (CH2)r OR10d, (CH2)r SR10d, (CH2)r NR10a R10a', (CH2)r C(O)OH, (CH2)r C(O)R10b, (CH2)r C(O)NR10a R10a', (CH2)r NR10a C(O)R10a, (CH2)r NR10a C(O)H, (CH2)r C(O)OR10b, (CH2)r OC(O)R10b, (CH2)r OC(O)NR10a R10a', (CH2)r NR10a C(O)OR10b, (CH2)r S(O)p R10b, (CH2)r S(O)2NR10a R10a', (CH2)r NR10a S(O)2R10b, C1-6 haloalkyl, a (CH2)r-C3-carbocyclic residue substituted with 0-5 R10c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10c;
R10a and R10a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R10e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10e;
alternatively, R10a and R10a', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR10g, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R10b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R10e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10e;
R10c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR10f R10f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R10b, (CH2)r C(O)NR10f R10f, (CH2)r NR10f C(O)R10a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R10b, (CH2)r C(=NR10f)NR10f R10f, (CH2)r S(O)p R10b, (CH2)r NHC(=NR10f)NR10f R10f, (CH2)r S(O)2NR10f R10f, (CH2)r NR10f S(O)2R10b, and (CH2)r phenyl substituted with 0-3 R10e;
R10d, at each occurrence, is selected from C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R10c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R10c;
R10e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR10f R10f, and (CH2)r phenyl;
R10f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R10g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R10f, C(O)OR10h, and SO2R10h;
R10h, at each occurrence, is selected from C1-5 alkyl, and C3-6 cycloalkyl;
alternatively, R9 and R10 join to form =O, a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR10g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
with the proviso that when either of R9 or R10 is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other of R9 or R10 is not bonded to the carbon to which it is attached through a heteroatom;
R11, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)q OH, (CH2)q SH, (CH2)q OR11d, (CH2)q SR11d, (CH2)q NR11a R11a', (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11a R11a', (CH2)q NR11a C(O)R11a, (CH2)q OC(O)NR11a R11a', (CH2)q NR11a C(O)OR11b, (CH2)q NR11a C(O)NHR11a, (CH2)r C(O)OR11b, (CH2)q OC(O)R11b, (CH2)q S(O)p R11b, (CH2)q S(O)2NR11a R11a', (CH2)q NR11a S(O)2R11b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11c;
R11a and R11a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;

alternatively, R11a and R11a', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR11g, 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R11b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R11e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR11f R11f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11f R11f, (CH2)r NR11f C(O)R11a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R11b, (CH2)r C(=NR11f)NR11f R11f, (CH2)r NHC(=NR11f)NR11f R11f, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)r NR11f S(O)2R12b, and (CH2)r phenyl substituted with 0-3 R11e;
R11d, at each occurrence, is selected from methyl, CF3, C2-6 alkyl substituted with 0-3 R11e, C3-6 alkenyl, C3-6 alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 R11c;

R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR11f R11f, and (CH2)r phenyl;

R11f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;

R11g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R11f, C(O)OR11h, and SO2R11h;

R11h, at each occurrence, is selected from C1-5 alkyl, and C3-6 cycloalkyl;

R12 is selected from H, C1-6 alkyl, (CH2)q OH, (CH2)r C3-6 cycloalkyl, and (CH2)t phenyl substituted with 0-3 R12a;

R12a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR9f R9f, and (CH2)r phenyl;

alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 2-2 heteroatoms selected from O, S, and NR11g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;

R13, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, (CF2)w CF3, (CH2)NR13a R13a', (CH2)q OH, (CH2)q OR13b, (CH2)q SH, (CH2)q SR13b, (CH2)w C(O)OH, (CH2)w C(O)R13b, (CH2)w C(O)NR13a R23a', (CH2)q NR13d C(O)R13a, (CH2)w C(O)OR13b, (CH2)q OC(O)R13b, (CH2)w S(O)p R13b, (CH2)w S(O)2NR13a R13a', (CH2)q NR13d S(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;

R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;

R13b, at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 R13c R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR13d R13d;

R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;

R14, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, NO2, CN, (CHR')r NR14a R14a', (CHR')r OH, (CHR')r O(CHR')r R14d, (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R14d, (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R14b, (CHR')r C(O)NR14a R14a', (CHR')r NR14f C(O)(CHR')r R14b, (CHR')r C(O)O(CHR')r R14d, (CHR')r OC(O)(CHR')r R14b, (CHR')r C(=NR14f)NR14a R14a', (CHR')r NHC(=NR14f)NR14f R14f, (CHR')r S(O)p(CHR')r R14b, (CHR')r S(O)2NR14a R14a', (CHR')r NR14f S(O)2(CHR')r R14b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', (CHR')r phenyl substituted with 0-3 R14e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14e, or two R14 substituents on adjacent atoms on ring A form to join a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from N, 0, and S substituted with 0-2 R14e;
R', at each occurrence, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, and (CH2)r phenyl substituted with R14e;
R14a and R14a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R14e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14e;

R14b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R14e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14e;
R14d, at each occurrence, is selected from C3-8 alkenyl, C3-8 alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 R14e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R14e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R14e;
R14e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, F, Br, I, CN, No2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR14f R14f, and (CH2)r phenyl;
R14f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R14 joins with R4 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle fused to ring A, the spirocycle substituted with 0-3 R a;
R a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR b R b, (CH2)r OH, (CH2)r OR c, (CH2)r SH, (CH2)r SR c, (CH2)r C(O)R b, (CH2)r C(O)NR b R b, (CH2)r NR b C(O)R b, (CH2)r C(O)OR b, (CH2)r OC(O)R c, (CH2)r CH(=NR b)NR b R b, (CH2)r NHC(=NR b)NR b R b, (CH2)r S(O)p R c, (CH2)r S(O)2NR b R b, (CH2)r NR b S(O)2R c, and (CH2)r phenyl;
R b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R c, at each occurrence, is selected from C1-6 alkyl, C3-cycloalkyl, and phenyl;
R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, NO2, CN, (CHR2)r NR15a R15a', (CHR')r OH, (CHR')r O(CHR')r R15d, (CHR2)r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R15d, (CHR2)r C(O)OH, (CHR')r C(O)(CHR')r R15b, (CHR2)r C(O)NR15a R15a', (CHR')r NR15f C(O)(CHR')r R15b, (CHR2)r NR15f C(O)NR15f R15f, (CHR')r C(O)O(CHR')r R15d, (CHR2)r OC(O)(CHR')r R15b, (CH2)r OC(O)NR15a R15a', (CH2)r NR15a C(O)OR15b, (CHR')r C(=NR15f)NR15a R15a', (CHR')r NHC(=NR15f)NR15f R15f, (CHR')r S(O)p(CHR')r R15b, (CHR')r S(O)2NR15a R15a', (CHR')r NR15f S(O)2(CHR')r R15b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', (CHR')r phenyl substituted with 0-3 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R15e R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e alternatively, R15a and R15a', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR15g, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R15b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R15e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e R15d, at each occurrence, is selected from C3-8 alkenyl, C3-8 alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 R15e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R15e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15e;
R15e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 Cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR15f R 15f, and (CH2)r phenyl;
R15f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R15g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)rphenyl, C(O)R15f, C(O)OR15h, and SO2R15h;
R15h, at each occurrence, is selected from C1-5 alkyl, and C3-6 cycloalkyl;
R16, at each occurrence, is selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, NO2, CN, (CHR')r NR16aR16a', (CHR') r OH, (CHR') r O (CHR') r R16d, (CHR') r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R16d, (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R16b, (CHR')r C(O)NR16aR16a', (CHR')r NR16f C(O)(CHR')r R16b' (CHR')r C(O)O(CHR')r R16d, (CHR')r OC(O)(CHR')r R16b' (CHR')r C(=NR16f)NR16a R16a', (CHR')r NHC(=NR16f)NR16fR16f, (CHR')r S(O)p(CHR')r R16b, (CHR')r S(O)2NR16aR16a', (CHR')r NR16f S(O)2(CHR')r R16b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', and (CHR')rphenyl substituted with 0-3 R16e R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R16e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R16e R16b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, a (CH2)r C3-6 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e R16d, at each occurrence, is selected from C3-8 alkenyl, C3-8 alkynyl, methyl, CF3, C2-6 alkyl substituted with 0-3 R16e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16e R16e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)r NR16f R16f, and (CH2)r phenyl;
R16f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl, and phenyl;
g is selected from 0, 1, 2, 3, and 4;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and p is selected from 0, 1, and 2.
2, The compound of claim 1, wherein:
Z is selected from O, S, NCN, NCONH2, CHNO2, and C(CN)2;
E is selected from:

R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, (CH2)rC3-6 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4aR4a', and (CH2)r phenyl;
alternatively, R4 joins with R7 or R9 or R14 to form a 5, 6 or 7 membered piperidinium spirocycle substituted with 0-3 R a;
R1 and R2 are independently selected from H and C1-4 alkyl;

R6, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CF2)r CF3, CN. (CH2)rOH, (CH2)r OR6b, (CH2)r C(O)R6b, (CH2)r C(O)NR6aR6a', (CH2)r NR6dC(O)R6a, and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)rOH, (CH2)r SC1-5 alkyl, and (CH2)r NR6dR6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7, is selected from H, C1-3 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)q OH, (CH2)q OR7d, (CH2)q NR7aR7a', (CH2)r C(O)R7b, (CH2)r C(O)NR7aR7a', (CH2)q NR7aC(O)R7a, (CH2)qOC(O)NR7aR7a', (CH2)q NR7aC(O)OR7b, C1-6 haloalkyl, (CH2)r phenyl with 0-2 R7C;

R7a and R7a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, a (CH2)r phenyl substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R7e;
R7C, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR7f R7f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r C(O)R7b, (CH2) r C (O) NR7f R7f, (CH2) r NR7f C (O) R7a (CH2)r S(O)p R7b, (CH2)r S(O)2NR7f R7f, (CH2)r NR7f S(O)2R7b, and (CH2)r phenyl substituted with 0-2 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-6 CYcloalkyl, (CH2)r phenyl substituted with 0-3 R7e;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R7f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;

R8 is H or joins with R~ to form C3-~ cycloalkyl, =0, or -NRBb:
R11, is selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qORlld~
(CH2)qNR11aR11a'~ (CH2)rC(0)Rllb~
(CH2)rC(O)NR12aR11a'~ (CH2)qNRllaC(O)Rlla~
(CH2)qOC(O)NR11aR11a'~ (CH2)qNRllaC(0)ORlla~ C1-6 haloalkyl, (CH2)rphenyl with 0-2 R11C, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
Rlla and Rlla'~ at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, a (CH2)rphenyl substituted with 0-3 Rlle;
alternatively, Rlla and Rlla', along with the N to which they are attached, are joined to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NRllg, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
Rllb, at each occurrence, is selected from C1-6 alkyl, C2-g alkenyl, C2-g alkynyl, (CH~)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 Rlle Rllc~ at each occurrence, is selected from C1_4 alkyl, C2-g alkenyl, C2-g alkynyl, (CH~)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR11fR11f~

(CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r C(O)R11b, (CH2)r C(O)NR11f R11f, (CH2)r NR11f C(O)R11a, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)r NR11f S(O)2R11b, and (CH2)r phenyl substituted with 0-2 R11e;
R11d, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R11e;
R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (Cf2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR11f R11f, and (CH2)r phenyl;
R11f, at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;
R11g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R11f, C(O)OR11f, and SO2R11f;
R12 is H;
alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR11g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;

R13, at each occurrence, is selected from C1-4 alkyl, C3-6 cycloalkyl, (CH2)NR13a R13a', (CH2)OH, (CH2)OR13b, (CH2)w C(O)R13b, (CH2)w C(O)NR13a R13a', (CH2)NR13d C(O)R13a, (CH2)w S(O)2NR13a R13a', (CH2)NR13d S(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13b, at each occurrence, is selected from C1-6 alkyl, cycloalkyl, and phenyl substituted with 0-3 R13c;
R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, and (CH2)r NR13d R13d;
R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
3. The compound of claims 1-2, wherein:
ring A is selected from:

R5 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CR5'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
4. The compound of claims 1-3, wherein the compound of formula (I-i) is:
R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2, CN, OH, (CH2)r OR6d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b, (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl; and R16f, at each occurrence, is selected from H, and C1-5 alkyl.
5. The compound of claims 1-3, wherein the compound of formula (I-ii) is:
R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH3)r NR16a R16a', NO2, CN, OH, (CH3)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b, (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl; and R16f, at each occurrence, is selected from H, and C1-5 alkyl.
6. The compound of claims 1-4, wherein:
R5 is CH2phenyl substituted with 0-3 R16;
R9, is selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, F, Cl, CN, (CH2)r OH, (CH2)r OR9d, (CH2)r NR9a R9a', (CH2)r OC(O)NHR9a, (CH2)r phenyl substituted with 0-5 R9e, and (CH2)r-heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
R10 is selected from H, C1-5 alkyl, OH, and CH2OH;
R10g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R10f, C(O)OR10f, and SO2R10f;
alternatively, R9 and R10 join to form =O, a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR10g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
with the proviso that when either of R9 or R10 is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other of R9 or R10 is not bonded to the carbon to which it is attached through a heteroatom;

R11 is selected from H, C1-8 alkyl, (CH2)r phenyl substituted with 0-5 R11e, and a (CH2)r-heterocyclic system substituted with 0-2 R11e, wherein the heterocyclic system is selected from.
pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R11e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
R11g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R11f, C(O)OR11f, and SO2R11f;
R12 is H;
alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR11g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R14, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR14a R14a', NO2, CN, OH, (CH2)r OR14d, (CH2)r C(O)R14b, (CH2)r C(O)NR14a R14a', (CH2)r NR14f C(O)R14b, (CH2)r S(O)p R14b, (CH2)r S(O)2NR14a R14a', (CH2)r NR14f S(O)2R14b, (CH2)r phenyl substituted with 0-3 R14e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e; or two R14 substituents on adjacent atoms on ring A form to join a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from N, O, and S substituted with 0-2 R15e;
R14a and R14a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R14b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e;
R14d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R14e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl; and R14f, at each occurrence, is selected from H, and C1-5 alkyl;
and r is selected from 0, 1, and 2.
7. The compound of claims 1-3, and 5, wherein:
R5 is CH2phenyl substituted with 0-3 R16;
R9, is selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, F, Cl, CN, (CH2)r OH, (CH2)r OR9d, (CH2)r NR9a R9a', (CH2)r OC(O)NHR9a, (CH2)r phenyl substituted with 0-5 R9e, and (CH2)r-heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
R10 is selected from H, C1-8 alkyl, OH, and CH2OH;
R10g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R10f, C(O)OR10f, and SO2R10f;

alternatively, R9 and R10 join to form =O, a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR10g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
with the proviso that when either of R9 or R10 is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other of R9 or R10 is not bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1-8 alkyl, (CH2)r phenyl substituted with 0-5 R11e, and a (CH2)r-heterocyclic system substituted with 0-2 R11e, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R11e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-alkyl;
R11g is selected from H, C1-6 alkyl, C3-6 cycloalkyl, (CH2)r phenyl, C(O)R11f, C(O)OR11f, and SO2R11f;
R12 is H;

alternatively, R11 and R12 join to form a C3-10 cycloalkyl, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR11g and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
R14, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR14a R14a', NO2, CN, OH, (CH2)r OR14d, (CH2)r C(O)R14b, (CH2)r C(O)NR14a R14a', (CH2)r NR14f C(O)R14b, (CH2)r S(O)p R14b, (CH2)r S(O)2NR14a R24a', (CH2)r NR14f S(O)2R14b, (CH2)r phenyl substituted with 0-3 R14e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e; or two R14 substituents on adjacent atoms on ring A form to join a 5-6 membered heterocyclic system containing 1-3 heteroatoms selected from N, O, and S substituted with 0-2 R15e;
R14a and R14a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e;
R14b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e;

R14d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R14e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
R14f, at each occurrence, is selected from H, and C1-5 alkyl;
and r is selected from 0, 1, and 2.
8. The compound of claims 1-4 and 6, wherein:
J is selected from CH2 and CHR5;
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;
R3 is selected from a C1-10 alkyl substituted with 0-3 R3g, C3-10 alkenyl substituted with 0-3 R3g, and C3-10 alkynyl substituted with 0-3 R3g;
R3g, at each occurrence, is selected from Cl, Br, I, F, NO2, CN, NR3a R3a', OH, O (CHR')r R3d, SH, C(O)H, S(CHR')r R3d, C(O)OH, C(O)(CHR')r R3b, C(O)NR3a R3a', NR3f C(O)(CHR')r R3b, C(O)O(CHR')r R3d, OC(O)(CHR')r R3b, (CH2)r OC(O)NR3a R3a', (CH2)q NR3a C(O)OR3a, S(O)p(CHR')r R3b, S(O)2NR3a R3a', NR3f S(O)2(CHR')r R3b, phenyl substituted with 0-3 R15, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl, provided that when R3g is a carbocyclic residue or a heterocyclic system, R3 has at least one other R3g, which is not a carbocyclic residue or a heterocyclic system;
R3a and R3a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3b, at each occurrence, is selected from C1-6 alkyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3d, at each occurrence, is selected from C1-6 alkyl and phenyl substituted with 0-3 R3e;
R3e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH;
R3f, at each occurrence, is selected from H, C1-5 alkyl;

R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR15a R15a', NO2, CN, OH, (CH2)r OR15d, (CH2)r C(O)R15b, (CH2)r C(O)NR15a R15a', (CH2)r NR15f C(O)R15b, (CH2)r OC(O)NR15a R15a', (CH2)q NR15a C(O)OR15a, (CH2)r S(O)p R15b, (CH2)r S(O)2NR15a R15a', (CH2)r NR15f S(p)2R15b, (CH2)r phenyl substituted with 0-3 R15e, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;
R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;
alternatively, R15a and R15a', along with the N to which they are attached, are joined to form a morpholine, piperidine, or piperazine ring, and the piperazine optionally substituted With R15g;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;

R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl; and R15f, at each occurrence, is selected from H, and C1-5 alkyl.
9. The compound of claims 1-3, 5, and 7, wherein:
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;
R3 is selected from a C1-10 alkyl substituted with 0-3 R3g, C3-10 alkenyl substituted with 0-3 R3g, and C3-10 alkynyl substituted with 0-3 R3g;
R3g, at each occurrence, is selected from Cl, Br, I, F, NO2, CN, NR3a R3a', OH, O(CHR')r R3d, SH, C(O)H, S(CHR')r R3d, C(O)OH, C(O)(CHR')r R3b, C(O)NR3a R3a', NR3f C(O)(CHR')r R3b, C(O)O(CHR')r R3d, OC(O)(CHR')r R3b, (CH2)r OC(O)NR3a R3a', (CH2)q NR3a C(O)OR3a, S(O)p(CHR')r R3b, S(O)2NR3a R3a', NR3f S(O)2(CHR')r R3b, phenyl substituted with 0-3 R15, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl, provided that when R3g is a carbocyclic residue or a heterocyclic system, R3 has at least one other R3g, which is not phenyl or a heterocyclic system;
R3a and R3a', at each occurrence, are selected from H, C1-6 alkyl, C3-8 alkenyl, C3-8 alkynyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3b, at each occurrence, is selected from C1-6 alkyl, and (CH2)r-phenyl substituted with 0-3 R3e;
R3d, at each occurrence, is selected from C1-6 alkyl and phenyl substituted with 0-3 R3e;
R3e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH;
R3f, at each occurrence, is selected from H, C1-5 alkyl;
R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR15aR15a', NO2, CN, OH, (CH2)r OR15d, (CH2)r C(O)R15b, (CH2)r C(O)NR15a R15a', (CH2)r NR15f C(O)R15b, (CH2)r OC(O)NR15a R15a', (CH2)q NR15a C(O)OR15a, (CH2)r S(O)p R15b, (CH2)r S(O)2NR15a R15a', (CH2)r NR15f S(O)2R15b, (CH2)r phenyl substituted with 0-3 R15e, and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl;

R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;

alternatively, R15a and R15a', along with the N to which they are attached, are joined to form a morpholine, piperidine, or piperazine ring, and the piperazine optionally substituted with R15g;

R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;
R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl; and R15f, at each occurrence, is selected from H, and C1-5 alkyl.
10. The compound of claims 1-4, 6, and 8, wherein:
E is Z is selected from O and N(CN);
R3 is selected from C3-8 alkyl wherein the C3-8 alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, methylpentyl, dimethylpentyl, and trimethylpentyl, and wherein the C3-8 alkyl is substituted with 0-2 R3g;

R3g, at each occurrence is selected from C(O)OR3b, OR3b OH, OC (O) H, NHC (O) R3b, CN, NR3a R3a', and phenyl;

R3a and R3a', at each occurrence, are selected from H and methyl;

R3b, at each occurrence, is selected from H, methyl, ethyl, propyl, and phenyl; and R16 is selected from F, Cl, Br, and I.
11. The compound of claims 1-3, 5, 7, and 9, wherein:
E is Z is selected from O and N(CN);

R3 is selected from C3-8 alkyl wherein the C3-8 alkyl is selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, pentyl, methylpentyl, dimethylpentyl, and trimethylpentyl, and wherein.
the C3-8 alkyl is substituted with 0-2 R3g;

R3g, at each occurrence is selected from C(O)OR3b, OR3b, OH, OC (O) H, NHC (O) R3b, CN, NR3a R3a', and phenyl;
R3a and R3a', at each occurrence, are selected from H and methyl;
R3b, at each occurrence, is selected from H, methyl, ethyl, propyl, and phenyl; and R16 is selected from F, Cl, Br, and I.
12. The compound of claim 1 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from:

N-(t-butyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-(i-propyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-(ethoxycarbonylmethyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[(1R,S)-1-(methoxycarbonyl)-2-methyl-propyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[(1S)-1-(methoxycarbonyl)-2-phenylethyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[2,4,4-trimethyl-2-pentyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexy 1]-urea, N-[(1S)-2-hydroxy-1-phenylethyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-urea, 2-({[(1R,2S)-2-{[(3S)-3-(4-fluorobenyl)piperidinyl]methyl}cyclohexyl)amino}car bonyl}amino)acetamide, N-(2-methoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-urea,~

N-(2-ethoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-urea, N"-cyano-N-(ethoxycarbonylmethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine, 2-{[((1R,2S)-2-{[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl)amino][( 2-methoxyethyl)amino]methylene}malonitrile, N"-cyano-N-(2-phenoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine, N"-cyano-N-(2-methoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine, N-(2-dimethylaminoethyl)-N'-{(1R,2R)-2-[(3S)-3-(4-fluorobenzyl)piperidine-1-carbonyl]cyclohexyl}-urea, and N"-cyano-N-(2-ethoxyethyl)-N'-(1R,2S)-2-[[(3S)-3-(4-fluorophenyl)methyl)piperidinyl]methyl]cyclohexyl]-guanidine.
13. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claims 1-12.
14. A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-12.
15. A method for modulation of chemokine receptor activity comprising contacting a CCR3 receptor with an effective inhibitory amount of a compound of Claims 1-12.
16. A method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-12.
17. A method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claims 1-12.
18. A method for treating or preventing inflammatory disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claims 1-12, wherein the inflammatory disorder is selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.
19. The method of Claim 18 for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, and inflammatory bowel diseases.
CA002413421A 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity Abandoned CA2413421A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21320800P 2000-06-21 2000-06-21
US09/597,400 2000-06-21
US60/213,208 2000-06-21
US09/597,400 US6525069B1 (en) 1998-12-18 2000-06-21 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PCT/US2001/019752 WO2001098270A2 (en) 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
CA2413421A1 true CA2413421A1 (en) 2001-12-27

Family

ID=26907864

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002413421A Abandoned CA2413421A1 (en) 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Country Status (5)

Country Link
EP (1) EP1294690A2 (en)
JP (1) JP2004516238A (en)
AU (1) AU7135901A (en)
CA (1) CA2413421A1 (en)
WO (1) WO2001098270A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002951995A0 (en) 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
SE0400208D0 (en) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
US7326729B2 (en) 2004-05-12 2008-02-05 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
US20080009418A1 (en) * 2004-10-04 2008-01-10 Alchemia Ltd. Selective Inhibitors
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
CA2620281A1 (en) * 2005-08-26 2007-03-01 Astrazeneca Ab A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
JP2009523748A (en) * 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ Modulators of α7 nicotinic acetylcholine receptors and their use in therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993897A (en) * 1961-07-25 S-triazinylmethyl ureas
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
NL7800026A (en) * 1977-01-07 1978-07-11 Acna PROCESS FOR THE PREPARATION OF SUBSTITUTED AMINO-BENZENES.
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
SE9802209D0 (en) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
AU5473400A (en) * 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity

Also Published As

Publication number Publication date
AU7135901A (en) 2002-01-02
WO2001098270A3 (en) 2002-05-30
EP1294690A2 (en) 2003-03-26
WO2001098270A2 (en) 2001-12-27
JP2004516238A (en) 2004-06-03

Similar Documents

Publication Publication Date Title
US6444686B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6521592B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6492400B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6486180B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1140086A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035449A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413421A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413274A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6897234B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2001271359A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA01006148A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Legal Events

Date Code Title Description
FZDE Dead